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Et ethyl 
Fmoc 9-fluorenylmethoxycarbonyl 
HATU N-[(dimethylamino)(1H-1,2,3-triazolo[4,5-b]pyridine-1-yl)methylene]-N-
methylmethanaminium hexafluorophosphate-N-oxide 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HFIP hexafluoroisopropanol 
Hmb 2-hydroxy-4-methoxybenzyl 
HOBt 1,2,3-benzotriazol-1-ol 
IC50 half maximal inhibitory concentration 
ICAMs intercellular adhesion molecules 
MALDI-ToF matrix-assisted laser desorption/ionization time of flight 
MS mass spectrometry 
NMR nuclear magnetic resonance 
NPY neuropeptide Y 
ORD optical rotary dispersion 
ORD optical rotary dispersion 
Pgm platinum group metal 
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R.T. room temperature 
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SPPS solid-phase peptide synthesis 
Su succinimide 
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tBu tert-butyl 
TCTU 1-[Bis(dimethylamino)methylen]-5-chlorobenzotriazolium-3-oxide 
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TFA trifluoroacetic acid 
  
 
 
TFE trifluoroethanol 
TGF-β transforming growth factor beta 
TIS triisopropylsilane 
tR retention time 
Trt triphenylmethyl 
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UNCAs urethane-protected α-amino acid N-carboxyanhydride 
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1 Supramolecular Chemistry of Peptides and Recognition by Receptors 
 1
1 Supramolecular Chemistry of Peptides and        
Recognition by Receptors 
 
 
1.1 Thermodynamics of the Association of Peptide 
Ligands and Protein Receptors 
 
A new class of low-molecular compounds, including synthetic vaccines, synthetic 
diagnostics, peptide-originated drugs, are flourishing based on developments of 
peptide libraries, supramolecular chemistry of peptides in their recognition to 
corresponding protein receptors, and structure-based peptidyl ligand design. 
 
Structure-based design is based on the observation that ligands bind to clearly defined 
molecular targets. Receptors are mostly membrane-bound proteins that selectively 
bind small molecules, referred to as ligands that elicit some physiological response. A 
strong and selective binding can be obtained from a high structural and chemical 
complementarity between the receptor and the ligand.[1, 2] Structure-based ligand 
design may therefore be described as the search for small molecules that fit into the 
binding site of the target and can form favorable interactions. 
 
The basic force to promote the ligand-receptor interaction could be regarded as the 
reach of low energy state of the ligand-receptor complex, which is described by the 
equilibrium shown below: 
ligand + receptor
kon
koff
ligand-receptor complex
 
 
The biological activity of a ligand is referred to its binding affinity for the 
corresponding receptor, which could be reflected as the stability of the generated 
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ligand-receptor complex. This stability is commonly quantified with Kd, the 
dissociation constant for the ligand-receptor complex at equilibrium: 
 
Kd = [ligand] [receptor]/ [ligand-receptor] 
 
The smaller the Kd, the larger the concentration of the ligand-receptor complex at its 
balanced equilibrium, the more stable is the generated complex, and hence the greater 
is the affinity of the ligand to its receptor.  
 
From the thermodynamics point of view, the process of association of ligand and its 
receptor, namely, ligand-receptor complex formation, is entropically unfavorable, 
since it causes a loss in conformational degrees of freedom for both the receptor and 
ligand, as well as the loss of three rotational and three translational degrees of 
freedom.[3] That is to say, the strong association of ligand to its receptor greatly limits 
the degree of freedom of both ligand and receptor, which results in the loss of the net 
entropy of this literally close-system. Solely from the entropic viewpoint, this 
association is regarded as adverse. Therefore, highly favorable enthalpic gain, which 
is corresponded to the interactions between the receptor and the ligand, must 
compensate for the adverse entropic loss during the same association process. 
 
The selective binding of a low-molecular-weight peptide ligand to a specific protein 
receptor is determined by structural recognition of peptide ligand to its protein 
receptor and their thermodynamics parameters in the association process. The binding 
affinity can be measured from the experimentally measured binding constant Kd:   
 
ΔG = - RT ln Kd = ΔH – TΔS 
 
The experimentally determined binding constant Kd is typically in the range of 10-2 to 
10-12 M, corresponding to a Gibbs free energy of binding ΔG between -10 and -70 
kJ/mol in aqueous solutions.[4,5] 
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The enthalpic and entropic components of the binding affinity can be determined 
experimentally, e.g., by isothermal titration calorimetry (ITC). The available data 
indicate that there is always a substantial compensation between enthalpic and 
entropic contributions.[6- 78] The available data also show that the binding may be 
enthalpy-driven (e.g., streptavidin-biotin, ΔG = -76.5 kJ/mol, ΔH = -134 kJ/mol) or 
entropy driven (e.g., streptavidin-HABA, ΔG = -22.0 kJ/mol, ΔH = 7.1 kJ/mol).[8F9] 
Data from protein mutants yield estimates of 5 ± 2.5 kJ/mol for the contribution from 
individual hydrogen bonds to the binding affinity.[9F10-10F11F12] Similar values have been 
obtained for the contribution of an intramolecular hydrogen bond to protein 
stability.[12F13-13F14F15] The consistency of values derived from different proteins suggests 
some degree of additives in the hydrogen bonding interactions.  
 
Identifying a ligand to a given receptor is just the first step in the process of 
discovering a new drug that offers a therapeutic opportunity for the treatment of a 
disease.  
 
1.2 Non-Covalent Interactions between Peptide Ligands 
and Receptors 
 
1.2.1 General Introduction 
Low-molecular peptide ligands are capable of interacting with their corresponding 
macromolecular protein receptors through both covalent and non-covalent interactions. 
Non-covalent and reversible covalent binding could be normally characterized by the 
equilibrium thermodynamics of their association process. 
 
The majority of the currently available peptide ligands functions through non-covalent 
interactions with their corresponding protein receptors. Non-covalent interactions are 
therefore of particular interest in peptide ligand design and the deeper study of the 
mechanisms of non-covalent interactions should be hugely beneficial to optimize the 
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affinities of peptide ligands to their receptors. Important non-covalent interactions 
basically include hydrogen bonds, ionic interactions and hydrophobic interactions, as 
well as π-π interactions.  
 
Generally speaking, direct interactions between the protein receptor and peptide 
ligand are very important for binding. The most important direct non-covalent 
interactions are highlighted in Figure 1.1. Structural data on unfavorable 
protein-ligand interactions are sparser, despite that they are sometimes also pretty 
instructive to the design of appropriate peptide ligand candidates to some certain 
receptors. Understandably, structures of weakly binding ligands are more difficult to 
obtain and are usually considered less interesting by many structural biologists. 
However, these data are vital for the development of scoring functions. Some 
conclusion can be drawn from the available data: unpaired buried polar groups at the 
protein-ligand interfaces are strongly adverse to binding. Few buried CO and NH 
groups in folded protein fail to form hydrogen bonds.[15F16] Therefore, in the ligand 
design process one has to ensure that polar functional groups, either of the protein or 
the ligand, will find suitable counterparts if they become buried upon ligand binding. 
Another situation that leads to a decreased binding affinity is imperfect steric fit, 
leading to holes at the hydrophobic part of the protein-ligand interface. 
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Figure 1.1 Typical non-covalent interactions found in protein-ligand complexes 
 
 
1.2.2 Category of Non-covalent Interactions in the Association 
of Peptide Ligands and Protein Receptors 
 
1. Ionic (Electrostatic) Interactions 
For the protein receptor at physiological pH (generally taken as 7.4) basic amino acid 
residues such as Lys, Arg, and to a less extent, His are normally protonated and, thus, 
provide a cationic microenvironment. Acidic residues, such as Asp and Glu, are 
deprotonated and bear anionic groups under this circumstance. Ligand and receptor 
will be mutually attracted if they bear opposite charges. This electrostatic interaction 
can function across larger distances than those required for other types of interactions, 
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and it lasts longer. This electrostatic interaction could thus possibly associate the 
ligands and receptors bearing opposite charges provided a steric complementarity 
exists between them. 
 
2. Ion-Dipole and Dipole-Dipole Interactions 
The greater electronegative properties of atoms such as F, Cl, Br, I, S, N, and O, 
compared to C, will result in an asymmetric distribution of electron density and lead 
to electronic dipole in C-X bonds, where X is an electronegative atom shown above. 
These dipoles in ligand/receptor can interact with ions (dipole-ion interactions) or 
with other dipoles (dipole-dipole interactions) in the opposite counterpart of 
ligand/receptor, which contributes to the binding of ligands to their receptors. 
 
3. Hydrogen Bonds 
Hydrogen bonds could be categorized to the dipole-dipole interaction formed between 
the protons of a group X-H, where X represents an electronegative atom, while other 
electronegative atom (Y) contains a pair of non-bonded electrons. Hydrogen bonds 
are essential to maintain the structural integrity of helix and β-sheet conformation of 
peptides and proteins. Hydrogen bonds play crucially important roles in the 
recognition of ligands to their receptors. Binding affinities increase by about one 
order of magnitude per hydrogen bond. Some ligands form many hydrogen bonds 
with the protein but exhibit only very weak binding.[16F17-17F18F19] Interestingly, these ligands 
are all characterized by the absence of significant hydrophobic groups. Despite that 
the affinities they exert on binding of ligands to their receptors are not as strong as 
those from hydrophobic interaction, the existence of hydrogen bonds can increase the 
specificity of the bindings between ligands and their receptors.  
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4. Hydrophobic Interactions 
In the presence of a nonpolar molecule or region of a molecule, the surrounding water 
molecules orient themselves and, therefore, are in a higher energy state than in the 
bulk water. When two hydrophobic molecules, such as peptide ligand and its protein 
receptor, surrounded by ordered water molecules, approach each other, these water 
molecules commence to disassociate from their bound ligand/receptor and associate 
with other water molecules. This water-liberation process increases the systematic 
entropy as the water molecules are no more limited to the certain domains of the 
ligand or receptor, thus resulting in a decrease of the net Gibbs free energy, which 
stabilizes the ligand-receptor complex and in turn reinforces the binding of ligands to 
their receptors. This interaction is popularly described as hydrophobic interaction. In 
principle, this is not the type of the force that fuse the two hydrophobic 
molecules/domains of molecules, but rather an inclination to decrease the free energy 
of nonpolar molecules/groups because of the increased entropy of the surrounding 
water molecules. Hydrophobic interactions might be the most important single factor 
responsible for non-covalent interactions between the molecules in aqueous solution. 
 
NH
HO
NH
O-O
NH S
NH
OH
H
N
NH2
NH
O
O
O
O
O
O
hydrogen bond
hydrogen bond
ionic or ion-dipole interaction
hydrogen bond
hydrophobic interaction
hydrophobic 
interaction
 
Figure 1. 2 Example of potential multiple peptide-receptor interactions. 
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In Figure 1. 2 the cyclic peptide cyclo-(-Ser-Asp-Met-Ser-D-Lys-Gly-) was used as an 
example of peptide ligand to show the variety of non-covalent interactions that are 
possible. This peptide was designed in this thesis as the ligand of the membrane- 
protein receptor integrin α3β1. The binding of this cyclic peptide to integrin α3β1 could 
block the association of invasin with its membrane-protein receptor, thus inhibiting 
the internalization of invasin into mammal cell. 
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Figure 1.3 Non-covalent intra-molecular interactions in a β-hairpin peptide that sustain its 
conformation 
 
Non-covalent interactions are crucial not only to the recognition of ligand to its 
receptor, but also decisive in determining or sustaining bioconformations of peptides 
under certain circumstances. Figure 1.3 exhibits the multiple non-covalent 
intra-molecular interactions in an amphiphilic peptide which adopts β-hairpin 
conformation in halogenated alcohol solvent such as HFIP. Hydrogen bond, ionic 
interactions, and aromatic interactions, which might be either counteracting or 
stimulative, determine the conformation of this peptide jointly. Factors that jeopardize 
or promote some of these non-covalent forces would probably lead to destabilization 
or reinforcement of its original β-hairpin conformation.  
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1.2.3 Evaluation of the Non-covalent Interactions in the 
Recognition of Peptide Ligands to Protein Receptors 
 
1.2.3.1 Water Molecules in Peptide Ligand/Protein Receptor Recognition 
The biggest challenge in the quantitative treatment of protein-ligand interactions is 
still an accurate description of the role of water molecules. In particular, the 
contribution of hydrogen bonds to the binding affinity strongly depends on solvation 
and desolvation effects (see Figure 1.4). It has been shown by comparing the binding 
affinities of ligand pairs differing by just one hydrogen bond that the contribution of 
an individual hydrogen bond to the binding affinity can sometimes be very small or 
even adverse to binding.[19F20] Charge-assisted hydrogen bonds are stronger than neutral 
ones, but this is paid for by higher desolvation penalties. The electrostatic interaction 
of an exposed salt bridge is worth as much as a neutral hydrogen bond 
(5±1 kJ/mol),[20F 21] while the same interaction in the interior of a protein can be 
significantly larger.[21F22] 
N
H
O
H H
O
H
H
O
N
H
O
O
H
H
O
H H
CH3
O
H H
CH3
O
H
H
CH3
CH3
O
H
H
O
H H
protein
ligand
protein-ligand
complex
protein
ligand protein-ligand
complex  
Figure 1.4 Role of water molecules in hydrogen bonds (upper part) and hydrophobic interactions 
(lower part). In the unbound state (left side), the polar groups of the ligand and the protein form 
hydrogen bonds to water molecules. These water molecules are replaced upon complex formation. 
Total number of hydrogen bonds does not change. In contrast, the formation of hydrophobic contact 
increases the total number of hydrogen bonds due to the release of water molecules from the 
unfavorable hydrophobic environment. 
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1.2.3.2 Electrostatic Interactions in Peptide Ligand/Protein Receptor 
Recognition 
Our current knowledge indicates that unpaired buried polar groups at the 
protein-ligand interface are strongly adverse to binding. A statistical analysis of 
high-resolution protein structures showed that in protein less than 2% of the polar 
atoms are buried without forming a hydrogen bond.[22F23] 
 
1.2.3.3 Hydrophobic Interactions in Peptide Ligand/Protein Receptor 
Recognition 
Hydrophobic interactions are essentially contacts between apolar parts of the protein 
and the ligand. The generally accepted view is that hydrophobic interactions are 
mainly due to the replacement and release of ordered water molecules and are 
therefore entropy-driven.[23F24,24F25] The entropy gain is obtained when the water molecules 
are no longer positionally confined. There are also enthalpic contributions to 
hydrophobic interactions. Water molecules occupying hydrophobic binding sites are 
unable to form hydrogen bond. If they are released, they can form strong hydrogen 
bonds with bulk water. It has been shown in many cases that the contribution to the 
binding affinity is proportional to the hydrophobic surface area buried from solvent 
with values in the range of 80-200 J/(mol Å2).[ 25F26,26F27] 
 
Many protein-ligand complexes are characterized by the presence of both polar and 
hydrophobic interactions. The bound conformation of the ligand is determined by the 
relative importance of these contributions. The process of forming a complex between 
a small molecule ligand and a protein is a complex equilibrium process. A solvated 
ligand likely exists as an equilibrium mixture of several conformers; likewise the 
solvated protein also exists as several conformers in equilibrium. To form a complex 
the solvent molecules that occupy the binding sites are displaced by the ligand to 
produce a solvated complex. Tight complexes will result when the protein-ligand 
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interactions are significantly stronger than the interactions of the protein alone and 
ligand alone with solvent. Small variations in complex stability measured in kJ/mol 
translate into significant differences in ligand affinity for a protein.  
 
1.2.4 Empirical Approaches in the Design of Peptide Ligands 
 
1.2.4.1 General Experiences of the Tight Associations of Peptide Ligands 
and Protein Receptors 
 
What are the most important properties that allow a peptide ligand to bind tightly and 
selectively to a protein receptor? Our current understanding of protein-ligand 
interactions is still far from being sufficient to answer this question fully. The most 
important prerequisite appears to be a good steric and electronic complementarity 
between protein and ligand. However, due to desolvation effects this criterion alone is 
not sufficient to fully describe tight binding of ligands. 
 
Basically, there are several features found in all complexes of tightly binding ligand: 
 
1. There is a high level of steric complementarity between the peptide ligand and 
protein receptor. This observation is also described as the lock-and-key paradigm. 
2. There is usually high complementarity of the surface properties between the 
protein receptor and the ligand. Many tight binding ligands form significant 
hydrophobic interactions with the protein receptor. If the hydrophobic contact 
surface can be enlarged by an additional hydrophobic substituent, enhanced 
binding affinity is frequently observed. Therefore, the search for unoccupied 
hydrophobic pockets should always be one of the first steps in the design of new 
ligands. Hydrophobic parts of the ligands are most frequently found to be in 
contact with hydrophobic parts of the protein receptor. Polar groups are usually 
paired with suitable polar protein groups to form hydrogen bonds or ionic 
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interactions. A burial of unpaired polar groups upon ligand binding leads to a loss 
of binding affinity and should be avoided. With very few exceptions, there are no 
repulsive interactions between the ligand and the protein. 
3. Additional hydrogen bonds do not always lead to improved binding affinities but 
may be nevertheless able to improve the selectivity and to make the compound 
more water soluble. 
4. The binding of a ligand to a protein receptor always leads to the displacement of 
water molecules. If the ligand can form more hydrogen bonds than the water 
molecules that are released, then a very tight binding can be achieved. 
5. The ligand usually binds in an energetically favorable conformation. Rigid ligands 
can bind more strongly than flexible ligands because the entropy loss due to the 
freezing of internal degrees of freedom is smaller. 
6. Water can form strong hydrogen bonds but is not particularly well suited as a 
transition metal ligand. For transition metal-containing enzymes such as 
metalloproteases, it is therefore a good idea to incorporate functional groups into 
the ligands that are known to bind well to metal ions (e.g. thiols, hydroxamic 
acid). 
 
1.2.4.2 Approaches to Structure-Based Ligand Design 
Structure-based ligand design basically originated from the thorough research of 
certain target receptor molecule. In most of these cases this knowledge is resided in 
the natural substrate, a cofactor or the extracellular protein receptor. In some cases, 
such prototype molecules could possibly lead directly to derivative compounds with 
drug properties. In other cases, structural resemblance to a known ligand is too elusive 
to be carried out (structurally too complex, too difficult to synthesize, unwanted 
physicochemical properties, ect.) and alternative design approaches are favored. 
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Ligands Derived from Substrate or Natural Ligand 
For most of the targets, the natural substrate or ligand is luckily known. Structural 
analogs of the substrate can serve as inhibitors if they are no longer processed or 
transformed by the enzyme. In other cases, modified mimetics of natural ligands 
could lead to antagonists or agonists of their corresponding protein receptors. 
Typically, natural ligands of protein receptor can be modified to improve its affinity to 
the receptor, increase the selectivity, or optimize the physicochemical properties.  
 
Structures Derived from 3D Database Searchers 
Since the pharmacological action is mediated through the 3D shape of the ligand 
molecule in the receptor-bound conformation, efforts have been made to construct 
low-energy 3D structures from 2D databases. A pharmacophore hypothesis can be 
derived from a series of known inhibitors and their consensus 3D features. From this 
technology the molecules with lead structure could be designed and derived. A lot of 
computer-assisted program such as Catalyst have been invented and applied to 
generate a pharmacophore hypothesis using a number of reference compounds as 
input. 
 
De-novo Design of Ligands 
The sequence and structure information in biostructure research is growing 
exponentially. Increasingly, we find ourselves in a situation where the structure of an 
enzyme or a receptor protein is known and suggestions for new inhibitors are 
desirable. This is where so-called de-novo design tools are applied.[27F 28 ] In this 
approach to structure-based design, it is attempted to construct new molecules 
completely from scratch. These tools either build up candidate ligands from atoms or 
fragments, or they search databases of existing structures for complementary 
molecules. 
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2 Peptides as Integrin Ligands 
 
 
2.1 Integrins 
Integrins form a protein family present in many animal cells. They are permanently 
attached to the enclosing or separating tissue called the plasma membrane, which acts 
as a barrier around a cell. Proteins such as integrin, that are permanently attached to a 
0Hbiological membrane such as the plasma membrane, are called integral membrane 
proteins. The plasma membrane is composed of lipid molecules, such as 1Hfats, and is 
semipermeable. 
 
Integrins play a role in the attachment of cells to other cells, as well as in the 
attachment of a cell to the 2Hextracellular matrix. Besides the attachment role, integrins 
also mediate 3Hsignal transduction, a process by which a cell tranforms one kind of 
signal or stimulus into another. The signal that the integrin converts comes from the 
extracellular matrix to the cell. 
 
There are many types of integrin, and many cells have multiple types on their surface. 
Integrins are of vital importance to all 4Hanimals and have been found in all animals 
tested, from sponges to mammals. Integrins have been extensively studied in humans. 
Other types of 5Hprotein that play a role in cell-cell and cell-matrix interaction and 
communication are 6Hcadherins, 7HCAMs and 8Hselectins. 
 
Integrins are approximately 280 Å long heterodimeric membrane glycoproteins, 
composed of an α- (150 to 180 kD) and a β- (~90 kD) subunit, both of which are type 
I membrane proteins.[28F29] 19 α and 8 β mammalian subunits are known, which 
assemble noncovalently to give 24 different heterodimers.[15H29] Although these subunits 
could in theory associate to give more than 100 integrin heterodimers, the actual 
diversity appears to be much more restricted. Contacts between the α and β subunits 
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primarily involve their N-terminal halves, which together form a globular head, the 
remaining portions form two rod-shaped tails that also span the plasma membrane. 
Each integrin subunit has a large extracellular domain, a single membrane spanning 
domain and usually a short cytoplasmic domain (40-60 amino acids).[16H29] These short 
cytoplasmic domains of the α and β integrin subunits do not have intrinsic enzymatic 
activities, but can interact with a variety of cytoplasmic proteins, including 
cytoskeletal and signaling molecules. The α-cytoplasmic domains are highly diverse, 
whereas the β-cytoplasmic domains are somewhat conserved but they are necessary 
and sufficient for integrin-dependent signaling.[17H29] Association of α- and β-subunits 
defines distinct, although largely overlapping ligand specificity. Integrin binding to 
extracellular matrices can be classified as either RGD-dependent (binding e.g. 
fibronectin, vitronectin and fibrinogen) or RGD-independent (binding e.g. collagen 
and invasin). In addition, some integrins can bind to counterreceptors (such as 
intercellular adhesion molecules ICAMs) on adjacent cells leadings to homotypic and 
heterotypic cell-cell interaction. Like other receptors, integrins transmit signals to the 
cell interior ("outside-in" signaling), which regulates organization of the cytoskeleton, 
activates kinase-signaling cascades, and modulates the cell cycle and gene 
expression.[29F30] Unlike other receptors, ligand binding to integrins is not generally 
constitutive but is regulated to reflect the activation state of the cell. This "inside-out" 
regulation of integrin protects the host from pathological integrin–mediated 
adhesion.[30F31] It is known that inside-out and outside-in signaling are associated with 
distinct conformational changes in the integrin extracellular segment.
 
Table 2.1 compiles the members of the β1-integrin family together with their putative 
or confirmed extracellular ligands.
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Table 2.1 Extracellular ligands for β1-integrins 
 
2.2 State-of-the-art: Cyclic Peptides 
 
2.2.1 General Introduction 
Homodetic cyclic peptides are 9Hpolypeptide chains whose amino and carboxyl termini 
are themselves linked together with a peptide bond, forming a circular chain. They 
create a large family of naturally occurring or synthetic compounds which hold a 
variety of unique biological properties compared to their linear counterpart.[31F32] One 
interesting property of cyclic peptides is that they tend to be resistant to degradation 
by proteases. This property makes cyclic peptides attractive in drug design as 
scaffolds.  
 
Integrin Ligand 
α3β1 Epiligrin, Fibronectin, Reelin, Invasin, Thrombospondin, Laminin 
α4β1 
Fibronectin, Osteopontin, Invasin, VCAM-1, Prepro von 
Willebrandt factor, Coagulation factor XIII, Angiostatin, Tissue 
transglutaminase, Rotavirus 
α5β1 
Fibronectin, Fibrinogen, Invasin, Tissue transglutaminase, 
ADAM-15, -17 
α6β1 
Laminin, Sperm fertilin, Cystein-rich angiogenic protein 61, 
Fisp12/mCTGF, Papilloma virus, Invasin 
αvβ1 
Fibronectin, Invasin, Vitronectin, TGFβ latency-associated peptide, 
Parechovirus 
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Furthermore, the cyclization of the linear precursor peptide could possibly lock the 
peptide inhibitor in an advantageous conformation, thus decreasing the relevant 
entropy loss upon its binding to the receptor, enhancing its binding affinity. The 
constrained geometry of cyclic peptides is understandably capable of locking the 
referred peptides in a favorable and stable conformation as the bioactivities are 
concerned. The cyclic peptide scaffolds have gained extreme importance as templates 
for turn-forming peptide structures. Unusual amino acids residues, such as β-amino 
acids, γ-amino acids, D-amino acids, α,β-didehydro amino acids,  N-alkyl amino 
acids, proline and analogues, and Cα,α-disubstituted amino acids, are frequently 
incorporated into the natural or synthetic cyclic peptides, resulting in peptides with 
certain geometry. These special properties of cyclic peptides afford the drug designer 
a superb idea reservoir to construct peptide ligands with biologically active 
conformations. Structure-activity relationship studies on bioactive cyclic peptides are 
one of the main interests concerning these special peptides, which include 
conformational explorations with respect to peptide ligand/receptor interaction, since 
the ring closure of linear precursor peptides could possibly bring forward some 
special conformational properties and improved bioactivities. Cyclic peptides serve as 
models of protein-recognition motifs, and are used to mimic β-sheets, β-hairpins, 
β-turns, or γ-turns. These properties of cyclic peptides have already been fused into 
the study of structure-based ligand design. 
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2.2.2 Examples of Cyclic Peptide Ligands with -Arg-Gly-Asp-  
Recognition Motif 
2.2.2.1 Cilengitide: cyclo-(-Arg-Gly-Asp-D-Phe-N-Me-Val-) 
Among the cyclic peptides bearing biological activities, those with -Arg-Gly-Asp- 
motif are most intensively researched. Cilengitide (see Figure 2.1) is one of the most 
known examples of this family. It is a cyclic pentapeptide containing -Arg-Gly-Asp- 
motif, designed and synthesized at Technical University Munich in collaboration with 
Merck KGaA in Darmstadt.[32F33] 
HNNH
NH
N
HN
O
O
O
O
O OH
O
NHHN
NH2  
Figure 2.1 Cyclic pentapeptide Cilengitide: cyclo-(-Arg-Gly-Arg-D-Phe-N-Me-Val-) 
 
Inhibitors with the -RGD- sequence locked in a favorable conformation have been 
extensively studied as potential competitors against some natural ligands of the 
integrin family, since integrin receptors frequently recognize a primary peptide 
sequence, -Arg-Gly-Asp-, with certain conformation in their target ligands. 
Cilengitide, with the sequence cyclo-(-Arg-Gly-Asp-D-Phe-N-Me-Val-), was found to 
be a highly active ligand addressing integrin αvβ3, which is expressed by endothelial 
cells and plays a role in the attachment of endothelial cells to the extracellular matrix. 
Cilengitide was proved to exhibit high affinity to integrin αvβ3 and integrin α5β1 
in vitro.[33F34] Inhibition of integrin αvβ3 activity by cyclic RGD peptides has been shown 
to induce endothelial apoptosis,[34F35] inhibit angiogenesis,[35F36,36F37] and increase endothelial 
monolayer permeability.[37F 38 ] The inhibition of integrin αvβ3 activity has been 
associated with decreased tumor growth in breast cancer xenografts and melanoma 
xenografts.[38F39,39F40] 
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2.2.2.2 Cilengitide Derivatives: cyclo-(-Arg-Gly-Asp-(±)-β-Acc-Val-) 
On the basis of the finding of cilengitide, the research group of Prof. Sewald decided 
to optimize the acitivity of the peptide inhibitor with -RGD- primary sequence. For 
the rational design of a peptide with improved biological activity, the elucidation of 
the three-dimentional structure is highly necessary, in order to establish a 
structure-activity relationship. The idea of spatial screenings of peptides and 
peptidomimetics is an important concept,[40F41] which applied the concerned peptides 
with diverse conformations in order to search the bioactive conformation of peptide 
ligand. 
 
It is known that the incorporation of a β-amino acid residue in a cyclopeptide may 
stabilize its conformation, leading to a possible improved activity of concerned 
peptide ligand through the entropy effect, provided that the receptor-bound 
conformation of the peptide ligand remained obtainable. If a β-amino acid residue is 
incorporated into a cyclopentapeptide, it would preferentially occupy the central 
position of a γ-turn, which is elongated by a methylene group compared with a regular 
γ-turn, named derivatively as pseudo-γ-turn (Ψγ).[41F42] A binding motif, such as -RGD- 
sequence could be combined with a secondary structure inducer like D-amino acid, 
N-alkyl amino acid, or β-amino acid in order to engender a more favorable 
conformation as bioactivity is concerned. 
 
Inspired by this methodology, derivatives of cis-β-aminocyclopropane carboxylic acid 
(β-Acc)[42F43-43F44F45F46] were introduced into the target peptides (see Figure 2.2).  Two cyclic 
pentapeptides containing (+)-β-Acc or (-)-β-Acc, as well as -RGD- motif as 
derivatives of cilengitide were synthesized, and tested in cell adhesion assay. These 
two peptides, with the sequence cyclo-(-Arg-Gly-Asp-(+)-β-Acc-Val-) 1 and 
cyclo-(-Arg-Gly-Asp-(-)-β-Acc-Val-) 2, respectively, were evaluated in cell adhesion 
assays with two cancer cell lines WM115 and K562. Adhesion of K562 and WM115 
cell lines to their ligands fibronectin and vitronectin is predominantly mediated by 
integrin α5β1 and integrin αvβ3, respectively.[46F47] The ability of the RGD peptides 1 and 
2.2 State-of-the-art: Cyclic Peptides 
 20 
2 to inhibit the adhesion of the K562 and WM115 cells to their ligands was compared 
to the previously described peptides cyclo-(-Arg-Gly-Asp-D-Phe-Val-) 3 and 
cyclo-(-Arg-Gly-Asp- D-Phe-β-Ala-) 4 as references. 
 
It turned out that peptide 1 showed 10 fold higher affinity biological activity[47F48] than 
the reference peptide 3,[18H41] as inhibition of adhesion of WM 115 cells to vitronectin 
through integrin αvβ3 is concerned. The inhibition capacity of 2 in this regard is nearly 
comparable to 3. Peptide 4 displayed rather moderate influence on WM115 cell 
adhesion to vitronectin. Integrin α5β1 mediated cell adhesion of K562 cells to 
fibronectin was nearly equally inhibited by peptides 1 and 2.[19H48] In this assay both 
peptides 1 and 2 were approximately five- to sixfold more active than reference 
peptide 4, which in turn was about twice as active as peptide 3.[20H48] 
 
The significantly increased affinity of the RGD peptide 1 to integrin αvβ3 is 
interpreted as a consequence of the introduction of the rigid β-Acc derivative, with 1 
as the most active ligand of the integrin αvβ3 investigated so far.[21H48] 
 
COOH
COOHH2N
COOH
COOHH2N
(+)-β-Acc (-)-β-Acc  
Figure 2.2 Secondary structure inducer: (+)-β-Acc and (-)-β-Acc 
 
Through the introduction of cyclic β-amino acid (+/-)-β-Acc, the conformation of 
their parent cyclopentapeptide were enormously restricted. In peptide 1 Gly was 
locked in the central position of a γ-turn, while (+)-β-Acc was resided in i+1 position 
of a pseudo-β-turn. In peptide 2 Asp was locked in the central position of a γi-turn. 
This structure has the torsion angle of a 310-helix between the residue (-)-β-Acc and 
Gly, which was originally characterized as βIII-turn, in which the Val and Arg resided 
in i+1 and i+2 positions, respectively.[22H48] (see Figure 2.3)  
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This project shows the important roles cyclic peptide play as conformational restricted 
ligands to certain receptors. The underlying structure-activity relationship and diverse 
conformational propensity of amino acid residues afford abundant valuable 
informations for the structure-based design of peptide drugs. 
Val Arg
Gly
Asp
(-)-β-Acc
β III/310-Helix
γi
Glyψ β γ
Arg
Asp
(+)-β-Acc
Val
(1)
(2)
 
Figure 2.3 Schematic structures of peptide 1 and 2 obtained by NMR and molecular dynamic  
calculations  
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2.3 Internalization of Yersinia Sp. through Integrins 
 
2.3.1 General Introduction of Yersinia 
Yersinia is a genus of Gram-negative rod shaped bacteria in the family 
Enterobacteriaceae. It is a few micrometers long and fractions of a micrometer in 
diameter, and is facultative anaerobe.[48F49] Some members of Yersinia are pathogenic to 
humans. Rodents are the natural reservoirs of Yersinia; less frequently other mammals 
serve as the host. Infection may occur either through blood (in the case of Yersinia 
pestis) or in an alimentary fashion, through occasionally via consumption of food 
products (especially vegetables, milk-derived products and meat) contaminated with 
infected urine or feces.[23H49] 
 
There are three human-pathogenic Yersinia species: Yersinia pestis, Yersinia 
enterocolitica and Yersinia pseudotuberculosis. 
 
2.3.1.1 Yersinia pseudotuberculosis 
 
Yersinia pseudotuberculosis is a Gram-negative bacterium which primarily causes 
disease in animals; humans occasionally get infected zoonotically, most often through 
the food-borne route.[24H49] Yersinia pseudotuberculosis is the least common of the 3 
main Yersinia species to cause infections in humans. It is primarily a zoonotic 
infection with variable hosts, including domestic and sylvatic animals and birds. The 
condition has been associated with food-borne infection, including a few outbreaks. 
The organism primarily leads to a gastroenteritis (diarrheal component 
uncharacteristic) characterized by a self-limited mesenteric lymphadenitis that mimics 
appendicitis.[49F50] The organism invades mammalian cells and survives intracellularly; 
the primary virulence factor is a plasmid-encoded protein that causes increased 
invasiveness. Postinfectious complications include erythema nodosum and reactive 
arthritis.[50F 51] Thus, a major triad for infection with this organism include fever, 
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abdominal pain, and rash. Rarely, it has been associated with septic complications 
(often in patients who are immunocompromised with chronic liver diseases). 
 
In animals, Y. pseudotuberculosis can cause tuberculosis-like symptoms, including 
localized tissue necrosis and granulomas in the spleen, liver, and lymph node.[25H51] In 
humans, symptoms are similar to those of infection with Y. enterocolitica (fever and 
right-sided abdominal pain), except that the diarrheal component is often absent, 
which sometimes makes the resulting condition difficult to diagnose. Y. 
pseudotuberculosis infections can mimic appendicitis, especially in children and 
younger adults, and, in rare cases the disease may cause skin complaints (erythema 
nodosum), joint stiffness and pain (reactive arthritis), or spread of bacteria to the 
blood (bacteremia).[51F52] 
 
Infection usually becomes apparent 5–10 days after exposure and typically lasts 1–3 
weeks without treatment.[52F53] In complex cases or those involving immunocompromi- 
sed patients, antibiotics[26H53] may be necessary for resolution; ampicillin, amino- 
glycosides, tetracycline, chloramphenicol, or a cephalosporin may all be effective. 
 
The recently described syndrome Izumi-fever has been linked to infection with 
Y .pseudotuberculosis.[53F54] 
2.3.1.2 Yersinia enterocolitica 
Yersinia enterocolitica is a species of gram-negative coccobacillus-shaped bacterium, 
belonging to the family Enterobacteriaceae. It causes primarily a 10Hzoonotic disease 
(cattle, deer, pigs, and birds); animals which recover frequently become asymptomatic 
carriers of the disease.[54F55] 
 
Acute Y. enterocolitica infections produce severe diarrhea in humans, along with 
Peyer's patch necrosis, chronic 11Hlymphadenopathy, and hepatic or splenic abscesses. 
Additional symptoms may include entero-colitis, fever, mesenteric adenitis, erythema 
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nodosum and acute terminal ileitis, which may be confused with appendicitis or 
Crohn's disease.[55F56]  
 
Treatment of Y. enterocolitica infections requires aggressive antibiotic therapy, 
typically involving a combination of chloramphenicol, ampicillin, and polymyxin.[ 27H55]  
 
Y. enterocolitica infections are sometimes followed by chronic inflammatory diseases 
such as arthritis.[28H49] Y. enterocolitica seems to be associated with autoimmune 
Graves-Basedow thyroiditis.[56F 57 ] Whilst indirect evidence exists, direct causative 
evidence is limited,[57F58] and Y. enterocolitica is probably not a major cause of this 
disease, but may contribute to the development of thyroid autoimmunity arising for 
other reasons in genetically susceptible individuals.[58F59] It has also been suggested that 
Y. enterocolitica infection is not the 12Hcause of auto-immune thyroid disease, but rather 
is only an 13Hassociated condition; with both having a shared inherited susceptibility.[59F60]  
2.3.1.3 Yersinia pestis 
Yersinia pestis is a Gram-negative facultative anaerobic bipolar-staining (giving it a 
safety pin appearance) bacillus bacterium belonging to the family 
Enterobacteriaceae.[29H55] The infectious agent of bubonic plague, Y. pestis infection can 
also cause pneumonic and septicemic plague.[30H49] All three forms have been responsi- 
ble for high mortality rates in 14Hepidemics throughout human history, including the 
Great Plague and the Black Death. 
 
Pathogenicity of Y. pestis is in part due to two anti-phagocytic antigens, named F1 
(Fraction 1) and V, both important for virulence.[31H55] These antigens are produced by 
the bacterium at 37 °C. Furthermore, Y. pestis survives and produces F1 and 
V antigens within blood cells such as monocytes, but not in polymorphonuclear 
neutrophils. Natural or induced immunity is achieved by the production of specific 
opsonic antibodies against F1 and V antigens; antibodies against F1 and V induce 
phagocytosis by neutrophils.[60F61] 
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The traditional first line treatment for Y. pestis has been streptomycin,[61F62,62F63] chlor- 
amphenicol, tetracycline,[63F64] and fluoroquinolones. There is also good evidence to 
support the use of doxycycline or gentamicin.[64F65] 
 
It should be noted that strains resistant to one or two agents specified above have been 
isolated: treatment should be guided by antibiotic sensitivities where available. 
Antibiotic treatment alone is insufficient for some patients, who may also require 
circulatory, ventilatory, or renal support. 
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2.3.2 Invasin 
 
2.3.2.1 Entry into Mammalian Cells by Yersinia pseudotuberculosis 
The interaction of bacterial pathogens with host cells is an important step in the 
establishment of a productive infection. Bacterial adhesion to the mammalian cell 
surface allows either extracellular colonization[65F66-66F67F68] or penetration within the host 
cell.[68F69-69F70F71F72] Once internalized, the pathogen may replicate within the protective niche of 
the cell or translocate into deeper tissues where multiplication occurs.[72F73,73F74]  
invasin
(membrane domain)
invasin
(extracellular domain)
 
Figure 2.4 Invasin-mediated Yersinia Internalization.[ 74F75] 
 
The latter strategy is used by the enteropathogenic bacterium Yersinia 
pseudotuberculosis.[75F76-76F77F78] Yersinia pestis and Y. enterocolitica are entero- pathogenic 
Gram-negative bacteria that cause gastroenteritis when they are translocated across 
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the intestinal epithelium at Peyer’s patches by way of M cells.[78F79] Translocated 
bacteria enter the lymphatic system and colonize the liver and spleen, where they 
grow mainly extracellularly.[79F80] Y. pseudotuberculosis is internalized by normally 
nonphagocytic cultured mammalian cells via two pathways.[80F81] The best studied and 
most efficient of these mechanisms is mediated by the bacterial protein invasin.[81F82] 
Members of the invasin family of proteins are found in a variety of enteropathogens, 
each of which contributes to the interaction with host cells.[82F83,83F84]  
 
Invasin mediates entry into eukaryotic cells by binding to members of the β1 integrin 
family that lack I, or insertion, domains, such as α3β1, α4β1, α5β1, α6β1, and αvβ1[84F85] 
(see Figure 2.4). Integrins are heterodimeric integral membrane proteins that mediate 
communication between the extracellular environment and the cytoskeleton by 
binding to cytoskeletal components and either extracellular matrix proteins or cell 
surface proteins.[85F86] Invasin binding to β1 integrins is thought to activate a reorgani- 
zation of the host cytoskeleton to form pseudopods that envelop the bacterium.[ 86F87] 
Another family of enteropathogenic bacterial proteins related to invasin, the intimins, 
does not appear to use integrins as its primary receptors for invasin.[87F88] Instead, 
intimins mediate attachment of the bacteria to host cells by binding to a bacterially 
secreted protein Tir, which upon secretion becomes inserted into the host 
membrane.[32H88] 
 
2.3.2.2 Structure of Invasin 
Yersinia pseudotuberculosis invasin is a 986-residue protein. The approximately 500 
NH2-terminal amino acids, which are thought to reside in the outer membrane,[88F89] are 
related (~36% sequence identity) to the analogous regions of intimins.[ 89F 90 ] The 
COOH-terminal 497 residues of invasin, which make up the extracellular region, can 
be expressed as a soluble protein (Inv497) that binds integrins and promotes uptake 
when attached to bacteria or beads.[90F91] The shortest invasin fragment capable of 
binding integrins consists of the COOH-terminal 192 amino acids.[33H89] This fragment is 
not homologous to the integrin-binding domains of fibronectin [the fibronectin type 
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III repeats 9 and 10 (Fn-III 9–10)],[34H90] although mutagenesis studies and competition 
assays indicate that invasin and fibronectin bind to α3β1 and α5β1 integrins at the same 
or overlapping sites.[91F92] The integrin-binding region of invasin also lacks significant 
sequence identity with the corresponding regions of intimins (~20% identity).[35H90] To 
gain insight into enteric bacterial pathogenesis and to compare the structural basis of 
integrin binding by invasin and Fn-III domains, the crystal structure of Inv497 was 
solved by Isberg et al.[92F93] 
 
Inv497 was expressed in Escherichia coli and purified.[36H91] The structure was solved to 
2.3 Å by multiple isomorphous replacement with anomalous scattering.[93F94,94F95] Inv497 
is a rodlike molecule with overall dimensions of ~180 Å × 30 Å × 30 Å (see 
Figure 2.5 A), consistent with analytical ultracentrifugation analyses suggesting an 
extended monomeric structure of the fragment in solution.[37H93] The Inv497 structure 
overall resembles that of another α5β1-binding fragment, Fn-III repeats 7 through 10 
(Fn-III 7–10),[95F96] as they are both elongated molecules composed of tandem domains. 
The first four Inv497 domains (D1, D2, D3, and D4) are composed mainly of 
β-structure, and the fifth domain (D5) includes α-helices and β-sheets. Despite only 
20% sequence identity, [38H90] the D3 to D5 region of Inv497 is structurally similar to a 
280-residue fragment of the extracellular portion of enteropathogenic E. coli 
intimin.[39H96]  
 
The four NH2-terminal domains of Inv497 adopt folds resembling eukaryotic 
members of the immunoglobulin superfamily (IgSF),[96F97] although the Inv497 domains 
do not share significant sequence identity with IgSF domains and lack the disulfide 
bond and core residues conserved in IgSF structures.[40H90,41H97] D1 belongs to the I2 set of 
the IgSF, and D2 and D3 belong to the I1 set.[42H97] D4 adopts the folding topology of the 
C1 set of IgSF domains, a fold seen in the constant domains of antibodies, T cell 
receptors, and major histocompatability complex (MHC) molecules.[43H97] Unlike these 
C1 domains, D4 of Inv497 includes a 15–amino acid insertion between strands A and 
B that forms two additional β-strands (see Figure 2.5 B). D1 and D2 of the intimin 
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fragment are also Ig-like, and the second domain includes an insertion similar to that 
found in Inv497 D4.[ 44H96] 
 
Inv497 D5 is composed of two antiparallel β-sheets with interspersed α helical and 
loop regions and includes a disulfide bond linking helix-1 to β-strand 5 (see 
Figure 2.5 B). 
                   
 
 
Figure 2.5 (A) Ribbon diagram of the structure of Y. 
pseudotuberculosis Inv497. Residues implicated in integrin binding 
[Asp911, Asp811, and possibly Arg883] are green. The α-helical 
regions in D5 and a 310-helix in D4 are red. The disulfide bond in D5 is 
yellow, and β-strands are blue (D4 and D5) or green (D1 through D3).  
 
(B) Topology diagrams for domains of invasin and related proteins. 
Inv497 D5 is shown beside a canonical C-type lectin CRD [from 
E-selectin]; Inv497 D4 is shown beside a C1-type IgSF domain. The 
β-strands are blue, helices are red, and disulfide bonds are yellow. The 
calcium-binding loop in E-selectin (residues 54 to 89) and its truncated 
counterpart in Inv497 (residues 956 to 959) are green. [ 45H79] 
 
Extensive interactions between Inv497 D4 and D5 create a 
superdomain that is composed of the 192 residues identified as necessary and 
sufficient for integrin binding.[46H89] The interface between D4 and D5 is significantly 
larger than the interfaces between tandem IgSF domains and between the Ig-like 
invasin domains (D4 to D5 buried surface area is 1925 Å2 in comparison with ~500 
Å2 for IgSF interfaces).[47H79] The D4-D5 interface is predominantly hydrophobic, 
although a number of hydrogen bonds are also present (see Figure 2.6).  
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The large buried surface area at the D4-D5 interface (see Figure 2.5 A) and the 
consequent rigidity of this portion of invasin contrasts with the flexibility between the 
integrin-binding portions of fibronectin, inferred from interdomain buried surface 
areas that are lower than average at these interfaces (Fn-III 9–10 and 
Fn-III 12–13).[48H79,49H96] Interdomain flexibility in fibronectin was proposed to facilitate 
integrin binding[50H97] and is also observed in the structures of two other integrin-binding 
proteins, ICAM-1[51H96] and VCAM-1.[52H96] However, invasin, which shows little or no 
interdomain flexibility in its integrin-binding region, binds at least five different 
integrins and binds α5β1 with an affinity that is ~100 times that of fibronectin.[53H87,54H92] 
High-affinity binding of invasin is necessary for bacterial internalization, as studies 
have shown that bacteria coated with lower affinity ligands for α5β1 bind, but do not 
penetrate, mammalian cells.[55H87,56H92]  
 
Figure 2.6 Comparison of interdomain interfaces in integrin-binding regions of Inv497 (D4-D5), 
fibronectin type III repeats 9 and 10 (D9-D10),[ 57H96] and VCAM-1 (D1-D2). Hydrogen bonds are shown 
as dashed yellow lines. Additional hydrogen bonds, van der Waals contacts, and a three- to fivefold 
larger interdomain surface area stabilize Inv497 D4-D5 and restrict interdomain flexibility, compared 
to the other interfaces. [ 58H79] 
 
Invasin residues that are important for integrin binding include 903 to 913,[59H89,97F98] which 
form helix 1 and the loop after it in D5. Although invasin lacks an -Arg-Gly-Asp- 
(RGD) sequence, which is critical for the interaction of Fn-III 10 with integrins,[60H86] an 
aspartate in Inv497 D5 (Asp911) is required for integrin binding.[61H89,62H98] Like the 
aspartate in the Fn-III RGD sequence, Asp911 is located in a loop (see Figure 2A and 
4B). Other host proteins, such as VCAM-1 and MAdCAM-1, which bind integrins 
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that lack I domains, also contain a critical aspartate residue on a protruding loop.[63H97] A 
second region of invasin that is ~100 amino acids apart from Asp911 contains 
additional residues that are implicated in integrin binding, including Asp811 (see 
Figure 2.5 A and 2.7 B).[64H98] This region of invasin is reminiscent of the fibronectin 
synergy region located in Fn-III 9, which is required for maximal α5β1 
integrin-dependent cell spreading.[98F99] Invasin Asp811 is located in D4 and lies on the 
same surface as Asp911, separated by approximately 32 Å (measured between 
carbon-α atoms). The distance between Fn-III 10 Asp1495 in the RGD sequence and 
Fn-III 9 Asp1373 in the synergy region is also 32 Å,[ 65H80] although the side-chain 
orientation of Asp1373 differs from that of Asp811 in invasin (see Figure 2.7). 
Within the Fn-III synergy region, a critical residue for integrin binding is Arg1379 
[32 Å from Asp1495 (see Figure 2.7 B)].[ 66H99] The invasin synergy-like region also 
includes a nearby arginine, Arg883 [32 Å from Asp911 (see Figure 2.7 B)]. The 
overall similarity in the relative positions of these three residues suggests that invasin 
and host proteins share common integrin-binding features. 
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Figure 2.7 Comparison of integrin-binding regions of invasin and fibronectin. Despite different folding 
topologies and surface structures, the relative positions of several residues implicated in interactions 
with integrins are similar [Asp811, Asp911, and Arg883 in Inv497; Asp1373, Asp1495, and Arg1379 
in Fn-III 9 and 10; (aspartates are red; arginines are blue)]. 
(A) Surface representations of the structures of Inv497 and Fn-III 7-10.[ 67H96]  
(B) Ribbon representations of Inv497 D4-D5 and Fn-III 9-10.[ 68H79] Addition of one or more residues to 
the COOH-terminus of invasin (indicated as “COO -”) interferes with integrin binding,[ 69H79] suggesting 
that the rather flat region between Asp811 and Asp911 is at the integrin-binding interface. By contrast, 
the integrin-binding surface of fibronectin contains a cleft resulting from the narrow link between 
Fn-III 9 and 10. 
 
The transmembrane regions of outer membrane proteins of known structure are 
β-barrels, as represented by the structures of porins.[70H89] Assuming that the 
membrane-associated region of invasin is also a β-barrel,[71H89] the structure of intact 
invasin may resemble the model shown in Figure 2.7, in which the cell-binding 
region projects ~180 Å away from the bacterial surface, ideally positioned to contact 
host cell integrins. Similarities between invasin and fibronectin demonstrate 
convergent evolution of common integrin-binding properties. However, the 
integrin-binding surface of invasin does not include a cleft, as found on the binding 
surface of fibronectin (see Figure 2.6); thus, invasin may bind integrins with a larger 
interface. Together with the restricted orientation of the invasin integrin-binding 
domains, a larger binding interface provides a plausible explanation for the increased 
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integrin-binding affinity of invasin as compared with fibronectin. Differences between 
the integrin-binding properties of invasion and fibronectin illustrate how a bacterial 
pathogen is able to efficiently compete with host proteins to establish contact and 
subsequent infection, thereby exploiting a host receptor for its own purposes.
2.4 Aims of the Cyclopeptide Invasin Inhibitor Research 
Upon the thorough study of the crystal structure of invasin, especially the domain 
responsible for binding to integrin α3β1, peptide ligands to this integrin that mimic the 
binding motif of invasin could be rationally designed, imitating both its primary 
sequence and spatial geometry. This structure-based design could generate the 
synthetic low-molecular ligands to integrin α3β1 that inhibit the association of invasin 
to its receptor, which switches off the path of the internalization of invasin, thus in 
turn blocking the invasion of human pathogenic Yersinia Sp. into the cell. If the 
synthesized peptide/peptidomimetic inhibitors possess higher or matchable binding 
affinities relative to natural ligand such as invasin, they would be capable of blocking 
the harmful association of natural ligand to their membrane receptor under 
physiological conditions, which contains underlying applications in medicine to cure 
diseases such as gastroenteritis, erythema, reactive arthritis,[72H51] Graves-Basedow 
thyroiditis,[73H57] pneumonic and septicemic plague,[74H49] which are caused by the infection 
of pathogenic Yersinia Sp.. 
 
The designed peptide inhibitors are supposed to block the interactions between the 
invasin and integrin α3β1. Ideally, the binding between the artificial peptides and 
invasin is supposed to be as strong as the interactions between the natural ligands and 
receptors. The most common peptide inhibitors are reversible, and mostly compete 
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with the substrate fro active site binding. These are known as competitive reversible 
inhibitors, compounds that have structures similar to those of the ligands (in this case 
invasin) of receptors (integrin α3β1) and which bind at the ligand binding sites, 
thereby blocking ligand binding (see Figure 2.8). Actually, these peptide inhibitors 
establish their binding equilibria with the receptors rapidly, so that inhibition is 
observed as soon as the receptor is assayed for activity, although there are some cases 
in which inhibition can be relatively slow.[99F100] A common measurement for inhibition 
is IC50 value, the inhibitor concentration that produces 50 % receptor inhibition in the 
presence of ligands. The lower the IC50 value is, the stronger and more efficient the 
inhibitor is regarding its inhibitions property.  
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Figure 2.8 Synthesized cyclic peptides as inhibitors for the binding between integrin α3β1 and invasin.  
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As is already explained, cyclization of peptide could lower the flexibility of the 
precursor linear peptide and reinforce some certain kind of secondary structure in 
cyclic peptide by introduction some special amino acid residues. This conformational 
restriction by cyclization could possibly result in the increase of biological activities 
of concerned peptides as ligands of some protein receptors.[75H48] One of the main 
purposes of this project is to rationally design the high-efficient low-molecular 
synthetic peptides as ligands to the membrane protein receptor integrin α3β1, which 
contains underlying applications in medicine domain, such as the blocking of the 
infections of pathogenic Yersinia Sp..[76H49] 
 
Through the close study of the crystal structure of invasin, which is the natural ligand 
to integrin α3β1 promoting the infection of Yersinia by internalization into the 
mammal cells,[77H82,78H85] as well as the similarity[79H92,80H96] of its binding domains with those of 
fibronectin, which is also the natural ligand of integrin α3β1,[81H87,82H92,83H97] rational design of 
peptide inhibitors to integrin α3β1 could be carried out. These structure studies 
crucially facilitate the structure-based ligand design. By mimicking the integrin 
binding regions of invasin, a library of peptide inhibitors could be rationally designed 
and synthesized, among which the lead is supposed to be screened out. Furthermore, 
through the residue substitution, the binding mechanism could be to some extent 
elucidated, which can in turn promote the optimization of ligand design. 
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2.5 Results and Discussion 
 
2.5.1 Structure-based Peptide Ligand Design 
2.5.1.1 General Introduction 
2.5.1.1.1 State-of-the-art 
The state-of-the-art design process relies, in large part, on a quantitative 
understanding of the molecular recognition of protein-ligand complexes based largely 
upon analogies to other systems. This structural information is usually obtained from 
X-ray crystal structures of the protein-ligand complex. Protein crystallography does 
not determine these structures to atomic resolution; therefore, there is some 
uncertainty in the exact position of each atom. Given a high resolution structure of a 
protein, new ligands can be designed completely de novo, in which the ligand is 
designed purely on considerations of protein structure, or more commonly, the design 
can be based on the modification of known ligands for the target protein.  
 
Crystal Structure
of Receptor
Computational Analyses
Ligand
Design
Organic Synthesis
of Ligand
Biochemical Evaluation
of Ligand Effect
Drug Lead
Crystallographic Analysis of 
Ligand-Receptor Complex
Figure 2.9 Schematic design of protein ligands as drug candidates 
 
The utilization of iterative design processes has greatly advanced the use of protein 
structure for the design of drug candidates (see Figure 2.9).[100F101,101F102] 
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2.5.1.1.2 Cyclic Peptides 
As is already elucidated, one interesting property of cyclic peptides is that they tend to 
be extremely resistant to degradation. This property makes cyclic peptides attractive 
in drug design for use as scaffolds. Furthermore, the cyclization of the linear 
precursor peptide could possibly lock the peptide inhibitor in an advantage 
conformation, thus decreasing the relevant entropy loss upon its binding to the 
receptor, promoting its binding affinity. In this project, incorporation of special amino 
acid residue into the peptide sequence and cyclization of peptides was performed in 
order to finetune the bioactive conformations for integrin α3β1 binding.   
 
2.5.1.1.3 Alanine Scan 
A rational approach to investigate the role which the ligand plays is the alanine scan, a 
method frequently used to screen the amino acid sequence of peptide ligands for the 
contribution of each residue to the receptor-ligand interaction. In an alanine scan, 
every single amino acid of a peptide's natural sequence is replaced by L-alanine. 
Alanine residues in the natural sequence are usually replaced by glycine. For example, 
a complete alanine scan of neuropeptide Y revealed residues that are important for 
NPY’s interactions with the NPY-Y1 and NPY-Y2 receptors.[102F 103] This idea and 
methodology is especially efficient to elucidate the role of the side-chain residues in 
the interaction between the ligand and receptor, since the substitutions of these amino 
acid residues in the natural sequence by alanine eliminate the potential interactions 
between the ligand and receptor while holding the structure of the original peptide 
ligand basically untouched. 
 
Based on the findings from an alanine scan, further peptides can be synthesized in 
which residues involved in the receptor recognition are substituted by homologous 
amino acids in order to improve the binding affinity between the ligand and receptor. 
Interesting in this context is also the use of conformationally constrained analogues in 
which amino acid residues such as the helix breaker proline or the turn-inducing 
motive Ala-Aib are introduced into the natural peptide sequence. 
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2.5.1.2 Design of Peptides as Inhibitors for the Binding between Invasin 
and Integrin α3β1 
2.5.1.2.1 Design of the Cyclic Peptide/Peptidomimetic Templates 
The integrin binding motif consists of one loop region with conservative Asp911 
residue and two synergistic regions. The critical Asp911 residue is found in i+1 
position of the β turn in the sequence -Ser-Asp-Met-Ser- (see Figure 2.10) 
 
 
Figure 2.10 Binding Epitope of Invasin with Crucial Asp on i+1 Position in β turn 
 
In this project, peptides and peptidomimetics would be designed to mimic the binding 
moieties in invasin which are responsible for the specific binding to its correlative 
receptor, namely integrin α3β1, resided on cell surfaces. The crucial primary sequence 
-Ser-Asp-Met-Ser- found in invasin, which is assumably responsible for the specific 
binding to integrin α3β1, is supposed to be included in the designed peptide or 
peptidomimetic inhibitors. Moreover, according to the crystal structure of the native 
invasin, the corresponding fragment of this sequence adopts a β-turn strcture in which 
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the crucial aspartate residue is locked in i+1 position. The design of peptide inhibitors 
should hence take this information into account. The synthesized peptide inhibitors 
should not only fuse the -Ser-Asp-Met-Ser- moiety into their primary sequence, but 
also guarantee that that this binding moiety be locked in a active conformation. 
 
The cyclo-(-Ser-Asp-Met-Ser-D-Lys-Gly-) peptide was synthesized as template 
inhibitor of invasin binding to β1 integrins such as integrin α3β1 which is applied in 
this project. Peptide conformation of the recognition sequence -Ser-Asp-Met-Ser- is 
locked for binding to the integrin by incorporation of a single D-amino acid (see 
Figure 2.11). The D-amino acid induces usually a βII'-turn in a cyclic hexapeptide and 
leads to the formation of an additional complementary β-turn, in which Asp occupies 
i+1 position. 
 
N
NAsp Met
N Ser
N D-Lys
NGly
N
Ser
β
β ΙΙ'
 
Figure 2.11 Proposed Conformation of cyclo-(-Ser-Asp-Met-D-Lys-Gly-) 
 
Furthermore, a library of synthetic peptide inhibitors (Table 2.2) was synthesized with 
the aim to elucidate the interaction modes between the invasin/laminin-332 and 
integrin α3β1 through mutations of component or conformational building blocks of 
the reference peptide inhibitor cyclo-(-Ser-Asp-Met-Ser-D-Lys-Gly-) (Table 2.3). By 
2.5 Results and Disccussion 
 40 
screening the pepide library, the lead could be probably figured out, and the 
informations gathered in this process is beneficial to rationally optimize the design of 
the next generation of peptide/peptidomimetic inhibitors for integrin α3β1.  
 
Table 2.2 List of the Library of Synthetic Peptide Inhibitors without Spacers 
No. Sequence 
PI 1 H-Ser-Asp-Met-Ser-D-Lys-Gly-OH 
PI 2 H-Ser-Asp-Met-Ser-Lys-Gly-OH 
PI 3 cyclo-(-Ser-Asp-Met-Ser-Lys-Gly-) 
PI 4 cyclo-(-Ser-Asp-Met-Ser-D-Lys-Gly-) 
PI 5 cyclo-(-Ser-Asp-Met(O)-Ser-Lys-Gly-) 
PI 6 cyclo-(-Ser-Asp-Met(O)-Ser- D-Lys-Gly-) 
PI 7 cyclo-(-Ser-D-Asp-Met-Ser-D-Lys-Gly-) 
PI 8 cyclo-(-Ser-D-Asp-Met-Ser-Lys-Gly-) 
PI 9 cyclo-(-Ser-Asp-Aib-Ser-D-Lys-Gly-) 
PI 10 cyclo-(-Ser-Asp-Aib-Ser-Lys-Gly-) 
PI 11 cyclo-(-Ser-Asp-Met-Ser-Lys-Sar-) 
PI 12 cyclo-(-Ser-Asp-Met-Ser-D-Lys-Sar-) 
PI 13 cyclo-(-Ser-Glu-Met-Ser-Lys-Gly-) 
PI 14 cyclo-(-Ser-Glu-Met-Ser-D-Lys-Gly-) 
PI 15 cyclo-(-Ser-Asp-Met-Ser-Ala-Gly-) 
PI 16 cyclo-(-Ser-Ala-Met-Ser-D-Lys-Gly-) 
PI 17 cyclo-(-Ser-Ala-Met-Ser-Lys-Gly-) 
PI 18 cyclo-(-Ser-Asp-Ala-Ser-D-Lys-Gly-) 
PI 19 cyclo-(-Ser-Asp-Met-Ser-Arg-Gly-) 
PI 20 cyclo-(-Ser-Asp-Met-Ser-Gly-) 
PI 21 cyclo-(-Ser-Asp-Met-Ser-Asp-Met-) 
PI 22 cyclo-(-Ala-Asp-Met-Ser-D-Lys-Gly-) 
PI 23 H-Ser-Asp-Met-Ser-OH 
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Comparison of the binding affinity of the linear peptide PI 1 with its cyclic 
counterpart PI 4 was performed in order to find out whether the cyclization of PI 1 
could lock the inhibitor in a conformationally advantageous status. Furthermore, 
compare the binding affinity of PI 1 with its diastereomer PI 2 was carried out as well 
to identify the conformational influence of the incorporation of D-amino acid into 
cyclic hexapeptide and its effect on inhibitory capacities. Similarly, PI 2 was 
synthesized in order to compare the its binding affinity with its cyclic counterpart PI 3 
to find out whether the cyclization of PI 2 could lead to a bioactive conformation as 
inhibitory effect was concerned. Compare the binding affinity of PI 2 with its 
diastereomer PI 1 was another purpose to find out the role of configuration of lysine. 
 
Comparison of the binding affinity of PI 3 with its D-Lys-containing diastereomer 
counterpart PI 4 was performed to find out what influence it could bring forward 
when a β-turn inducer such as D-amino acid is incorporated in the reference cyclic 
hexapeptide at i+1 position of a βII'-turn and Asp is locked in i+1 position of the 
complementary β-turn.. 
 
PI 5 was synthesized to explore the role of methionine in the reference cyclic 
hexapeptide PI 3 when binding to integrin α3β1. Oxidation of methionine to its 
sulfoxide derivative could lower the hydrophobicity of the reference peptide and 
drastically increase its ability as hydrogen bond acceptor. Similarly, PI 6 was 
designed and synthesized to find out the role of methionine in the reference cyclic 
hexapeptide PI 4 when binding to integrin α3β1.  
 
PI 7 was designed and synthesized with the aim to explore the role of the 
configuration of crucial aspartate in the sequence -Ser-Asp-Met-Ser- and to find out 
the advantageous conformation as inhibition is concerned. Comparison of its 
inhibitory effect with its diastereomer counterpart PI 4 was performed. Similarly, PI 8 
was synthesized to find the role of the configuration of crucial aspartate in the 
sequence -Ser-Asp-Met-Ser-. Comparsion of its inhibitory capacity with its 
diastereomer counterpart PI 3 was carried out. 
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The incorporation of Aib into the cyclic hexapeptide PI 9 has two purposes: 
Evaluation of the role which the methionine residue plays for binding to integrin α3β1; 
the occupation of i+2 position in the βII (II')-turn motif by a α,α-tetrasubstituted 
amino acid residue such as Aib[103F104] could reinforce the stability of β-turn in which the 
crucial aspartate occupies i+1 position as is required. Comparison of the inhibitory 
capacity of PI 9 with PI 4 was performed. Similarly, comparison of the inhibitory 
capacity of PI 10 with PI 3 was carried out with the aim to elucidate the function of 
methionine upon the association of peptide ligand to integrin α3β1. 
 
The substitution of glyine by its N-alkyl amino acid such as sarcosine in the reference 
cyclic hexapeptide PI 11 could reinforce the stability of β-turn conformation at 
-Ser-Asp-Met-Ser- region, as an N-alkyl amino acid prefers to occupy the i+2 
position in the β-turn, thus locking the crucial aspartate in i+1 position of hence 
generated complementary β-turn in the cyclic hexapeptide. Comparison of the 
inhibitory capacity of PI 11 with PI 3 was performed to prove this hypothesis. 
Similarly, PI 12 was designed and synthesized in order to compare its inhibitory 
capacity with that of PI 4. 
 
The substitution of Asp by Glu increases the freedom degree of the side chain by 
introduction a extra methylene group. PI 13 was therefore designed under this 
guidance to explore the role the crucial Asp plays upon the association of the ligand 
with its receptor integrin α3β1. Comparison of the inhibitory capacity of PI 13 with its 
Asp-containing counterpart PI 3 was performed. Similarly, comparison of the 
inhibitory capacity of PI 14 with its Asp-containing counterpart PI 4 was also carried 
out. 
 
Substitution of Lys by Ala through the systematic alanine-scan is to explore the 
function of Lys upon the binding of peptide inhibitor to integrin α3β1. PI 15 was 
designed and synthesized to find out whether the cationic side chain of Lys under 
physiological conditions could establish favourable electrostatic interactions with the 
complementary binding domain on the receptor integrin α3β1. 
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Substitution of Asp with Ala by systematic alanine-scan is to explore the function of 
Asp upon the binding of peptide inhibitor to integrin α3β1. Comparison of the 
inhibitory capacity of PI 16 with PI 4 was performed. Similarly, PI 17 was designed 
and synthesized to elucidate the function of Asp upon association to integrin α3β1 
through the comparison of its inhibitory capacity with that of PI 3. 
 
Substitution of Met with Ala by systematic alanine-scan is to explore the function of 
Met upon the binding of peptide inhibitor to integrin α3β1. PI 18 was designed and 
synthesized with this purpose. Comparison of the inhibitory capacity of PI 18 with 
PI 4 was performed. 
 
Substitution of basic residue Lys with basic residue Arg is to explore the function of 
Lys upon the binding of peptide inhibitor, finding out whether electrostatic 
interactions exist at this position upon the binding of peptide inhibitor to integrin α3β1. 
PI 19 was designed and synthesized with this purpose. Comparison of its inhibitory 
capacity with those of PI 3 and PI 4 was performed. 
 
PI 20 was synthesized with the conversion of cyclic hexapeptide to pentapeptide by 
excluding Lys. This approach is to find out whether Lys is imperative in the 
association of peptide ligand to its receptor integrin α3β1. The inhibitory capacity 
could be improved by shrinking of the peptide size and restricting the flexibility of the 
concerned inhibitor which results in the decrease of entropic loss upon binding. The 
alteration of the peptide conformation by excluding lysine residue could also lead to a 
change of inhibitory capacity. 
 
Incorporation of the dual -Ser-Asp-Met-Ser- sequence in a single cyclic hexapeptide 
could possibly result in an improved inhibitory capacity, since this crucial sequence 
happens to start and end with Ser. PI 21 was therefore designed under this guidance, 
with the purpose to find out whether the inhibitory capacity could be increased since 
this motif is crucially important for the binding of peptide inhibitors to integrin α3β1. 
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Substitution of Ser with Ala through systematic alanine-scan is to explore the function 
of Ser upon the binding of peptide inhibitor to integrin α3β1. Comparison of the 
inhibitory capacity of PI 22 with PI 4 was performed. 
 
PI 23 was designed and synthesized to find out whether shortening of the inhibitor to 
linear truncated sequence SDMS could lead to an improved inhibitory capacity. 
 
2.5.1.2.2 Design of the Peptides with Scaffold 
As is already discussed in the foregoing chapter, Asp811 ad Arg883 in the native 
invasin protein could probably also participate the binding of invasin to integrin α3β1. 
These synergy regions therefore bestow the researcher another domain which could 
possibly be beneficial to peptide/peptidomimetic inhibitor design. The fusion of these 
domains into peptide/peptidomimetic inhibitors that contain the -Ser-Asp-Met-Ser- 
sequence through the rational design and reasonable spatial incorporation, taking the 
native invasin as template, could assumably enhance the affinity strength of the 
synthesized peptide/peptidomimetic inhibitors to integrin α3β1, provided that a 
accurate balance is found between the additions of binding moiety and the entropy 
effect. This optimization should be obtained by the introduction of a linker with the 
reasonable length bearing Asp/Arg on the flank to the cyclic peptide with SDMS 
binding motif (see Figure 2.12). According to the crystal structure of invasin, the 
distance between Asp911 Cα and Asp811 Cα is 31.54 Å, while that between Asp911 Cα 
and Arg883 Cα is 27.29 Å. Two categories of linkers were designed with the aid of 
Molecular Modelling in order to simulate these distances in the natural protein, as is 
shown in Table 2.3 and 2.4. In the synthesized peptide derivatives, the distance 
between Cα of aspartate in cyclic peptide and Cα of Asp/Arg on the top of the linker 
peptide is supposed to be kept similar to that in invasin through the incorporation of 
linker template with the reasonable length. Two categories of linker were designed 
based on oligo β-Ala and (Pro-Pro-Ala)n which adopt different conformation under 
physiological conditions. 
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Figure 2.12 Introduction of Linker Bearing Asp/Arg to cyclo-(-Ser-Asp-Met-Ser-D-Lys-Gly-) 
 
The distance between the Cα of Asp911 and the Cα of Asp811 in native invasin is 
approximately 31.54Å, this length falls into the range of polymerization degree 
between 5 and 7 for linker 1, namely oligo β-alanine, provided that poly β-alanine 
peptide adopts an extended conformation according to the theory (see also Table 2.3). 
 
Similarly, the distance between the Cα of Asp911 and the Cα of Arg883 Cα in native 
invasion is approximately 27.29 Å. This length falls into the range of polymerization 
degree between 4 and 6 for linker1, provided that poly β-alanine peptide adopts an 
extended conformation according to the theory (see also Table 2.3). 
 
A:        c-(-Ser-Asp-Met-Ser-D-Lys (H-Arg-Linker1)-Gly-) 
B:        c-(-Ser-Asp-Met-Ser-D-Lys (H-Asp-Linker1)-Gly-) 
 
Linker1:  (β-Ala)n  extended conformation      A (n=4-6), B (n=5-7) 
 
Table 2.3 Correlation between the length of linker (β-Ala)n and degree of 
polymerization 
 
n dmax (Å) 
4 26.2 
5 30.4 
6 34.4 
7 38.4 
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On the other hand, The distance between the Cα of Asp911 and the Cα of Asp811 in 
native invasin is approximately 31.54Å, this length is in accordance with the 
polymerization degree between 8 and 10 for linker 2, namely (Pro-Pro-Ala)n, 
provided that (Pro-Pro-Ala)n adopts polyproline conformation according to the theory. 
In the same way, the distance between the Cα of Asp911 and the Cα of Arg883 Cα in 
native invasin is approximately 27.29 Å, which is in accordance with the 
polymerization degree between 7 and 9 for linker 2 (see also table 2.4). 
 
A:        c-(-Ser-Asp-Met-Ser-D-Lys (H-Arg-Linker2)-Gly-) 
B:        c-(-Ser-Asp-Met-Ser-D-Lys (H-Asp-Linker2)-Gly-) 
 
Linker2:  (Pro-Pro-Ala)n  polyproline helix φ = -79º, ψ = +149º, A (m=7-9), B 
(m=8-10) (m represents the number of amino acid residues in the linker peptide) 
 
Table 2.4 Correlation between the length of linker (Pro-Pro-Ala)n and degree of 
polymerization  
 
m dmax (Å) 
7 27.0 
8 29.6 
9 33.2 
10 35.2 
 
On these molecular modeling bases, a library of peptide inhibitors for integrin α3β1 
was designed and synthesized (Table 2.5). 
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Table 2.5 List of the Library of Synthetic Peptide Inhibitors with Spacers 
No. Sequence 
PI 24 Cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Arg-(β-Ala)4-Gly-) 
PI 25 Cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Arg-(β-Ala)5-Gly-) 
PI 26 Cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Arg-(β-Ala)6-Gly-) 
PI 27 Cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Asp-(β-Ala)5-Gly-) 
PI 28 Cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Asp-(β-Ala)6-Gly-) 
PI 29 Cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Asp-(β-Ala)7-Gly-) 
PI 30 Cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Arg-Ala-Pro-Pro-Ala-Pro-Pro-Ala-)-Gly-) 
PI 31 Cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Arg-Pro-Ala-Pro-Pro-Ala-Pro-Pro-Ala-)-Gly-)
PI 32 Cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Arg-(Pro-Pro-Ala)3-Gly-) 
PI 33 Cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Asp-Pro-Ala-Pro-Pro-Ala-Pro-Pro-Ala-)-Gly-)
PI 34 Cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Asp-(Pro-Pro-Ala)3-Gly-) 
PI 35 Cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Asp-Ala-(Pro-Pro-Ala)3-Gly-) 
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2.5.2 Synthesis of Peptides/Peptidomimetics as Inhibitors of the 
Interaction between Integrin α3β1 and Invasin 
 
2.5.2.1 General Introduction 
The peptide synthesis in this project was fulfilled by SPPS (solid-phase peptide 
synthesis) methodology according to Fmoc/tBu strategy (see Figure 2.13). The first 
amino acid was immobilized on Trityl(2-Cl) chloride resin across its carboxy group. 
For the synthesis of a cyclic peptide, the choice of the sequence of precursor linear 
peptide could be multiple and hence should be carefully balanced. In this project 
glycine was chosen as the C-terminus of the precursor linear peptide, since this 
residue is achiral and racemization upon the activation of the C-terminal component 
during the cyclization reaction could be avoided. 
 
Fmoc protecting group on the N-terminus was quantitatively removed by a secondary 
amine such as piperidine. The second Nα-Fmoc-protected amino acid was coupled 
with activation of the carboxy group by a coupling reagent such as TBTU or HATU 
with DIPEA as base. The peptide chains bound to the resin were thus elongated until 
the full sequence was completed. The thus obtained peptidyl resin was treated with 
1% TFA in DCM to liberate the fully side-chain protected peptide from the solid 
support. The synthesis of fully protected linear peptides in this project turned out to be 
smooth and problem free. Since there were almost no so-called "difficult coupling" in 
the SPPS of the concerned peptides in this project, most fully protected linear peptides 
are obtained with almost quantitative yields. 
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Figure 2.13 Strategy of SPPS 
 
This process can be done manually or by an automated peptide synthesizer (see 
Figure 2.14). Additionally, peptide synthesis was performed under microwave 
irradiation as the input energy to drive the whole process of SPPS. The irradiation of 
microwave could possibly destroy the intra/inter-molecular hydrogen bonds which 
impede the smooth elongation of the peptide chains on the resin. The introduction of 
microwave to SPPS is therefore advantageous for some certain kinds of peptide 
synthesis. In this project, however, manual synthesis also achieved comparative and 
satisfactory yields. 
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Figure 2.14 CEM Microwave Peptide Synthesizer 
 
2.5.2.2 Avoidance of the Alkylation and Oxidation of Methionine 
Residues 
Two of the main concerns in the synthesis of 
methionine-containing peptides, no matter in 
solution or on solid support, are alkylation 
and oxidation at the sulfur atom on the 
thioether side chain of the methionine. 
Carbocations generated at the side-chain 
deprotection steps are capable of provoking 
thioether alkylation reactions to give 
sulfonium salts which might undergo 
subsequent degradation reactions.[104F 105 -105F106F 107 ] 
Ox- idation of methionine 5 to the 
correspond- ing sulfoxide Met(O) 6 or even 
[O]
[O]
methionine sulfoxide
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sulfone 7 occurs in a multistep peptide synthesis (Scheme 2.1), especially under the 
acidic conditions which are applied in the final side-chain cleavage reactions, unless 
precautions are taken to operate in degassed, peroxide-free solvents under inert gas 
atmosphere. Acid-catalyzed oxidation of methionine is extremely prone to take place 
in peptide deprotection and resin-cleavage steps with strong acids. The generation of 
side-product Met(O) is usually detected with RP-HPLC, since the Met(O) derivatives, 
which are more polar with the introduction of the oxygen atom, exhibit shorter 
retention times than the non-oxidized peptides in RP-HPLC.  
 
Since the methionine resiue in the reference peptide inhibitors in this project could 
play an extremely important role in the interactions between the peptide ligand and 
receptor integrin α3β1, such as affording the necessary binding affinities and 
selectivities, it is therefore crucial to assure the thioether functional group in the side 
chain of methionine to be intact during the whole process of synthesis. Oxidation of 
thioether to sulfoxide or even sulfone could potentially reduce the binding capacities 
of the concerned peptide inhibitors, which should be definitely abstained in the 
synthetic process of this project. During the synthesis of SDMS derivative peptides, 
every single step is supposed to take place under the protection of inert gas 
atmosphere such as argon. When a potential peroxide-containing solvent such as ethyl 
ether was applied in the process of the peptide synthesis, it was distilled before usage 
in order to remove the peroxide derivatives which might lead to methionine oxidation. 
Extreme care should be taken for the acidic side-chain removal reactions. The choice 
of scavengers seems to play an important role in avoiding thioether oxidation. When 
the routine deprotecting cocktail such as 95%TFA/2.5%H2O/ 2.5%triisopropylsilane 
was subjected to the final deprotection, SDMS derivative peptides were partially 
oxidized under the standard reaction condition. Reagent K, which is composed of 
TFA, phenol, H2O, thioansiol, ethane-1,2-dithiol (82.5:5:5:5:2.5), is the preferable 
choice of deprotection cocktail for the peptides which contain methionine residues. 
No methionine sulfoxide or methionine sulfone derivatives were detected by 
MALDI-ToF-MS or RP-HPLC in this project with argon protection and the 
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application of Reagent K. Meanwhile, no alkylation side-reactions took place upon 
the acidic side-chain cleavage reactions. The carbocations generated in this reaction 
were efficiently trapped by the corresponding nucleophilic components (phenol, 
dithiol, thioether, water) in Reagent K. The thioether functionality in the concerned 
SDMS derivative peptides remained unoxidized and unalkylated in the whole process 
of synthesis in this project. 
 
2.5.2.3 Oxidation of Methionine Residue to Sulfoxide Derivative in 
Cyclic SDMS Peptide 
Contrary to the cautions to avoid methionine oxidation in the synthetic process in this 
project, deliberate oxidation of methionine to methionine sulfoxide in cyclic SDMS 
derivative peptides was carried out in the synthesis of PI 5 and PI 6, in order to 
analyze the role which methionine residue plays in the interaction between SDMS 
binding domain in invasin and integrin α3β1. The interaction mode of methionine to its 
corresponding binding domains on the receptor could therefore be explored by the 
comparison of reference peptides PI 3 and PI 4 with their oxidized derivatives PI 5 
and PI 6. 
 
Generally, oxidation of L-methionine yields a mixture of S- and R-sulfoxides and, 
depending on the conditions used, even a mixture of the related sulfone (Scheme 2.1). 
At least by oxidation with hydrogen peroxide the R-sulfoxide is formed in a preferred 
manner,[ 107F108] isomeric pure Met(O) derivatives are obtained by isolation of the isomers 
from the S,R-sulfoxide mixture. 
 
The cyclic peptides subjected to the oxidation reaction in this project were fully 
deprotected (Scheme 2.2), which assure them of the avoidance of the final 
deprotection reaction, as deprotecting cocktails contain substances with reducing 
abilities, such as phenol and EDT which could possibly reduce the methionine 
sulfoxide back to thioether derivatives. On the other hand, no other residues in the 
referred peptides could be influenced by the subjected oxidant, thus validating this 
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methodology. 
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Scheme 2.2 Oxidation of Methionine-Containing Peptide to the Correspoding Methionine Sulfoxide 
Derivative 
 
The oxidation of cyclic peptide cyclo-(-Ser-Asp-Met-Ser-D-Lys-Gly-) PI 4 was 
carried out with utmost caution in order to avoid the further oxidation of sulfoxide 
functional group to corresponding sulfone derivative (Scheme 2.1). Single-Channel- 
Syringe-Pump was utilized to assure the slow injection of hydrogen peroxide into the 
cyclo-(-Ser-Asp-Met-Ser-D-Lys-Gly-) PI 4 solution in order to avoid the real time 
excess of oxidant relative to unoxidized peptide, assuring the oxidation reaction to 
retain at the stage of methionine sulfoxide. Subsequent MALDI-ToF-MS and 
analytical RP-HPLC analysis testified the efficiency of this methodology since neither 
sulfone nor unoxidized thioether derivatives was detected. The oxidized species of 
peptides exhibited obvious shorter retention time on analytical RP-HPLC than their 
unoxidized counterparts. 
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2.5.2.4 Introduction of α-Aminoisobutyric Acid through 
Azidoacidchloride 
The incorporation of some constraints into the cyclic peptides will induce or reinforce 
certain kinds of secondary structures. α,α-disubstituted amino acids such as Aib 8 
(α-aminoisobutyric acid) possess the inclination to induce the 310-turn (also known as 
type III β-turn) at i+2 position. To replace the methionine residue by Aib in the 
reference peptides PI 3 and PI 4 could thus potentially reinforce the β-turn in which 
crucial aspartic acid resides at i+1 position. On the other hand, the substitution of 
methionine by Aib could also testify the function of thioether side chain on 
methionine upon the association to corresponding binding domain on the 
integrin α3β1. 
 
The incorporation of sterically hindered Aib into the peptide chain 
proved to be difficult and inefficient with the routine coupling 
methodology both in solution and on solid support. Due to the sluggish 
coupling reactions concerning α,α-disubstituted amino acid residues into the peptide 
chain, series of problematic side reactions are to be aroused in this very process.  
 
Diketopiperazine cyclization, attributed to the gem dialkyl effect, can occur readily 
with certain Aib-containing dipeptides and related fragment during N-deprotection. 
Another obvious problem associated with Aib incorporation is extensive racemization 
in R-Aib-Xaa-OH sequences during carbodiimide activation through oxazolone 
intermediate 9 (Scheme 2.3). 
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Racemization of the penultimate residue of peptides containing C-terminal Aib 
residues during activation has also been documented (Scheme 2.4) despite the fact that 
Aib is racemization-free. 
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Scheme 2.4 Racemization of the Penultimate Residue of the Peptide with Aib as C-Terminus 
Despite the advances of phosphonium salts-type coupling reagent with various levels 
of efficiency of the Aib coupling, such as BOP, PyBOP, BroP, PyBroP, and PyCloP 
(Scheme 2.5), the methodology for this kind of coupling reaction still remains to be 
improved, especially for those with extremely hindered amino acid derivatives. 
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Scheme 2.5 Phosphonium Salts-Type Coupling Reagent Applied in the Coupling of Aib Residues into 
the Peptides 
 
In order to bypass the problems caused by the sluggish coupling of 
α,α-disubstituted amino acid residues, α-azido acid chlorides, such as 
2-azido-2-aminoisobutyric acid chloride 10, which are readily reduced 
to α-amino derivative, are introduced as building blocks in the peptide synthesis.  
 
As the Nα-azido protecting groups is much less hindered than the bulky routine 
carbamate protecting groups such as Fmoc, Boc, and Z, the incorporation of 
N2=Aib-Cl 10 to the growing peptide chain will be much faster and efficient than the 
routine methods, which lead to the avoidance of the side reactions aforementioned. 
Furthermore, the acid chloride is more efficient as the property of electrophilicity is 
concerned.  
N3
O
Cl
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The Nα-azido group is smoothly reduced with Sn(SPh)2 and thiophenol under basic 
conditions to liberate the free amine. The aforementioned reduction process could be 
performed on solid support, making this methodology compatible with SPPS 
(Scheme 2.6). 
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Scheme 2.6 Incorporation of Aib Residue to the Peptide Chain on Solid Support through N2=Aib-Cl, 
Subsequent Reduction of Azide to Amine and Chain Elongation 
 
Upon the introduction of Aib residue to the growing peptide chain on solid support, 
the next incoming Fmoc-amino acid residue could be coupled to the peptide chain, 
whose N-terminal component is Aib, according to the routine methodology, namely, 
TBTU as coupling reagent and DIPEA as base. The efficiency of this coupling could 
be confirmed by the MALDI-ToF-MS. Inhibitor peptides PI 9 and PI 10 were 
synthesized successfully according to this method. 
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2.5.2.5 Cyclization of Nα-free side-chain Protected Linear Peptide 
 
General Method of Peptide Cyclization in Solution 
The fully protected linear peptide precursor is cyclized in DMF with 3 equiv. HATU 
as coupling reagent, and DIPEA as base. 
 
Oligomerization Side Reaction in Peptide Cyclization 
In the synthesis of cyclic peptides, the readiness of a linear precursor to cyclize 
depends on the size of the ring to be closed, and usually no difficulties arise with the 
cyclization of peptides containing six or more amino acid residues. However, the 
increase of the number of amino acid residues in the linear peptide to be cyclized 
could lead to side reacitions such as dimerization or oligomerization. Although ring 
closure with pentapeptides is more hampered, the cyclization is facilitated by the 
presence of turn structure-inducing amino acids such as glycine, proline or a D-amino 
acid.[108F109,109F110] The only pentapeptide synthesized in this project is PI 20, with the 
sequence cyclo-(-Ser-Asp-Met-Ser-Gly-). The occurence of glycine in the peptide 
guarantees the smooth ring closure reaction. No linear precursor was detected after 
the cyclization reaction was completed. For linear peptides which do not contain 
amino acid residues which stabilize turn structures, the cyclization reaction may be an 
inherently improbable or slow process, and side reactions, such as cyclodimerization, 
may dominate even at high dilutions (10-3-10-4M).[110F111]  
 
Formation of Guanidinium of N-terminus in Peptide Cyclization 
The rate decrease of a cyclization reaction could also result in the formation of 
guanidinium adduct at the N-terminus of the linear peptide precursor, since coupling 
reagents such as HATU are capable of reacting with the amino moiety of the amino 
acid under basic conditions. In this project, however, no guanidinium adduct side 
products were found in the cyclization reactions. The occurrence of secondary 
inducing amino acid such as Gly, Aib, D-amino acid, and Sar favored the successful 
ring closure reactions, with no dectectable oligomer or guanidinium side products. 
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The unique cyclic peptide which does not contain such as secondary strucuture 
inducer is PI 21, with the sequence cyclo-(-Ser-Asp-Met-Ser-Asp-Met-). Despite that 
this cyclic peptide consists of exclusively L-amino acids which do not possess clear 
secondary structure inclinations, the cyclization reactions turned out to be problem 
free. The property of hexapeptide seems to be in favor of smooth cyclization in terms 
of the tension status of an 18-atom-member ring molecule. 
 
Racemization of C-terminus in Peptide Cyclization 
The prolonged existence of the activated carboxyl group resulted from the slow ring 
closure reaction could increase the likelihood of racemization of the C-terminal 
residue in the linear peptide through the oxazol-5-(4H)-one intermediate. The extent 
of racemization may be diminished by application of the azide method[111F 112 ] or 
modified azide methods using DPPA (Scheme 2.7).[112F113] However, these cyclization 
methods are extremely slow, usually requiring many hours or even several days.[84H112,113F114] 
In comparison with DPPA, TBTU[ 114F 115] and BOP[ 115F 116] (Scheme 2.7) provide fast 
cyclization,[116F117,117F118] but may also lead to racemization levels which are comparable to 
those observed with DCC/HOBt.[ 118F119] In this project, the racemization of C-terminal 
residue is not the major concern, since the cyclization reactions process at relatively 
high rates which barely bestow chances to the racemization side reaction through 
oxazolone formation. More importantly, most linear peptide cyclized in this project 
possess glycine or sarcosine as their C-terminus which are racemization free because 
of the absence of a chiral center on their Cα, with the mere exceptions of PI 21. The 
rational choices for the C-terminus in the SPPS of linear peptide precursors avoid the 
problems of the C-terminus racemization upon ring closure reactions. 
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Scheme 2.7 Coupling reagent applied in peptide cyclization 
 
Initiation of Pseudo High Dilution Condition in Peptide Cyclization 
As the main concern in peptide ring closure reaction centers on the possibility of 
dimerization or oligomerization of the linear precursors to be cyclized under routine 
conditions, it is therefore necessary to apply a method which could to some extent 
abstain from the reaction conditions which favor such a side reaction. However, it is 
not feasible to cyclize a large amount of peptide under high dilution conditions from 
the aspect of economy. However, dimerization or even higher degree of oligo- 
merization occurs if the concentration of the peptide to be cyclized is not dilute 
enough to avoid the collision between the linear peptide molecules (Scheme 2.8), 
especially for the lengths and sequences which are not prone to cyclize under routine 
conditions, such as pentapeptide, and those which do not contain favorable residues 
like Gly, α,α-dialkyl amino acid, or D-amino acid. Cyclization on resin could abstain 
from the problems asscociated with high concentration. However, this methodology 
requests the C-terminal residue to be trifunctional and thus does not possess the 
universality. 
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Scheme 2.8 Dimerization side reaction in peptide cyclization 
 
In this project the linear precursor peptides which contain SDMS sequence were 
synthesized by SPPS (Scheme 2.9), the linear peptides were cleaved from the resin by 
1%TFA with the side-chain protecting groups remaining intact and subsequently 
cyclized under the pseudo high dilution conditions which were developed by the 
Sewald group.[119F120] (see Figure 2.15)  
 
Figure 2.15 Pseudo high dilution conditions generated by two-channel-syringe-pump  
 
According to the grogram, both the peptide solution and the coupling reagent solution 
are added dropwise by the syringe to the three-neck flask containing solvent for 
cyclization. The added linear peptide molecules are consumed continually with the 
conversion to cyclic derivatives in the presence of HATU. The "real-time" dilution 
condition for linear peptides is thus created. This "pseudo high dilution" condition 
circumvents the dimerization or oligomerization side reactions which are promoted by 
the relatively high concentration of linear peptides. Furthermore, this reaction 
condition is favored from the point of economy consideration. 
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Scheme 2.9 Procedure of peptide cyclization in solution 
 
No dimerized side products are detected by MALDI-ToF-MS or RP-HPLC through 
the aforementioned cyclization methodology in this project, which testifies its 
feasibility to some certain species such as hexapeptides. The herein obtained totally 
protected cyclic peptide is then subjected to the acid-catalyzed side-chain cleavage 
reactions. Reagent K is used on this occasion for the reason which has been clarified 
beforehand. The whole synthetic process proved to be smooth and problem-free.  
 
2.5.2.6 Segment Condensation 
 
2.5.2.6.1 Preconditions of Segment Condensation 
As is introduced in chapter 2.5.1.2.2, the remote synergic Asp/Arg binding moieties 
are supposed to be incorporated into the cyclic peptides containing -Ser-Asp-Met-Ser- 
sequence through molecular modelling programmed spacers with certain spatial 
conformation, in order to enhance the binding affinities through the additional 
association forces introduced by these remote binding moieties. The introduction of 
these spacers has to be achieved through a hinge which is capable of "anchoring" the 
linear spacers covalently to the parent cyclic peptides in which -Ser-Asp-Met-Ser- 
primary sequence is resided. From the viewpoint of chemical reaction, this operation 
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needs a reactive functional group on the cyclic peptide which could covalently bond 
to the corresponding functionality on the spacer. As the aspect of binding between 
ligand and receptor is taken into consideration, the "consumption" of this functional 
group on the cyclic peptide should not jeopardize the potential interactions between it 
and the opposite functionalities on the receptor. The choice of this anchor position is 
therefore supposed to be balanced between the chemical and biological standpoints. 
Ideally, the cyclic peptide side chain which does not participate in the association of 
peptide inhibitors to the integrin α3β1 is chosen preferably. D-Lys residue in the 
reference peptide PI 4 is regarded putatively as the starting point to introduce the 
spacer through its primary ω-amine functional group on the flank of its side chain, 
which is perfectly in accordance with the peptide synthetic methodologies. On this 
basis, peptide-based inhibitors PI 24-35 (see also Table 2.5) were designed and 
synthesized.  
 
2.5.2.6.2 Aloc as ω-amino Protecting Groups for Orthogonal Deprotection 
Strategy 
The introduction of peptide-based spacers to the parent cyclic peptide containing 
-Ser-Asp-Met-Ser- sequence at the side chain of D-Lys is performed on the premise 
that the protecting group for amine be cleaved. However, the acid labile tBu-based 
routine protecting groups such as Boc, which are compatible with Fmoc SPPS, are not 
appropriate for the selective removal, since the OtBu protecting group on aspartic acid 
could be removed as well under the same acidic deprotection conditions. The carboxy 
group on the aspartic acid side chain should be unconditionally protected during the 
segment condensation reaction since its reactivity is equivalent or even superior to 
that of the C-terminal carboxy group on the linear scaffold peptide. This brings 
forward the necessity of selective cleavage of the protecting group on the lysine side 
chain. Orthogonal protection of lysine is therefore imperative, which means the 
removal of the protecting group on lysine is supposed to be performed under the 
condition in which the other protecting groups, especially the one for aspartic acid, 
remain intact. 
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The allyl-type protecting groups are characterized by full stability towards moderate 
strong acids and towards basic conditions as used in Boc/Bzl and Fmoc/tBu strategies 
in solution and on solid supports, but are readily removed by palladium-catalyzed 
cleavage. Correspondingly, these carboxy, hydroxy, and amino protecting groups 
offer a new level of full orthogonality in side-chain protecting for regioselective 
deprotection of selected functionalities on resin or in solution for additional 
postsynthetic site-directed chemical reactions. The readily and quantitatively removed 
allyl-type protecting groups through the application of palladium-mediated cleavage 
reactions make this type of protecting groups ideal choice for the aforementioned 
site-selective modification reactions. The orthogonality of allyl-based protection 
towards Boc and Fmoc groups allows its use for the side-chain protection of linear 
and branched peptides as well as for glycopeptides. It also enables specific 
deprotection at preselected side-chain groups for macrocyclization of peptides. 
 
Cleavage of the Aloc Protecting Group 
The deprotection of allyl-protectected functional groups is achieved through a 
palladium-catalyzed transfer of the allylic group to a nucleophilic species as 
represented in Scheme 2.10. 
 
R1 [Pd(0)] (cat.)
Pd2+
+
R1-
Nu- H+
Nu
R1H Pd(0)
 
Scheme 2.10 Palladium-Catalyzed Transfer of an Allyl Group to a Nucleophile 
 
Many complexes of palladium in the zerovalent state, differing by the nature of ligand 
on the metal, can be used for allylic cleavage but in the majority of the cases it is the 
commercially available tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4] that is 
used. Pd(PPh3)4 partially dissociates in solution into triphenylphosphine and 
Pd(PPh3)2, which is assumed to be the true catalytic species. Typically, 2 to 5 mol% 
of catalyst are used in deprotection reactions in solution but greater amounts are often 
required in solid-phase chemistry. The reaction is preferentially run under an inert 
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atmosphere (argon, nitrogen). A necessary condition for successful removal of allyl 
groups is that the protected function possesses sufficient leaving group ability to allow 
the formation of the π-allyl complex. As far as peptide synthesis is concerned, allyl 
esters of carboxylic, phosphonic and phosphoric acids, allyl phenoxides, and 
allyloxycarbonylderivatives of amines are the main protected functions, which fulfill 
this condition. On the contrary allyl ethers or sulfides and allylamines in their 
nonprotonated form are not cleaved by the palladium(0) catalyst. In most cases allylic 
carbamates undergo decarboxylation contamitantly with allylic cleavage thus leading 
directly to the amine (Scheme 2.11).  
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Scheme 2.11 Allyl Cleavage with Concomitant Decarboxylation of Allyl Carbamates 
 
The deprotected amine may then compete with the nucleophilic scavenger in the 
trapping of the η3-allylpalladium complex. To avoid the formation of allylamines it is 
therefore better to use deprotection systems that lead to the amine in a protonated or 
another masked non-nucleophilic form or to use an allyl group scavenger in large 
excess. In the presence of the palladium catalyst alone allyl carbamates may also form 
allylamines [ 120F121,121F122] through unimolecular decarboxylative rearrangement of the corres- 
ponding carbamato π-allyl complex [ 85H122] as presented in Scheme 2.12. 
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Scheme 2.12 Formation of Allylamines from Allyl Carbamates 
 
Fortunately, this process, which is quite rapid in the case of carbamates derived from 
derived from secondary amines, is relatively slow with Aloc derivatives of primary 
2.5 Results and Disccussion 
 65
amines in general and Nα-Aloc derivatives of amino acids in particular.[122F123] It is, 
nevertheless, highly advisable not to expose Nα-Aloc derivatives to the catalyst 
without adding nucleophilic scavengers. 
 
Deprotection with Tin or Silicon Hydrides or Amine-Based Complexes 
A large variety of nucleophiles may be used as allyl group scavengers in the 
palladium-mediated deprotection of allylic derivatives, including oxygen, nitrogen, 
carbon, or sulfur nucleophiles, and hydride donors.[86H123] 
 
Various hydride donors have been used as allyl group scavengers in palladium- 
catalyzed deallylation reactions leading to propene as the byproduct. These include 
formic acid[123F 124 ] and several semimetal hydrides, including tributyltin hydride 
(Bu3SnH),[124F125] phenylsilane (PhSiH3),[125F126] lithium or sodium borohydrides,[126F127,127F128] and 
amine-borane complexes such as borane-ammonia complex (BH3·NH3) and 
borane-dimethylamine complex (BH3·NHMe2).[128F129] They are efficient not only for the 
deprotection of allyl carbamates and esters but also for the deprotection of allyl 
phenoxides, in contrast to the other allyl group scavengers mentioned (vide supra). 
With borohydride and tributyltin hydrides, the air-stable palladium divalent complex 
dichlorobis(triphenylphosipine)palladium(II) is assumed to be qualified as alternative 
to of tetrakis(triphenylphosphine)palladium(0) as it is reduced in situ to Pd(PPh3)2. 
Tributyltin hydride,[87H125] phenylsilane,[129F130] and the amine-borane complexes[88H129] have 
been used in solid-phase peptide synthesis for Aloc deprotection as these procedures 
lead to complete cleavage in less than 10 minutes at ambient temperature. Strong 
activation by palladium of the otherwise poor nucleophile tributyltin hydride is likely 
to take place through the formation of an intermediate palladium hydrido species. 
Tributylsin hydride is not indefinitely stable in the presence of palladium zerovalent 
complexes but decomposes to hexabutyldistannane (Bu3SnSnBu3) and H2. This 
process is sufficiently slow so as not to interfere with the deprotection reaction in the 
majority of cases. Phenylsilane gives slower deprotection reactions compared to 
tributyltin hydride, but is apparently indefinitely stable in the presence of palladium 
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catalyst.[89H126] When the hydride donor and amine-borane complexes are used as allyl 
group scavengers, the primary products of deprotection are not free functional groups 
but the corresponding metallic salts. 
 
2.5.2.6.3 Poisoning of Palladium Catalyst by Sulfur-Containing Molecules  
The activity of a catalyst is reduced gradually when 
the unwanted, harmful components of impurities are 
accumulated on the catalyst’s surface and slowly 
poison the catalyst. Poisoning is defined as a loss of 
catalytic activity due to the chemisorption of 
impurities on the active sites of the catalyst (see 
Figure 2.16). It follows that the analysis of poisoned 
catalysts may be complicated since the content of poison of a fully deactivated 
catalyst can be as low as 0.1 wt-% or even less (Forzatti & Lietti 1999). Lead (Pb), 
sulfur (S), phosphorus (P), zinc (Zn), calcium (Ca), and magnesium (Mg) compounds 
are typical catalyst poisons. 
 
Sulfur species (H2S, RSH, RSSR…) are poisons [130F 131] for all catalytic processes 
employing reduced metals as the primary active phase. They are generally considered 
temporary, although their effect can be permanent depending on the process 
conditions, ease of regeneration, etc. Pgm (Platinum Group Metal) catalyst(s) react 
readily with H2S to form sulfides. Sulfur may cause significant deactivation even at 
very low concentrations, due to the formation of strong metal-S bonds. Sulfur 
chemisorbs onto and reacts with the active catalyst sites, preventing reactant access. 
Furthermore, the stable metal-adsorbate bonds can lead to non-selective side reactions, 
which modify the surface chemistry. 
 
S
COP
Metal
Figure 2.16 Poisoning of Catalyst
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Since the target peptides contain methionine residues with thioether groups on the 
side chains, this residue is therefore prone to cause the poisoning of the palladium in 
the reaction of Aloc cleavage, in which palladium (0) is applied as catalyst. This 
hypothesis is approved by the experimental results. When 0.1-0.2 equiv Pd(PPh3)4, 
according to the theoretical amount, are applied to the Aloc cleavage reactions, the 
Aloc protecting groups on the side chains of lysines would not be removed 
quantitatively even with the elongation of the reaction duration. The Aloc cleavage 
reaction goes to completion only when the amount of palladium catalyst is increased 
to 1.0 equiv. in terms of Aloc protecting groups. This phenomenon clearly 
substantiates the fact that sulfur containing molecules are potential palladium catalyst 
poisons.  
 
One of the methodologies to avoid the poiosoning of Pd cataylsts is to use the liquid 
ammonia as the solvent of the Aloc deprotecting reaction instead of the routine DMF. 
The deprotection is carried out at -33 ºC with the reflux of liquid ammonia. 0.2 equiv 
Pd(PPh3)4 is enough to achieve the quantitative removal of the Aloc protecting groups 
with the application of 30 eqv. PhSiH3 as scavenger. It is not clear whether this 
obvious improvement is contributed to the unique properties of liquid ammonia as 
solvent or due to the drastic decrease of the reaction temperature, which might 
influences the balance of the absorbance of sulfur-containing molecules on the 
surfaces of the palladium catalysts.  
 
2.5.2.6.4 Strategy of Segment Condensation 
The linker peptide, such as 12, with crucial binding residues (Arg/Asp) on the flank, 
is supposed to be condensed with the partially protected cyclic SDMS derivative 
peptide 13 containing free lysine side chain in solution (Scheme 2.13) in order to 
incorporate the remote binding moieties Asp/Arg into peptide complex 14, which was 
rationally designed according to the 3-dimensional spatial binding domain in natural 
invasin protein. This condensation reaction was fulfilled with HATU 11 as coupling 
reagent and DIPEA as base.  
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Scheme 2.13 Segment Condensation of Linker Peptide 12 with Cyclic SDMS Derivative Peptide 13 in 
Solution 
 
Theoretically, this type of condensation reaction could be performed with in-situ or 
preactivation manner. However, in this project the linker peptides should be 
preferably preactivated at the C-terminus before being condensed with the partially 
protected SDMS derivative peptide 13 containing free lysine residue (Scheme 2.14). 
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Scheme 2.14 Segment Condensation Reaction with Preactivation of the the C-Terminal Component 
 
If this condensation reaction is not to be carried out in the preactivation manner, but 
with the routine in-situ activation mode, side reaction concerning guanidinium would 
stand out. If C-terminal component peptide 12 and uronium-type coupling reagent 
(especially HATU 11, which possesses stronger nucleophilicity relative to TBTU) 
were added simultaneously to N-terminal component peptide 13 without being 
premixed, the side product guanidinium salt adducts 15 would be formed through the 
reaction of the free amino group on 13 with HATU 11 (Scheme 2.15). This side 
product could be detected by MALDI-ToF-MS. It is inert and therefore resistant to the 
further nucleophilic attack.  
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Scheme 2.15 Guanidinium Salt Adducts 15 Formation through in-situ Activation Reaction 
 
This side reaction could be satisfactorily circumvented with the preactivation of 
C-terminal component peptide 12 with the uronium-type coupling reagent for 5 min 
with the absence of N-terminal component peptide 13 before combining the two 
peptide components (Scheme 2.14). However, this preactivation should not process 
over too long time in order to minimize the racemization of the C-terminal residue. 
 
The conjugates in this project, which were condensed from the partially protected 
cyclic SDMS derivative peptide 13 and linker peptide 12, were achieved by 
preactivation as mentioned above, with the excess of linker peptide 12 by 0.5 equiv in 
order to achieve the maximal conversion of the cyclic peptide to the target product. 
The reaction was carried out at ambient temperature overnight under argon 
atmosphere. The condensation efficiency was monitored by MALDI-ToF-MS, the 
completion of the condensation being indicated by the disappearance of the signals of 
peptide 13. The target peptide conjugate was then purified through RP-HPLC. Due to 
the difficulties in the application of RP-HPLC in these conjugate species which are 
highly hydrophobic, the yields of the product after RP-HPLC normally lie below 10%. 
The obtained pure fully protected conjugates were subjected firstly to 20% piperidine 
in DMF to remove the Fmoc moiety on the flank of the spacer, and subsequently 
applied to Reagent K to quantitatively cleave the side-chain protecting groups. The 
fully deprotected conjugates were purified by RP-HPLC. 
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2.5.3 Results and Discussions of Inhibitory Experiments 
 
2.5.3.1 Laminin-332 as Natural Ligand to Integrin α3β1 
As the association efficiency between invasin and integrin α3β1 is extraordinary high, 
we chose extracellular matrix (ECM) protein laminin-332 in our ELISA experiment as 
model ligand to integrin α3β1. It is known (see Table 2.1) that laminin family belongs 
to the natural ligands of cell adhesion molecules among which integrins stand out.[131F132] 
The laminin-binding integrins, such as integrin α3β1, integrin α6β1, integrin α6β4, and 
integrin α7β1, vary in their binding preference towards the different laminin isoforms. 
Whereas integrin α6β1 integrin binds to most laminin isoforms, the binding of 
integrin α3β1 is more restricted to certain members of the laminin family such as 
laminin-332.[132F133-133F134F135F136] It was exhibited that a synthetic peptide derived from the carboxy 
terminus of the laminin A chain represents a binding site for integrin α3β1,[136F137] and 
invasin is able to thoroughly inhibit the binding of laminin-332 to integrin α3β1,[90H133] 
suggesting sterically overlapping or identical binding sites. It is therefore reasonable 
to apply laminin-332 as the natural ligand to integrin α3β1 in our ELISA experiments 
to measure the relative capacities of synthesized peptides/peptidomimetics as 
inhibitors for the adhesion between integrin α3β1 and invasin. 
 
2.5.3.2 Methodology of Biological Assay 
2.5.3.2.1 General Introduction of ELISA 
Enzyme-Linked Immuno Sorbent Assay (ELISA) is a biochemical technique used 
mainly in immunology to detect the existence of an antibody or antigen in the sample. 
In the ELISA, antigens are immobilized in the plastic surface before the 
correspondent antibodies are added, so that specific binding between the antigen and 
antibody takes place. This antibody is linked to an enzyme, to which the relative 
substrates are added. The degradation of substrate initiated by the enzyme leads to a 
visible compound which could be detected by certain spectrometer, so that the amount 
of antigens in the sample could be determined. 
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2.5.3.2.2 Sandwich ELISA in Determination of Inhibitory Capacities of 
Peptide/Peptidomimetic Ligand for Integrin α3β1 
 
Sandwich ELISA is a variant of the ELISA technique, which is metaphorized into 
“sandwich” because of the topology of the overlapped sample, antibody and second 
antibody. (see Figure 2.17) 
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Figure 2.17 Schematic Step of Sandwich ELISA 
 
(1) Coating: Prepare a stationary phase (microtiter plate) by immobilizing certain 
amount of capture antibody/receptor.  
Blocking: Endcap any non-specific binding sites on the plate. 
(2) Binding: Apply the antigen/ligand-containing sample to the plate, binding 
takes place between the immobilized capture antibody or receptor and the 
corresponding antigen or ligand in the sample. 
Washing: Wash the plate, so that any unbounded antigen/ligand is removed. 
Fixation: Apply fixation solution to the plate-well in order to fix the 
association between antigen/antibody or ligand/receptor. 
(3) First Antibody: Apply the first antibody that binds specifically to the 
antigen/ligand. 
Washing: Removal the superfluous unbound first antibody. 
   (4) Enzyme-linked Second Antibody: Apply the enzyme-linked second antibody 
to the plate, specific binding takes place between the first and second antibody. 
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      Washing: Remove the superfluous unbound second antibody. 
(5) Substrate: Apply the substrate to the plate, which is converted by enzyme into 
a visible metabolite which could be quantified by spectrometry. 
Termination: Add the termination solution to the plate to stop the 
color-generating reaction. 
Quantification: Measure the absorbance the of the plate wells to determine the 
presence and quantity of antigen/ligand in the sample. 
 
2.5.3.3 Screening of Synthetic Peptide Inhibitors of the Interaction 
between Laminin-332 and Integrin α3β1 
As the mechanism of adhesion between invasin and integrin α3β1 remains ambiguous, 
it is thus necessary to elucidate the modes of their interactions with the screening of a 
synthetic peptide library. The diversity of the concerned peptides could be established 
by the mutations of the amino acid residues in the reference peptide (see also 
Table 2.2 and 2.5). It is instructive to test their capacities to inhibit the adhesion of 
laminin-332 to integrin α3β1 upon the screening of the individual members in the 
peptide library. Some preliminary binding mechanisms could be possibly figured out 
by analysing of the peptides with deliberate mutations at certain positions. For 
instance, the substitution of an ionic amino acid residue by a neutral one such as 
alanine could be applied to probe whether there is an ionizable domain on the 
corresponding receptor. Likewise, a hydrogen bond donor/acceptor residue in 
reference peptide could be replaced by a hydrogen acceptor/donor to check the 
hydrogen bond properties of the corresponding domain on the receptor. The inversion 
of the configuration of a crucial single amino acid residue could also be applied to 
probe the association manner between the functional domains on the ligand and 
receptor. The combinatorial mutations on components or conformational building 
blocks of synthetic peptides are thus instructive to explore the modes of interactions 
between the ligand and the receptor and thus instructive for peptide ligand 
optimization. The optimization of inhibitory properties is thus obtainable through 
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fusing the favorable elements in a single peptide/peptidomimetic molecule. 
 
Figure 2.18 displays the inhibitory properties of the synthetic peptide library. The 
replaced amino acid functions as a probe to explore the interactions between the 
peptide inhibitor and the corresponding adhesion moiety of the receptor integrin α3β1. 
The feedback of such an exploration could be systematic analyzed and the 
advantageous factors are supposed to be integrated for an improved inhibitory 
capacity. The concentrations of integrin α3β1 and peptide inhibitor applied in ELISA 
are 50 nM and 1.8 mM, respectively. The inhibitions were performed at room 
temperature under physiological pH 7.4. The relative inhibition was calculated 
according to the reference of negative blank (applying EDTA in the inhibition as the 
supplement, blocking the adhesion of integrin α3β1 to immobilized laminin-332, 
which could be regarded as that 100% inhibition takes place) and positive control 
(adding no peptide inhibitors in the experiment, permitting the full adhesion of 
integrin α3β1 to immobilized laminin-332, which could be regarded as that no 
inhibition took place). For concrete procedures see also experiment part. 
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Figure 2.18 Inhibiton of the Interaction between Laminin-332 and Integrin α3β1 by the Synthesized 
Peptides. 
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It is discernable from Figure 2.18 that the synthesized peptide inhibitors possess 
divergent inhibitory capacities in terms of the association of laminin-332 with 
integrin α3β1. Peptide PI 3 and PI 4, in which SDMS binding sequence is resided, 
could be regarded in this project as the reference peptide inhibitors. The evaluation of 
the inhibitory properties of other peptides/peptidomimetics could be determined 
through the comparison to these reference peptide inhibitors.  
 
2.5.3.3.1 Substitution of Aspartate in Reference Peptides 
Through the X-ray structure of invasin and its similarity to other known integrin 
ligands, especially Fibronectin, the Asp911 residue in the native invasin was assumed 
to play a crucial role in the adhesion of invasin to integrin α3β1. This assumption 
could be validated in the inhibitory experiments of the peptide derivatives with 
mutations in the primary sequence at the Asp postion. The Asp could be substituted 
by Ala, which diminished its side-chain interactions to the corresponding domain of 
the receptor; or by Glu, which insert an additional methylene group in the side-chain, 
thus extending the scope of its interactions. These operations would not change the 
conformations of the reference peptides basically, which sustains the validity of this 
methodology and the subsequent analysis. Alternatively, the configuration of Asp 
could be changed to its enantiomeric counterpart, namely D-Asp. This operation could 
elucidate the favorable configuration of the Asp upon the adhesion to the 
corresponding moiety of the receptor. 
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Figure 2.19 Inhibitory Results of the Peptides with Mutations at Asp in the Reference Peptides 
 
Figure 2.19 clearly shows the importance of the Asp for the adhesion of the peptides 
to integrin α3β1. The peptide derivatives with the mutation at Asp position relative to 
reference peptide PI 3 and PI 4 lost their inhibitory abilities drastically, as is shown in 
Figure 2.19.  
 
PI 16 and PI 17, with the sequence cyclo-(-Ser-Ala-Met-Ser-D-Lys-Gly-) and 
cyclo-(-Ser-Ala-Met-Ser-Lys-Gly-), respectively, were almost thoroughly deprived of 
the inhibitory properties upon the alanine scans at the Asp position. These results fully 
elucidate the crucial roles of the side-chain of Asp in the adhesion of the ligand to 
integrin α3β1, since the mutation to Ala abolished both the fully contact of the peptide 
inhibitor to its receptor and the ionic interactions between the two binding 
participants. 
 
PI 13 and PI 14, with the sequence cyclo-(-Ser-Glu-Met-Ser-Lys-Gly-) and 
cyclo-(-Ser-Glu-Met-Ser-D-Lys-Gly-), respectively, showed obviously inferior 
inhibitory properties upon the Glu substitution at the Asp position in the reference 
peptides. This information indicated the accuracy of the steric complementary 
between the ligand of invasin at this position and the corresponding binding moiety 
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on the receptor integrin α3β1, since the similarity of Glu and Asp is evident, no matter 
from the aspect of pKa or their comformational inclinations in peptides. Substitution 
of Asp or Glu results in the dominant difference of the extension of the side-chain by 
a methylene group which elongates the interaction scope of the carboxy group on its 
flank. However, as the inhibition results showed, this operation hugely decreased the 
inhibitory properties of the reference peptides, which account for the precision of the 
contact between Asp position on invasin and opposite domains on integrin α3β1. On 
the other hand, the introduction of an extra methylene group into the side chain of Asp 
increased the flexibility of the concerned molecule, which could result in the 
decreased activities. A flexible molecule can adopt several conformations and is thus 
less likely to be in its bioactive conformation. The association of Glu containing 
peptide inhibitors to their recptors would result in relative larger entropy cost which is 
adverse to tight binding. Furthermore, the increase flexibility of the ligand, which 
increases the chances of interacting with a variety of targets, could possibly lead to 
inferior selectivity. This hypothesis was nevertheless not exhibited in this experiment. 
 
PI 7 and PI 8, with the sequence cyclo-(-Ser-D-Asp-Met-Ser-Lys-Gly-) and 
cyclo-(-Ser-D-Asp-Met-Ser-D-Lys-Gly-), respectively, indicated markedly decrease of 
inhibitory capacities. The inversion of the configuration of the Asp resulted in the 
distinct loss in the binding efficacy of reference peptides. It showed that the favorable 
configuration of Asp adopted upon the binding to integrin α3β1 should be 
L-configuration. The change to its enantiomer led to the inappropriate directions of 
the aspartate side chain, which prevented the full contact between the aspartate and 
opposite binding domain on the integrin α3β1. The conformational change upon the 
binding of D-Asp containing peptides to integrin α3β1 would result in a bigger entropy 
loss which was adverse to the efficient binding. 
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2.5.3.3.2 Substitution of Methionine in Reference Peptides 
The X-ray structure of invasin and its similarity to other native integrin ligand did not 
present a clear image of the functions of methionine upon the adhesion of invasin to 
integrin α3β1. This defect could be remedied through the introduction of peptide 
derivatives with the mutation at the methionine position, such as alanine scan or 
oxidation of methyl sulfide side-chain of methionine into sulfoxide or even sulfone 
derivatives. Through the screening of these mutation species, the functions of 
methionine in adhesion of invasin to integrin α3β1 could be extracted.  
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Figure 2.20 Inhibitory Results of the Peptides with Mutations at Methionine in the Reference Peptides 
 
Figure 2.20 explained the important roles played by methionine in the binding of 
peptide inhibitors to integrin α3β1. The inhibitory capacities of peptide derivatives 
with the mutations at methionine relative to reference peptides PI 3 and PI 4 were 
reduced to different extent, as shown in Figure 2.20.  
 
PI 5 and PI 6, with the sequence cyclo-(-Ser-Asp-Met(O)-Ser-Lys-Gly-) and 
cyclo-(-Ser-Asp-Met(O)-Ser-D-Lys-Gly-), respectively, displayed slightly reduced 
inhibitory properties relative to their parent peptides PI 3 and PI 4. The oxidation of 
sulfide of the side-chain of methionine in PI 3 and PI 4 to the sulfoxide derivatives in 
PI 5 and PI 6 might not alternate the conformation of the cyclic peptides drastically. 
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However, what it did change is the hydrogen-bond properties of the side-chains. The 
sulfide group in the side-chain of methionine could be regarded as a very weak 
hydrogen-bond acceptor which forms very weak or no hydrogen bonds,[137F138] while its 
oxidated state possess a much stronger hydrogen-bond capacity as the acceptor. The 
reduced inhibitory properties of PI 5 and PI 6 relative to PI 3 and PI 4 indicated that 
there is a very weak or no hydrogen-bond donor on the corresponding binding 
domains of integrin α3β1. It was already explained in chapter 1.2.4.1 that a burial of 
unpaired polar groups upon ligand binding leads to a loss of binding affinity and 
should be avoided. The oxidation of sulfide side-chain of methionine to sulfoxide 
increased its hydrophilicity, while there was no matching component in the receptor, 
which led to a reduced binding affinity between the peptide inhibitors and 
integrin α3β1.  
 
PI 9 and PI 10, with the sequence cyclo-(-Ser-Asp-Aib-Ser-D-Lys-Gly-) and 
cyclo-(-Ser-Asp-Aib-Ser-Lys-Gly-), respectively, lost their binding affinities 
extraordinarily upon the substitution of Met by Aib in the reference peptides. The 
α,α-disubstituted amino acids such as Aib possess inclinations to occupy the i+2 
position of a type-II (II') β-turn as well as i+1 and i+2 position of type-I (I') and 
type-III (III') β-turn.[91H104] The incorporation of Aib at the position originally occupied 
by methionine could reinforce the β-turn structure of the cyclic hexapeptide in which 
aspartate locked at the favorable i+1 position. However, as is shown by Figure2.24, 
the potential sustainment of the β-turn did not result in the optimized inhibitory 
capacities of the concerned pepides compared to reference peptides. On the contrary, 
their binding affinities to integrin α3β1 were obviously weakened. These results 
showed the roles of methionine in the adhesion of peptide inhibitors to integrin α3β1. 
Mutations at this place are supposed to be carried out with extreme caution.  
 
PI 18, with the sequence cyclo-(-Ser-Asp-Ala-Ser-D-Lys-Gly-), exhibited a markedly 
reduced binding affinity compared to the reference peptide PI 4. These results 
sustained the conclusion that methionine plays an important role in the adhesion of 
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peptide inhibitors to integrin α3β1. As the reason why it possessed better inhibitory 
capacity relative to Aib-containing counterpart PI 9, a`conformational research should 
be initiated to compare the differences between the two peptides. It was assumed that 
the incorporation of Aib locked the aspartate into an unfavorable type of β-turn which 
weakened its fully contact with the corresponding binding domains on integrin α3β1. 
 
2.5.3.3.3 Substitution of Serine in Reference Peptides 
The function of serine in the reference peptides could be studied through the mutation 
operations such as alanine scan. 
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Figure 2.21 Inhibitory Results of the Peptides with Mutations at Serine in the Reference Peptides 
 
Interestingly, the binding efficacy of the reference peptides PI 4 was evidently 
increased upon the substitution by alanine, as is shown by Figure 2.21 that peptide 
PI 22, with the sequence cyclo-(-Ala-Asp-Met-Ser-D-Lys-Gly-), indicating optimized 
inhibitory property compared to its Ser-containing counterpart PI 4. As the ethyl 
hydroxy group on the side-chain of serine can function as both hydrogen donor and 
acceptor, while the methyl side chain of alanine prevents the formation of hydrogen 
bonds, it is therefore assumed that the serine in PI 4 might not be able to discover the 
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suitable hydrogen donor or acceptor on the integrin α3β1. This unpaired polar group 
could possibly lead to the destabilization of the peptide/integrin complex. The 
substitution of serine by alanine was then able to counteract this adverse factor, so 
that the binding capacity was increased. 
 
2.5.3.3.4 Substitution of Lysine in Reference Peptides 
The incorporation of a lysine residue in the reference peptides was based on two 
reasons: on one hand, the D-lysine at its position was to induce a β-II' turn in which it 
occupies i+1 position, thus locking the aspartate in a complementary β-turn at i+1 
position; on the other hand, the amine group on the side-chain of lysine functions as a 
hinge where the spacer peptide is able to be introduced. Mutations at this position was 
carried out with Arg, Ala, and L-Lys, in order to find out whether the side-chain of 
lysine plays a role on adhesion of the peptide inhibitors to integrin α3β1, as well as the 
influences of the conformations of the cyclic peptide inhibitors on their binding 
affinities. 
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Figure 2.22 Inhibitory Results of the Peptides with Mutations at D-lysine in the Reference Peptides 
 
2.5 Results and Disccussion 
 82 
Inhibitors PI 3 and PI 4 are diastereomers with the mere difference at the 
configuration of lysine. Interestingly, the introduction of D-lysine at its position did 
not bring forward the improved inhibitory properties. On the contrary, peptide PI 3 
which contains L-lysine at the same position in the cyclic hexapeptide displayed 
superior inhibitory capacity, as is shown by Figure 2.22. It is known that the D-amino 
acid preferentially occupies the i+1 position of a type II' β-turn in a cyclic peptide,[92H104] 
the Asp in the reference cyclic hexapeptide cyclo-(-Ser-Asp-Met-Ser-D-Lys-Gly-) is 
therefore supposed to be locked passively in a complementary β-turn. However, the 
generated complementary β-turn around aspartate is not necessarily the most 
appropriate type. As the unique amino acid residues bearing no side-chain, Gly 
preferentially occupies the i+2 position in type II β-turn and the i+1 positioins in type 
II' β-turn.[138F 139 ] (see Figure 2.23) As is known, glycine is often regarded as a 
“proteinogenic D-amino acid”, the incorporation of glycine into the cyclic 
hexapeptide exerts its influence of conformational inclination to induce β-turn. In 
peptide PI 4 glycine probably occupied i+1 position in a type II β-turn, leading to a 
favourable complementary β-turn in which aspartate resides in i+1 position. This is 
the putative explanation for the better inhibitory capacity of PI 4 relative to its 
D-Lys-containing counterpart PI 3. Another possible explanation for the discrepancy 
between D- and L-Lys containing peptides is that the side chain of D-Lys might induce 
slightly disadvantageous interactions with the receptor compared with that of the 
L-configuration. 
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Figure 2.23 Four Most Common Types of β-turn 
PI 15 and PI 19, with the sequence cyclo-(-Ser-Asp-Met-Ser-Ala-Gly-) and 
cyclo-(-Ser-Asp-Met-Ser-Arg-Gly-), respectively, were provided with the matchable 
inhibitory capacities compared to the L-Lys-containing reference peptide PI 3. 
Seemingly, the lysine residue in the cyclic hexapeptide inhibitors did not exert 
obvious influences on the adhesion of the peptides to integrin α3β1, since the binding 
properties are to some extent indifferent to the mutations at this position. This results 
bestow us the rationality to choose the side-chain of lysine in the cyclic hexapeptide 
to introduce the spacers with remote synergic binding moieties at the flank.  
 
2.5.3.3.5 Substition of Glycine in Reference Peptides 
The functions of Gly in the referred cyclic hexapeptide could be probed through the 
N-alkylation, namely, substitution by sarcosine. N-alkyl (or imino acid) residues 
exhibit reduced preferences for the trans conformation normally assumed by 
secondary amides, and this effect can lead to biologically relevant β-turn structures, 
similar to those often induced by proline residues.[139F140] 
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Figure 2.24 Inhibitory Results of the Peptides with Mutations at Glycine in the Reference Peptides 
 
The substitution of glycine in the reference peptide PI 4 by its N-methylated 
derivative sarcosine brought forward the optimized inhibitory capacity, as is shown by 
Figure 2.24. Peptide PI 12, with the sequence cyclo-(-Ser-Asp-Met-Ser-D-Lys-Sar-), 
exhibited markedly improvement regarding the inhibitory capacity to integrin α3β1. 
N-methylated amino acids are known to preferentially occupy the i+2 position in the 
β-turns.[93H126] It is assumed that the conformational inclination of sarcosine and D-amino 
acid exerted cooperative influences to lock the aspartate in the favorable type of the 
complementary β-turn, while sarcosine and L-configuration amino acid at their 
positions might result in counteractive secondary structure inducing effects, as PI 3 
cyclo-(-Ser-Asp-Met-Ser-Lys-Gly) and PI 11 cyclo-(-Ser-Asp-Met-Ser-Lys-Sar-) 
displayed similar inhibitory capacities possibly because the positive influences 
produced by sarcosine could be counteracted by the existence of L-type of lysine. 
Anyway, this experiment implied that the introduction of an N-alkylated amino acid at 
the position of glycine could improve the inhibitory capacities of the referred 
peptides. 
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2.5.3.3.6 Comparison of Inhibitory Capacities between Linear and Cyclic 
Peptides 
One of the major advanges of cyclic peptides over their linear precursors lies in the 
constrained conformations with the cyclization of the linear peptides, which leads to a 
decreased entropy loss upon the binding of peptide to their receptor and an improved 
inhibitory capacity as an antagonist. In this project, the integrin recognition sequence 
-Ser-Asp-Met-Ser- was fused into a relatively rigid cyclic hexapeptide molecule, with 
the aim to lock it in a favourable conformation and to obtain a better binding affinity 
to integrin α3β1. The comparison of the inhibitory capacities between the linear and 
cyclic peptides was performed to validate this theory. Furthermore, the recognition 
sequence H-Ser-Asp-Met-Ser-OH was extracted and examined in order to lower the 
molecular weight with the aim to achieve an improved binding affinity. 
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Figure 2.25 Inhibitory Results of the Cyclic and Linear Peptides 
As is shown by Figure 2.25, the linear peptides PI 1 H-Ser-Asp-Met-Ser-D-Lys- 
Gly-OH and PI 2 H-Ser-Asp-Met-Ser-Lys-Gly-OH obviously displayed inferior 
inhibitory capacities compared with their cyclic counterparts PI 3 and PI 4, which 
fully validated the rationality of the cyclization strategy. Peptide PI 23, with the 
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recognition sequence H-Ser-Asp-Met-Ser-OH, also showed evidently weakend 
inhibitory affinity. These results indicated that the recognition sequences should be 
locked in a constrained template such as cyclic peptides in order to maximize their 
functions as competitive ligands. 
 
2.5.3.3.7 Repeating Recognition Sequence in the Cyclic Peptide 
Since the recognition sequence -Ser-Asp-Met-Ser- begins and ends with the same 
amino acid residue Ser, it could be rational to design a palindromic sequence which 
contains two such sequences in one single molecule. It is not realistic to expect that 
one such molecule could bind to two receptors. However, this type of inhibitor might 
possess the advantage to reduce the entropy loss upon the adhesion to its receptor, 
since for this kind of inhibitor it is perhaps not as necessary as for the normal peptide 
to adjust its conformation to achieve the optimal interaction with the receptor. 
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Figure 2.26 Inhibitory Results of the Cyclic Peptide with Palindromic Sequence 
 
As is shown in Figure 2.26, the cyclic hexapeptide with palindromic sequence 
cyclo-(-Ser-Asp-Met-Ser-Asp-Met-Ser-) PI 21 displayed a slightly improved 
inhibitory capacity relative to PI 3. It is currently not quite clear whether this 
improvement resides in the aforementioned entropy advantages. At least, it brought 
2.5 Results and Disccussion 
 87
forward a new idea and strategy to optimize the binding affinity for those antagonists 
that possess a recognition sequence with the same start and end residues.  
 
2.5.3.4 Results and Discussions of Inhibitory Capacities of Peptides with  
Spacers 
PI 24-PI 35 (Table 2.6), which bear spacers of oligo β-alanine or (Pro-Pro-Ala)n with 
remote synergic Asp or Arg binding domains at their flanks, as well as reference 
peptides PI 3 and PI 4 (Table 2.3) were applied to ELISA. Their capacities of 
inhibition of the interaction between laminin-332 and integrin α3β1 were measured 
under the same conditions as those for PI 1-23. The results are summarized in 
Figure 2.27.  
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Figure 2.27 Inhibition of Laminin-332 Binding to Integrin α3β1 by Synthetic Peptides PI 24-35 and 
PI 3-4.  
 
Interestingly, the peptide inhibitors PI 24-35 with linkers bearing the synergic 
aspartate and arginine at the flank display weaker inhibitory properties relative to 
those without linkers. That is the case for both PPA-peptides and β-Ala-peptides. On 
average, the former peptide derivatives show higher binding affinities than the latter.  
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The series of linkers was designed by computer-assisted molecular modelling. The 
lengths of poly (Pro) linkers were calculated on the basis of their theoretical Poly Pro 
conformation. There should be two main conformations distributed as results of cis? 
trans (ω torsion angle) (see Figure 2.28) and cis' ? trans' (ψ torsion angle) equilibria, 
which bestows the poly (Pro) linker certain degrees of flexibility. 
 
Amide bonds are usually found in the trans conformation (ω=180°) in linear peptides, 
whereas cis amide bonds (ω=0o) are observed in constrained situations such as those 
occurring in cyclic peptides, particularly if they are characterized by small size. A 
trans amide bond in a secondary amide is energetically more stable than a cis bonding 
by ≈ 2 kcal/mol,[ 140F141] which explains the overwhelming occurrence in linear peptides 
of the trans bonding in the crystal state and its large preponderance in solution. 
However, the energy difference between the two conformations markedly decreases 
in tertiary amides. Thus, not surprisingly, the cis bondings reported in the literature 
for linear peptides in almost all cases involve a tertiary amide in a Xxx-Yyy- sequence 
where Yyy is a Pro or an N-alkylated (Sar, MeAla, peptoid unit, ect.) residue. 
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Figure 2.28 Isomerization of Proline 
 
Pro-Pro bonds generally adopt the trans conformation but, in some instances, 
particularly when the peptide is short or the sequence is syndiotactic (L-D or D-L), cis 
bonding does occur.[141F142] Interestingly, the homopolymer poly (Pro) is dimorphic in 
that, under appropriate experimental conditions, the "all trans" peptide bond 
conformation (type II) may exhibit a transition to the "all cis" peptide bond 
conformation (type I).[94H141] Both helices are left-handed (for L-residues) and show quite 
similar φ,ψ values. The classical poly (Pro) type II is a ternary helix, which, with 
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appropriated side-chain replacements (e.g. an –OH function at position 4 of the ring), 
may be endowed with an amphiphilic character. The transition from poly (Pro) type I 
to type II helix implies a remarkable increase in the long dimension of the 
3D-structure. 
 
As for the φ,ψ torsion angles in Pro-based peptides, the former is almost invariant 
(-70±20°) owing to the restrictions imposed by the five-membered pyrrolidine 
ring.[95H141] The ψ values accessible to Pro residues either correspond to the 
semi-extended region mentioned above (trans conformation) or the the 310-/α- helical 
region (cis conformation). This latter 3D-structure, usually stabilized by 1←4 (or 
1←5) intramolecular C=O┄H-N hydrogen bonds, cannot be formed by Pro residue 
only. Pro residues, in fact, can exclusively occur at the first two (three) positions of a 
310- (α-) helix, respectively, because any following Pro residue would act as a helix 
breaker in that it lacks the H-bonding donor (NH) functionality. The presence of a 
single Pro in those helices normally induces a bend in the structure. In the large 
majority of published examples, the semi-extended conformation is that preferentially 
adopted by Pro, indicating that this residue has an intrinsic propensity to be in the 
poly (Pro) structures (and at position i+1 of a type-II β-turn as well). This finding is 
especially verified in the longest homo-poly (Pro) and is related to unfavourable to 
unfavourable steric interactions originating between the δ-carbon of a Proi residue and 
the β-carbon of a Proi-1 residue if both are folded in an α-/310-helical conformation. As 
for the role of the Pro pyrrolidine ring, no rationale seems to correlate the type of 
puckering that each residue assumes with its backbone conformation. In other words, 
ring conformations seem to have little control over φ,ψ. However, the flexibility of 
the pyrrolidine ring is expected to expand the rang of φ,ψ values available to the Pro 
residue, leading to a minimization of unfavourable short-range interactions. 
 
In summary, it is confirmed that short poly (Pro) spacers and templates cannot be 
acritically viewed as "rigid rods", as usually considered, but rather that the cis ? trans 
(ω torsion angle) and cis' ? trans' (ψ torsion angle) equilibria, typical of the Pro 
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reidue. Interestingly, recent calculations have shown that even long poly (Pro) 
peptides may be quite flexible with a defined tendency to fold in a "worm-like" chain 
characterized by multiple bends.[142F143] It is then understandable that the molecular 
modelling concerning poly (Pro) had better take the cis ? trans as well as cis' ? 
trans' equilibrium into consideration. However, this exactitude would be extremely 
challenging for the molecular design. 
 
Rigid molecular platforms provide well-defined distances and orientations between 
appropriate probes or functional groups, thus greatly facilitating a reliable and correct 
interpretation of experimental results based on the 3D-strucuture dependence of 
organic and physical chemistry processes. Peptide-based systems of different lengths 
present a remarkable advantage over other types of derivatized skeletons because they 
are easily synthetically assembled.  
 
Oligopeptide 3D-structures based on Cα-trisubstituted (e.g. protein) α-amino acids of 
variable length have already been used as templates. However, particularly in the case 
of relatively short peptides, only a partially restricted mobility has been achieved. The 
most commonly used oligopeptides series in this context are poly (Pro), followed by 
(Gly)n, (Ala)n, and γ-substituted (Glu)n. (Gly)n polymers are known to fold either in 
the ternary helix poly (Gly) I or in the antiparallel β-sheet conformation poly (Gly) II, 
while (Ala)n and γ-substituted (Glu)n oligomers may adopt either the α-helical or the 
β-sheet conformation. In addition, statistically unordered forms occur largely in the 
complex conformational equilibria of this type of short oligopeptides, with their 
population being inversely proportional to the peptide main-chain length. 
 
Ideally, the linker peptides should adopt the favorable conformation to assist the 
probes on their flank to arrive at the relative functional domains. A compromise to 
this ideal situation is a linker with a certain flexibility, which could assure the 
envisaged directional interactions of the probes with their functional target, instead of 
a rigid linker led to a frozen but unfavorable direction. However, this compromise is 
achieved at the cost of entropy lost, which is adverse to tight affinity. As it is clear 
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that none of the peptide series discussed above can produce truly rigid backbone 
templates, in the past few years many groups concentrated their efforts on 
oligopeptides rich in the structurally severely restricted Cα-tetrasubstituted α-amino 
acids.[143F144] An appropriate choice of specific members of this latter class of amino 
acids will allow one to tailor well-determined peptides 3D-structures endowed with 
exactly specified, intramolecular Cα┄Cα distances. 
 
However, in the search for rigid templates/spacers, additional problems may arise 
from rotations about amino acid side-chain single bonds.[144F145] Indeed, most investiga- 
tions have exploited as probes or reactive pendants: (i) flexible, unmodified, protein 
amino acids (His, Trp, Tyr, Cys, Met, Glu, Asp, Ser) or (ii) flexible, appropriately 
side-chain modified, protein amino acids (Cys, Ser, Lys, Glu, Asp, Pro, Phe). 
Although a limited side-chain flexibility might in general be tolerated, or may even be 
beneficial, that arising from protein amino acids is definitely too large, making any 
conclusion quite approximate. In other words, by utilizing this type of side chain, any 
investigation inevitably suffers a range of uncertainty even larger than that saved from 
the restrictions imposed by rigidification of the backbone. 
 
As is already explained, there should be two main conformations distributed as results 
of cis ? trans (ω torsion angle) and cis' ? trans' (ψ torsion angle) equilibria. 
However, it is hard to estimate the population of the conformation, which makes the 
molecular modelling deviated from the actual conformation of the poly (Pro) linkers. 
The equilibria of the two conformation makes the corresponding inhibitors not as 
effective as the counterparts with poly (β-Ala) peptide as spacer, since the 
conformation of poly (β-Ala) is regarded as random coil in solution and the calculated 
linker length of this type serves as a statistically average value. The molecular 
modelling decided lengths of poly (β-Ala) linker bears therefore relatively less 
deviations from those of actual situations, despite the fact that poly β-Ala linkers are 
quite flexible and their orientations are accordingly less accurate and less controllable.  
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The backbone of poly (Pro-Pro-Ala) spacer is not rigid enough to maintain its length 
in solution; the flank synergic Arg/Asp residue might be unable to bind to the 
corresponding target on invasin with the accuracy assumed by the computer-assisted 
molecular modelling on the basis of the poly (Pro) conformation hypothesis. 
 
A fundamental limitation for the application of geometric fitting procedure is that the 
complexation free engergies are the sum of enthalpic and entropic contribution. 
ΔG = - RT ln Ki = ΔH – TΔS 
Positive cooperativity between different interactions in a complex will usually lead to 
tighter association at the expense of motional freedom and thus of entropy.[145F146]  
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Figure 2.29 Entropy effect in Lingand Binding to Receptor 
 
Entropy and enthalpy can often interplay and make compensation for each other upon 
the binding of ligand to receptor. As is already explained previously, some 
complexation processes are entropy-driven, while some are enthalpy-driven. The 
different distance dependence of non-covalent interaction mechanism necessarily 
modifies the size-matching requirements. For example, cyclodextrin complexes with 
tightly fitting and highly polarizable guest molecules form mainly by enthalpy gain, 
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whereas those with loose fit and aliphatic substrates in their cavity show some 
hydrophobic entropic contributions.  
 
As for the complexation of the aforementioned peptide derivatives with integrin α3β1, 
the incorporation of the spacer might generate a dual effect. Indeed, it promotes the 
synergic motifs of the inhibitor to reach their functional zone on the target protein. On 
the other hand, the introduction of the spacer into the peptide inhibitors enlarges their 
degrees of freedom，which might generate a relative bigger entropic loss when 
binding with the corresponding protein target explained by entropy effect (see 
Figure 2.29). Positive cooperation between different interactions in a complex will 
usually lead to tighter association at the expense of motional freedom and thus of 
entropy. For the binding with the above dual mechanism, it seems that the loss of the 
entropy cannot be compensated by the gain of enthalpy upon the binding, and such 
binding would therefore be adverse. It explains the phenomenon that peptide PI 4 and 
PI 3, without any spacers, hold better inhibitory effects than the corresponding 
peptide complexes bearing poly β-Ala and poly (Pro-Pro-Ala) as spacers, which 
might be to some extent too flexible and are therefore more adverse upon the binding 
from the sense of entropy loss.  
L1
L1
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1
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Figure 2.30 Negative Cooperativity in Synthetic Allosteric Model  
 
Another possibility is that despite the fact that both -Ser-Asp-Met-Ser- and 
Asp811/Arg883 in native invasin are resided in different domains, the interface 
between these domains is relatively flexible and is regarded as allosteric site. 
Conformational changes upon the binding of invasin to its receptor could take place 
and the relative orientations between these two binding domains might be altered. 
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While in the design of artificial peptide inhibitors it would be extremely difficult to 
take this into account, since the crystal structure of integrin α3β1 and that of its 
complex with invasin are up to now unavailable. Negative cooperativity can be 
realized if occupation of one binding site leads to the release of a substrate at the 
second binding site, which does not fit anymore after the induced conformational 
change (see Figure 2.30). However, this hypothesis was unable to be validated in this 
project. 
 
In summary, the synthesized peptide conjugates applied in the biological test did not 
exhibite optimal inhibitory capacities to inhibite the binding of laminin332 to integrin 
α3β1. However, these peptide conjugates did possess capability of inhibiting the 
association between integrin α3β1 and laminin-332 to some extent, although not 
optimally.  
 
2.5.3.5 Analysis of Biological Assay Error 
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Figure 2.31 Inhibitory Capacities of Same Peptides In Two Batch Assay 
 
It is necessary to analyze the factors of error in the biological assay. For the first batch 
of analysis (shown as the red bars in Figure 2.31), the peptides were weighed with a 
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balance with an accuration of 0.1 mg. As the amounts of peptides subjected to the 
biological assay were mostly in a couple of milligram range, the herein generated 
errors could be relatively large. The second batch of biological assay were associated 
with a balance accurated at 0.01 mg. From the comparison of two batch analysis, it is 
discernable that there are some discrepancies between the same peptide inhibitors in 
different assays as their inhibitory capacities are concerned. This might be due to the 
systematic weighing errors as was analyzed above. Other factors such as the different 
extent of integrin activations could also be attributed to the inhibitory discrepancies 
between the different assays. However, the trends of inhibitory capacities between the 
two batch analyses are comparative as is shown by the Figure. The relative inhibitions 
between the diverse peptides are reliable in the biological assay. 
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2.6 Experiments 
 
2.6.1 General Methods 
 
Flash Chromatography 
Silica gel 60 (40-63 μm), Merck. 
 
Thin Layer Chromatography 
TLC Plate (Silica gel 60 F254) Merck; Detection: UV (254 nm, MinUVIS) Desaga. 
 
Solvent 
Solvents were technical grade and freshly distilled except otherwise mentioned; 
Acetonitrile for RP-HPLC was from Merck with LiChrosolv® grade; Water for 
RP-HPLC was processed by MiliQ water purification apparatus (resistance = 
18.2 MΩ·cm-1). Dichloromethane was distilled first over K2CO3, and then redistilled 
over CaH2. DMF was distilled over ninhydrin under vacuum. THF and Et2O were first 
distilled over KOH, and then redistilled over Na/benzophenone. Toluene was distilled 
over Na. 
 
NMR Spectroscopy 
DRX-500 (Bruker), Measure Frequency: 1H-NMR: 500.13 MHz, room temperature 
 
MALDI-ToF Mass Spectrometry 
The Voyager-DE BioSpectrometry Workstaton (Applied Biosystems) MALDI-ToF 
Mass Spectrometer with a 1.20 m flight tube was operated with a positive mode. The 
ionized compounds were desorbed by LSI-Nitrogen-Laser (λ = 337 nm, Pulse Range: 
3 ns, Repeat Frequency: 3 Hz). Accelerating voltage: 20 Kv, grid voltage: 94%, guide 
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wire: 0.05%, extraction delay time: 100 ns. 2,5-Dihydroxy benzoic acid (DHB) was 
used as matrix for MALDI-Tof MS measurements.  
 
Digital Polarimeter 
DIP-360 (Jasco), cell length: 10 cm, wavelength: 589 nm, room temperature 
 
Microwave Peptide Synthesizer 
CEM Microwave Peptide Synthesizer.  
Fmoc Deprotection (twice): 1st time: 75 °C, 30 s, 35 w;  
2nd time: 75 °C, 180 s, 35 w 
Coupling: 75 °C, 300 s, 20 w. 
 
CD Spectroscopy 
CD spectroscopy was done on a J-810 Spectrometer (Jasco) in the range of 
185-300 nm. Parameters: band width: 1 nm; response: 1 s; sensitivity: standard   
datapitch: 0.2 nm; scanning speed: 50 nm/min, optical path: 0.2 mm, accumulation: 3. 
 
The measured CD spectra were smoothed through Means-Movement method, and 
converted to molar ellipticity of mean amino acid residue ([θ]MRW). 
 
Analytical RP-HPLC 
Pump: Thermo Separation Products P4000 
Detector: Thermo Separation Products UV6000 LP, λ = 220 nm/ 254 nm 
Column: Phenomenex® Jupiter Proteo C12 (4 μm, 250×4.6 mm) 
Eluent A: CH3CN/H2O/TFA, 95:5:0.1 
Eluent B: H2O/CH3CN/TFA, 95:5:0.1 
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Method I 
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 0 100 1.0 
5 5 95 1.0 
25 50 50 1.0 
30 0 100 1.0 
 
Method II 
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 0 100 1.0 
3 0 100 1.0 
40 100 0 1.0 
50 0 100 1.0 
 
Preparative RP-HPLC 
 
Apparatus A 
Pump: Thermo Separation Products P4000 
Detector: Thermo Separation Products UV1000 LP, λ = 220 nm 
Column: Phenomenex® Jupiter Proteo C12 (90 Å, 10 μm, 250×21.2 mm) 
Eluent A: CH3CN/H2O/TFA  95:5:0.1 
Eluent B: H2O/CH3CN/TFA  95:5:0.1 
Apparatus B 
Pump: Merck Hitachi L-7150 
Detector: Merck Hitachi UV-VIS L-7420, λ = 220 nm 
Cloumn: Phenomenex® Jupiter Proteo C18 (300 Å, 10 μm, 250×21.2 mm) 
Eluent A: CH3CN/H2O/TFA  95:5:0.1 
Eluent B: H2O/CH3CN/TFA  95:5:0.1 
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Method 1                            
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 0 100 13.0 
5 0 100 13.0 
50 10 90 13.0 
55 10 90 13.0 
60 0 100 13.0 
65 0 100 13.0 
Method 2 
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 0 100 13.0 
5 0 100 13.0 
50 20 80 13.0 
55 20 80 13.0 
60 0 100 13.0 
65 0 100 13.0 
Method 3                                                                           
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 0 100 13.0 
5 0 100 13.0 
50 1 99 13.0 
55 1 99 13.0 
60 0 100 13.0 
65 0 100 13.0 
Method 4 
 
 
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 0 100 13.0 
5 0 100 13.0 
100 1 99 13.0 
110 1 99 13.0 
120 0 100 13.0 
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Method 5  
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 0 100 13.0 
50 5 95 13.0 
55 5 95 13.0 
65 0 100 13.0 
70 0 100 13.0 
Method 6  
Time (min) Eluent A (%) Eluent B (%) Flow Rate 
0 0 100 13.0 
50 10 90 13.0 
55 10 90 13.0 
65 0 100 13.0 
70 0 100 13.0 
Method 7  
Time (min) Eluent A (%) Eluent B (%) Flow Rate 
0 0 100 10.0 
10 0 100 10.0 
20 0 100 10.0 
30 0 100 10.0 
40 0 100 10.0 
50 0 100 10.0 
Method 8 
Time (min) Eluent A (%) Eluent B (%) Flow Rate 
0 0 100 10.0 
60 20 80 10.0 
65 0 100 10.0 
75 0 100 10.0 
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Method 9  
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 0 100 13.0 
30 30 70 13.0 
35 30 70 13.0 
40 0 100 13.0 
Method 10  
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 70 30 10.0 
30 100 0 10.0 
50 100 0 10.0 
60 8 92 10.0 
65 8 92 10.0 
Method 11 
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 0 100 13.0 
15 100 0 13.0 
20 100 0 13.0 
25 0 100 13.0 
30 0 100 13.0 
Method 12  
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 0 100 13.0 
50 50 50 13.0 
55 0 100 13.0 
65 0 100 13.0 
70 0 100 13.0 
Method 13  
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 0 100 13.0 
30 40 60 13.0 
35 40 60 13.0 
40 0 100 13.0 
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Method 14  
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 10 90 10.0 
5 10 90 10.0 
40 50 50 10.0 
45 50 50 10.0 
50 0 100 10.0 
55 0 100 10.0 
Method 15  
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 0 100 10.0 
5 0 100 10.0 
40 30 70 10.0 
45 30 70 10.0 
50 0 100 10.0 
55 0 100 10.0 
Method 16  
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 30 70 13.0 
40 100 0 13.0 
45 100 0 13.0 
50 0 100 13.0 
Method 17  
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 8 92 13.0 
5 8 92 13.0 
35 50 50 13.0 
40 50 50 13.0 
50 0 100 13.0 
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Method 18  
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 20 80 13.0 
40 35 65 13.0 
45 35 100 13.0 
50 0 100 13.0 
55 0 100 13.0 
Method 19  
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 25 75 13.0 
40 40 60 13.0 
45 40 60 13.0 
50 0 100 13.0 
55 0 100 13.0 
Method 20  
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 8 92 13.0 
5 8 92 13.0 
35 100 0 13.0 
40 100 0 13.0 
50 0 100 13.0 
Method 21  
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 70 30 13.0 
40 85 15 13.0 
45 100 0 13.0 
50 0 100 13.0 
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Method 22 
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 0 100 13.0 
50 20 80 13.0 
55 20 80 13.0 
65 0 100 13.0 
70 0 100 13.0 
Method 23  
Time (min) Eluent A (%) Eluent B (%) Flow Rate (ml/min)
0 0 100 13.0 
30 80 20 13.0 
35 80 20 13.0 
40 0 100 13.0 
45 0 100 13.0 
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2.6.2 Synthetic Experiments 
 
2.6.2.1 General Methodology of SPPS 
2.6.2.1.1 Loading of o-chlorotritylchloride Resin and Quantification 
The o-chlorotritylchloride resin applied in the SPPS was first swollen in dry CH2Cl2. 
3 equiv of Fmoc-amino acid and 3 equiv DIPEA were dissolved in dry CH2Cl2 (ca. 
10 ml DCM/1 g amino acid). After shaking the mixture at room temperature for 5 min, 
additional 4.5 equiv DIPEA were added. The resin was shaken gently at room 
temperature for further 60 min before methanol (ca. 0.8 ml methanol/1 g resin) was 
introduced to the reaction system in order to trap residual unreacted Trt(2-Cl) chloride 
functionalities on the resin. The endcapping process took normally 15 min at room 
temperature. The Fmoc-amino acid loaded resin was then filtered and subsequently 
washed with 4×DCM, 4×DMF, 4×DCM, 4×CH3OH in turn. The resin was dried 
under vacuum overnight until its weight remained constant.  
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Scheme 2.15 Quantification of the loading rate of Fmoc-amino acid on resin 
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Ca. 1 mg dried Fmoc-amino acid loaded resin 16 was treated with 3 ml 
20% piperidine /DMF. The Fmoc-protecting group is cleaved under this basic 
condition and the dibenzofulvene intemediate 17 is captured by piperidine to generate 
the piperidine-dibenzofulvene-adduct 19, which was quantified by UV absorption at 
290 nm (Scheme 2.15). The resin loading with Fmoc-amino acid was thus calculated 
through the following empirical equation: 
 
Resin Loading (mmol/g) = Abs/(weight of resin (mg) × 1.65)    (Abs: absorption) 
 
As the Fmoc group on the solid support could be possibly cleaved gradually at 
ambient temperature, the dibenzofulvene 17 is able to initiate a series of side reactions 
in the following peptide synthetic process. The Fmoc-amino acid loaded resin 16 is 
therefore supposed to be treated with Fmoc deprotection before storage. 
Fmoc-deprotecting solution pipieridine/DBU/DMF (2:2:96) was added to 16 at room 
temperature in order to remove the Fmoc protecting groups. The obtained Nα-free 
amino acid loaded resin 18 was then washed by 4×DCM, 4×DMF, 4×DCM, 
4×CH3OH in turn. The resin was dried under vacuum overnight until its weight 
remained constant. 
 
2.6.2.1.2 On-resin Peptide Chain Elongation by Fmoc/tBu Chemistry 
Except otherwise mentioned, 3 equiv Fmoc-amino acid (with respect to the Nα-free 
amino acid loaded resin 18) were dissolved in a minimum volume of DMF (ca. 
1 mmol amino acid/ml). 3 equiv uronium-type coupling reagent, e.g. TBTU, TCTU, 
or HATU, also dissolved in minimal volume of DMF separately, were added and then 
6 equiv DIPEA were added to the reaction mixture. The duration of this preactivation 
process should be kept less than 5 min to prevent the formation of oxazolone 
intermediate that causes substantial racemization of the amino acid bearing the chiral 
α-carbon. The solution of activated Fmoc-amino acid was then transferred to the 
Nα-free peptidyl-resin under argon. The coupling reaction took approximately 45 
minutes at room temperature, depending on the sequence. The coupling result could 
be controlled by MS such as MALDI-ToF-MS. Alternatively, the Kaiser Test, which 
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detects the primary amine functionalities, can be applied to probe if there is still 
unreacted amine group on the peptidyl resin. If the coupling did not go to completion, 
a second coupling could be carried out to enhance the efficiency. Otherwise, the 
uncoupled truncated peptidyl chain could be capped using Ac2O in the presence of 
tertiary amine such as pyridine or triethylamine, which do not cleave the Nα-Fmoc 
temporary protecting group. Upon completion of the coupling, the peptidyl resin was 
washed with DMF at least four times to remove the remaining reagents attached on 
the resin. 
 
The Nα-Fmoc temporary protecting group on the peptidyl resin was treated with 20% 
piperidine in DMF twice at room temperature for 5 minutes and 15 minutes, 
respectively. The Nα-free peptidyl-resin was subsequently washed with DMF at least 
four times to remove the remaining reagents attached to the resin.  
 
2.6.2.1.3 Acetylation of the N-terminus of Peptide 
3 equiv Ac2O (in terms of Nα-free peptidyl resin) and 3 equiv Et3N were dissolved in 
DMF, which was subsequently transferred to the Nα-free peptidyl resin. The mixture 
was agitated by argon bubbling at room temperature for approximately 30 min. The 
N-acetylation was analyzed by MALDI-ToF-MS and Kaiser Test. After the 
completion of the acetylation was the N-acetyl peptidyl resin washed by CH2Cl2 (4×), 
DMF (4×), CH2Cl2 (4×) in turn. 
 
2.6.2.1.4 Cleavage of the Fully Protected Peptide from the Resin 
The Nα-unprotected, side-chain protected peptidyl resin was washed consecutively 
with DMF and CH2Cl2. 5 ml 1% TFA in CH2Cl2 were then added. The system was 
agitated by bubbling argon through it at room temperature for approximately 5 min. 
The resin was then filtered and the filtrate was neutralized by pyridine and collected. 
Another portion of 5 ml of fresh 1% TFA in CH2Cl2 was added to the resin, this cycle 
was repeated 10 times and the the resin was washed with CH2Cl2 until its color 
converted from red to yellow. The solvent of the filtrate was removed under reduced 
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pressure and the yielded raw fully protected peptide was lyophilized for the next step 
of reaction or purification.  
 
2.6.2.2 Microwave Synthesis of Peptide with SPPS Manner 
For a 0.25 mmol peptide synthesis scale, 10 ml of 20% piperidine in DMF were added 
to the peptidyl resin for Fmoc removal. The reaction was performed at 75 °C for 30 
seconds with 35 watt microwave. After draining and washing, further 10 ml of 20% 
piperidine in DMF were added, reacted with peptidyl resin at 75 °C for 180 seconds 
in 35 watt microwave. At the coupling reaction stage 5 ml 0.2 M amino acid DMF 
solution, 2 ml 0.5 M TBTU solution in DMF, and 1 ml 2 M DIPEA solution in NMP 
were added to the peptidyl resin, reacted at 75 °C for 300 seconds in 20 watt 
microwave. The cleavage of complete fully protected peptide from the resin, 
side-chain deprotection and consequent purification of target peptide was employed as 
described for manual peptide synthesis (see also chapter 2.6.2.1). 
 
2.6.2.3 Cyclization of Nα-free Side-chain Protected Linear Peptides 
DMF was added to a certain amount of Nα-unprotected, side-chain protected peptide. 
The peptide solution was transferred into a syringe attached to a needle. 3 equiv 
uronium coupling reagent e.g. HATU were dissolved in the same amount of DMF 
before being transferred into another syringe of the same type. The two syringes were 
fixed to the double-channel-syringe-pump. The peptide solution and coupling reagent 
solution were added dropwise over 24 hours into a three-neck-flask containing 
6 equiv DIPEA dissolved in DMF. Approximately 1 mg HATU was also added to the 
flask as to prevent that the peptide solution was dropped prior to HATU, which 
abstains the real time excess of peptide. As the oxygen can sometimes exert negative 
influences on the coupling reaction, and is furthermore problematic for some kind of 
amino acids, such as methionine or cysteine, the cyclization reaction system is 
preferably protected by inert gas. After the peptide and HATU solution were 
completely added into the flask, the solvent was then removed under reduced pressure 
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and the crude peptide was lyophilized for the next step of reaction or purification. 
 
2.6.2.4 Side Chain Deprotection 
The cocktail composed of mild acid such as TFA and scavengers like phenol, H2O, 
thiol, and silane, Reagent K (TFA/phenol/H2O/thioanisol/ethane-1,2-dithiol, 
82.5:5:5:5:2.5) for instance, was added to the lyophilized side-chain-protected peptide 
to bring about deprotection. For peptides without sulfur-containing amino acids, the 
deprotection cocktail consisting TFA/H2O/triisopropylsilane (92.5:2.5:2.5) can cleave 
the side-chain protecting groups smoothly and quantitatively at ambient temperature. 
For peptides containing cysteine or methionine, which are readily oxidized under the 
acidolytic deprotection conditions, extra protection afforded by scavengers is 
necessary. Under these kinds of circumstances, Reagent K is the preferable choice as 
a deprotection cocktail. Except the special scavengers for the methionine- or 
cysteine-containing peptides, the deproctection of these peptides should be carried out 
under inert gas. Under cautious treatment, no oxidation at the methionine residue was 
observed during the deprotection process of the sulfur-containing peptides.  
 
For short- and medium-size peptides, the duration of the deprotection normally lasts 
no longer than 3 hours at room temperature before the quantitative reaction is 
obtained. For longer peptides, or those who are readily aggregating in solutions so 
that deprotection is to some extent impeded, longer deprotection times or slight 
increase of the deprotection temperature are used to achieve quantitative cleavage. For 
some acid-sensitive sequences and aspartate-rich peptides, the aforementioned 
methods could lead to decomposition of the peptide at the sensitive sequence region 
and the side reaction of the aspartimide formation, respectively. Hence, the real-time 
analysis of the deprotection reaction with the method such as MALDI-ToF-MS is 
necessary.  
 
After complete deprotection of the concerned peptides, the solvent was removed 
under reduced pressure. A small amount of TFA was added to the peptide residues 
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afterwards in order to have them fully dissolved. The peptide solution was slowly 
added to ice-cold diethyl ether resided in an ice-water bath. The target peptides 
precipitate upon addition of the solution into cold ether. The suspension was stirred 
for approximately 30 minutes at 0 ºC before the scavenger derivative-containing 
diethyl ether fraction was removed after centrifugation. The solid peptide was again 
added to another portion of fresh ice-cold diethyl ether and stirred for 30 minutes in 
the ice-water bath. Likewise, the ether solution was removed by centrifugation. The 
obtained peptide solids were dissolved in water or water/acetonitrile, lyophilized and 
purified by RP-HPLC. 
 
2.6.2.5 On-resin Coupling of α-Aminoisobutyric Acid through Azido 
Acid Chloride 
The Nα-free peptidyl resin (1 equiv) was swollen in the mixture of 10 equiv NEt3 in 
dry CH2Cl2. The concerned azidoacidchloride (N2=Aib-Cl, 7 equiv) was cautiously 
and slowly added to Nα-free peptidyl resin. The reaction system was agitated through 
argon bubbling at room temperature for approximately 30-45 min. For MS analysis of 
the coupling results, a small amount of resin could be sampled and cleaved by HFIP 
(20% in CH2Cl2) after washing. Provided that the coupling did not go to completion, 
methods such as elongation of the coupling time or, alternatively, multiple coupling 
could be carried out. After the completion of the reaction the resin was filtered and 
washed by CH2Cl2 (4×), DMF (4×), CH2Cl2 (4×) orderly. 
 
A suspension of Sn(SPh)2 (10 equiv in terms of peptidyl resin) in dry CH2Cl2 with 
thiophenol (30 equiv) and NEt3 (50 equiv) was mixed at room temperature for 5 min, 
which was subsequently added to the Nα-azido peptidyl resin in order to yield the free 
N-terminus for the next coupling. The deprotection reaction was agitated gently by 
argon bubbles at room temperature for approximately 20 min. N2 was yielded upon 
the deprotection. Upon the completion of reaction the peptidyl resin was filtered and 
washed by CH2Cl2 (4×), DMF (4×), CH2Cl2 (4×). 
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2.6.2.6 Selective Removal of Aloc with Palladium(0) Catalyst  
Approximately 20 μmol fully protected cyclic SDMS derivative peptide containing 
Lys(Aloc) residue in the sequence were dissolved in 2-3 ml dry DCM, 1 equiv 
Pd(PPh3)4 and 30 equiv PhSiH3 were added to the peptide solution. Bubbles were 
formed upon the addition of palladium(0) catalyst and silicon hydride scavengers. The 
solution was stirred at the ambient temperature for approximately 3 hours with the 
protection of inert gas such as argon until the Aloc protecting group was removed 
quantitatively, which was monitored by MALDI-ToF-MS. Upon completion of the 
Aloc deprotecting reaction the solvent was removed under reduced pressure. The 
residue was dissolved in DMF and subjected to RP-HPLC in order to remove the 
palladium catalyst and purify the peptide. The obtained peptide was analyzed by 
MALDI-ToF-MS and analytical RP-HPLC. The portion of cyclic SDMS derivative 
with the free Lys residue was lyophilized and applied to the segment condensation. 
 
2.6.2.7 Segment Condensation of Cyclic Peptide with Linker Peptides  
1.1-1.5 equiv (relative to cyclic SDMS derivative peptide with unprotected Lys 
residue) N-Fmoc side-chain protected linker peptides with Asp/Arg at the flank (see 
also chapter 2.5.1.2.2) were dissolved in a minimal amount of dry DMF, 2.2-3.0 equiv 
HATU and 4.4-6.0 equiv DIPEA (relative to cyclic SDMS derivative peptide) were 
added to the linker peptide solution. The solution was stirred for approximately 10-15 
min at ambient temperature before being added to the DMF solution of cyclic SDMS 
derivative peptide with unprotected Lys residue. The combined solution was stirred at 
ambient temperature for approximately 30 min under argon. Further 2.2-3.0 equiv 
HATU and 4.4-6.0 equiv DIPEA were then added to the solution, the mixture was 
stirred at room temperature overnight under argon until the completion of segment 
condensation, as analyzed by the MALDI-ToF-MS. The solvent was then removed 
under the reduced pressure. The solids of peptide mixtures were dissolved in DMF 
and applied to RP-HPLC for purification. The residue was analyzed by 
MALDI-ToF-MS and analytical RP-HPLC. 
2.6 Experiments 
 112 
2.6.2.8 Synthetic Peptide/Peptidomimetic Inhibitors 
H-Ser-Asp-Met-Ser-D-Lys-Gly-OH (PI 1) 
 
H2N
O
OH
H
N
O
N
H O
H
N
O
N
H
HO
O
H
N
NH2
O
OH
HO
O
S
PI 1  
 
The synthesis of fully protected peptide H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)- 
D-Lys(Boc)-Gly-OH Prot.PI 1 was carried out manually according to the general 
procedure of SPPS (Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl 
resin (0.923 mmol/g, 0.3 mmol), TBTU as coupling reagent. Deprotection of the 
peptide was achieved with the deprotection cocktail Reagent K. 
 
(Except otherwise mentioned, all the yields listed in this project represent those after 
RP-HPLC. vide infra) 
 
Yield: H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-D-Lys(Boc)-Gly-OH (Prot.PI 1)  
0.100g/0.11 mmol 
 H-Ser-Asp-Met-Ser-D-Lys-Gly-OH (PI 1) 0.0289g/0.0463 mmol (15.4%) 
 
Formula: C23H41N7O11S 
 
Molecular Mass: 623.26 g/mol 
 
MS (MALDI-ToF): m·z-1 = 625.00 [M+H]+, 646.99 [M+Na]+, 662.96 [M+K]+, 668.98 
[M+2Na-H]+ 
Calculated Mass: [C23H42N7O11S]+ = 624.27, [C23H41N7NaO11S]+ = 646.25, 
[C23H41KN7O11S]+ = 662.22, [C23H40N7Na2O11S]+ = 668.23 
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Preparative RP-HPLC: Apparatus A, Method 1, tR = 10.90 min 
 
Analytical RP-HPLC: Method I, tR = 6.63 min, 100% (220 nm) 
 
H-Ser-Asp-Met-Ser-Lys-Gly-OH (PI 2) 
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The synthesis of fully protected peptide H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)- 
Lys(Boc)-Gly-OH Prot.PI 2 was carried out manually according to the general 
procedure of SPPS (Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl 
resin (0.923 mmol/g, 0.15 mmol), TBTU as coupling reagent. Deprotection of the 
peptide was achieved with the deprotection cocktail Reagent K  
 
Yield: H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Lys(Boc)-Gly-OH (Prot.PI 2)  
0.098 g/0.11 mmol 
    H-Ser-Asp-Met-Ser-Lys-Gly-OH (PI 2) 0.0193 g/0.031 mmol (20.7%) 
 
Formula: C23H41N7O11S 
 
Molecular Mass: 623.26 g/mol 
 
MS (MALDI-ToF): m·z-1 = 625.17 [M+H]+, 647.14 [M+Na]+, 663.12 [M+K]+, 669.12 
[M+2Na-H]+ 
Calculated Mass: [C23H42N7O11S]+ = 624.27, [C23H41N7NaO11S]+ = 646.25, 
[C23H41KN7O11S]+ = 662.22, [C23H40N7Na2O11S]+ = 668.23 
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Preparative RP-HPLC: Apparatus A, Method 1, tR = 11.20 min 
 
Analytical RP-HPLC: Method I, tR = 6.35 min, 100% (220 nm) 
 
cyclo-(-Ser-Asp-Met-Ser-Lys-Gly-) (PI 3) 
NH
HO
NH
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NH S
NH
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O
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The synthesis of fully protected linear peptide H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)- 
Lys(Boc)-Gly-OH Prot.PI 3 was carried out manually according to the general 
procedure of SPPS (Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl 
resin (0.923 mmol/g, 0.3 mmol), TBTU as coupling reagent. Cyclization of the 
precursor linear peptide Prot.PI 3 was carried out under pseudo high dilution 
conditions with HATU as coupling reagent. Deprotection of the fully protected cyclic 
peptide Cyc.Pro.PI 3 was achieved with the deprotection cocktail Reagent K. 
 
Yield: H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Lys(Boc)-Gly-OH (Prot.PI 3) 
0.1466 g/0.16 mmol 
      cyclo-(-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Lys(Boc)-Gly-) (Cyc.Pro.PI 3) 
0.068 g/0.077 mmol 
    cyclo-(-Ser-Asp-Met-Ser-Lys-Gly-) (PI 3) 0.0088 g/0.015 mmol (5.0%) 
 
Formula: C23H39N7O10S 
 
Molecular Mass: 605.25 g/mol 
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MS (MALDI-ToF): m·z-1 = 607.53 [M+H]+, 629.52 [M+Na]+, 645.53 [M+K]+, 651.52 
[M+2Na-H]+ 
Calculated Mass: [C23H40N7O10S]+ = 606.26, [C23H39N7NaO10S]+ = 628.24, 
[C23H39KN7O10S]+ = 644.21, [C23H38N7Na2O10S]+ = 650.22 
 
Preparative RP-HPLC: Apparatus A, Method 2, tR = 19.00 min 
 
Analytical RP-HPLC: Method I, tR = 11.58 min, 100% (220 nm) 
 
cyclo-(-Ser-Asp-Met-Ser-D-Lys-Gly-) (PI 4) 
 
NH
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The synthesis of fully protected linear peptide H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)- 
D-Lys(Boc)-Gly-OH Prot.PI 4 was carried out manually according to the general 
procedure of SPPS (Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl 
resin (0.923 mmol/g, 0.3 mmol), TBTU as coupling reagent. Cyclization of the 
precursor linear peptide Prot.PI 4 was carried out under pseudo high dilution 
conditions with HATU as coupling reagent. Deprotection of fully protected cyclic 
peptide Cyc.Prot.PI 4 was achieved with the deprotection cocktail Reagent K. 
 
Yield: H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-D-Lys(Boc)-Gly-OH (Prot.PI 4)  
0.2352 g/ 0.264 mmol 
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cyclo-(-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-D-Lys(Boc)-Gly-) (Cyc.Prot.PI 4) 
0.1688 g/0.193 mmol 
 cyclo-(-Ser-Asp-Met-Ser-Lys-Gly-) (PI 4) 0.0190 g/0.031 mmol (10.3%) 
 
Formula: C23H39N7O10S 
 
Molecular Mass: 605.25 g/mol 
 
MS (MALDI-ToF): m·z-1 = 606.89 [M+H]+, 628.86 [M+Na]+, 644.93 [M+K]+, 650.89 
[M+2Na-H]+ 
 
Calculated Mass: [C23H40N7O10S]+ = 606.26, [C23H39N7NaO10S]+ = 628.24, 
[C23H39KN7O10S]+ = 644.21, [C23H38N7Na2O10S]+ = 650.22 
 
Preparative RP-HPLC: Apparatus A, Method 2, tR = 18.67 min 
 
Analytical RP-HPLC: Method I, tR = 11.78 min, 100% (220 nm) 
 
cyclo-(-Ser-Asp-Met(O)-Ser-Lys-Gly-) (PI 5) 
 
NH
HO
NH
OHO
NH S
NH
OH
H
N
NH2
NH
O
O
O
O
O
O
O
PI 5  
The synthesis of deprotected cyclic peptide PI 3 was carried out as mentioned above. 
0.03 mmol peptide PI 3 was dissolved in DMF, into which 1 ml 30 % (v/v) H2O2 was 
injected slowly through single-channel syringe pump over 1 h at ambient temperature. 
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The oxidation reaction was detained at the sulfoxide level through this method, as 
monitored by MALDI-ToF-MS. The target oxidized derivative peptide PI 5 was 
subsequently purified by RP-HPLC. 
 
Yield: cyclo-(-Ser-Asp-Met(O)-Ser-Lys-Gly-) (PI 5) 0.0091 g/0.015 mmol (50.0%) 
 
Formula: C23H39N7O11S 
 
Molecular Mass: 621.24 g/mol 
 
MS (MALDI-ToF): m·z-1 = 622.87 [M+H]+, 644.83 [M+Na]+, 660.08 [M+K]+, 667.10 
[M+2Na-H]+ 
Calculated Mass: [C23H40N7O11S]+ = 622.25, [C23H39N7NaO11S]+ = 644.23, 
[C23H39KN7O11S]+ = 660.21, [C23H38N7Na2O11S]+ = 666.22 
 
Preparative RP-HPLC: Apparatus A, Method 3, tR = 8.04 min 
 
Analytical RP-HPLC: Method I, tR = 4.79 min, 100% (220 nm) 
cyclo-(-Ser-Asp-Met(O)-Ser-D-Lys-Gly-) (PI 6) 
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The synthesis of deprotected cyclic peptide PI 4 was carried out as mentioned above. 
0.03 mmol peptide PI 4 was dissolved in DMF, into which 1 ml 30 % (v/v) H2O2 was 
injected slowly through single-channel syringe pump over 1 h at ambient temperature. 
The oxidation reaction was detained at the sulfoxide level by this method, as 
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monitored by MALDI-ToF-MS. The target oxidized derivative cyclic peptide PI 6 
was subsequently purified by RP-HPLC. 
 
Yield: cyclo-(-Ser-Asp-Met(O)-Ser-Lys-Gly-) (PI 6) 0.0099 g/0.016 mmol (53.3%) 
 
Formula: C23H39N7O11S 
 
Molecular Mass: 621.24 g/mol 
 
MS (MALDI-ToF): m·z-1 = 623.25 [M+H]+, 645.04 [M+Na]+, 661.08 [M+K]+, 667.05 
[M+2Na-H]+ 
Calculated Mass: [C23H40N7O11S]+ = 622.25, [C23H39N7NaO11S]+ = 644.23, 
[C23H39KN7O11S]+ = 660.21, [C23H38N7Na2O11S]+ = 666.22 
 
Preparative RP-HPLC: Apparatus A, Method 4, tR = 8.04 min 
 
Analytical RP-HPLC: Method I, tR = 4.16 min, 100% (220 nm) 
 
cyclo-(-Ser-D-Asp-Met-Ser-D-Lys-Gly-) (PI 7) 
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The synthesis of protected linear peptide H-Ser(tBu)-D-Asp(OtBu)-Met-Ser(tBu)- 
D-Lys(Boc)-Gly-OH Prot.PI 7 was performed manually according to the general 
procedure of SPPS (Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl 
resin (0.923 mmol/g, 0.3 mmol), TBTU as coupling reagent. Cyclization of the 
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precursor linear peptide Prot.PI 7 was carried out under pseudo high dilution 
conditions with HATU as coupling reagent. Deprotection of the fully protected cyclic 
peptide Cyc.Prot.PI 7 was achieved with the deprotection cocktail Reagent K. 
 
Yield: H-Ser(tBu)-D-Asp(OtBu)-Met-Ser(tBu)-D-Lys(Boc)-Gly-OH (Prot.PI 7) 
0.1403 g/ 0.16 mmol 
       cyclo-(-Ser(tBu)-D-Asp(OtBu)-Met-Ser(tBu)-D-Lys(Boc)-Gly-)  
(Cyc.Prot.PI 7) 0.0892 g/0.10 mmol 
    cyclo-(-Ser-D-Asp-Met-Ser-D-Lys-Gly-) (PI 7) 0.0242 g/0.04 mmol (13.3%) 
 
Formula: C23H39N7O10S 
Molecular Mass: 605.25 g/mol 
MS (MALDI-ToF): m·z-1 = 607.80 [M+H]+, 629.28 [M+Na]+, 645.83 [M+K]+, 651.84 
[M+2Na-H]+ 
Calculated Mass: [C23H40N7O10S]+ = 606.26, [C23H39N7NaO10S]+ = 628.24, 
[C23H39KN7O10S]+ = 644.21, [C23H38N7Na2O10S]+ = 650.22 
 
Preparative RP-HPLC: Apparatus A, Method 2, tR = 15.04 min 
Analytical RP-HPLC: Method I, tR = 11.63 min, 100% (220 nm) 
 
cyclo-(-Ser-D-Asp-Met-Ser-Lys-Gly-) (PI 8) 
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Fully protected linear peptide H-Ser(tBu)-D-Asp(OtBu)-Met-Ser(tBu)-Lys(Boc)- 
Gly-OH Prot.PI 8 was synthesized manually according to the general procedure of 
SPPS (Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl resin 
(0.923 mmol/g, 0.3 mmol), TBTU as coupling reagent. Cyclization of the fully 
protected precursor linear peptide Prot.PI 8 was carried out under pseudo high 
dilution conditions with HATU as coupling reagent. Deprotection of the fully 
protected cyclic peptide Cyc.Prot.PI 8 was achieved with the deprotection cocktail 
Reagent K. 
 
Yield: H-Ser(tBu)-D-Asp(OtBu)-Met-Ser(tBu)-Lys(Boc)-Gly-OH (Prot.PI 8) 
0.1811g/ 0.203mmol 
cyclo-(-Ser(tBu)-D-Asp(OtBu)-Met-Ser(tBu)-Lys(Boc)-Gly-) (Cyc.Prot.PI 8)  
0.113 g/0.13 mmol 
    cyclo-(-Ser-D-Asp-Met-Ser-Lys-Gly-) (PI 8) 0.0363 g/0.06 mmol (20%) 
 
Formula: C23H39N7O10S 
 
Molecular Mass: 605.25 g/mol 
 
MS (MALDI-ToF): m·z-1 = 607.93 [M+H]+, 629.96 [M+Na]+, 645.99 [M+K]+, 652.00 
[M+2Na-H]+ 
Calculated Mass: [C23H40N7O10S]+ = 606.26, [C23H39N7NaO10S]+ = 628.24, 
[C23H39KN7O10S]+ = 644.21, [C23H38N7Na2O10S]+ = 650.22 
 
Preparative RP-HPLC: Apparatus A, Method 2, tR = 16.33 min 
 
Analytical RP-HPLC: Method I, tR = 11.72 min, 100% (220 nm) 
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cyclo-(-Ser-Asp-Aib-Ser-D-Lys-Gly-) (PI 9) 
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The fully protected linear peptide H-Ser(tBu)-Asp(OtBu)-Aib-Ser(tBu)-D-Lys(Boc)- 
Gly-OH Prot.PI 9 was synthesized manually according to the general procedure of 
SPPS (Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl resin 
(0.8 mmol/g, 0.3 mmol), TBTU as coupling reagent. Aib was incorporated into the 
growing peptide chains on the support as the form of N2=Aib-Cl 13 (7 equiv) in the 
presence of 10 equiv NEt3. Deprotection of Nα-Azido group was achieved with 
10 equiv Sn(SPh)2, 30 equiv PhSH, and 50 equiv NEt3. Cyclization of the precursor 
linear peptide Prot.PI 9 was carried out under pseudo high dilution conditions with 
HATU as coupling reagent according to the aforementioned procedure. Deprotection 
of the fully protected cyclic peptide Cyc.Prot.PI 9 was achieved with the 
deprotection cocktail Reagent K. 
 
Yield: H-Ser(tBu)-Asp(OtBu)-Aib-Ser(tBu)-D-Lys(Boc)-Gly-OH (Prot.PI 9) 
0.2777 g/ 0.16 mmol  
cyclo-(-Ser(tBu)-Asp(OtBu)-Aib-Ser(tBu)-D-Lys(Boc)-Gly-) (Cyc.Prot.PI 9) 
0.1208 g/0.15mol  
cyclo-(-Ser-Asp-Aib-Ser-D-Lys-Gly-) (PI 9) 0.0772 g/0.14 mmol (46.6%) 
 
Formula: C22H37N7O10 
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Molecular Mass: 559.26 g/mol 
 
MS (MALDI-ToF): m·z-1 = 560.53 [M+H]+, 582.54 [M+Na]+, 598.53 [M+K]+, 604.52 
[M+2Na-H]+ 
Calculated Mass: [C22H38N7O10]+ = 560.27, [C22H37N7NaO10]+ = 582.25, 
[C22H37KN7O10]+ = 598.22, [C22H36N7Na2O10]+ = 604.23 
 
Preparative RP-HPLC: Apparatus A, Method 3, tR = 8.34 min 
 
Analytical RP-HPLC: Method I, tR = 5.41 min, 100% (220 nm) 
 
cyclo-(-Ser-Asp-Aib-Ser-Lys-Gly-) (PI 10) 
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The fully protected linear peptide H-Ser(tBu)-Asp(OtBu)-Aib-Ser(tBu)-Lys(Boc)- 
Gly-OH Prot.PI 10 was synthesized manually according to the general procedure of 
SPPS (Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl resin 
(0.8 mmol/g, 0.3 mmol), TBTU as coupling reagent. Aib was incorporated into the 
growing peptide chains on the support as the form of N2=Aib-Cl 13 (7 equiv) at the 
presence of 10 equiv NEt3. Deprotection of Nα-Azido group was achieved with 
10 equiv Sn(SPh)2, 30 equiv PhSH, and 50 equiv NEt3. Cyclization of the precursor 
linear peptide Prot.PI 10 was carried out under pseudo high dilution conditions with 
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HATU as coupling reagent according to the aforementioned procedure. Deprotection 
of the fully protected cyclic peptide Cyc.Prot.PI 10 was achieved with the 
deprotection cocktail Reagent K. 
 
Yield: H-Ser(tBu)-Asp(OtBu)-Aib-Ser(tBu)-Lys(Boc)-Gly-OH (Prot.PI 10) 
0.2887 g/ 0.16 mmol 
    cyclo-(-Ser(tBu)-D-Asp(OtBu)-Met-Ser(tBu)-Lys(Boc)-Gly-) (Cyc.Prot.PI 10) 
0.1308 g/0.16 mmol 
cyclo-(-Ser-Asp-Aib-Ser-Lys-Gly-) (PI 10) 
0.0606 g/0.11 mmol (36.6%) (after multiple RP-HPLC purification) 
 
Formula: C22H37N7O10 
 
Molecular Mass: 559.26 g/mol 
 
MS (MALDI-ToF): m·z-1 = 560.65 [M+H]+, 582.60 [M+Na]+, 598.68 [M+K]+, 604.68 
[M+2Na-H]+ 
Calculated Mass: [C22H38N7O10]+ = 560.27, [C22H37N7NaO10]+ = 582.25, 
[C22H37KN7O10]+ = 598.22, [C22H36N7Na2O10]+ = 604.23 
 
Preparative RP-HPLC: Apparatus A, Method 3, tR = 8.00 min 
 
Analytical RP-HPLC: Method I, tR = 5.58 min, 100% (220 nm) 
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cyclo-(-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-D-Lys-Gly-) (13) 
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The fully protected linear peptide H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-D-Lys(Aloc)- 
Gly-OH Prot.13 was synthesized manually according to the general procedure of 
SPPS (Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl resin 
(0.3 mmol), TBTU as coupling reagent. Cyclization of the precursor linear 
peptide Prot.13 was carried out under pseudo high dilution conditions with HATU as 
coupling reagent according to the aforementioned procedure. The fully protected 
cyclic peptide Cyc.Pro.13 was applied to selective deprotection with 1.0 equiv 
Pd(PPh3)4 and 30 equiv PhSiH3 in dry DCM at room temperature for 3 h, or 
alternatively, with 0.1 equiv Pd(PPh3)4 and 30 equiv PhSiH3 in liquid ammonia under 
-33oC for 3 h.  
 
Yield: H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-D-Lys(Aloc)-Gly-OH (Prot.13) 
0.2251g/ 0.25mmol 
       cyclo-(-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-D-Lys(Aloc)-Gly-) (Cyc.Prot.13) 
0.1886 /0.22 mmol 
   cyclo-(-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-D-Lys-Gly-) (13) 
0.1393 g/0.18 mmol (60.0%) 
 
Formula: C35H63N7O10S 
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Molecular Mass: 773.44 g/mol 
 
MS (MALDI-ToF): m·z-1 = 774.82 [M+H]+, 796.94 [M+Na]+, 812.89 [M+K]+ 
Calculated Mass: [C35H64N7O10S]+=774.44, [C35H63N7NaO10S]+=796.42, 
[C35H63KN7O10S]+=812.40 
 
Preparative RP-HPLC: Apparatus A, Method 3, tR = 8.34 min 
 
Analytical RP-HPLC: Method I, tR = 5.41 min, 100% (220 nm) 
 
cyclo-(-Ser-Asp-Met-Ser-Lys-Sar-) (PI 11) 
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The fully protected linear peptide H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Lys(Boc)- 
Sar-OH Prot.PI 11 was synthesized manually according to the general procedure of 
SPPS (Fmoc/tBu), with Fmoc-Sar-OH being loaded on the o-chlorotrityl resin 
(0.71 mmol/g, 0.3 mmol), TBTU as coupling reagent. Cyclization of the precursor 
linear peptide Prot.PI 11 was carried out under pseudo high dilution conditions with 
HATU as coupling reagent. Deprotection of the fully protected cyclic 
peptide Cyc.Prot.PI 11 was achieved with the deprotection cocktail Reagent K. 
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Yield: H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Lys(Boc)-Sar-OH (Prot.PI 11)  
0.0922 g/ 0.10 mmol 
       cyclo-(-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Lys(Boc)-Sar-) (Cyc.Prot.PI 11) 
0.0617 g/0.07 mmol 
cyclo-(-Ser-Asp-Met-Ser-Lys-Sar-) (PI 11) 
0.0335g/0.05 mmol (16.6%) 
 
Formula: C24H41N7O10S 
 
Molecular Mass: 619.26 g/mol 
 
MS (MALDI-ToF): m·z-1 = 621.50 [M+H]+, 643.51 [M+Na]+, 659.53 [M+K]+, 665.54 
[M+2Na-H]+ 
Calculated Mass: [C24H42N7O10S]+ = 620.27, [C24H41N7NaO10S]+ = 642.25, 
[C24H41N7KO10S]+ = 658.23, [C24H40N7Na2O10S ]+ = 664.24 
 
Preparative RP-HPLC: Apparatus A, Method 2, tR = 18.77 min 
 
Analytical RP-HPLC: Method I, tR = 12.11 min, 100% (220 nm) 
 
cyclo-(-Ser-Asp-Met-Ser-D-Lys-Sar-) (PI 12) 
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The fully protected linear peptide H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-D-Lys(Boc)- 
Sar-OH Prot.PI 12 was synthesized manually according to the general procedure of 
SPPS (Fmoc/tBu), with Fmoc-Sar-OH being loaded on the o-chlorotrityl resin 
(0.71 mmol/g, 0.3 mmol), TBTU as coupling reagent. Cyclization of the precursor 
linear peptide Prot.PI 12 was carried out under pseudo high dilution conditions with 
HATU as coupling reagent. Deprotection of the fully protected cyclic 
peptide Cyc.Prot.PI 12 was achieved with the deprotection cocktail Reagent K. 
 
Yield: H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-D-Lys(Boc)-Sar-OH (Prot.PI 12) 
0.0921 g/0.102 mmol 
    cyclo-(-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)- D-Lys(Boc)-Sar-) (Cyc.Prot.PI 12)  
0.054g/0.06 mmol 
    cyclo-(-Ser-Asp-Met-Ser- D-Lys-Sar-) (PI 12)  
0.0149g/0.024 mmol (8.0%) 
 
Formula: C24H41N7O10S 
 
Molecular Mass: 619.26 g/mol 
 
MS (MALDI-ToF): m·z-1 = 621.22 [M+H]+, 643.24 [M+Na]+, 659.22 [M+K]+, 
665.26 [M+2Na-H]+ 
Calculated Mass: [C24H42N7O10S]+ = 620.27, [C24H41N7NaO10S]+ = 642.25, 
[C24H41N7KO10S]+ = 658.23, [C24H40N7Na2O10S ]+ = 664.24 
 
Preparative RP-HPLC: Apparatus A, Method 2, tR = 20.60 min 
 
Analytical RP-HPLC: Method I, tR = 12.04 min, 100% (220 nm) 
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cyclo-(-Ser-Glu-Met-Ser-Lys-Gly-) (PI 13) 
NH
HO
NH
NH S
NH
OH
H
N
NH2
NH
O
O
O
O
O
O
O
OH
PI 13  
 
The fully protected linear peptide H-Ser(tBu)-Glu(OtBu)-Met-Ser(tBu)-Lys(Boc)- 
Gly-OH Prot.PI 13 was synthesized manually according to the general procedure of 
SPPS (Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl resin 
(0.923 mmol/g, 0.3 mmol), TBTU as coupling reagent. Cyclization of the precursor 
linear peptide Prot.PI 13 was carried out under pseudo high dilution conditions with 
HATU as coupling reagent. Deprotection of the fully protected cyclic 
peptide Cyc.Prot.PI 13 was achieved with the deprotection cocktail Reagent K. 
 
Yield: H-Ser(tBu)-Glu(OtBu)-Met-Ser(tBu)-Lys(Boc)-Gly-OH (Prot.PI 13)  
0.1050 g/ 0.118 mmol 
 cyclo-(-Ser(tBu)-Glu(OtBu)-Met-Ser(tBu)-Lys(Boc)-Gly-) (Cyc.Prot.PI 13)  
0.0565 g/0.064 mmol 
       cyclo-(-Ser-Glu-Met-Ser-Lys-Gly-) (PI 13)  
0.0080 g/0.013 mmol (4.3%) 
 
Formula: C24H41N7O10S 
 
Molecular Mass: 619.26 g/mol 
 
MS (MALDI-ToF): m·z-1 = 620.78 [M+H]+, 642.48 [M+Na]+, 658.78 [M+K]+, 664.78 
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[M+2Na-H]+ 
Calculated Mass: [C24H42N7O10S]+ = 620.27, [C24H41N7NaO10S]+ = 642.25, 
[C24H41N7KO10S]+ = 658.23, [C24H40N7Na2O10S]+ = 664.24 
 
Preparative RP-HPLC: Apparatus A, Method 2, tR = 22.29 min 
 
Analytical RP-HPLC: Method I, tR = 10.59 min, 100% (220 nm) 
 
cyclo-(-Ser-Glu-Met-Ser-D-Lys-Gly-) (PI 14) 
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HO
NH
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O
O
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The fully protected linear peptide H-Ser(tBu)-Glu(OtBu)-Met-Ser(tBu)-D-Lys(Boc)- 
Gly-OH Prot.PI 14 was synthesized manually according to the general procedure of 
SPPS (Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl resin 
(0.923 mmol/g, 0.3 mmol), TBTU as coupling reagent. Cyclization of the precursor 
linear peptide Prot.PI 14 was carried out under pseudo high dilution conditions with 
HATU as coupling reagent. Deprotection of the fully protected cyclic 
peptide Cyc.Prot.PI 14 was achieved with the deprotection cocktail Reagent K. 
 
Yield: H-Ser(tBu)-Glu(OtBu)-Met-Ser(tBu)-D-Lys(Boc)-Gly-OH (Prot.PI 14) 
0.2021 g/ 0.223 mmol 
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cyclo-(-Ser(tBu)-Glu(OtBu)-Met-Ser(tBu)-D-Lys(Boc)-Gly-) (Cyc.Prot.PI 14) 
0.1342 g/0.151 mmol 
 cyclo-(-Ser-Glu-Met-Ser- D-Lys-Gly-) (PI 14)  
0.0256 g/0.041 mmol (13.7%) 
 
Formula: C24H41N7O10S 
 
Molecular Mass: 619.26 g/mol 
 
MS (MALDI-ToF): m·z-1 = 621.34 [M+H]+, 643.34 [M+Na]+, 659.34 [M+K]+, 665.34 
[M+2Na-H]+ 
Calculated Mass: [C24H42N7O10S]+ = 620.27, [C24H41N7NaO10S]+ = 642.25, 
[C24H41N7KO10S]+ = 658.23, [C24H40N7Na2O10S]+ = 664.24 
 
Preparative RP-HPLC: Apparatus A, Method 2, tR = 19.82 min 
 
Analytical RP-HPLC: Method I, tR = 12.01 min, 100% (220 nm) 
 
cyclo-(-Ser-Asp-Met-Ser-Ala-Gly-) (PI 15) 
NH
HO
NH
OHO
NH S
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O
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The fully protected linear peptide H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Ala-Gly-OH 
Prot.PI 15 was synthesized manually according to the general procedure of SPPS 
(Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl resin 
(0.923 mmol/g, 0.3 mmol), TBTU as coupling reagent. Cyclization of the precursor 
linear peptide Prot.PI 15 was carried out under pseudo high dilution conditions with 
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HATU as coupling reagent. Deprotection of the fully protected cyclic 
peptide Cyc.Prot.PI 15 was achieved with the deprotection cocktail Reagent K. 
 
Yield: H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Ala-Gly-OH (Prot.PI 15) 
 0.1406 g/ 0.191 mmol 
    cyclo-(-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Ala-Gly-) (Cyc.Prot.PI 15) 
0.0449 g/0.063 mmol 
cyclo-(-Ser-Asp-Met-Ser-Ala-Gly-) (PI 15)  
0.0098 g/0.0178 mmol (5.9%) 
 
Formula: C20H32N6O10S 
 
Molecular Mass: 548.19 g/mol 
 
MS (MALDI-ToF): m·z-1 = 549.62 [M+H]+, 571.65 [M+Na]+, 587.59 [M+K]+ 
Calculated Mass: [C20H33N6O10S]+ = 549.20, [C20H32N6NaO10S]+ = 571.18, 
[C20H32N6KO10S]+ = 587.15 
 
Preparative RP-HPLC: Apparatus A, Method 2, tR = 25.68 min 
 
Analytical RP-HPLC: Method I, tR = 12.46 min, 100% (220 nm) 
 
cyclo-(-Ser-Ala-Met-Ser-D-Lys-Gly-) (PI 16) 
 
NH
HO
NH
NH S
NH
OH
H
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O
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O
O
PI 16  
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The fully protected linear peptide H-Ser(tBu)-Ala-Met-Ser(tBu)-D-Lys(Boc)-Gly-OH 
Prot.PI 16 was synthesized manually according to the general procedure of SPPS 
(Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl resin 
(0.923 mmol/g, 0.3 mmol), TBTU as coupling reagent. Cyclization of the precursor 
linear peptide Prot.PI 16 was carried out under pseudo high dilution conditions with 
HATU as coupling reagent. Deprotection of the fully protected cyclic 
peptide Cyc.Prot.PI 16 was achieved with the deprotection cocktail Reagent K. 
Yield: H-Ser(tBu)-Ala-Met-Ser(tBu)-D-Lys(Boc)-Gly-OH (Prot.PI 16)  
0.1687 g/ 0.213 mmol 
cyclo-(-Ser(tBu)-Ala-Met-Ser(tBu)-D-Lys(Boc)-Gly-) (Cyc.Prot.PI 16) 
0.1004 g/0.130 mmol 
cyclo-(-Ser-Ala-Met-Ser- D-Lys-Gly-) (PI 16)  
0.0296 g/0.053 mmol (17.7%) 
 
Formula: C22H39N7O8S 
 
Molecular Mass: 561.26 g/mol 
 
MS (MALDI-ToF): m·z-1 = 563.32 [M+H]+, 585.35 [M+Na]+, 601.34 [M+K]+ 
Calculated Mass: [C22H40N7O8S]+ = 562.27, [C22H39N7NaO8S]+ = 584.25, 
[C22H39N7KO8S]+ = 600.22 
 
Preparative RP-HPLC: Apparatus A, Method 2, tR = 19.71 min 
 
Analytical RP-HPLC: Method I, tR = 12.13 min, 100% (220 nm) 
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cyclo-(-Ser-Ala-Met-Ser-Lys-Gly-) (PI 17) 
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NH
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The fully protected linear peptide H-Ser(tBu)-Ala-Met-Ser(tBu)-Lys(Boc)-Gly-OH 
Prot.PI 17 was synthesized manually according to the general procedure of SPPS 
(Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl resin 
(0.923 mmol/g, 0.3 mmol), TBTU as coupling reagent. Cyclization of the precursor 
linear peptide Prot.PI 17 was carried out under pseudo high dilution conditions with 
HATU as coupling reagent. Deprotection of the fully protected cyclic 
peptide Cyc.Prot.PI 17 was achieved with the deprotection cocktail Reagent K. 
 
Yield: H-Ser(tBu)-Ala-Met-Ser(tBu)-Lys(Boc)-Gly-OH (Prot.PI 17) 
 0.1209 g/ 0.153 mmol 
 cyclo-(-Ser(tBu)-Ala-Met-Ser(tBu)-Lys(Boc)-Gly-) (Cyc.Prot.PI 17) 
0.0385 g/0.0498 mmol 
cyclo-(-Ser-Ala-Met-Ser-Lys-Gly-) (PI 17)  
0.0175 g/0.031 mmol (10.3%) 
 
Formula: C22H39N7O8S 
 
Molecular Mass: 561.26 g/mol 
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MS (MALDI-ToF): m·z-1 = 563.26 [M+H]+, 585.31 [M+Na]+, 601.38 [M+K]+ 
Calculated Mass: [C22H40N7O8S]+ = 562.27, [C22H39N7NaO8S]+ = 584.25, 
[C22H39N7KO8S]+ = 600.22 
 
Preparative RP-HPLC: Apparatus A, Method 5, tR = 24.90 min 
 
Analytical RP-HPLC: Method I, tR = 15.77 min, 100% (220 nm) 
 
cyclo-(-Ser-Asp-Ala-Ser-D-Lys-Gly-) (PI 18) 
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NH
OHO
NH
NH
OH
H
N
NH2
NH
O
O
O
O
O
O
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The fully protected linear peptide H-Ser(tBu)-Asp(OtBu)-Ala-Ser(tBu)-D-Lys(Boc)- 
Gly-OH Prot.PI 18 was synthesized manually according to the general procedure of 
SPPS (Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl resin 
(0.923 mmol/g, 0.3 mmol), TBTU as coupling reagent. Cyclization of the precursor 
linear peptide Prot.PI 18 was carried out under pseudo high dilution conditions with 
HATU as coupling reagent. Deprotection of the fully protected cyclic 
peptide Cyc.Prot.PI 18 was achieved with the deprotection cocktail Reagent K. 
 
Yield: H-Ser(tBu)-Asp(OtBu)-Ala-Ser(tBu)-D-Lys(Boc)-Gly-OH (Prot.PI 18)  
0.1850 g/ 0.222 mmol 
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cyclo-(-Ser(tBu)-Asp(OtBu)-Ala-Ser(tBu)-D-Lys(Boc)-Gly-) (Cyc.Prot.PI 18)  
0.1286 g/0.158 mmol 
 cyclo-(-Ser-Asp-Ala-Ser- D-Lys-Gly-) (PI 18) 0.0181 g/0.033 mmol (11.0%) 
 
Formula: C21H35N7O10 
 
Molecular Mass: 545.24 g/mol 
 
MS (MALDI-ToF): m·z-1 = 546.88 [M+H]+, 568.89 [M+Na]+, 584.86 [M+K]+ 
Calculated Mass: [C21H36N7O10]+ = 546.25, [C21H35N7NaO10]+ = 568.23, 
[C21H35KN7O10]+ = 584.21  
 
Preparative RP-HPLC: Apparatus A, Method 4, tR = 7.00 min 
 
Analytical RP-HPLC: Method I, tR = 4.36 min, 100% (220 nm) 
 
cyclo-(-Ser-Asp-Met-Ser-Arg-Gly-) (PI 19) 
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The fully protected linear peptide H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Arg(Pbf)- 
Gly-OH Prot.PI 19 was synthesized manually according to the general procedure of 
SPPS (Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl resin 
(0.923 mmol/g, 0.3 mmol), TBTU as coupling reagent. Cyclization of the precursor 
linear peptide Prot.PI 19 was carried out under pseudo high dilution conditions with 
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HATU as coupling reagent. Deprotection of the fully protected cyclic 
peptide Cyc.Prot.PI 19 was achieved with the deprotection cocktail Reagent K. 
 
Yield: H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Arg(Pbf)-Gly-OH (Prot.PI 19)  
0.1820 g/ 0.173 mmol 
 cyclo-(-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Arg(Pbf)-Gly-) (Cyc.Prot.PI 19)  
0.1087 g/0.105 mmol 
cyclo-(-Ser-Asp-Met-Ser-Arg-Gly-) (PI 19)  
0.0170 g/0.0268 mmol (8.9%) 
Formula: C23H39N9O10S 
 
Molecular Mass: 633.25 g/mol 
 
MS (MALDI-ToF): m·z-1 = 634.68 [M+H]+, 656.59 [M+Na]+, 672.67 [M+K]+, 678.70 
[M+2Na-H]+ 
Calculated Mass: [C23H40N9O10S]+ = 634.26, [C23H39N9NaO10S]+ = 656.24, 
[C23H39N9KO10S]+ = 672.22, [C23H38N9Na2O10S] = 678.23 
 
Preparative RP-HPLC: Apparatus A, Method 2, tR = 20.09 min 
 
Analytical RP-HPLC: Method I, tR = 17.81 min, 100% (220 nm) 
 
cyclo-(-Ser-Asp-Met-Ser-Gly-) (PI 20) 
 
NH
O
OH
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The fully protected linear peptide H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Gly-OH 
Prot.PI 20 was synthesized manually according to the general procedure of SPPS 
(Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl resin 
(0.998 mmol/g, 0.3 mmol), TBTU as coupling reagent. Cyclization of the precursor 
linear peptide Prot.PI 20 was carried out under pseudo high dilution conditions with 
HATU as coupling reagent. Deprotection of the fully protected cyclic 
peptide Cyc.Prot.PI 20 was achieved with the deprotection cocktail Reagent K. 
 
Yield: H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Gly-OH (Prot.PI 20)  
0.1113 g/0.168 mmol 
    cyclo-(-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Gly-) (Cyc.Prot.PI 20)  
0.0144 g/0.022 mmol 
cyclo-(-Ser-Asp-Met-Ser-Gly-) (PI 20)  
0.0017 g/0.0036 mmol (1.2%) 
 
Formula: C17H27N5O9S 
 
Molecular Mass: 477.15 g/mol 
 
MS (MALDI-ToF): m·z-1 = 478.89 [M+H]+, 500.92 [M+Na]+, 516.93 [M+K]+ 
Calculated Mass: [C17H28N5O9S]+ = 478.16, [C17H27N5NaO9S]+ = 500.14, 
[C17H27KN5O9S]+ = 516.12 
 
Preparative RP-HPLC: Apparatus A, Method 5, tR = 20.62 min 
 
Analytical RP-HPLC: Method I, tR = 14.05 min, 100% (220 nm) 
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cyclo-(-Ser-Asp-Met-Ser-Asp-Met-) (PI 21) 
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The fully protected linear peptide H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Asp(OtBu)- 
Met-OH Prot.PI 21 was synthesized manually according to the general procedure of 
SPPS (Fmoc/tBu), with Fmoc-Met-OH being loaded on the o-chlorotrityl resin 
(0.85 mmol/g, 0.3 mmol), TBTU as coupling reagent. Cyclization of the precursor 
linear peptide Prot.PI 21 was carried out under pseudo high dilution conditions with 
HATU as coupling reagent. Deprotection of the fully protected cyclic 
peptide Cyc.Prot.PI 21 was achieved with the deprotection cocktail Reagent K. 
 
Yield: H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Asp(OtBu)-Met-OH (Prot.PI 21) 
0.1862 g/ 0.205 mmol 
 cyclo-(-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-Asp(OtBu)-Met-) (Cyc.Prot.PI 21) 
0.0479 g/0.054 mmol 
    cyclo-(-Ser-Asp-Met-Ser-Asp-Met-) (PI 21)  
0.0212 g/0.032 mmol (10.7%) 
 
Formula: C24H38N6O12S2 
 
Molecular Mass: 666.20 g/mol 
 
MS (MALDI-ToF): m·z-1 = 667.62 [M+H]+, 689.66 [M+Na]+, 705.64 [M+K]+ 
Calculated Mass: [C24H39N6O12S2]+ = 667.21, [C24H38N6NaO12S2]+ = 689.18, 
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[C24H38N6NaO12S2]+ = 705.16 
 
Preparative RP-HPLC: Apparatus A, Method 6, tR = 47.40 min 
 
Analytical RP-HPLC: Method I, tR = 18.80 min, 100% (220 nm) 
 
cyclo-(-Ala-Asp-Met-Ser-D-Lys-Gly-) (PI 22) 
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The fully protected linear peptide H-Ala-Asp(OtBu)-Met-Ser(tBu)-D-Lys(Boc)- 
Gly-OH Prot.PI 22 was synthesized manually according to the general procedure of 
SPPS (Fmoc/tBu), with Fmoc-Gly-OH being loaded on the o-chlorotrityl resin 
(0.923 mmol/g, 0.3 mmol), TBTU as coupling reagent. Cyclization of the precursor 
linear peptide Prot.PI 22 was carried out under pseudo high dilution conditions with 
HATU as coupling reagent. Deprotection of the fully protected cyclic 
peptide Cyc.Prot.PI 22 was achieved with the deprotection cocktail Reagent K. 
 
Yield: H-Ala-Asp(OtBu)-Met-Ser(tBu)-Asp(OtBu)-Met-OH (Prot.PI 22) 
0.2090 g/ 0.255 mmol 
 cyclo-(-Ala-Asp(OtBu)-Met-Ser(tBu)-Asp(OtBu)-Met-) (Cyc.Prot.PI 22) 
0.1603 g/ 0.200 mmol 
    cyclo-(-Ala-Asp-Met-Ser-Asp-Met-) (PI 22)  
0.0560 g/ 0.095 mmol (31.7%) 
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Formula: C23H39N7O9S 
 
Molecular Mass: 589.25 g/mol 
 
MS (MALDI-ToF): m·z-1 = 590.30 [M+H]+,  612.29 [M+Na]+, 628.30 [M+K]+ 
Calculated Mass: [C23H40N7O9S]+ = 590.26, [C23H39N7NaO9S]+ = 612.24, 
[C23H39KN7O9S]+ = 628.21 
 
Preparative RP-HPLC: Apparatus A, Method 6, tR = 21.07 min 
 
Analytical RP-HPLC: Method I, tR = 17.35 min, 100% (220 nm) 
 
H-Ser-Asp-Met-Ser-OH (PI 23) 
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The fully protected linear peptide H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-OH 
Prot.PI 23 was synthesized manually according to the general procedure of SPPS 
(Fmoc/tBu), with Fmoc-Ser(tBu)-OH being loaded on the o-chlorotrityl resin 
(0.85 mmol/g, 0.3 mmol), TBTU as coupling reagent. Deprotection of the fully 
protected linear peptide Prot.PI 23 was achieved with the deprotection cocktail 
Reagent K. 
 
Yield: H-Ser(tBu)-Asp(OtBu)-Met-Ser(tBu)-OH (Prot.PI 23) 
  0.1758 g/ 0.29 mmol 
 H-Ser-Asp-Met-Ser-Asp-Met-OH (PI 23)  
  0.0876 g/ 0.20 mmol (66.7%) 
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Formula: C15H26N4O9S 
 
Molecular Mass: 438.14 g/mol 
 
MS (MALDI-ToF): m·z-1 = 439.20 [M+H]+,  461.15 [M+Na]+, 477.15 [M+K]+ 
Calculated Mass: [C15H27N4O9S]+ = 439.15, [C15H26N4NaO9S]+ = 461.13, 
[C15H26KN4O9S]+ = 477.11 
 
Preparative RP-HPLC: Apparatus A, Method 6, tR = 10.50 min 
 
Analytical RP-HPLC: Method I, tR = 7.45 min, 100% (220 nm) 
 
Conjugation of SDMS peptides with a remote Arg/Asp with a linker 
1.5 equiv N-Fmoc side-chain protected linker peptides with a remote Asp/Arg at the 
flank (see also chapter 2.5.1.2.2) in DMF (in relative to cyclo-(-Ser(tBu)-Asp(OtBu)- 
Met-Ser(tBu)-D-Lys-Gly-) 13) was mixed with 3 equiv HATU and 6 equiv DIPEA at 
room temperature for approximately 15 min before being added to 1 equiv 13 in DMF. 
The two peptide fragments were condensed overnight at room temperature. The 
formation of the target peptide complex was monitored by MALDI-ToF-MS. This 
totally protected peptide conjugate was purified by RP-HPLC. Subsequently the Fmoc 
protecting group was cleaved with 2% DBU, 2% piperidine in DMF. This process 
took 15-20 min at room temperature before the solvent was removed at reduced 
pressure. The residue was then treated with reagent K to cleave the acid-labile 
protecting groups without further purification. The deprotecting process took 
approximately 30 min at room temperature. The target peptide conjugate was purified 
by RP-HPLC and analyzed by MALDI-ToF-MS and analytical RP-HPLC. 
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cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Arg-(β-Ala)4-)-Gly-) (PI 24) 
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Yield: 2.9 % 
Formula: C41H71N15O15S 
Molecular Mass: 1045.50 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1045.19 [M+H]+, 1067.15 [M+Na]+, 1083.16 [M+K]+, 
1089.14 [M+2Na-H]+ 
Calculated Mass: [C41H72N15O15S]+ = 1046.50, [C41H71N15NaO15S]+ = 1068.49, 
[C41H71KN15O15S]+ = 1084.46, [C41H70N15Na2O15S] = 1090.48 
 
Preparative RP-HPLC: Apparatus A, Method 6, tR = 32.52min 
Analytical RP-HPLC: Method I, tR = 13.50 min, 100% (220 nm) 
 
cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Arg-(β-Ala)5-)-Gly-) (PI 25) 
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Yield: 3.5 % 
Formula: C44H76N16O16S 
Molecular Mass: 1116.53 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1117.76 [M+H]+, 1139.80 [M+Na]+, 1155.90 [M+K]+ 
Calculated Mass: [C44H77N16O16S]+ = 1117.54, [C44H76N16NaO16S]+ = 1139.52, 
[C44H76KN16O16S]+ = 1155.50 
 
Preparative RP-HPLC: Apparatus A, Method 6, tR = 33.55 min 
 
Analytical RP-HPLC: Method I, tR = 14.02 min, 100% (220 nm) 
 
cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Arg-(β-Ala)6-)-Gly-) (PI 26) 
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Yield: .4.5 % 
Formula: C47H81N17O17S 
Molecular Mass: 1187.57 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1188.02 [M+H]+, 1210.13 [M+Na]+, 1226.19 [M+K]+ 
Calculated Mass: [C47H82N17O17S]+ = 1188.58, [C47H81N17NaO17S]+ = 1210.56, 
[C47H81KN17O17S]+ = 1226.54 
 
Preparative RP-HPLC: Apparatus A, Method 6, tR = 34.52min 
 
Analytical RP-HPLC: Method I, tR = 14.46 min, 100% (220 nm) 
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cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Asp-(β-Ala)5-)-Gly-) (PI 27) 
NH
HO
NH
O
HO
NH
S
NH
HO
HN HN
NH O
O
O O
O
O
H
N
O
NH2
O
O
OH
5
PI 27  
Yield: 5.1 % 
Formula: C42H69N13O18S 
Molecular Mass: 1075.46 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1076.47 [M+H]+, 1098.41 [M+Na]+, 1114.40 [M+K]+ 
Calculated Mass: [C42H70N13O18S]+ = 1076.47, [C42H69N13NaO18S]+ = 1098.45, 
[C42H69KN13O18S]+ = 1114.42 
 
Preparative RP-HPLC: Apparatus A, Method 7, tR = 28.37min 
 
Analytical RP-HPLC: Method I, tR = 13.11 min, 100% (220 nm) 
 
cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Asp-(β-Ala)6-)-Gly-) (PI 28) 
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Yield: 9.8 % 
Formula: C45H74N14O19S 
Molecular Mass: 1146.50 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1147.35 [M+H]+, 1169.37 [M+Na]+, 1186.05 [M+K]+ 
Calculated Mass: [C45H75N14O19S]+ = 1147.51, [C45H74N14NaO19S]+ = 1169.49, 
[C45H74KN14O19S]+ = 1185.46 
 
Preparative RP-HPLC: Apparatus B, Method 8, tR = 40.2 min 
 
Analytical HPLC: Method I, tR = 13.25 min 100% (220 nm) 
 
cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Asp-(β-Ala)7-)-Gly-) (PI 29) 
NH
HO
NH
O
HO
NH
S
NH
HO
HN HN
NH O
O
O O
O
O HN
O
NH2
O
O
OH
7
PI 29  
Yield: 5.5 % 
Formula: C48H79N15O20S 
Molecular Mass: 1217.53 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1218.44 [M+H]+, 1239.92 [M+Na]+, 1254.97 [M+K]+ 
Calculated Mass: [C48H80N15O20S]+ = 1218.54, [C48H79N15NaO20S]+ = 1240.52, 
[C48H79KN15O20S]+ = 1256.50 
 
Preparative RP-HPLC: Apparatus A, Method 9, tR = 37.79min 
 
Analytical RP-HPLC: Method I, tR = 17.75 min, 100% (220 nm) 
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cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Arg-Ala-Pro-Pro-Ala-Pro-Pro-Ala)-Gly-)  
(PI 30) 
NHHO
NH
O
HO
NH
S
NH
OH
HN
N
H
NH O
O
O O
O
O
N
O
N
ONH
HN
O
NH2
O
NH
NH2HN
O
PI 30
2
Yield:6.0 % 
Formula: C58H94N18O18S 
Molecular Mass: 1362.67 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1364.05 [M+H]+, 1386.10 [M+Na]+, 1402.11 [M+K]+ 
Calculated Mass: [C58H95N18O18S]+ = 1363.68, [C58H94N18NaO18S]+ = 1385.66, 
[C58H94KN18O18S]+ = 1401.64 
 
Preparative RP-HPLC: Apparatus A, Method 6, tR = 38.12min 
 
Analytical RP-HPLC: Method I, tR = 16.11 min, 100% (220 nm) 
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cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Arg-Pro-Ala-Pro-Pro-Ala-Pro-Pro-Ala)-Gly-)  
(PI 31) 
 
NHHO
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Yield: 10.3 % 
Formula: C63H101N19O19S 
Molecular Mass: 1459.72 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1460.99 [M+H]+, 1482.02 [M+Na]+, 1499.01 [M+K]+ 
Calculated Mass: [C63H102N19O19S]+ = 1460.73, [C63H101N19NaO19S]+ = 1482.71, 
[C63H101KN19O19S]+ = 1498.69 
 
Preparative RP-HPLC: Apparatus A, Method 6, tR = 39.98 min 
 
Analytical RP-HPLC: Method I, tR = 17.57 min, 100% (220 nm) 
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cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Arg-Pro-Pro-Ala-Pro-Pro-Ala-Pro-Pro-Ala)- 
Gly-) (PI 32) 
NHHO
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Yield: 6.9 % 
Formula: C68H108N20O20S 
Molecular Mass: 1556.78 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1558.16 [M+H]+, 1580.11 [M+Na]+, 1596.17 [M+K]+ 
Calculated Mass: [C68H109N20O20S]+ = 1557.78, [C68H108N20NaO20S]+ = 1579.77, 
[C68H108KN20O20S]+ = 1595.74 
 
Preparative RP-HPLC: Apparatus A, Method 6, tR = 40.97 min 
 
Analytical RP-HPLC: Method I, tR = 18.19 min, 100% (220 nm) 
 
 
 
 
 
 
 
 
 
 
2.6 Experiments 
 149
cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Asp-Pro-Ala-Pro-Pro-Ala-Pro-Pro-Ala)-Gly-) 
(PI 33) 
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Yield: 8.1 % 
Formula: C61H94N16O21S 
Molecular Mass: 1418.65 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1441.73 [M+Na]+, 1457.63 [M+K]+ 
Calculated Mass: [C61H94N16NaO21S]+ = 1441.64, [C61H94KN16O21S]+ = 1457.61 
 
Preparative RP-HPLC: Apparatus A, Method 6, tR = 38.97 min 
 
Analytical RP-HPLC: Method I, tR = 17.55 min, 100% (220 nm) 
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cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Asp-Pro-Pro-Ala-Pro-Pro-Ala-Pro-Pro-Ala)- 
Gly-) (PI 34) 
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Yield: 7.9 % 
Formula: C66H101N17O22S 
 
Molecular Mass: 1515.70 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1516.69 [M+H]+, 1538.59 [M+Na]+, 1554.56 [M+K]+ 
Calculated Mass: [C66H102N17O22S]+ = 1516.71, [C66H101N17NaO22S]+ = 1538.69, 
[C66H101KN17O22S]+ = 1554.67 
 
Preparative RP-HPLC: Apparatus A, Method 6, tR = 39.25 min 
 
Analytical RP-HPLC: Method I, tR = 18.63 min, 100% (220 nm) 
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cyclo-(-Ser-Asp-Met-Ser-D-Lys(H-Asp-Ala-Pro-Pro-Ala-Pro-Pro-Ala-Pro-Pro- 
Ala)-Gly-) (PI 35)  
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Yield: 9.8 % 
Formula: C69H106N18O23S 
Molecular Mass: 1586.74 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1587.89 [M+H]+, 1609.88 [M+Na]+, 1625.90 [M+K]+ 
Calculated Mass: [C69H107N18O23S]+ = 1587.75, [C69H106N18NaO23S]+ = 1609.73, 
[C69H106KN18O23S]+ = 1625.70 
 
Preparative RP-HPLC: Apparatus A, Method 6, tR = 39.90 min 
 
Analytical RP-HPLC: Method I, tR = 19.11 min, 100% (220 nm) 
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2.6.3 Inhibition of the Interaction between Laminin-332 and 
Integrin α3β1 by Synthetic Peptide/Peptidomimetic 
 
1. Coating: 100 μl 6 μg/ml laminin-332 solutions are applied to every well of the              
microtiter plate for ELISA. The plate is incubated at 4 oC overnight and then 
washed 3 times with TBS/MgCl2. 
2. Blocking: The non-binding sites on the plate are endcapped with 1% BSA in 
TBS/MgCl2 buffer at room temperature for 2 hours. 
3. Integrin/Peptide Solution Preparation: The peptide samples are dissolved in TBS 
buffer to prepare a 20 mM solution. 248 μl 0.449 μg/ml integrin α3β1 are dissolved 
in 142 μl 1 mg/ml monoclonal antibody 9EG7, 7.11 ml 1%BSA/TBS/MgCl2 and 
7.5 ml 1 M MnCl2.  
Negative Control: 8.8 μl 0.5 M EDTA is subjected to 396 μl 55 nM integrin α3β1 
and 35.2 μl TBS/MgCl2 buffer. 
   Positive Control: 396 μl integrin α3β1 is subjected to 44 μl TBS/MgCl2 buffer. 
4. Binding: 198 μl solution of integrin α3β1 and 22 μl peptide solution are mixed. 
The final concentrations of integrin α3β1 and peptide are 50 nM and 1.8 mM, 
respectively. 100 μl peptide/integrin α3β1 mixtures are subjected to every well 
except positive and negative control wells. The processes of inhibition of the 
interaction between integrin α3β1 and immobilized laminin-332 by synthetic 
peptides take 2 hours at room temperature before the solutions in every well are 
removed. The plate is then washed 3 times: inhibition wells with HEPES buffer; 
EDTA wells with 10 mM EDTA solution. 
5. Fixation: 2.5% glutardialdehyde is subjected to 50 mM HEPES in 150 mM NaCl, 
2 mM MgCl2, 1 mM MnCl2. The fixation takes approximately 10 min at room 
temperature. The fixation solution is then removed and the plate is washed 3 times 
with TBS/MgCl2 buffer. 
6. First Antibody: Anti β1 is diluted by 1000 times with 1%BSA in TBS/MgCl2 buffer. 
100 μl anti β1 solution are added to each well. The process takes 1.5 hour at room 
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temperature. The anti β1 solution is then discarded and the plate is washed with 
TBS/MgCl2 3 times. 
7. Second Antibody: Second antibody IgG coupled with enzyme alcaline 
phosphatase is diluted by 1000 times. 100 μl enzyme-linked IgG solution is added 
to each well. The process takes 1.5 hour at room temperature. The IgG solution is 
then discarded and the plate is washed with TBS/MgCl2 for 3 times. 
8. Substrate: 100 μl 1 mg/ml phosphylphenyl phosphate in 0.1 M glycine/NaOH 
containing 10 μl 1 M Zn(OAc)2 and MgCl2 (pH 10.2) is added to each well. It 
takes approximately 4-5 min before the color appears in the well. 
9. Termination: 1.5 M NaOH solutions are added to each well in order to stop the 
color-generating reactions. 
10. Quantification: The absorbance of the solution in each plate well is measured to 
determine the content of unbound integrin α3β1. 
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2.7  Summary 
 
In this project, integral membrane protein integrins were chosen as the research target. 
Integrin α3β1, a member of the integrin family, is the receptor to several extracellular 
ligands such as fibronectin, invasin, and laminin. It presents a good target for the 
structure-based ligand design research, possessing both theoretical and applied 
significances. Design, screen, target and optimization of a integrin α3β1 ligand is 
challenging because no crystal structure of integrin α3β1 is yet available, and the 
research with regard to this integrin and its antagonists are not sufficiently in depth 
and lags behind that of other members of the integrin family. Invasin, whose X-ray 
single crystal structure is available, is one of the naturally occurring ligand of 
integrin α3β1. It mediates the internalization of bacteria Yersinia Sp. into the 
mammalian cells through tight association with integrin α3β1. Synthetic ligands which 
possess stronger affinities to integrin α3β1 could serve as antagonists and thus block 
the adhesion of invasin to integrin α3β1, which in turn prevents the uptake of Yersinia. 
On the basis of the similarities between invasin and other integrin α3β1 ligands, 
especially fibronectin, the integrin α3β1 binding domains on invasin had been assigned. 
Asp911 was considered to play an important role for the adhesion of invasin to 
integrin α3β1. Furthermore, Asp811 and Arg883, which are on the same side of invasin 
as Asp911 and are approximately 32 Å (literature value) apart from Asp911, could 
assist the binding of invasin to integrin α3β1; they are thus regarded as synergic region. 
There is a striking similarity between fibronectin and invasin, which could be 
regarded as the proof to locate the binding domain of invasin to integrin α3β1. The 
crucial Asp911 was resided at a bulge contour on invasin, this factor is supposed to be 
taken into consideration as peptide/peptidomimetic ligand design is concerned.  
 
Despite that -Ser-Asp-Met-Ser- sequence in the D5 domain in invasin is regarded as 
the binding moiety for the adhesion of invasin to integrin α3β1, this conclusion was 
nevertheless drawn out of the similarities of X-ray crystal structures of invasin and 
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other natural ligands. This aspect was not validated by experimental results. One of 
the major purposes of this project is to confirm the SDMS recognition sequence by 
the synthetic peptide ligands containing this binding moiety. The primary sequence 
-Ser-Asp-Met-Ser- centered on the crucial Asp911 in invasin served as starting point 
in the ligand design process. Asp911 is located at i+1 position of a β-turn in the native 
sequence. This positional element should be kept constant in the synthetic peptides in 
order to obtain good binding affinity to integrin α3β1. Cyclization of a peptide 
containing SDMS recognition sequence could lock the flexible macromolecule into a 
preferable conformation which leads to an improved bioactivity, this is achieved with 
the incorporation of special secondary structure inducing residues, such as D-amino 
acid, α,α-disubstituted amino acid, or N-alkylated amino acid. The idea of spatial 
screenings of peptides and peptidomimetics is an important concept, which applied 
the concerned peptides with diverse conformations in order to search the bioactive 
conformation of peptide ligand. Spatial screening was performed by the incorporation 
of different secondary structure inducers such as D-Lys, Aib, or Gly in this project to 
confirm the bioactive conformation. The cyclization could also evidently lower the 
flexibility of the concerned peptide, locking them in a favorable conformation as 
affinity to a receptor is concerned. This adavantage meets the criteria of the active 
ligand design.  
 
In this project, e.g. a D-amino acid was incorporated into the cyclic hexapeptide as the 
secondary structure inducer. D-amino acids are known to preferentially occupy i+1 
position of a β-turn in a cyclic hexapeptide, the crucial Asp was thus locked in i+1 
position in a complementary β-turn. The parent peptide of this series, 
cyclo-(-Ser-Asp-Met-Ser-D-Lys-Gly-), was successfully synthesized and taken as the 
reference for the screening and optimization. Residue mutations of this reference 
peptide were performed in addition to explore the mechanism of the adhesion of the 
peptide inhibitors to integrin α3β1, optimize the synthetic ligand, and screen the lead 
compound. ELISA studies were carried out to analyze the affinities of the synthesized 
peptides to integrin α3β1. Laminin-332 was applied as the natural ligand of 
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integrin α3β1 in this project. It was confirmed that the Asp residue in the cyclic peptide 
plays a crucially important role for adhesion. The inhibitory capacity was almost 
totally lost upon its substitution by Ala. Methionine in the reference peptide was 
proved to be indispensable, as its substitution by Ala or Aib, as well as oxidation of 
the side chain to sulfoxide derivative led to a significant decrease in affinity. The 
serine preceeding aspartate seemed to tolerate modification, as its substitution by 
alanine resulted in even superior binding affinity. The lysine residue was assumed to 
be relevantly indifferent to mutation, as its replacement by alanine and arginine did 
not cause a substantial change of inhibitory capacities, thus validating the choice of 
this residue as the hinge of the peptide scaffold. However, it was found that peptide 
with L-lysine at this position displayed higher affinity than the D-lysine containing 
derivative. It could be probably caused by the type of the induced β-turn, the thus 
formed complementary β-turn, in which aspartate occupies i+1 position, may not 
match the type of the prototype, or due to the orientation of the side chain of D-lysine 
leading to a unfavorable interaction with the corresponding domain on the 
integrin α3β1. For the L-lysine-containing peptide, glycine could also serve as the 
secondary structure inducer, as it is commonly regarded as "proteinogenic D-amino 
acid" because of its special conformational influence. The substitution of glycine by 
sarcosine led to an increased affinity. N-alkylated amino acids such as sarcosine 
(N-methyl glycine) preferentially occupy i+2 position of β-turn in a cyclic 
hexapeptide. This β-turn centered on lysine and sarcosine could stabilize the structure 
with the aspartate in the complementary β-turn. The combination of sarcosine and 
D-lysine led to one of the most efficient inhibitors in the peptide library. 
Cyclo-(-Ser-Asp-Met-Ser-Asp-Met-) with a palindrome sequence also exhibited a 
good affinity to integrin α3β1. The combination of these favorable elements in a single 
cyclic peptide/peptidomimetic could be promising for an optimized second generation 
of integrin α3β1 ligands. 
 
As Asp811 and Arg883 in invasin are assumed to exert synergic influence on its 
association to integrin α3β1, these binding moieties are supposed to be incorporated 
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into the peptide to achieve improved affinity. The peptide scaffold oligo β-alanine and 
(Pro-Pro-Ala)n was fused into the reference peptide in order to introduce these 
synergic binding element Asp811 or Arg883. Molecular modeling was applied to 
design the scaffold rationally. The structures adopted by the scaffold under 
physiological conditions were taken into consideration.  
 
The introduction of synergic residues Asp811 and Arg883 through the peptide scaffold, 
however, did not generate the expected improved inhibitory capacities. This could be 
due to the increased entropy loss brought forward by the introduction of flexible 
peptide scaffold upon binding to integrin. On the other hand, the adhesion of the 
binding motif -Ser-Asp-Met-Ser- to its corresponding association domain on integrin 
could possibly lead to an induced conformational change of the protein receptor or 
peptide ligand, this dynamic process might result in a discrepancy between the ligand 
design and the actual situation. The third possible explanation is that the single amino 
acid Asp/Arg might not be specifically recognized by their binding domains on the 
protein. 
 
In summary, synthesis of the peptide library was successfully completed through 
manual and microwave assisted SPPS; orthogonal deprotection was achieved by the 
Aloc protecting groups on the side chain of lysine; cyclization of linear protected 
peptides was carried out under high-pseudo-dilution condition implemented by two 
channel syringe pump, no dimerization was found in this project; segment 
condensation was smoothly and nearly quantatively converted; deprotection and 
subsequent purification was also fulfilled. The synthesized peptide library was applied 
to ELISA test as the inhibitors to the binding of laminin-332 to integrin α3β1. 
Favorable elements for inhibition were screened. Mechanism of binding was 
preliminarily analyzed along with the screen process. The thus obtained lead 
compound and relative conclusions could be integrated and applied to the 
optimization and design of the next peptide inhibitor generation.  
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Optimization of the peptide complexes could be achieved if the properties of the 
linker were improved, namely, to increase its rigidity property upon the exact 
simulation with proper techniques of molecular modelling and meticulous design. The 
incorporation of the cooperative binding residue Asp/Arg should be more 
sophisticated with the binding moiety instead of single amino acid residue, in order to 
achieve the more positive enthalpy gain upon the binding to compensate the loss of 
the entropy loss. The optimization of template peptide cyclo-(-Ser-Asp-Met-Ser- 
D-Lys-Gly-) could also be achieved. 
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3 Peptides in Biomineralizations 
 
3.1 Biomineralization 
Scientists and engineers have long been fascinated by the beautiful structures and 
functional properties of the materials formed within living organisms, especially those 
finely and orderly organized hard tissues of organisms such as bones, teeth, mollusc 
shells, which are composed of diverse minerals that are typically in close association with 
an organic polymeric phase, and thus are biocomposites. The nature is presenting us 
beautiful templates as to how these minerals selectively precipitate and subsequently 
orderly grow in the organism. Calcium for example, exists abundantly in the blood of 
organisms, while they choose bones or teeth as locations to precipitate and be precisely 
assembled instead of in the organs like muscle or skin. Even in different hard tissues, the 
pattern of the nucleation of calcium differentiates markedly from each other, leading to 
diverse forms of tissues and structures. 
 
It seems that there are diverse batons behind the scene, directing and controlling the 
growth pattern of minerals in living organism. Sophisticated strategies have been 
developed by organism to direct and control the growth pattern of inorganic constituents 
such as calcium in their mineralized tissues as the target. Active and effective control 
mechanisms take place at almost all levels of structural hierarchy, ranging from the 
nanoscopic regime – the nucleation of a crystallite at a specific site – up to the 
macroscopic regime, where the biophysical properties of the mineralized tissue have to 
be matched to certain functions.  
 
The mineral crystals formed by organisms, so-called biominerals, normally have shapes 
that are very different from the crystals produced inorganically outside the living 
organism. Molluscs are among the most thoroughly investigated organisms in this regard, 
which build concrete shells from CaCO3.[ 0F1] The mollusc shell may be regarded as a 
microlaminate composite consisting of layers of highly oriented CaCO3 crystals which 
are interspersed with thin sheets of an organic matrix. Crystals within separate shell 
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layers usually consist of either pure aragonite or pure calcite. Vaterite, when present, is 
usually associated with shell repair. Shell formation occurs in two principal phases. The 
first involves the cellular processes of ion transport and organic matrix synthesis which 
occur in different compartments of the molluscan mineralizing system. The second phase 
comprises a series of crystal nucleation and growth processes taking place in a 
specialized mineralization compartment, the so-called extrapallial space (see 
Figure 3.1).[1F2] 
 
 
 
Figure 3.1 Transverse section of the mantle edge of a bivalve showing the system of compartments.[ 0H2] 
 
The actual biological processes that direct and control the formation of a complete 
mineralized mollusc shell are largely unknown. However, the widely accepted consensus 
is that the crystal nucleation and growth events are strictly regulated by a number of 
highly specialized organic macromolecules. Control is believed to be exerted through 
specialized proteins that recognize specific crystal surfaces during the growth of the 
crystals. Recognition is based on molecular complementarity between the protein and the 
crystal structure on defined planes. The understanding of these processes is also relevant 
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to research on advanced materials. Biology provides an insight into unconventional 
strategies of a degree of sophistication yet unconceivable in artificial materials. 
Unfortunately, a deeper understanding of the biomineralization processes at the 
molecular level of structural hierarchy is hampered by the fact that our knowledge of the 
three-dimensional structures of macromolecules which are directly associated with the 
mineral layer is very poor. The conformation of these natural macromolecular templates 
and their properties play a crucially important role in deciding the manners of their 
interactions with the minerals and subsequently the assembly pattern of these crystalline 
biominerals. 
 
The mimic of the naturally existing macromolecular templates that direct the assembly of 
the biominerals is supposed to be a suitable and promising tactic to gain a deeper 
understanding of this biological process. Biomimetics are defined as microstructural 
processing techniques that can either mimic or be inspired by biological processes. 
Seemingly, it would be difficult for material engineers to mimic complex cellular 
processes, however, material chemistry aspects of biomineralization can be studied by 
model systems, and utilized for biomimetic engineering. One particular aspect of interest 
to material chemists is the means by which these organisms use macromolecular organic 
constituents to mediate the growth of the mineral phase. For example, macromolecular 
templates are used to direct the nucleation event, manage vesicular compartments to 
delineate particle size and shape, and order solubilized proteins to regulate the kinetics of 
crystal nucleation and growth. In recent years, scientists have utilized some of these 
concepts to produce novel materials.  
 
The secondary and tertiary structures of macromolecules directly involved in 
mineralization have been so far relatively insufficiently determined. The available 
information about the primary structures of peptides associated with this process is listed 
in Table 3.1 and 3.2. Macromolecules that were isolated from mollusc tissues have been 
traditionally categorized into two different classes, based on their water solubility 
properties. Chemical analysis showed that the water insoluble fraction mainly consists of 
fibrous proteins (collagen, keratin) and/or polysaccharides. These macromolecules 
together build a rigid framework upon which specific macromolecules from the soluble 
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fraction may be precisely adsorbed and assembled. The surface of this macromolecular 
assembly may serve as a supramolecular template for oriented nucleation of single 
crystals, and in fact crystallization experiments employing reconstructed matrices of 
purified mollusc shell macromolecules have shown that it is possible to switch between 
different CaCO3 polymorphs[2F3] and to rebuild in vitro the gross structural features of the 
nacreous layer, respectively.[3F4] 
 
Table 3.1 Summary of water-insoluble proteins isolated from mollusc shells 
Name Source Characteristic sequence moif 
Associated 
mineral 
Proposed 
function Ref. 
MSI60 
Pearl oyster 
protein from 
the nacreous 
layer 
[Ala9–13] and [Gly3–15] Aragonite 
Framework 
protein, 
binding of 
Asp-rich sol. 
glycoproteins
 [4F5] 
MSI31 
Pearl oyster 
protein from 
the 
prismatic 
layer 
[Gly3–5] and 
[Glu–Ser–Glu–Glu–Asp–X], 
(X = Thr or Met) 
Calcite 
Framework 
protein, 
binding of 
Asp-rich sol. 
glycoproteins
[1H5] 
MSI7 
Pearl oyster 
protein from 
the epithelia 
of the 
mantle 
[Glyx-y] 
Aragonite 
Calcite 
Framework 
protein, 
acceleration of 
nucleation and 
precipitation 
of CaCO3 
 [5F6] 
N14, N66 
Pearl oyster 
protein from 
the nacreous 
layer 
[Asn–Gly]12 and [Asn–Gly]57 Aragonite 
Carbonic 
anhydrase 
(N66) 
[6F7] 
N16 
Pearl oyster 
protein from 
the nacreous 
layer 
[Asn–Gly]6 
(as well as 4 acidic domains) Aragonite 
Control of 
crystal growth 
and 
morphology 
[2H4] 
Lustrin A 
Abalone 
protein from 
the nacreous 
layer 
[Gly–Ser–Ser–Ser] and 
[Gly–Ser] 
(as well as 1 basic domain) 
Aragonite Adhesion protein [7F8] 
Prismalin-14 
Pearl oyster 
protein from 
the 
prismatic 
layer 
[Asp]-and [Gly/Tyr]-rich 
domains, [Pro-Ile-Tyr-Arg] 
repeats 
Calcite Framework protein [8F9] 
 
 
3.1 Biomineralization 
 173
Table 3.2 Summary of water-soluble proteins isolated from mollusc shells 
Name Source Characteristic sequence moif 
Associated 
mineral 
Proposed 
function Ref. 
MSP-1 
Scalop shell 
glycoprotein 
from the folia
ted layer 
[Asp–Gly–Ser–Asp]  
and [Asp–Ser–Asp] Calcite 
Induction of 
crystal 
nucleation, 
control of 
CaCO3 
polymorphism
[9F10]
Nacrein 
Pearl oyster 
protein from 
the nacreous 
layer 
[Gly–X–Asn] 
 (X = Glu, Asn, or Asp) Aragonite 
Carbonic 
anhydrase, 
Ca-binding 
[10F 1]
Mucoperlin 
Fan mussel 
protein from 
the nacreous 
layer 
[Asp–X–Ser–Asp–X–Asp–X
–Asp] (X =Val, Arg, Lys) Aragonite 
Induction of 
crystal 
nucleation, 
control of 
CaCO3 
polymorphism
[11F 2]
Perlucin 
Abalone 
protein from 
the nacreous 
layer 
C-type lectin domains Aragonite Glycoprotein receptor [12F 3]
Perlustrin Abalone protein [Cys–X–Cys–Cys–X–X–Cys] Aragonite 
Insulin-like 
growth factor 
binding protein
[13F 4]
Aspein 
Pearl oyster 
highly acidic 
protein from 
the prismatic 
layer 
[Asp2-10] punctuated with 
[Ser–Gly] dipeptides Calcite 
Control of 
CaCO3 
polymorphism
[14F 5]
AP7 
AP24 
Abalone 
protein from 
the nacreous 
layer 
[Asp-Asp] 
 [Asp-Asp-Asp-Glu-Asp] Aragonite 
Control of 
CaCO3 
polymorphism
[15F 6]
 
For the induction of calcite and aragonite nucleation, systematic investigations on 
biological and suitably assembled artificial systems have shed some light on the structural 
requirements of a putative nucleation site, especially in mollusc shells. [16F17] The model 
proposes structurally pre-organized domains of acidic residues, such as aspartic acid and 
glutamic acid, which could serve as a supramolecular template for oriented crystal 
nucleation. Such highly ordered domains could result from acidic macromolecules being 
adsorbed on a rigid scaffold of insoluble matrix proteins (see Figure 3.2).[3H17,17F18] Inspired 
by this discovery, artificial macromolecules, which hold ordered structures by themselves 
without the assist of scaffold, could be served as the ideal candidates for directing the 
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process of nucleation of mineral crystals. 
 
Figure 3.2 Left: Schematic representation of the organic matrix in the nacreous layer of Atrina. The 
β-chitin lamella are interspersed in a highly hydrated silk fibroin gel. The gel contains soluble Asp-rich 
glycoproteins, which can bind to the β-chitin surface by means of hydrophobic or electrostatic interactions.  
Right: Structure model of a putative nucleation site in molluscan tissues. The sulfate groups, linked to  
flexible oligosaccharide side chains, concentrate Ca2+ ions on an Asp-rich oligopeptide domain that is 
assumed to adapt a highly regular β sheet conformation. A first layer of Ca2+ ions may thus be fixed and 
oriented in space upon which further mineral growth ensues. [ 4H17, 5H18] 
 
As an example, the interlamellar organic sheets of nacre from mollusc shells consist of 
thin sheets of β-chitin[18F 19 ] sandwiched between thicker sheets of silk fibroin-like 
proteins.[19F 20 ] Silk fibroin itself possesses microcrystalline domains of repeating 
[Gly-Ala-Gly-Ala-Gly-Ser]n units that adopt an antiparallel β-pleated sheet conformation. 
These domains have a highly regular and hydrophobic surface upon which acidic 
macromolecules are adsorbed from solution. In the course of adsorption, the acidic 
macromolecule has to fold into the appropriate conformation, in order to maximize its 
hydrophobic interactions with the silk fibroin surface. Possible candidates for acidic 
macromolecules interacting with silk fibroin in the described way are oligopeptides that 
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include sequence motifs of [Asp-Xaa]n, (Xaa = Gly, Ser), which have a strong tendency 
to fold into a β sheet conformation in the presence of Ca2+ ions.[20F21] As a consequence, the 
aspartic acid residues of [Asp-Xaa]n sequences would be positioned at only one side of 
the β-pleated sheet, resulting in an organized two-dimensional array of carboxylate 
ligands. 
 
It is tempting to assume that carboxylate residues coordinate a first layer of Ca2+ which 
would in turn become the first layer of an epitaxially growing CaCO3 crystal. However, 
more profound analysis so far has failed to provide evidence for an epitaxial growth 
mechanism or a close stereochemical complementarity between the nucleating 
macromolecules and the incipient CaCO3 crystal surface.[21F22] Acidic proteins extracted 
from different calcified tissues were shown to exert vast control on polymorph selection, 
texture and morphology of CaCO3 crystals.[22F23] However, up to now only a few artificial 
oligopeptides have been designed and tested for specific interactions with CaCO3 single 
crystals in vitro.[23F24] 
 
An approach using amphiphilic peptides comprising alternating hydrophilic (Asp or Glu) 
and hydrophobic (Phe) amino acid rediues is adopted in order to imitate the epitopes of 
acid proteins from calcified tissues (see Figure 3.3).[6H22] 
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Figure 3.3 Artificial acidic peptides mimicking the potential binding epitopes of highly acidic peptides of 
the water-soluble fraction from mollusc shells. 
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Calcite crystals grown in the presence of T 2 significantly differ in shape from the control. 
A specific inhibition of calcite {11.0} and {01.2} crystal faces occurs, as is shown by 
Figure 3.4.[7H22] 
 
Figure 3.4 Scanning electron micrographs of calcite crystals grown in the presence of T 2. 
 
The {01.2} plane is a polar plane whereas the {11.0} plane is non-polar. However, 
biogenic calcite crystals display these faces quite often.[24F25] The growth inhibition of {01.2} 
and {11.0} faces of calcite induced by acidic peptides containing a repeating Phe-Asp or 
Phe-Glu sequence motif is the first example where artificial peptides exert the same 
influence on the growth habit of calcite crystals as natural acidic proteins isolated from 
skeletal elements of various organisms. Moreover, this is the first example where single 
peptides selectively interact with two distinct crystal faces of calcite.  
 
X-ray crystallographic analysis of T 3 reveals an antiparallel β-sheet structure with 
formation of carboxylic acid dimers between adjacent strands (see Figure 3.5). The 
amphiphilic arrangement leads to an ordered projection of functional groups in different 
layers of the sheet.[25F26] 
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Figure 3.5 Packing plot of the crystal structure of H-(Phe-Glu)2-OH•CF3COOH. (Crystallographic 
data:triclinic, space group P1; a = 10.1259 , b = 11.7410, c = 14.7942 Å; a = 82.81, b = 70.26, g = 89.83°; 
Z = 2.)[ 8H26] 
 
 
As already discussed before, the three dimensional structure of the macromolecule 
template peptides remains to be a bottle-neck, the deep research of the conformation of 
these β-hairpin template peptides will be extremely important to decipher the process of 
biomineralization.  
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3.2 Secondary Structure of Peptides 
 
3.2.1 Secondary Structure Motifs 
In biochemistry and structural biology, secondary structure is the general 
three-dimensional form of local segments of biopolymers such as proteins and nucleic 
acids (DNA/RNA). It does not, however, describe specific atomic positions in 
three-dimensional space, which are considered to be tertiary structure. 
 
Secondary structure is formally defined by the hydrogen bonds of the biopolymer, as 
observed in an atomic-resolution structure. The hydrogen bonding is correlated with other 
structural features however, which has given rise to less formal definitions of secondary 
structure. For example, residues in protein helices generally adopt backbone dihedral 
angles in a particular region of the Ramachandran plot; thus, a segment of residues with 
such dihedral angles is often called a "helix", regardless of whether it has the correct 
hydrogen bonds. 
 
Secondary structure in proteins consists of local inter-residue interactions mediated by 
hydrogen bonds. The most common secondary structures are α-helices and β-sheets. 
Other helices, such as the 310-helix and π-helix, are calculated to have energetically 
favorable hydrogen-bonding patterns but are rarely if ever observed in natural proteins 
except at the ends of α helices due to unfavorable backbone packing in the center of the 
helix. Other extended structures such as the polyproline-helix and α-sheet are rare in 
native state proteins but are often hypothesized as important protein folding intermediates. 
Tight turns and loose, flexible loops link the more regular secondary structure elements. 
The random coil is not a true secondary structure, but is the class of conformations that 
indicate an absence of regular secondary structure. 
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3.2.2 β-Sheet Geometry 
 
3.2.2.1 Geometric Parameters of β-Sheet Conformation 
One of the major structural elements found in globular proteins is the β-sheet. This 
structure is built up from a combination of several regions of the polypeptide chains, in 
contrast to α helix, which is built up from one continuous region. These regions, β strands, 
are usually from 5 to 10 residues long and are in an almost fully extended conformation 
with φ, ψ angles within the broad structurally allowed region in the upper left quadrant of 
the Ramachandran plot.  
 
The majority of β-strands/sheets are arranged adjacent to other strands and form an 
extensive hydrogen bond network with their neighbors in which the NH groups in the 
backbone of one strand establish hydrogen bonds with the C=O groups in the backbone 
of the adjacent strands (see Figure 3.6). In the fully extended β-strands, successive side 
chains point straight up, then straight down, then straight up, and so on. Adjacent 
β-strands in a β-sheet are aligned so that their Cα atoms are adjacent and their side chains 
point in the same direction. The "pleated" appearance of β-strands arises from tetrahedral 
chemical bonding at the Cα atom; for example, if a side chain points straight up, then the 
bond to the Cα must point slightly downwards, since its bond angle is approximately 
109.5°. The pleating causes the distance between Cαi and Cαi+2 to be approximately 6 Å, 
rather than 7.6 Å (2 × 3.8 Å) expected from two fully extended trans peptide virtual 
bonds. The "sideways" distance between adjacent Cα atoms in hydrogen-bonded β strands 
is roughly 5 Å.  
 
However, β-strands are rarely perfectly extended; rather, they exhibit a slight twist due to 
the chirality of their component amino acids. The energetically preferred dihedral angles 
(φ, ψ) = (–135°, 135°) (broadly, the upper left region of the Ramachandran plot) diverge 
somewhat from the fully extended conformation (φ, ψ) = (–180°, 180°).[26F27] The twist is 
often associated with alternating fluctuations in the dihedral angles to prevent the 
individual β-strands in a larger sheet from splaying apart.  
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The side chains point outwards from the folds of the pleats, roughly perpendicularly to 
the plane of the sheet; successive residues point outwards on alternating faces of the 
sheet. 
 
3.2.2.2 Hydrogen Bonding Patterns 
Because peptide chains have directionality conferred by their N-terminus and C-terminus, 
β-strands can be said to be directional, too. They are usually represented in protein 
topology diagrams by an arrow pointing toward the C-terminus. Adjacent β strands can 
form hydrogen bonds in antiparallel, parallel, or mixed arrangements. 
 
In an antiparallel arrangement (see Figure 3.6 A), the successive β-strands alternate 
directions so that the N-terminus of one strand is adjacent to the C-terminus of the next. 
This is the arrangement that produces the strongest inter-strand stability because it allows 
the inter-strand hydrogen bonds between carbonyls and amines to be planar, which is 
their preferred orientation. The peptide backbone dihedral angles (φ, ψ) are about 
(–140°, 135°) in antiparallel sheets. In this case, if two atoms Cαi and Cαj are adjacent in 
two hydrogen-bonded β-strands, then they form two mutual backbone hydrogen bonds to 
each other's flanking peptide groups; this is known as a close pair of hydrogen bonds. 
 
In a parallel arrangement (see Figure 3.6 B), all of the N-terminus of successive strands 
are oriented in the same direction; this orientation is slightly less stable because it 
introduces nonplanarity in the inter-strand hydrogen bonding pattern. The dihedral angles 
(φ, ψ) are about (–120°, 115°) in parallel sheets. It is rare to find less than five interacting 
parallel strands in a motif, suggesting that a smaller number of strands might be unstable. 
In this case, if two atoms Cαi and Cαj are adjacent in two hydrogen-bonded β-strands, then 
they do not hydrogen bond to each other; rather, one residue forms hydrogen bonds to the 
residues that flank the other (but not vice versa). For example, residue i may form 
hydrogen bonds to residues j − 1 and j + 1; this is known as a wide pair of hydrogen 
bonds. By contrast, residue j may hydrogen-bond to different residues all together, or to 
none at all. 
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Finally, an individual strand may exhibit a mixed bonding pattern, with a parallel strand 
on one side and an antiparallel strand on the other. Such arrangements are less common 
than a random distribution of orientations would suggest, indicating that this pattern is 
less stable than the antiparallel arrangement. 
 
The hydrogen bonding of β-strands need not be perfect, but can exhibit localized 
disruptions known as β-bulges. The hydrogen bonds lie roughly in the plane of the sheet, 
with the peptide carbonyl groups pointing in alternating directions with successive 
residues; for comparison, successive carbonyls point in the same direction in the α-helix. 
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Figure 3.6 Illustration of the hydrogen bonding patterns, represented by dotted lines, in an antiparallel 
β-sheet A and a parallel β-sheet B. 
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3.2.3 β-Turn and β-Hairpin Structure 
 
3.2.3.1 The Reverse Turn 
The simplest motif involving β-strands is two adjacent antiparallel strands joined by a 
loop. This motif, which is named as a hairpin unit, occurs rather frequently. It is present 
in most antiparallel β-sheets both as an isolated ribbon and as part of more complex 
β-sheets. There is a strong preference for β-strands when they are adjacent in the amino 
acid sequence to form a hairpin motif. The lengths of the loop region between β-strands 
vary but are generally from two to five residues long.  
 
Cross-strand side chain interactions have been proposed to account for observed amino 
acid preferences for parallel or antiparallel β-sheet structure. The side chain of residues in 
β-structure point at right angles alternately above and below the plane of propagating 
polypeptide chain. As a consequence, patterns in amino acid character in the primary 
sequence of a segment that adopts β-sheet structure can lead to sidedness in the character 
of a β-sheet. Alternating polar and nonpolar residues will creat an amphipathic sheet. 
 
If a β-strand is folded back on itself to form an antiparallel association with the 
succeeding region of polypeptide, there must necessarily be residues forming a chain 
reversal. Accomplishing this chain reversal with two corner residues and an i to i+3 
hydrogen bond leads to a conformational feature know as a β-turn. Initially recognized in 
silk proteins by Geddes et al.[27F28] and later defined stereochemically by Venkatachalam,[ 28F29] 
β-turns are widespread in proteins and both linear and cyclic peptides. The 
stereochemical constraints of establishing i to i+3 hydrogen bond and connecting to the 
incoming and outgoing β strands restricts the possible conformations of the i+1 and i+2 
residues in the turn. Two major classes of β-turn meet the stereochemical criteria with all 
peptides bonds trans: type I and type II. These turns differ in the orientation of the 
peptide bond between the corner residues and consequently in the preferred side chain 
dispositions in the corner position.  
 
In type I β-turn, both i+1 and i+2 positions accommodate L-residues; however, proline 
preferentially fits in the i+2 position. Type I β-turns are the most prevalent in naturally 
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occurring proteins.[29F30,30F31] In a type II β-turn, the i+1 position can accommodate an 
L-residue (proline fits in this position), whereas the i+2 position favors a glycine, small 
polar L-residue, or a D-residue due to the steric clash with a side chain in the 
L-configuration. Proline in position i+1 is a strong sequence determinant for either type I 
or type II β-turn because of the restriction on the φ angel from the cyclic side chain. 
 
Other β-turn geometries are also found: the mirror images of type I and type II are known 
as type I' and II'' and are energetically equivalent if residues of the opposite chirality 
occupy corresponding sequence positions. For example, a D-proline residue would be 
favored in position i+1 of a type I' turn or in position i+2 of a type II' turn. The 
intervening peptide bond (between position i+2 and i+3) can adopt a cis conformation 
and still allow the turn to form an i to i+3 hydrogen bond and link two β strands. The 
resulting turn is called a type VI β-turn. A single turn of 310-helix[31F32,32F33] forms the requisite 
i to i+3 hydrogen bond but has the incoming and outgoing strands significantly twisted 
with respect to on another. This is called a type III β-turn. 
 
3.2.3.2 The β-Turn Motif in β-Hairpin Conformation  
The stereochemical disposition of side chains in β-turn can be treated in a manner that is 
similar to R-group arrangements on cyclohexyl rings.[33F34] When the sidechain is oriented 
outward in the same plane as the polypeptide backbone, it can be called equatorial and, 
when it is oriented above or below the backbone plane, it can be called axial. The turn 
type and configuration of amino acids in the turn position will lead to predetermined side 
chain orientations, as summarized in Table 3.3. Assuming that the conformation of the 
turn sequence is tied down adequately, on can exploit turns to present side chains as 
reactive groups or as recognition moieties. Frequently, cyclization, either via the 
backbone or via side chain bridging, has been used to constrain turns and create desired 
handles for a range of purposes.[9H34] 
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Table 3.3 Turn Type and Configurations of Amino Acids at Corner Positions 
Position i+1 Position i+2 Turn Type 
L-Residue D-Residue L-Residue D-Residue 
I eq ax (down) ax (up) eq 
I' ax (up) eq eq ax (down) 
II eq ax (down) eq ax (down) 
II' ax (up) eq ax (up) eq 
III undetermined undetermined undetermined undetermined 
VI eq eq ax (down) ax (down) 
 
In summary, the category of turn structure is determined by their Ramachandaran angles 
of backbone at residue i+1 and i+2 (Table 3.4).[34F35-35F36F37] These two categories of β-turn are 
shown by statistic data to be the ones which are most frequently appear in the β-turn 
motif of the β-hairpin protein.[37F38,38F39] 
 
Table 3.4 φ and ψ values of residue i+1 and i+2 in type I' and II' β-turn. 
Position i+1 Position i+2 Turn Type 
φ ψ φ ψ 
I' +60º +30º +90º 0º 
II' +60º -120º -80º 0º 
 
In both of type I' and type II' turns, their φi+1 is positive and lies within a region of 
conformational space which is very poorly populated by L-amino acids, as a consequence 
of steric limitations.[39F40] Since the constraints of pyrrolidine ring formation restrict the φ 
value in D-Pro to be +60 ± 20º, D-Pro is thus often chosen as the residue in de novo design 
of the synthetic peptides to occupy the i+1 position of β-turn in order to nucleate the 
peptide into β-hairpin conformation. Less frequently, Asparagine residues, with a 
significant propensity for positive φ values are also observed at this position.[40F41] 
 
The successful design of a stable β-hairpin in an apolar octapeptide Boc-Leu-Val-Val- 
D-Pro-Gly-Leu-Val-Val-OMe has been achieved using a centrally positioned D-Pro-Gly 
segment to nucleate a type II'-β turn.[41F42] The L-Pro-Gly peptide derivative Boc-Leu-Val- 
Val-Pro-Gly-Leu-Val-Val-OMe does not adopt a β-hairpin conformation despite the 
presence of a Pro-Gly β-turn. Early analysis of β-hairpin structures in proteins reveals 
that type I'/II'-turns, both of which have positive φi+1 values, are favoured at the hairpin 
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turn positions.[10H38,11H39] A more recent analysis with a larger protein data set suggests that 
β-hairpins nucleated by type II β-turns are indeed found in proteins. However, strand 
links are in these cases significantly longer than the average hydrogen-bonded hairpin.[42F43] 
After the efficacy of D-Proline-containing loops was established in minimal β-hairpin 
models, the folding of a larger peptide that contained a β-hairpin was shown to be 
enhanced by a D-Pro-Gly loop, relative to an L-Pro-Gly loop.[43F44] 
 
D-Pro-X segments promote autonomous β-hairpin folding in aqueous solution. The first 
example involved peptides related to the amino-terminal segment of ubiquitin.[44F45] A 
series of 16-mers was prepared, MQIFVKSXXKTITLVKV-NH, with five different XX 
segments: D-Pro-D-Ala, L-Pro-L-Ala, D-Pro-L-Ala, D-Pro-Gly and L-Pro-Gly.[12H45] NMR 
data indicated that each of the D-proline-containing peptides displayed β-hairpin folding 
with a two-residue loop at D-Pro-X, while the L-proline containing peptides appeared to 
be completely disordered. More recently, the l2 residue designed peptide 
RYVEVXGOKILQ-NH, has been shown to adopt a β-hairpin conformation in aqueous 
solution when X is D-Pro, but not when X is L-Pro.[45F46] 
 
3.2.3.3 β-Hairpin Conformation Stabilization Factors 
Self-assembly of β-hairpin conformation is driven not only by numerous intramolecular 
hydrogen bonds, but also by side-chain to side-chain interactions. 
 
A β-hairpin peptide is composed of two antiparallel β strands (see Figure 3.7, carbonyl in 
the backbone not shown) linked by a short loop. When the loop contains only four 
residues, the two central residues correspond to positions i + 1 and i + 2 of a β-turn. The 
origin of the stability of isolated β hairpins in aqueous solution is unclear with contrasting 
opinions as to the relative importance of interstrand hydrogen bonding, hydrophobic 
interactions, and conformational preferences, the latter being associated largely with the 
turn sequence. 
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Figure 3.7 Antiparallel β-strands in β-hairpin peptide 
 
3.2.3.3.1 The Loop Segment  
Several recent studies highlight the importance of the loop residues in determining 
overall β-hairpin stability. de Alba et al.[46F47] examined a series of six decamers in which 
the central four residues were varied, but the first and last three residues were held 
constant. A remarkable range of β-hairpin conformations was detected by NMR within 
this small series. Three different loop structures are formed among these peptides, 
containing two, three or four residues. de Alba et al. concluded that "the turn residue 
sequence determines the turn conformation, and thereby, the other features of the 
β hairpin conformation, such as the pattern of interstrand residue pairing." Haque and 
Gellman[ 13H45] showed that a β-hairpin with natural registration could be achieved by 
replacing the native loop with a segment containing a D-proline residue. However, simply 
changing the proline configuration to L-counterpart abolished β-hairpin formation. 
Stranger and Gellman observed the same D-proline versus L-proline effect with a 
designed 12-residue sequence.[14H46] Griffiths-Jones et al.[47F48] have reported that an -Asn-Gly- 
segment can induce a modest extent of β-hairpin folding in water even when the attached 
strands are only two residues long. 
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3.2.3.3.2 Inter-strand Side chain-Side chain Interactions 
Ramirez-Alvarado et al.[48F49] observed that changing two or more of the highlighted strand 
residues of RGITVNGKTYGR to alanine abolished β-hairpin folding. The authors 
concluded that "inter-strand side chain-side chain interactions are essential for β-hairpin 
formation." de Alba et al.[49F50] noted, however, that the strength of this conclusion is 
"unclear, because alanine has an intrinsically low propensity to be in a β-strand". The 
authors concluded that they could identify several specific interstrand side chain-side 
chain interactions that were either favorable or unfavorable with respect to β-hairpin 
formation. The interactions identified in this way were consistent with favorable and 
unfavorable interstrand pairings that had previously been suggested by Wouters and 
Curmi[ 50F51] on the basis of statistical analysis of such pairings in the crystallographic 
database. Maynard et al.[51F 52 ] have reported thermodynamic analysis of the thermal 
unfolding of designed 16-mer Ac-KKYTVSINGKKITVSI in aqueous solution. The 
authors deduced that the β-hairpin conformation is stabilized by hydrophobic interactions 
among side chains on the two opposing β strands, based on the thermodynamic signature 
of the folding equilibrium, which includes a large, negative change in heat capacity at 
constant pressure. Interestingly, the thermodynamic signature of the folding equilibrium 
changes dramatically in water/methanol (1:1), relative to water, and the authors 
concluded that interstrand hydrogen-bond formation becomes an important stabilizing 
factor in the mixed solvent. Maynard et al.[15H52] note that although the loop segment plays 
an important role in β-hairpin formation, a favorable loop is probably not sufficient (i.e. 
that favorable interstrand interactions are required for β-hairpin formation). 
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3.3 Circular Dichroism Spectroscopy in Peptide 
Conformation Analysis 
 
3.3.1 CD Spectroscopy 
Circular Dichroism (CD) is very sensitive to the secondary structure of polypeptides and 
proteins. Circular Dichroism Spectroscopy is a form of light absorption spectroscopy that 
measures the difference in absorbance of right- and left-circularly polarized light (rather 
than the commonly used absorbance of isotropic light) by a substance. It has been shown 
that CD spectra between 260 and approximately 180 nm can be analyzed for the different 
secondary structural types: α-helix, parallel and antiparallel β-sheet, turn, and other. A 
number of excellent review articles are available describing the technique and its 
application (Woody, 1985; Johnson, 1990). In fact, optical rotary dispersion (ORD, vide 
infra) data suggested a right-handed helical conformation as a major protein structural 
element before the Pauling and Corey model (Pauling & Corey, 1951) and Kendrew's 
structure of myoglobin. Modern secondary structure determination in proteins by CD are 
reported to achieve accuracies of 0.97 for helices, 0.75 for β-sheet, 0.50 for turns, and 
0.89 for other structure types (Manavalan & Johnson, 1987).  
3.3.2 Physical Principles of CD 
Inherently asymmetric chromophores (uncommon) or symmetric chromophores in 
asymmetric environments will interact differently with right- and left-circularly polarized 
light resulting in two related phenomena. Circularly-polarized light rays pass an optically 
active medium at different velocities due to the different indices of refraction for right- 
and left-circularly polarized light called optical rotation or circular birefringence. The 
variation of optical rotation as a function of wavelength is called optical rotary dispersion 
(ORD). Right- and left-circularly polarized light will also be absorbed to different extents 
at some wavelengths due to differences in extinction coefficients for the two polarized 
rays called circular dichroism (CD). Optical rotary dispersion enables a chiral molecule 
to rotate the plane of polarized light. ORD spectra are dispersive (called a Cotton effect 
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for a single band) whereas circular dichroism spectra are absorptive. The two phenomena 
are related by the so-called König-Kramers transforms.  
 
It can be shown that if right- and left-circularly polarized light is absorbed to different 
extents at any wavelength, there will be a difference in refractive indices at virtually all 
wavelengths. This accounts for the ability of small saturated chiral molecules to rotate the 
plane of polarized light of the D-line of sodium (589 nm), far away from absorptive 
bands. The dispersive nature of ORD is also the reason CD spectroscopy is a more 
sensitive analytical technique. Unlike the dispersive ORD phenomenon, circular 
dichroism can only occur within a normal absorption band and thus requires either an 
inherently asymmetric chromophore (uncommon) or a symmetric one in an asymmetric 
environment. 
3.3.3 Secondary Structure from CD Spectra 
The simplest method of extracting secondary structure content from CD data is to assume 
that a spectrum is a linear combination of CD spectra of each contributing secondary 
structure type (e.g., "pure" α-helix, "pure" β-sheet etc.) weighted by its abundance in the 
polypeptide conformation. The major drawback of this approach is that there is no 
standard reference CD spectrum for "pure" secondary structures. Synthetic 
homopolypeptides used to obtain reference spectra are in general, poor models for the 
secondary structures found in proteins. For example, the CD of an α-helix has been 
shown to be length dependent and no homopolypeptide system has been found that is a 
good example of the β-sheet structure found in proteins.  
 
In response to these shortcomings, several methods have been developed which analyze 
the experimental CD spectra using a database of reference protein CD spectra containing 
known amounts of secondary structure (Provencher & Glöckner, 1981; Hennesey & 
Johnson, 1981; Manalavan & Johnson, 1987; Sreerama & Woody, 1994). These methods 
are in general more accurate and reliable than the novel approach outlined above.  
 
In one method (Manalavan & Johnson, 1987), single value decomposition is used to 
create orthogonal CD basis vectors from CD spectra of proteins with known secondary 
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structure. Using the statistical technique of variable selection, unimportant variables are 
removed from an underdetermined system of equations allowing the solution for the 
important ones. The great advantage of this technique (and others like it) is that one 
makes no assumptions on the form of the CD from the individual secondary structural 
elements. One needs only to be sure that the overall structural characteristics of the 
analyzed protein are represented in the set of reference spectra. In this way, irregularities 
of secondary structure and length dependencies should be taken into account. 
 
Two very important requirements for successful secondary structure analysis using these 
techniques deserve further comment. One is that the CD spectra need to be recorded from 
about 260 nm to at least 184 nm (and preferable 178 or below; Johnson, 1990) and the 
other is that an accurate protein concentration (< 10% error) is essential. The assumptions 
and limitations of these techniques are discussed in detail by Manning (1989).  
 
Circular dichroism spectroscpy has also been used to determine the tertiary structure class 
of globular proteins. The method proposed by Venyaminov & Vassilenko (1994) claim 
100% accuracy for predicting all α, α/β, and denatured proteins; 85% for α + β; and 75% 
for all β proteins.  
 
Circular dichroism spectroscopy has been extensively applied to the structural 
characterization of peptides. The application of CD for conformational studies in peptides 
(like proteins) can be largely grouped into a) monitoring conformational changes (e.g., 
monomer-oligomer, substrate binding, denaturation, etc.) and b) estimation of secondary 
structural content (e.g., this peptide is 25% helical under these conditions). As already 
mentioned, CD is particularly well-suited to determine structural changes in both proteins 
and peptides. However, the absolute structural content is more difficult to derive and is 
prone to over-interpretation. Length-dependencies of the CD spectra of "pure" secondary 
structures are only one potential caveat.  
 
The CD spectra of peptides have been reported in a number of solvent systems. The 
helix-promoting characteristics of trifluoroethanol (TFE) and hexafluoroisopropanol 
(HFIP) are well-known. A number of authors have argued that these solvents mimic a 
particular characteristic of the in vivo system and therefore attach relevance to structural 
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studies performed in these solvents. Of particular importance to this matter is a study by 
Waterhous & Johnson (1994) who demonstrated that peptide sequences could be induced 
to form α-helices or β-strands in TFE and non-micellar SDS solutions, respectively, 
regardless of their secondary structure in the native protein. This result underscores the 
difficulties in assigning relevance to structural studies in peptides using CD spectroscopy.  
 
All-β proteins usually have a single, negative and a single, positive CD band, whose 
intensities are much lower than those of α helix. Their CD spectra can vary considerably 
among different all-β proteins. Those of regular all-β proteins resemble the CD spectrum 
of the β sheet of (Lys)n , and usually have a single minimum between 210 and 225 nm 
and a stronger positive maximum between 190 and 200 nm. 
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3.4  Aims of the Study 
 
 
The ultimate purpose to explore the exact behaviors of natural phenomenon of 
biomineralization could be achieved by the thorough study of biomacromolecules which 
direct this process. The proteins extracted from the mollucs exhibited us some hints 
which could be utilized as templates to investigate. The relationships between the 
primary and secondary structures of concerned biomacromolecules and the behaviors of 
the biomineralization and the patterns of thus generated crystals is one of the focus of this 
project. Peptides which adopt amphiphilic β-hairpin conformation could stand out as 
appropriate candidates that mimic the naturally occurring macromolecules that direct the 
process of biomineralization. The air/water interface where these amphiphilic β-hairpin 
peptides are located could imitate the actual enviroments of macromolecules controlling 
biomineralization in the living organism. The hydrophilic acidic side chains on these 
amphiphilic β-hairpin peptides will point to the water and hydrophobic side chains point 
to the air. While in organism, the acidic side chains on the macromolecules which direct 
the biomineralization point to the water solution containing mineral ions such as calcium; 
the hydrophobic residues will interact with the hydrophobic core of the rigid scaffold of 
insoluble matrix protein. The extended conformation of β-hairpin peptides hold ordered 
structures by themselves without the assist of scaffold, making them quantified as ideal 
candidates for organizing the process of nucleation of minerals.  
 
As the process of biomineralization concerns the interactions between the protein 
templates in the tissues of molluscs and inorganic compounds which finally crystallize in 
the organisms, this natural phenomenon presents an ideal project to utilize the tool of 
supramolecular chemistry of peptides/protein to address questions in biomineralization. 
From the available information of the primary sequences of the peptides which 
participate in the process of biomineralization, mimics of these peptides should be 
synthetically obtained and applied. One of the most significant advantages of the 
application of synthetic peptides/peptidomimetics as templates to explore the 
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biomineralization lies in the fact that the relationship between the behaviors of 
biomineralization, crystal morphology and the secondary structures of the concerned 
peptide templates could be resolved. This achievement is more valuable when one 
considers that the useful information centered on this issue is specially limited and scarce. 
It is therefore extremely instructive for scientists and engineers who are enthusiastic in 
the beautiful structures and functional properties of the materials formed within living 
organisms. The decipherment of the structure-behavior relationship in biomineralization 
could not only bring forward the progress in the theoretical research field, but also the 
breakthrough in corresponding application domains in pharmacology and medicine. 
 
Another main purpose of this project is to explore the process of nucleation of the peptide 
chain into β-hairpin conformation, the factors which stabilize/destabilize their 
conformation, the primary sequence dependence, and the solvent dependence. The extent 
of the research about the formation of β-sheet and β-hairpin lags behind that of α-helix, 
partially because of the difficulties in the synthetic process of these peptides. Moreover, 
they are not easy to handle, because of the inclination to aggregate and poor solubility in 
common solvents. There are still some controversial viewpoints up to now about the 
formation of β-sheet and β-hairpin peptides.  
 
The β-hairpin peptides applied to the biomineralization in this project could be possibly 
utilized as templates to explore the factors to stabilize/destabilize the β-hairpin 
conformation by mutations of the amino acid residues in the primary sequences which 
could be crucial in determining the peptide conformation. By studying the conformational 
changes of the concerned peptides under different environments, such as distinctive 
solvents like water or halogenated alcohol, or at different pH values, the weight of factors 
which determine the conformational stabilities of the β-hairpin peptides could be possibly 
figured out. The results of the conformational analysis of concerned peptides applied in 
this project could potentially afford useful information related to the formation of 
β-hairpin structures, and could be therefore instructive for the de novo design of the 
β-sheet or β-hairpin peptides.[52F53] 
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It is forseeable that the synthesis of β-sheet derivative peptides is one of the challenging 
obstacles in the progress of the relative research domains, special synthetic 
methodologies are supposed to applied in this project. Since the intra-chain hydrogen 
bonds are regarded as the underlying factors that impede the smooth coupling of amio 
acids to the growing peptidyl chains on the resin, as well as the quantitive removal of the 
N-terminal Fmoc protecting groups, methods address the issues of intra-chain hydrogen 
bonds breaking should be utilized. Use of special solvent such as TFE or HFIP could be 
helpful but not addressing the essential problems. The incorporation of pseudo-proline 
analogues is efffective but not universal. Under these circumstances, the selective 
protections of the backbone amide groups by acid labile moity Hmb which is compatible 
with Fmoc/tBu chemistry of peptide synthesis could be one of the optimal choices. This 
methodology could be applied to all types of peptides, its incorporation and removal 
could be smooth and problem free. The incorporation of Hmb backbone protecting 
groups into the peptides which potentially adopt β-sheet or β-hairpin secondary structure 
could also increase their solubities, making them adaptable for chromatographic 
purification. Furthermore, the conformational influences the backbone- and sidechain- 
protecting groups bring forward are another research interest of the project. 
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3.5  Results and Discussion 
 
3.5.1 Design of the Peptide Templates in Biomineralization 
 
Calcium salts in organisms are packed and aligned cooperatively between organic 
matrices, such as collagens and some acidic proteins. This process is regarded as 
mineralization in a living body, a process known as biomineralization. During crystal 
formation, the organic matrix plays a role for the control of the location and pattern of 
nucleation. In order to imitate the natural process preferably, the synthetic 
macromolecules that mimic the naturally occurring protein matrices should preferentially 
resided in the interface between the hydrophobic and hydrophilic environments, which 
reproduces the water/protein biomineralization interface in organism.  
 
Peptide adopting a β-hairpin is basically a "flat" macromolecule, despite being distorted 
to some extent under normal conditions. In order to exist stably between the interfaces of 
hydrophobic and hydrophilic bulk enviroments, the hairpin peptides should possess 
side-chains with distinctively different polarities on the two "faces" of the hairpin 
structure. This design command introduced the conception of amphiphilic hairpin 
peptides. If the side chains pointing upwards are exclusively hydrophobic/hydrophilic, 
meanwhile the side chains pointing downwards are exclusively hydrophilic/hydrophobic, 
that is to say, the polarity properties of upward and downward side chains are opposite, 
and this category of β-hairpin peptide is named amphiphilic β-hairpin peptide. 
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Figure 3.8 Amphiphilic β-hairpin pepide EFEFEFEpGEFEFEFE HP 19 
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Figure 3.8 shows one example of amphiphilic β-hairpin peptides with the primary 
sequence EFEFEFEpGEFEFEFE HP 19, which was applied in this project as the 
template to explore the behaviour of biomineralization and structure properties. It is 
obvious that the side chains pointing upwards exclusively originate from acidic glutamic 
acid, meanwhile the side chains pointing downwards are exclusively originated from 
hydrophobic phenylalanine. Such an amphiphilic β-hairpin peptide represents an ideal 
template for the research of the behaviours of molecules at the interfaces, where 
biomineralization most probably takes place. 
 
It is known that the motif -D-Pro-Gly- is prone to nucleate to form a type II' β-turn at the 
central i+1 and i+2 position.[16H42] It is thus rational to introduce this motif to the β-hairpin 
peptide to alternate the direction of the strand and assist the formations of intrachain 
hydrogen bonds between the NH and CO groups on the backbone of the peptide, 
resulting in the β-hairpin conformation. The thus nucleated peptide would probably adopt 
the stable hairpin conformation at the interfaces of aqueous solution and air. The 
hydrophobic side-chains from phenylalanine would point to the air, while the hydrophilic 
side-chains of glutamate are supposed to be solvated by water molecules. This 
conformation adopted at the air-water interfaces affords the ideal imitation of the 
behaviors of the natural biomacromolecules which direct the process of biomineralization 
in the nature. Peptide design for the project is shown by Table 3.5. 
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Table 3.5 Designed Peptides for Biomineralization and Conformational Study 
No. Sequence 
HP 1 EpGE 
HP 2 DpGD 
HP 3 DpGK 
HP 4 FpGF 
HP 5 FDpGKF 
HP 6 FDpGDF 
HP 7 DFpGFD 
HP 8 FEpGEF 
HP 9 FEFEpGEFEF 
HP 10 FDFDpGDFDF 
HP 11 FDFDFDFD 
HP 12 FEFEFEFE 
HP 13 EFEpGEFE 
HP 14 FDFDpGDFDFpGFDFD 
HP 15 DFDFDFEpGEFDFDFD 
HP 16 EFEFEFDpGDFEFEFE 
HP 17 DFSFDFSpGDFSFDFS 
HP 18 DFDFDFDpGDFDFDFD 
HP 19 EFEFEFEpGEFEFEFE 
HP 20 EFSFEFSpGEFSFEFS 
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3.5.2 Synthesis of Peptides 
 
3.5.2.1 Purposes of Backbone Protection in Peptide Synthesis 
Successful assembly of peptides is often hampered by inherent problems such as poor 
solvation of the growing peptide chain during synthesis on solid supports, as well as 
limited solubility of fully protected peptides fragments in the solution approach. The 
synthesis of β-sheet peptides remains to be a tough challenge till now due to their 
insolubility in most of the common solutions applied in Solid Phase Peptide Synthesis 
(SPPS). The inter- as well as intra-molecular hydrogen bonds between the β-strand 
severely impede the freedom degree of the growing peptide chains and therefore prevents 
the incoming amino acid coupling with the peptide chains smoothly. Particular sequences 
that favor such phenomena have come to be known as "difficult sequences".[53F54] This 
obvious inherent drawback significantly lowers the coupling efficiency of the SPPS of 
β-sheet originated peptides, which generates series of truncated sequence of peptides.  
 
Another inherent disadvantage caused by inter- or intra-chain molecular bonds during 
β-sheet related peptide synthesis is the insolubility of such peptides in most of the 
solvents, which are applied as eluents in preparative Reverse Phase High Performance 
Liquid Chromatography (RP-HPLC), such as water, methanol, or acetonitrile. The 
synthesized crude peptides are therefore inapplicable for RP-HPLC purification 
methodology since their high hydrophobic properties will have them precipitated in these 
eluents.  
 
Many methods have been proposed to circumvent the solvation problems which are 
generated by inter- or intra-molecular hydrogen bonds during the β-sheet related peptide 
synthesis, including addition of chaotropic salts,[54F55-55F56F57F58] special solvent systems such as 
trifluoroethanol or hexafluoroisopropanol,[58F59] or so-called "magic mixtures" such as the 
mixture of halohydrocarbons and halo alcohols which are extremely efficient at 
disrupting self-association of peptide chains and enhancing peptide solubility, [59F60,60F61] 
elevated temperature,[61F 62 ] solubilizing protecting groups,[62F 63 ] and disruption of the 
symmetry of side-chain protecting groups.[63F64] These incomplete couplings can also be 
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improved by recouple. In such cases, the use of a different coupling method is advisable.  
 
Despite all the endeavors the peptide chemists are striving for, the methods shown above 
remained only partially effective. In order to address the key factor that generates the 
previously discussed problems during the synthesis of β sheet related peptide synthesis, 
Sheppard and co-workers have described the protection of the amide bond in peptides 
with the 2-hydroxy-4-methoxybenzyl (Hmb) group, which is compatible with the 
Fmoc/tBu strategy. This protecting group has also been used in the orthogonal 
solid-phase synthesis of N-glycopeptides to avoid aspartimide formation and to improve 
the solubility of protected peptides, one of the main drawbacks of the convergent 
approach. Such a backbone protection methodology is presently believed to be the best 
approach, since it addresses the problem at its root, i.e. formation of hydrogen bonds. To 
prevent this type of interaction and, correspondingly, aggregation phenomena and 
precipitation of the related peptides in most applicable solvents in RP-HPLC, substitution 
of every backbone amide is superfluous, but in the peptide synthetic process this 
backbone protection will have to be initiated before the chains begin to aggregate. As an 
empirical rule, it has been found that such backbone protection is efficient if they are 
implemented at every sixth residue during the chain elongation. For shorter sequences, or 
intermediate fragments of approximately ten residues, placing the backbone protection 
around the center of the molecule is apparently sufficient although some exceptions are 
known.[ 17H59]  
 
Backbone protection can also suppress aspartimide formation (see Figure 3.9) during the 
SPPS of some certain sequences that are prone to this problem, such as Asp-Asp or 
Asp-Gly 20. Aspartimide derivative 21 can be generated either by acidic or basic 
catalysis, which can be further transformed into racemic α-peptide 22 and β-peptide 23 
through hydrolysis with different ring-open manner, or into racemic piperidide of 
α-peptide 24 and racemic piperidide of β-peptide 25 through piperidolysis. If the amino 
acid residue preceding aspartate in the synthesis (residue i+1 if aspartate is taken as 
residue i) is backbone protected, the problem of aspartimide formation will be fully 
suppressed. As the amide group of residue i+1 is protected by e.g. Hmb, its 
nucleophilicity is extremely reduced, preventing it from attacking the carboxy group of 
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Asp side chain in order to avoid the aspartimide formation. Furthermore, the normally 
bulky backbone protecting groups will to some extent "freeze" the amide group and 
hence lower its reactivity. In summary, backbone protection is currently by far the most 
efficient method against aspartimide formation.  
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Figure 3.9 Aspartimide formation in peptide synthesis 
 
There are two main types of reversible backbone protection based on (i) the replacement 
of the amide hydrogen with a protecting group and (ii) bridging the amide nitrogen to a 
side-chain group of the amino acid residue (so-called pseudoproline methodology). The 
second approach is limited to the residues such as threonine, serine or cystine, which 
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bears a hydroxyl or thiol functional group on the side chain, which narrows its universal 
application. In the first approach, amino acids are Nα-substituted with a group that 
guarantees reversible backbone protection, and these derivatives are additionally 
protected by a second group at the amino group to prevent aminoacylation during their 
incorporation into the peptide chain. As is known, introduction of methoxy groups into 
the benzyl moiety enhances acidolytic cleavage, the aim of solubilizing the otherwise 
insoluble peptides has been fully fulfilled.  
 
For an appropriate adaptation of the benzyl-type backbone protection to the Fmoc/tBu 
strategy, the 2-hydroxy-4-methoxybenzyl (Hmb) group was proposed because 
incorporation of the 4-methoxy moiety leads to significantly enhanced acid lability.[64F65]  
 
The peptide chain elongation is achieved on the solid support applying Fmoc/tBu strategy 
(see Figure 2.13). This process could be completed manually or by e.g. an automated 
microwave peptide synthesizer (see Figure 2.14), in which microwave irradiation is 
applied as the input energy to drive the whole process of SPPS. 
 
3.5.2.2 Synthesis of N,O-bis-Fmoc-N-Hmb-Asp(OtBu)-OH  
Since the Hmb protecting group is stable under the basic conditions for Fmoc cleavage 
during SPPS, it affords the perfect orthogonality to the Fmoc/tBu chemistry strategy of 
solid phase peptide synthesis. As the Hmb protected amino acid is sterically hindered, it 
could possibly bring forward the problems such as sluggish acylating rate and low 
efficient of coupling yields, thus causing racemization and inherent truncated sequences. 
With respect to this inherent limitation of the Hmb backbone protection strategy, such 
amino acids which are sterically unhindered will be preferably chosen for Hmb protection 
group. In this project, the Asp residue is regarded as the optimal acceptor of backbone 
protecting group since the side-chain of Asp is non-β-branched and the incorporation of 
Hmb group to Nα-amine group proven to be smoothly and efficiently.  
 
The Hmb group is smoothly incorporated into the relevant amino acid by reductive 
amination. The 2-hydroxy-4-methoxybenzaldehyde forms the imine with the protected 
Nα-free amino acid, which is reduced by NaBH4 to give the target N-Hmb-Amino acid. 
(Scheme 3.1) 
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The reaction between H-Asp(OtBu)-OH 26 and 2-hydroxy-4-methoxybenzaldehyde 27 to 
give the H-(Hmb)Asp(OtBu)-OH 29 is achieved first by the nucleophilic addition of 
amino group of H-Asp(OtBu)-OH to the 2-hydroxy-4-methoxybenzaldehyde giving a 
hemiaminal –C(OH)(NHR) followed by an elimination of water to yield the imine 28. 
The pH of this reaction should be kept around 9.0 to activate the nucleophilicity of the 
amino group. Subsequently the imine intermediate 28 is cautiously reduced by sodium 
borohydride under basic conditions and the product is finally neutralized with HCl to 
generate the target compound H-(Hmb)Asp(OtBu)-OH 29. The reductive amination 
procedure is shown in Scheme 3.1.  
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Scheme 3.1 Synthesis of N-Hmb-Asp(OtBu)-OH 
 
As the Nα-Hmb-Asp(OtBu)-OH 29 is to be incorporated into the growing peptide chain 
on the solid support, the amino group of 29 requires protection with an appropriate 
temporary protecting group. Since the 2-hydroxy group is also nucleophilic, it can 
therefore also be theoretically acylated during the coupling steps. Studies of the 
mechanism of acylation of amino group with Nα-protected Hmb amino acid derivatives 
revealed a new type of reactive intermediate 31, which is formed independently of the 
coupling procedure applied. 
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Scheme 3.2 4,5-Dihydro-8-methoxy-1,4-benzoxazepin-2(3H)-one derivative intermediate 31 in the 
activation of Nα-Fmoc Nα-(2-Hydroxy-4-methoxybenzyl) amino acid 30. 
 
This intermediate was identified as 4,5-dihydro-8-methoxy-1,4-benzoxazepin-2(3H)- one 
derivative 31 (Scheme 3.2), which is believed to be the active component that undergoes 
aminolysis to produce the desired peptide 33.[65F 66 ] The acylating potency of this 
intermediate is, however, inferior to that of normal active esters and the coupling yields 
are hence low.[ 66F67] Furthermore, if the amino component of the coupling counterpart 32 is 
hindered and hence the coupling rate would be low, there will be some side reactions of 
this intermediate such as racemization. To prevent formation of the intermediate 
lactone 19, the phenolic group has to be protected. For this very reason, the N,O-bis- 
Fmoc-N-Hmb protected amino acid is chosen over the mono-Fmoc derivatives 
(Scheme 3.3). Due to acid lability, the Hmb strategy is preferably applied in Fmoc/tBu 
chemistry and thus the N,O-bis Fmoc derivatives of Hmb amino acid 22 is the choice.  
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Scheme 3.3 The activation of N,O-bisFmoc-N-Hmb-Asp(OtBu)-OH 34 and its coupling to another amino 
acid. 
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3.5.2.3 Introduction of N,O-bis-Fmoc-N-Hmb-Asp(OtBu)-OH and Peptide 
Chain Elongation 
 
N,O-bis-Fmoc-N-Hmb protected amino acids 34 are preferably prepared from 
H-(Hmb)Asp(OtBu)-OH 29 through the reaction with Fmoc-Cl 37 under basic conditions 
due to its high reactivity with amine (Scheme 3.4). The related azide Fmoc-N3 and 
N-hydroxysuccinimide ester Fmoc-OSu are not sufficiently reactive for this purpose.[18H66] 
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Scheme 3.4 Synthesis of N,O-bisFmoc-N-Hmb-Asp(OtBu)-OH 34 from N-Hmb-Asp(OtBu)-OH 29 
 
The incorporation of N,O-bis-Fmoc-N-Hmb amino acid 34 to the growing peptide chain 
is preferably carried out with the corresponding pentafluorophenyl (Pfp) ester[19H65, 67F68] or 
with carbodiimides.[ 20H65] The uronium guanidinium-type coupling reagent such as HATU is 
also able to fulfill such a task. The coupling efficiency is sequence dependent, as the 
yields strongly depend on the nature of the side chains. This can be explained by steric 
hindrance, especially with β-branched amino acids such as Val, Thr, and Ile. This 
observation suggests that only amino acids with unbranched side chains are suitable for 
backbone protection,[21H66] and among these glycine and phenylalanine are particularly 
recommended.[68F69] The acylation of N-terminal Hmb amino acid residues is more difficult 
and thus the sterically most unhindered sites are generally preferred for this acylation of 
Nα-Hmb protected amino acid derivative. HATU is a reliable candidate for this acylation 
reaction. UNCAs (urethane-protected α-amino acid N-carboxyanhydride) in a large 
excess appears also to be a method of choice.[69F70] Similarly efficient is the use of acyl 
fluorides.  
 
In the course of N-terminal peptide extension, the phenolic group of Hmb is acylated first 
as it is less hindered than the secondary amino group to form the intermediate 39. 
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Afterwards, O → N migration, which is an intramolecular base-catalyzed reaction, takes 
place in a second step leading to peptide bond formation, as shown in Scheme 3.5.  
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Scheme 3.5 Aminoacylation of Nα-(2-Hydroxy-4-Methoxybenzyl) Amino Acid Derivatives 38 
 
The mechanism of aminoacylation of Nα-Hmb-Amino acid derivative 38 serves as an 
argument that although Nα-Hmb-Amino acids or peptides are known to be sterically 
hindered with respect to aminoacylation, acylation of such an amino acid or peptide 
derivative proceeds surprisingly well.  
 
In SPPS, since the incoming amino acid 40 and the coupling reagents are used in excess, 
the N-terminal Hmb protected amino acid residue 41 could possibly be acylated at not 
only the N-amino group, but also the 2-hydroxy position to generate the intermediate 42. 
However, quantitative cleavage of this ester is assured in the subsequent Fmoc-removal 
with secondary amine such as piperidine, generating intermediate 43 with the free 
2-hydroxy group and free N-terminus, which is supposed to be coupled with the next 
activated amino acid derivative 44 to complete the chain elongation (Scheme 3.6). As the 
Hmb-protected amino acid is not present at the N-terminus any more, the acylation of 
2-hydroxy position will still take place at a less extent than before, assumably because of 
the steric hindrance. Nevertheless, it does not represent a problem in the process of chain 
elongation since the O-acylated moiety 42 is quantitatively smoothly cleaved by the 
standard Fmoc deproctection strategy. 
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Scheme 3.6 N,O-Acylation of N-Hmb-peptide in SPPS, subsequent basic cleavage of N-Fmoc and O-acidyl 
group, and the following peptide chain elongation. 
 
The argument for the aforementioned mechanism is supported in this project (synthesis of 
HP 17) by the real-time control of the condensation reaction of Fmoc-Gly-OH to the 
growing peptide H-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-Phe-Asp(OtBu)-Phe-Ser(tBu)- 
O-Trt(2-Cl)-Resin on the solid support by the correlative MALDI-ToF MS. The 
MALDI-ToF MS of the crude peptide Fmoc-Gly-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-Phe- 
Asp(OtBu)-Phe-Ser(tBu)-OH contains signals at m/z = 1806.32, 1821.21, 1827.04 
etc.(see Figure 3.10), which correspond to the O-acylated derivative of the 
aforementioned peptide (Scheme 3.7). While signals at m/z = 1504.20, 1526.15, 1542.07 
ect. belong to target peptide Fmoc-Gly-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-Phe- 
Asp(OtBu)-Phe-Ser(tBu)-OH.  
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Scheme 3.7 Piperidine treatment of N,O-acylation product of the N-terminal N-Hmb-protected peptide 45 
 
 
Figure 3.10 MALDI-ToF-Mass Spectrum of Fmoc-Gly-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-Phe-Asp(OtBu)- 
Phe-Ser(tBu)-OH andd its O-acylated derivative. 
 
After treatment of 45 with 20% piperidine in DMF (twice, 5min, 15min, respectively), 
the Fmoc-glycyl moiety on the 2-hydroxy group of Hmb is removed quantitatively, 
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yielding the target peptide product H-Gly-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-Phe- 
Asp(OtBu)-Phe-Ser(tBu)-O-Trt(2-Cl)-Resin 46. MALDI-ToF MS signals at m/z = 
1282.61, 1304.80, 1320.78, ect. correspond to H-Gly-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)- 
Phe-Asp(OtBu)-Phe-Ser(tBu)-OH (see Figure 3.11).  
 
 
Figure 3.11 MALDI-ToF-Mass Spectrum of H-Gly-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-Phe-Asp(OtBu)- 
Phe-Ser(tBu)-OH 
 
After acylation of the Hmb-protected amino acid by the subsequent amino acid residue, 
the peptide chain elongation returned to the "normal track", i.e., the routine coupling 
uronium reagent such as TBTU could be applied as coupling reagent. It promotes the 
coupling of amino acid properly. The peptide chain elongation is able to run smoothly 
until the end in the synthesis of template peptide HP 17 in this project.  
 
The introduction of Hmb moiety significantly improves the solubility of β-sheet forming 
peptides in organic solvent such as DMF which is routinely applied in peptide synthesis. 
Purification of Hmb containing totally protected peptides is feasible through RP-HPLC, 
which utilizes actonitrile/H2O or methanol/H2O as eluent with TFA as ion pairing agent. 
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Clean peptides are obtainable with this purification method. This can be testified through 
the combination of MALDI-ToF Mass Spectrometry and analytical RP-HPLC, amino 
acid analysis and NMR could also be applied if necessary.  
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Figure 3.12 Prevention of the formation of intra-chain hydrogen bond in β-hairpin peptide through the 
introduction of back-bone protection groups Hmb. 
 
The incorporation of Hmb backbone protecting groups significantly increase the 
solubility of the fully protected peptide in organic solvents such as DMF, probably 
through breaking of the intra-chain hydrogen bonds between the neighboring strand in the 
peptide chain (see Figure 3.12), thus making it feasible to purify the peptide derivative by 
RP-HPLC. This allows to obtain the homogenous totally protected peptide as an 
intermediate which can be subsequently deprotected by Reagent K 
(TFA/phenol/H2O/PhSMe/ethane-1,2-dithiol/triethylsilane, 82.5:5:5:5:2.5). The formed 
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final products could be easily purified without having to apply RP-HPLC, thus 
circumventing the inherent solubility problem of β-sheet related peptide for final 
RP-HPLC purification. The feasibility of the Hmb-backbone protection methodology for 
RP-HPLC purification in this project can be proven by the comparison of the following 
of chromatograms (see Figure 3.13). On the top is the C12 Preparative RP-HPLC 
chromatogram of a totally protected peptide with the sequence H-Glu(OtBu)-Phe- 
Glu(OtBu)-Phe-Glu(OtBu)-Phe-Glu(OtBu)-D-Pro-Gly-Glu(OtBu)-Phe-Glu(OtBu)-Phe- 
Glu(OtBu)-Phe-Glu(OtBu)-OH Prot. HP 19. Its chromatogram shows a very inferior 
result with unacceptable resolutions. As the peptide Prot. HP 19 bears no Hmb backbone 
protecting group, it shows a very limited solubility in acetonitrile/H2O mixed solvent 
which is applied as the eluent of RP-HPLC, so that most of the peptide Prot. HP 19 
precipitates on the chromatographic column during the purification process. The 
remaining material is not eluted simultaneously and thus generating a broad front or tail 
on the separation, impairing the resolution as well as selectivity of the RP-HPLC. A 
homologous peptide with similar polarity, while being protected at some certain amide 
groups on the backbone, with the sequence H-Asp(OtBu)-Phe-Ser(tBu)-Phe-N-Hmb- 
Asp(OtBu)-Phe-Ser(tBu)-D-Pro-Gly-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-Phe-Asp(OtBu)- 
Phe-Ser(tBu)-OH Prot. HP 17-Hmb, was also analized by RP-HPLC for comparison.  
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Figure 3.13 RP-HPLC of H-Glu(OtBu)-Phe-Glu(OtBu)-Phe-Glu(OtBu)-Phe-Glu(OtBu)-D-Pro-Gly- 
Glu(OtBu)-Phe-Glu(OtBu)-Phe-Glu(OtBu)-Phe-Glu(OtBu)-OH Prot. HP 19 (top) and  
H-Asp(OtBu)-Phe-Ser(tBu)-Phe-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-D-Pro-Gly-N-Hmb-Asp(OtBu)-Phe- 
Ser(tBu)-Phe- Asp(OtBu)-Phe-Ser(tBu)-OH Prot. HP 17-Hmb (bottom) (arrows point to target products) 
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The bottom chromatogram in Figure 3.13 reflects the HPLC purification of the 
selectively backbone-protected peptide with the sequence H-Asp(OtBu)-Phe-Ser(tBu)- 
Phe-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-D-Pro-Gly-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-Phe- 
Asp(OtBu)-Phe-Ser(tBu)-OH Prot. HP 17-Hmb. The otherwise so problematic HPLC 
purification was easily carried out upon the introduction of Hmb protecting group into the 
peptide sequence at some certain positions. It significantly increases the solubility of the 
peptide derivative, making it feasible to apply RP-HPLC to obtain the utmost purification. 
The last peak in the chromatogram represents the target peptide, its homogeneity could be 
testified through the combination of MALDI-Tof-Mass Spectroscopy (see Figure 3.14) 
and analytical RP-HPLC (see Figure 3.15). 
 
 
Figure 3.14 MALDI-ToF-Mass Spectrum of Prot. HP 17-Hmb 
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Figure 3.15 Analytical RP-HPLC chromatogram of Prot. HP 17-Hmb 
 
The cleavage of Hmb moiety proceeds smoothly. The presence of the methoxy group at 
the 4-position of 2-hydroxy benzyl moiety significantly increases the acid lability of the 
benzyl-based protecting group. Cleavage of the Hmb groups can be performed with TFA, 
although care has to be taken to avoid alkylation of tryptophan residues, since the 
carbocations generated in the acidolytic cleavage are highly electrophilic and hence are 
able to attack the nucleophilic functionalities of the peptide. The indole side chain of Trp, 
thiol side chain of Cys, and imidazole side chain of His are especially prone to be 
attacked by these carbocations. An efficient cocktail for acidolytic removal of all 
acid-labile protecting groups, Reagent K (TFA/phenol/H2O/PhSMe/ethane-1,2-dithiol, 
82.5:5:5:5:2.5) is highly recommended (Scheme 3.8). The addition of alkyl silane such as 
triisopropylsilane or triethylsilane to the deprotection cocktail is also advisable. The 
obtained peptides could be easily purified due to the huge polarity difference of the fully 
deprotected peptide and the organic by-products, thus bypassing the RP-HPLC 
purification which might practically bring forward the previously discussed problems. 
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Scheme 3.8 Cleavage of the totally protected peptide from the resin, RP-HPLC purification and acidolytic 
deprotection. 
 
a
Fmoc-Ser(tBu)-O-2-Cl-Trt-
b,c (repeat)
(a) 3eqv. Fmoc-Ser(tBu)-OH, 7.5eqv. DIPEA, DCM, rt. 60min
(b) 2x 20% piperidine in DMF, 5min, 15min, rt.
(c) 3eqv. Fmoc-Xaa-OH, 3eqv. TBTU, 6eqv. DIPEA, rt. 45min
H-Phe-Ser(tBu)-Phe-Asp(OtBu)-Phe-Ser(tBu)-O-2-Cl-Trt-
b
d,b(d)3eqv. N,O-bisFmoc-N-Hmb-Asp(OtBu)-OH, 3eqv. HATU, 6eqv.DIPEA, rt., 3h
H-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-Phe-Asp(OtBu)-Phe-Ser(tBu)-O-2-Cl-Trt-
2-Cl-Trt-Chloride-
(e)3eqv. Fmoc-Gly-OH, 3eqv. HATU, 6eqv. DIEPA rt., 3h
Fmoc-Gly-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-Phe-Asp(OtBu)-Phe-Ser(tBu)-O-2-Cl-Trt-
b,c (repeat)
H-Phe-Ser(tBu)-D-Pro-Gly-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-Phe-Asp(OtBu)-Phe-Ser(tBu)-O-2-Cl-Trt-
(d)3eqv. N,O-bisFmoc-N-Hmb-Asp(OtBu)-OH, 3eqv. HATU, 6eqv. DIPEA, rt., 3h
H-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-D-Pro-Gly-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-Phe-Asp(OtBu)-Phe-Ser(tBu)-O-2-Cl-Trt-
(f)3eqv. Fmoc-Phe-OH, 3eqv. HATU, 6eqv. DIEPA rt., 3h
Fmoc-Phe-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-D-Pro-Gly-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-Phe-Asp(OtBu)-Phe-Ser(tBu)-O-2-Cl-Trt-
f
d,b
b,c (repeat)
b
b
e
H-Asp(OtBu)-Phe-Ser(tBu)-Phe-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-D-Pro-Gly-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-Phe-Asp(OtBu)-Phe-Ser(tBu)-O-2-Cl-Trt-
g(g) 1%TFA in DCM, 10x5min, rt.
H-Asp(OtBu)-Phe-Ser(tBu)-Phe-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-D-Pro-Gly-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-Phe-Asp(OtBu)-Phe-Ser(tBu)-OH
h
H-Asp-Phe-Ser-Phe-Asp-Phe-Ser-D-Pro-Gly-Asp-Phe-Ser-Phe-Asp-Phe-Ser-OH
(h) Reagent K, rt., 4h
 
Figure 3.16 Synthetic process of DFSFDFSpGDFSFDFS HP 17 with backbone protecting methodology 
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Figure 3.16 shows the flow chart of the process of SPPS of DFSFDFSpGDFSFDFS 
HP 17by the Hmb back-bone protecting methodology. 
 
3.5.2.4 Synthesis of Peptides Other Than HP 17 
All peptides in this project (see also Table 3.5) except HP 17 were synthesized according 
to routine Fmoc/tBu peptide chemistry, either by manual or microwave methodology (see 
also Chapter 2.6.2).  
 
3.5.2.4.1 Yields Comparison of Manual and Microwave SPPS 
HP 20 was utilized as template peptide for the comparison of manual and microwave 
SPPS in terms of synthetic efficiency for "difficult sequence". HP 20, with the sequence 
EFSFEFSpGEFSFEFS, adopts partial β-hairpin conformation. It thus presents a good 
reference to compare the efficacy of manual and microwave peptide synthesis. The 
referred manual and microwave methodology is introduced in Chapter 2.6.2. Yield of 
crude fully protected HP 20 (lyophilized, without HPLC purification) with manual and 
microwave synthesis is 73.6 % and 98.0 %, respectively. Yield of fully deprotected 
HP 20 (with HPLC purification) with manual and microwave synthesis is 2.32 % and 
3.40 %, respectively. It can be concluded that the introduction of microwave irradiation is 
beneficial for the peptide with "difficult sequence" such as HP 20. Seemingly, 
microwave irradiation applied in the coupling as well as Fmoc removal step destroys the 
intrachain hydrogen bonds between the neighbouring β-strands, which promotes the 
smooth elongation of the peptide chains on resin and in turn suppresses the truncated 
sequences and enhances the yield of target peptide. 
 
3.5.2.4.2 Aspartimide Formation Comparison of Manual and Microwave SPPS 
Peptide HP 15, with the sequence DFDFDFEpGEFDFDFD, was used as a reference for 
the study of influences of microwave irradiation on aspartimide formation during SPPS. 
It was proven that the introduction of microwave irradiation during the coupling and 
Fmoc removal steps in SPPS could promote the aspartimide formation compared with 
manual synthesis in which microwave irradiation is absent. This conclusion was validated 
in the synthesis of HP 15 DFDFDFEpGEFDFDFD and HP 11 FDFDFDFD. No 
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aspartimide formation derivatives were found in the manual SPPS of these two peptides. 
While the aspartimide formation derivatives in the fully protected HP 15 product reached 
35.38 % in the microwave SPPS, with 20 % piperidine in DMF containing no HOBt as 
Fmoc deprotecting reagent. It was also proved that the addition of 0.1 M HOBt into 20 % 
piperidine/DMF as Fmoc deprotecting reagent could reduce the extent of aspartimide 
formation, despite not being able to fully suppress such a side reaction. In a parallel 
microwave SPPS of HP 15, in which all the parameters remained intact while 0.1 M 
HOBt was utilized as additive in 20 % piperidine/DMF, the extent of aspartimide 
formation derivatives in the fully protected HP 15 was reduced to 15.36%. 
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3.5.3  Conformational Studies by CD Spectrometry 
 
3.5.3.1 Theory Introduction of Secondary Structure Determination in 
Peptides 
CD is a method of choice for the quick determination of protein and peptide secondary 
structure, both quantitatively and qualitatively. CD spectrometry is so sensitive that it can 
distinguish between the secondary structure such as α-helix, β-sheet, turn and random 
coil. Although CD spetrometry is to some extent limited in deciphering the structures of 
peptides compared with NMR or X-ray diffraction, CD data is instructive as preliminary 
guide to peptide and protein conformation and conformational transition under a wide 
range of conditions.[70F71] 
 
The amide bonds in peptide and protein are the most important chromophores to be 
observed by CD spectroscopy. The elctronic transitions of amide chromophore have been 
characterized. The proportions of secondary structure elments α-helix, β-sheet, turn and 
random coil can be determined by their contributions to the curves in CD spectra of 
peptides or proteins. A typical α-helix is normally characterized by a negative band at 
222 nm (n-π*), a negative band at 208 nm, and a positive band at 190 nm (π-π*). The 
α-helix formation is evidently length dependent. Normally short peptides do not establish 
stable helices in solution.[71F 72] It had been shown that halogenated alcohol such as 
2,2,2-trifluoroethanol (TFE) is capable of stabilizing helix conformation in some peptides 
and is hence regarded as helical inducer.[72F 73] β-sheet is relatively less well-defined 
compared with α-helix,[73F74] and can be formed either in parallel or antiparallel manner. 
β-sheets display a typical negative band at 215 nm (n-π*) and a positive band at 198 nm 
(π-π*). Random coil conformations (unordered structure) are normally characterized by a 
strong negative band below 200 nm. Several algorithms are compiled for the 
computational calculations of proportions of secondary structures in peptides and proteins 
by fitting the observed spectrum with the combination of the characteristic absorption of 
the aforementioned three basic secondary structures. 
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3.5.3.2 Solvent Choice in CD Spectroscopy 
 
3.5.3.2.1 Halogenated Alcohol 
Halogenated alcohols such as TFE and HFIP are widely applied solvents for 
macromolecules in CD spectroscopy, because of their good transparency properties in the 
CD measurements, excellent solubilizing properties for some otherwise hardly soluble 
peptides such as β-sheet derivatives, and their inclination to stabilize the α-helix 
conformations in peptides.[22H73] Structures containing turns, β-hairpins, β-sheets, and 
hydrophobic clusters are also observable in the presence of TFE or HFIP.[74F75]  
 
Halogenated alcohol could exert substantial influences on peptide conformation by the 
enhancement of hydrogen bonds, the disruption of water structure and lessening of the 
hydrophobic effect, and preferential solvation of certain groups of the peptide chain.[23H75] 
 
Effect on Hydrogen Bond 
TFE/HFIP is better hydrogen bond donor but a poorer hydrogen bond acceptor compared 
with water.[75F76] It has therefore been assumed that TFE/HFIP preferentially bind to oxygen 
atoms of the main chain carbonyl groups, serving as a hydrogen bond donor in establish 
the hydrogen bonds with the main chains of the peptide (carbonyl group is often able to 
form two hydrogen bonds). This preference of solvation by TFE/HFIP in peptide leads to 
enhanced intra-chain hydrogen bonding of the amide group to carbonyl since the solvent 
exposure of amide is markedly decreased. In other words, hydrogen bonds between the 
amide groups from peptide and hydroxyl groups from TFE/HFIP are weakened because 
TFE/HFIP is relative poorer hydrogen bond acceptor compared with water, which leads 
to a less extent of solvation of amides. They are thus able to form hydrogen bonds with 
suitable carbonyl groups on the backbones of peptide, resulting in stabilized secondary 
structure such as α-helix. This consensus is regarded generally as the direct influence of 
halogenated alcohol to stabilize the local α-helix conformations in peptides. Indirect 
effect on hydrogen bond could arise from the altered dielectric constant of alcohol/water 
mixtures. As the solvent dielectric constant is lowered from 79 of water to 27 of TFE (25 
°C) electrostatic interactions become stronger.[76F77] 
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Effect on Non-polar Sidechains 
Several studies[77F78,78F79] have led to the conclusion that TFE/HFIP preferentially associate 
with hydrophobic sites on the protein surface and emphasized the hydrophobic nature of 
the CF3 group. TFE/HFIP could be modelled as mainly weakening hydrophobic- 
hydrophobic interactions.[79F80] The ability of TFE/HFIP to lessen the hydrophobic intera- 
ctions between residues distant in the primary sequence of peptide accounts for ability of 
cosolvent to disrupt structures such as β-sheet or β-hairpin, in which hydrophobic 
interactions play crucially important role to stabilize the local conformation. 
 
Effect on Solvent Strucuture 
The stability of secondary structures of peptides/protein is thought to be affected by 
solvent structure through hydrophobic interactions. It has been proven that water 
structure is affected by TFE/HFIP.[ 80F81,81F82]  In water rich mixtures, both CH3 and CF3 
groups of the alcohols are hydrophobic, enhancing neighboring water-water interactions. 
It is noticed that many of the peptides that have been studied in TFE and form the most 
stable helices are amphiphilic in nature.[82F83,83F84] It is therefore assumed that TFE/HFIP may 
selectively associate with the hydrophobic surfaces of helix or sheet, thus mimicking the 
environments of membrane or the interior of a protein. 
 
Effect on Turns 
Turn peptides frequently contain prolines, which serves as a structure breaker for β-sheet 
as well as α-helix. TFE/HFIP is not able to stabilize structure in certain proline containing 
peptides.[24H75] Turn formations in longer peptides are frequently associated with the peptide 
chain folding back on itself, forming either helix-turn-helix or hairpin conformations. 
Such association is usually driven by hydrophobic interactions between residues distant 
in the primary sequence, which are thought to be weakened by the presence of 
TFE/HFIP.[ 84F85 85F86F-87F88]  
 
Effect on β-sheet and β-hairpin Conformation 
The structures of β-sheet and β-hairpin are frequently stabilized by intra/inter-strand 
hydrophobic interactions, favorable electrostatic interactions, as well as hydrogen bonds 
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between the backbones of peptide chains. The hydrogen bonding pattern between strands 
seems to be entirely dependent on its own sequences. A frame shift of one residue has 
dramatic sequence for the pattern of hydrogen bonds, corresponding to 180° flip of one of 
the strands so that entirely different set of residue sidechains interact in the plane above 
and below the hydrogen bonded main chain.[25H75] It is assumed, however, that the effect of 
TFE/HFIP on structures of β-sheet and β-hairpin may not be mediated solely through 
hydrogen bonding. It should be specifically applied to individual peptide. The stability of 
β-sheet/β-hairpin conformation is synthetically determined by the interplay of hydrogen 
bonding, hydrophobic interactions, as well as electrostatic interactions. The role of 
TFE/HFIP in the determination of β-sheet/β-hairpin should be thus analyzed in a 
compositive manner, taking the weight of aforementioned factors into consideration. 
 
3.5.3.2.2 Water Titration 
Water is known to possess the inclination to break the intra/inter-chain hydrogen bonds in 
peptides, thus destroying local secondary structure such as α-helix. Since the forces to 
stabilize the β-hairpin conformation is relatively elusive to analyze, the role of water to 
stabilize/destabilize this structure is to be explored to some certain peptides, instead of 
drawing universal conclusions. Despite that water molecule could destroy the intra-chain 
hydrogen bonds between the neighboring backbones of β-hairpin, leading to unfolding of 
the local secondary structure, it could on the other hand strengthen the hydrophobic 
interactions in the β-hairpin peptides to reinforce this conformation, and lessen the 
electrostatic interactions which could be unfavorable with respect to β-hairpin 
conformation. The ultimate result that water brings forward to the conformation 
alternation of β-hairpin peptide should be in compositive manners. It depends on the fact 
that which factor is in the lead role. The titration of peptide HFIP solution with water is 
thus a choice to explore the weight of different forces in the determination of the 
β-hairpin conformation.  
 
3.5.3.2.3 pH Dependence 
For the peptides which contain ionizable residues, electrostatic interactions would rise to 
an important role in determination of the secondary structures. Under this circumstance, 
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the pH value of the environment would be a decisive parameter with respect to β-hairpin 
conformation. The protonation/deprotonation of ionizable side-chain could possibly 
stabilize or destabilize the local conformation. The structure conversion with the change 
of pH value of the solution is therefore instructive to valuate the factors that determine 
the peptide conformation. 
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3.5.3.3 CD Spectroscopy Analysis 
 
The peptide was accurately weighed and the solution were carefully preparted for the CD 
measurement. The parameters of CD spectrometer were adjusted according to the 
description of General Methods in the experiments part (see also Chapter 2.6.1). The 
measured CD values were converted to molar ellipticity of mean amino acid residue 
([θ]MRW) (vide infra). The measurements were performed at the room temperature. 
 
Conformation of H-Asp-Phe-Asp-Phe-Asp-Phe-Asp-D-Pro-Gly-Asp-Phe-Asp-Phe- 
Asp-Phe-Asp-OH (HP 18) and H-Glu-Phe-Glu-Phe-Glu-Phe-Glu-D-Pro-Gly-Glu- 
Phe-Glu-Phe-Glu-Phe-Glu-OH (HP 19) in HFIP 
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Figure 3.17 CD spectra of HFIP solution of HP 18 (1mg/ml, blue, dotted line; 0.3 mg/ml, red, dotted line) 
and HP 19 (0.3 mg/ml, blue, solid line; 0.15 mg/ml, red, solid line) 
 
The CD spectrum of HP 18 in HFIP indicates the predominance of random coil 
conformation, with negative band at 195 nm and positive band at 183 nm (see 
Figure 3.17), which correspond the characteristic band of random coil. It did not show 
any positive band at wavelength above 190 nm, validating this conclusion. Interestingly, 
HP 18 did not adopt the targeted β-hairpin conformation which was not in accordance 
with the design.  
 
In contrast to the CD spectrum of peptide HP 18, peptide HP 19 adopted mainly a 
β-hairpin conformation in HFIP, with the typical positive band at 194 nm and the 
negative band at 221 nm and comparable molecular ellipticities, as was shown in 
Figure 3.17. Furthermore, the increase of the concentration of HP 19 from 0.15 mg/ml to 
0.3 mg/ml stabilized the β-hairpin conformation, exhibiting an additional positive band at 
wavelength 202 nm, which is characteristic of a β-turn. Despite the close analogy 
between HP 18 and HP 19, they adopt totally different conformations in HFIP.  
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H2O Titration of H-Glu-Phe-Glu-Phe-Glu-Phe-Glu-D-Pro-Gly-Glu-Phe-Glu-Phe- 
Glu-Phe-Glu-OH (HP 19) 
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Figure 3.18 H2O titration of HP 19 peptide solution in HFIP: 0.3mg/ml HP 19 in HFIP (red); 0.15mg/ml 
HP 19 in HFIP/H2O (1:1) (blue); 0.075mg/ml HP 19 in HFIP/H2O (3:1) (black) 
 
As is shown in Figure 3.18, with the addition of water to HFIP solution of peptide HP 19, 
the positive band at 194 nm shifted to 190 nm and the intensity increased significantly. 
Furthermore, the positive band at around 205 nm representing β turn was also intensified. 
It shows that the increase of the water concentration stabilizes the β hairpin conformation 
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of peptide HP 19 in the HFIP, presumably through the strengthening of the hydrophobic 
interactions between the side chains of phenylalanines on the neighboring strands. 
Another possible explanation is that water titration increase the dielectric constant of the 
mixture solvent, thus lowering the electrostatic interactions between the side chains of 
glutamate which destabilize the β-hairpin conformation. 
 
pH Dependence of H-Glu-Phe-Glu-Phe-Glu-Phe-Glu-D-Pro-Gly-Glu-Phe-Glu-Phe- 
Glu-Phe-Glu-OH (HP 19) 
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Figure 3.19 pH dependence of the conformation of peptide HP 19: 0.3 mg/ml HP 19 in HFIP (red); 
0.5 mg/ml HP 19 in 2 M NaOH/HFIP (1:1) (blue); 0.25 mg/ml HP 19 in 0.2 M HCl/HFIP (1:1) (black) 
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In order to examine the influence of pH on the conformation of HP 19, solutions with 
different pH values were examined. As shown in Figure 3.19, the addition of 0.2 M HCl 
to the solution of HP 19 in HFIP decreased the intensities of the positive bands at the two 
typical wavelength 194 nm and 221 nm. The β-hairpin conformation of HP 19 was 
destabilized to some extent by the addition of acid, while its conformation bascially 
remained as the β-hairpin. Since the addition of acid protonates the side chain carboxy 
groups and partially the backbone carbonyl group, the intra-chain hydrogen bonds 
between the backbone carbonyl functionalities and corresponding backbone amide 
groups were blocked. However, the influences of the side chain-side chain aromatic 
interaction as well as hydrophobic interaction seemed to exceed that of the backbone 
intra-chain hydrogen bond. On the contrary, the β-hairpin conformation of peptide HP 19 
was totally denaturized upon the addition of 2 M NaOH solution to the peptide HFIP 
solution. The pKa of the glutamate side chain carboxyl group in is approximately 4.5.[88F89] 
Consequently, most of them will be deprotonated with the addition of 2 M NaOH. The 
repulsive interactions between the deprotonated carboxylate side chains of glutamate thus 
exceeded the factors that stabilize the β-hairpin conformation, leading to the denaturation 
of the peptide and loss of the original conformation. It showed that the electrostatic 
interactions could be significantly important for β-hairpin conformation, and under some 
circumstances they could exceed the forces such as hydrophobic interactions and 
hydrogen bond as in this experiment. In addition, the blocking of backbone hydrogen 
bonds by acid could lead to the destabilization of β-hairpin conformation. 
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Water Titration of H-Asp-Phe-Asp-Phe-Asp-Phe-Asp-D-Pro-Gly-Asp-Phe-Asp-Phe- 
Asp-Phe-Asp-OH (HP 18) in HFIP 
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Figure 3.20 CD spectra of H2O titration of HP 18 in HFIP: 0.5 mg/ml HP 18 in HFIP (green); 0.5 mg/ml 
HP 18 in HFIP/H2O (1:1) (blue); 0.33 mg/ml HP 18 in HFIP/H2O (1:2) (red) 
 
As shown in Figure 3.20, it is obvious that upon the addition of water to the HFIP 
solution of peptide HP 18, a change of conformation took place. HP 18 adopts mainly 
random coil conformation in pure HFIP, while with the increase of water concentration, 
signs of β-strand appeared, shown by the positive band at around 195 nm. The higher the 
percentage of water, the more stable the β-strand conformation was. The negative band at 
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around 200 nm is the characteristic of random coil, which showed that, although the 
β-strand conformation was stabilized by the addition of water, the inherent primary 
sequence of HP 18 determined that it could not be converted to highly ordered secondary 
structure as HP 19. 
 
H-Glu-D-Pro-Gly-Glu-OH (HP 1), H-Asp-D-Pro-Gly-Asp-OH (HP 2) in HFIP, H2O 
and 0.02 M NaOH 
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Figure 3.21 Solvent and pH dependence of the conformation of  HP 1 and  HP 2: 2mg/ml peptide HP 1 
in H2O (red, dotted line); 2mg/ml peptide HP 1 in 0.02 M NaOH (blue, dotted line); 2 mg/ml peptide HP 1 
in HFIP (green, dotted line); 2 mg/ml peptide HP 2 in H2O (red, solid line); 2 mg/ml peptide HP 2 in 
0.02 M NaOH (blue, solid line); 2 mg/ml peptide HP 2 in HFIP (green, solid line) 
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HP 1 and HP 2, with the sequences H-Glu-D-Pro-Gly-Glu-OH and H-Asp-D-Pro-Gly- 
Asp-OH, occupy the turn regions of peptide HP 19 and HP 18, respectively. If cut from 
the parent peptides, they still adopt turn structures in H2O, while in HFIP, the 
conformation shift to random coil, as is shown in Figure 3.21. These results were in 
accordance with the findings in the literature (see also Chapter 3.4.5.2). [ 26H75] Despite the 
fact that HFIP is able to enhance the strength of intra-molecular hydrogen bonds, the 
stronger electrostatic interactions between the side chains of aspartic acid, which is 
caused by the low dielectric constant of HFIP, exceed the strength of the enhanced 
hydrogen bond interactions generated by HFIP. It seemed therefore that the repulsive 
electrostatic interactions between the side chains of Asp or Glu played a more important 
role in destabilization of the ordered structures of these peptides. Upon the addition of 
0.02 M NaOH to the aqueous solution of peptide HP 1, the stability of the peptide was 
shown to be impaired, while peptide HP 2 seems to be relatively indifferent to the pH 
change of the environment.  
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Conformation of H-Phe-D-Pro-Gly-Phe-OH (HP 4) in H2O    
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Figure 3.22 CD spectra of HP 4 in H2O: 2 mg/ml (red); 0.5 mg/ml (blue); 0.25 mg/ml (green); 0.1 mg/ml 
(black) 
 
HP 4 adopted a turn structure in H2O, as is shown in Figure 3.22, exhibiting a positive 
band at ~215 nm, thus bearing both the characters of turn and β-sheet. The interactions 
between the side chains of phenylalanine introduced the extra stabilizing factors besides 
the backbone hydrogen bonds. The conformation of HP 4 remained untouched also for 
very small concentration of 0.1 mg/ml. The aromatic interactions seemed to be a key 
factor in stabilizing the β-hairpin conformation. 
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Conformation of H-Phe-D-Pro-Gly-Phe-OH (HP 4) in HFIP 
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Figure 3.23 CD spectra of HP 4 in HFIP (2 mg/ml, red) and H2O (2 mg/ml, green) in comparison with 
HP 2 (2 mg/ml, in HFIP, black) and HP 1 (2 mg/ml, in HFIP, blue) 
 
As shown in Figure 3.23, the conformation of HP 4 was bascially indifferent to the 
solvent change from H2O to HFIP, which are both polar but with different dielectric 
constants and thus diverse capacity to function as hydrogen bond acceptor or donor. The 
aromatic interactions between the side chains of phenylalanine dominated the formation 
of the β-turn and quasi-hairpin since the major difference between HP 4 and HP 1/HP 2 
results from the replacement of electrostatic interactions between Asp/Asp or Glu/Glu by 
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aromatic interactions between Phe. They outweighed the influence of hydrogen bonds 
since the weakening of backbone hydrogen strength caused by addition of water did not 
lead to the destabilization of the β-hairpin conformation in HP 4. Differently, HP 1 and 
HP 2, in which the aromatic interactions were absent, adopted distinctively different 
conformations in H2O and HFIP, namely, β-turn structure in water and random coil in 
HFIP (see Figure 3.20). The absence of hydrophobic interactions in these peptides 
bestows the backbone hydrogen bonds crucial roles in determining the secondary 
structure stabilities. Under this circumstance, the solvent conversion could exert evident 
influences on the peptide conformation. 
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Conformation of H-Phe-Asp-D-Pro-Gly-Asp-Phe-OH (HP 6) in H2O 
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Figure 3.24 CD spectra of  HP 6 in H2O: 2 mg/ml (red, solid line); 0.5 mg/ml (blue); 0.25 mg/ml (black); 
0.1 mg/ml (green) in comparison with HP 4 in H2O (2 mgl/ml, red, dotted line) 
 
As shown by Figure 3.24, HP 6 adopted basically a β-hairpin conformation in HFIP. 
However, its conformational stability in comparison to HP 4 was obviously weaker, as its 
ellipticity was markedly lower. The insertion of two aspartic acid residues compared with 
HP 4 destabilized its β-hairpin conformation, since the repulsive ionic interactions 
(glutamate and aspartate are partially deprotonated in HFIP and water) between the side 
chains of aspartic acids were introduced. This experiment indicated that the "corner 
residues", i.e. the residues in position i and i+3 positions of a β-turn, played crucial roles 
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to stabilize the β-hairpin conformation. The residue swap at these positions could 
thoroughly alternate the pattern of hydrogen bond of the β-hairpin peptide (see also 
Chapter 3.4.5.2), thus leading to different stability of the conformation. 
 
Conformation of H-Phe-Asp-D-Pro-Gly-Asp-Phe-OH (HP 6) in HFIP 
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Figure 3.25 CD spectra of HP 6 in HFIP (2 mg/ml, red, solid line); HP 4 in HFIP (2mg/ml, red, dotted 
line); peptide HP 2 in HFIP (2 mg/ml, blue); peptide HP 1 in HFIP (2 mg/ml, black) 
 
The contribution of the β-hairpin conformation of HP 6 in HFIP was also inferior to that 
of HP 4, as was the case in water, shown in Figure 3.25. The β-hairpin conformation 
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proportion in the former was far more abundant than that of the latter, which could be 
observed from their ellipticities in CD spectra. On the other hand, the introduction of 
phenylalanine residues into the sequence brought forward the extra aromatic interactions 
which stabilized the β-hairpin conformation compared with HP 1 and HP 2, in which 
aromatic interactions were absent, despite that the corner positions in HP 6 were also 
occupied by aspartic acids which caused the repulsive electrostatic interactions inside the 
peptide molecule in HFIP or water. 
 
Comparison of the Conformation of H-Phe-Asp-D-Pro-Gly-Asp-Phe-OH (HP 6) in 
H2O and HFIP 
Phe Asp
D-Pro
Gly
AspPhe
HP 6
 
190 200 210 220 230 240 250 260 270 280
-4000
0
4000
8000
[θ 
] M
R
W
 [d
eg
 c
m
2  
dm
ol
-1
]
λ [nm]
 
Figure 3.26 CD spectra of HP 6 in H2O and HFIP: HP 6 in H2O (2 mg/ml, blue); HP 6 in HFIP (2 mg/ml, 
red) 
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The conformation of HP 6 in HFIP was partially impaired compared with that in H2O, as 
the positive band at ~218nm was no longer observed and a negative band was generated 
instead, which was shown in Figure 3.26. It indicated that the ordered β-hairpin 
conformation was partially unfolded and the conversion to random coil was taking place. 
This experiment again validated the conformational dependence of peptide on solvent, 
since different dielectric constant environment would exert diverse fluences on the forces 
that stabilize/destabilize the secondary conformation of peptides (see also Chapter 
3.4.5.2). 
 
H2O Titration of of H-Phe-Asp-D-Pro-Gly-Asp-Phe-OH (HP 6) in 
HFIP 
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Figure 3.27 CD spectra of HP 6 H2O titration in HFIP: HP 6 in H2O (2 mg/ml, red); HP 6 in H2O/HFIP 
(19:1) (2 mg/ml. blue); HP 6 in H2O/HFIP (3:1) (2 mg/ml, yellow); HP 6 in H2O/HFIP (1:1) (2 mg/ml, 
green); HP 6 in HFIP (2 mg/ml, black) 
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Upon the addition of water to the HFIP solution of HP 6, the proportion of β-hairpin 
conformation was gradually increased, as shown in Figure 3.27. HP 6 underwent the 
major conformational change at a content of water between 75% and 95%. Figure 3.26 
showed again that despite that HFIP molecules were able to strengthen the intra-chain 
hydrogen bonds between the two strands in HP 6, the stronger electrostatic interactions 
between the side chains of aspartic acid which was caused by the low medium dielectric 
constant of HFIP relative to water exceeded the strength of the enhanced hydrogen bonds. 
Consequently, the β-hairpin conformation was stabilized upon the addition of water under 
this balance which favored the weakening of electrostatic interactions. 
 
pH Dependence of H-Phe-Asp-D-Pro-Gly-Asp-Phe-OH 
(HP 6)  
 
190 200 210 220 230 240 250 260 270 280
-4000
0
4000
8000
[θ 
] M
R
W
 [d
eg
 c
m
2  
dm
ol
-1
]
λ [nm]
 
Figure 3.28 CD spectra of HP 6: HP 6 in H2O (2 mg/ml, blue, dotted line); HP 6 in 1 M NaOH (2 mg/ml, 
red) 
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In the 1 M NaOH solution of peptide 50, the carboxylic groups on the side chains of 
aspartic acid were deprotonated. Consequently, the increased repulsive ionic interaction 
between the side chains destabilized the orderd conformation of HP 6 under the basic 
conditions, as shown in Figure 3.28. The positive band at ~218 nm disappeared and 
shifted to the negative band upon the addition of NaOH. In addition, the ellipticity of the 
positive band at ~197 nm was significantly decreased. This experiment indicated that the 
repulsive ionic interactions between the aspartate side chains led to the partial unfolding 
of the ordered β-hairpin conformation. 
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Comparison of the Conformation of H-Asp-Phe-D-Pro-Gly-Phe-Asp-OH (HP 7) and 
H-Phe-Asp-D-Pro-Gly-Asp-Phe-OH (HP 6) in HFIP 
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Figure 3.29 Comparison of the CD spectra oF HP 6 and HP 7: 2 mg/ml HP 6 in HFIP (blue); 2 mg/ml 
HP 7 in HFIP (red) 
 
The swap of positions of the "corner residues" with the neighbouring residues could exert 
a significant influence on the conformation and the stability of the conformation of the 
β-hairpin peptide. The difference between HP 6 and HP 7 lies in their "corner residues" 
and the neighbouring residues. The exchange of the residues at these positions might alter 
the pattern of the intra-chain hydrogen bond combination. As shown in Figure 3.29, it is 
obvious that the β-hairpin conformation of HP 7 was more stable than that of HP 6 in 
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HFIP. As phenylalanine residues occupy the "corner positions" of the β-hairpin peptide, 
its conformation was substantially stabilized by the strong aromatic interactions between 
the side chains of phenylalanine residues. Despite that repulsive electrostatic interactions 
between the aspartate side chains exist in HP 7, they were nevertheless excluded from the 
crucial "corner positions" and their unfavorable influences on the stability of the 
conformation of β-hairpin peptides was perhaps hence weakened. Thus HP 7 adopted a 
more stable β-haipin conformation than its homologous derative HP 6, as the positive 
band appeared at ~210 nm for HP 7 while only negative bands were observed in this 
region for HP 6. The alteration of the corner residues assumably led to a change of the 
pattern of hydrogen bond network in the β-hairpin peptide, which finally affected the 
β-hairpin conformational stability. 
 
On the other hand, the introduction of phenylalanine residues in the sequence of HP 6 
produced the aromatic interactions which stabilized the β-hairpin conformation. As 
shown by the comparison of Figure 3.29 and Figure 3.23, HP 1 adopted an unordered 
structure in HFIP, while under the same conditions, HP 6 adopted partial β-hairpin 
conformation. This comparison accounts for the positive contribution of aromatic 
interactions in stabilizing the β-hairpin conformation. 
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pH Dependence of the Conformation of H-Asp-Phe-D-Pro-Gly-Phe-Asp-OH (HP 7) 
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Figure 3.30 CD spectra of HP 7 at different pH: 2 mg/ml HP 7 in 0.02 M NaOH (red); 2 mg/ml HP 7 in 
0.2 M HCl (blue); 2 mg/ml HP 7 in H2O (dotted line, black) 
 
Surprisingly, the pH dependence tendency of peptide HP 7 was contrary to the case of 
HP 6 (see Figure 3.28) and peptide HP 19 (see Figure 3.19), as the addition of HCl 
decreased the β-hairpin content of HP 7 while NaOH solution enhanced its 
conformational stability relative to its H2O solution (see Figure 3.30). It could probably 
be explained from the point of hydrogen bond pattern in the β-hairpin peptide. As is 
already known, the pattern of hydrogen bonding between strand appears to be entirely 
determined by its own sequence (see also Chapter 3.2.3.2).[27H75] The swap of residues on 
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the corner positions with those on their neighbouring positions could change the pattern 
of hydrogen bond networks. With this change, the protonation of the backbone carbonyl 
groups upon addition of HCl would drastically weaken the hydrogen bond interactions 
which might be more important than those in the other hydrogen bond pattern. This result 
showed the importance of corner residues from the viewpoint of the pattern of hydrogen 
bond networks. 
 
Comparison of the Conformation of H-Phe-Glu-D-Pro-Gly-Glu-Phe-OH (HP 8) and 
H-Phe-Asp-D-Pro-Gly-Asp-Phe-OH (HP 6) in HFIP and H2O 
 
Phe Asp
D-Pro
Gly
AspPhe
HP 6
Phe Glu
D-Pro
Gly
GluPhe
HP 8
 
190 200 210 220 230 240 250 260 270 280
-4000
0
4000
8000
[θ 
] M
R
W
 [d
eg
 c
m
2  
dm
ol
-1
]
λ [nm]
 
Figure 3.31 CD spectra comparison of HP 8 and HP 6 in HFIP and H2O: HP 8 in H2O (2mg/ml, blue, 
solid line); HP 8 in HFIP (2mg/ml, red, solid line); HP 6 in H2O (2mg/ml, blue, dotted line); HP 6 in HFIP 
(2mg/ml, red, dotted line) 
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The substitution of aspartic acid residues in peptide HP 6 by glutamic acids significantly 
stabilized the β-hairpin conformation of the concerned peptide, which was shown in 
Figure 3.31: the β-hairpin conformation of peptide HP 8 was more stable than that of 
peptide HP 6, both in H2O and HFIP. Furthermore, the conformation of peptide HP 6 in 
HFIP was partially unordered, which was shown by the negative band near 210 nm, while 
peptide HP 8 adopted β-hairpin conformation under the same conditions with two 
positive bands at ~200 nm and 216 nm (see Figure 3.31). 
 
The conformation difference between HP 6 and HP 8 is similar to their parent peptide 
pair HP 19 and HP 18 (see Figure 3.17). However, HP 6 does not differ from HP 8 as 
much as HP 18 from HP 19, with respect to the contribution of β-hairpin conformation 
(HP 6 was partially unordered in HFIP with the preservation of the positive band at 
~196 nm, while HP 18 was nearly totally random coil under the condition in which 
HP 19 adopted β-hairpin conformation). From this aspect one could deduce that the 
stabilization/destabilization effect on the peptide conformation is additive.  
 
The differences between the peptide conformation (between HP 18 and HP 19, as well as 
HP 6 and HP 8) in terms of β hairpin stability could be ascribed to the distinctions 
between the aspartic acid and glutamic acid residue. As the pKa of the carboxyl group in 
glutamate side-chain and aspartate side-chain are both approximately 4.5, [28H89] they would 
have the same degree of protonation under the same pH conditions, provided that the 
influence of the microenvironment was not taken into consideration. Since there is one 
more methylene group in the side chain of glutamic acid than aspartic acid, it will 
therefore possess more degrees of freedom that makes the side chain of glutamic acid 
more flexible compared to that of aspartic acid. Thus, the repulsive ionic intra-chain 
interactions between the glutamic acid side-chains resided on the opposite β-strand could 
be compensated to some extent, with the side chains of glutamic acids adopting 
favourable conformation, as is shown by the β-hairpin conformation of HP 19 and HP 8 
(see Figure 3.17 and 3.31). While in HP 18 and HP 6, the side chain of aspartic acid is 
relative rigid owing to the lack of one methylene group compared with glutamic acid, the 
side chains might thus possess relativly little room to preorganize and optimize their 
conformations in order to elude the repulsive ionic side-chain interactions which 
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destabilize their potential but not virtual β-hairpin conformations.  
 
Another important advantage for glutamic acid-containing β-hairpin peptides is that the 
addition of one more methylene group compared to the aspartic acid introduces extra 
hydrophobic interactions with the corresponding residues on the opposite strand, the 
β-hairpin conformation is hence stabilized. HP 8 also showed its property to adopt more 
stable β-hairpin conformation in H2O than in HFIP. This is in agreement with the early 
discussed phenomenon, which the β-hairpin conformation of glutamic acid-containg 
peptide is more stable than that of aspartic acid-containing homologous peptide. 
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Comparison of the Conformation of H-Phe-Glu-Phe-Glu-D-Pro-Gly-Glu-Phe-Glu- 
Phe-OH (HP 9) and H-Phe-Glu-D-Pro-Gly-Glu-Phe-OH (HP 8) in HFIP and H2O 
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Figure 3.32 CD spectra of HP 9 and HP 8: HP 9 in HFIP (2mgl/ml, red, dotted line); HP 8 in H2O 
(2mg/ml, red, solid line); HP 8 in HFIP (2mg/ml, blue, solid line) 
 
HP 9 adopted partially unordered structure in HFIP (this peptide is not soluble in H2O), 
as shown in Figure 3.32. Despite that two more phenylalanine residues and glutamic acid 
residues were introduced compared to the HP 8, the conformation of HP 9 was not 
consequently stabilized by the extra aromatic interactions and hydrophobic interactions 
brought forward by the phenylalanine and glutamic acid. It appeared that these 
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advantageous factors could not match the repulsive ionic interactions between the side 
chains of glutamic acids. No reasonable explanation was found so far to clarify the fact 
that HP 19 adopted more stable β-hairpin conformation than HP 9 with the regular chain 
elongation by alternate phenylalanine and glutamic acid. 
 
Comparison of the Conformation of H-Phe-Glu-Phe-Glu-D-Pro-Gly-Glu-Phe-Glu- 
Phe-OH (HP 9) and H-Phe-Asp-Phe-Asp-D-Pro-Gly-Asp-Phe-Asp-Phe-OH (HP 10) 
in HFIP 
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Figure 3.33 CD spectra of HP 9 and HP 10: HP 9 in HFIP (2mg/ml, red); HP 10 in HFIP (2mg/ml, blue)  
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HP 9 adopted a markedly different conformation from that of HP 10 in HFIP, as shown 
in Figure 3.33. HP 9 was partially random coil accompanied with a β-hairpin component 
exhibited by the positive band at ~200 nm; while HP 10 revealed no signs of β hairpin 
existence. This phenomenon could also be clarified by the same explanation for the 
conformational difference between HP 6 and HP 8 (see Figure 3.31) as well as HP 18 
and HP 19 (see Figure 3.17). The differences between the properties of aspartic acid and 
glutamic acid accounted for the differences between the conformational stabilities of 
HP 9 and HP 10. 
 
Comparison of the Conformation of H-Phe-Asp-Phe-Asp-D-Pro-Gly-Asp-Phe-Asp- 
Phe-OH (HP 10) and H-Phe-Asp-D-Pro-Gly-Asp-Phe-OH (HP 6) in HFIP  
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Figure 3.34 CD spectra of HP 10 and HP 6: HP 10 in HFIP (2mg/ml, red); HP 6 in HFIP (2mg/ml, blue) 
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HP 6 adopted partial β-hairpin and random coil conformation as shown in Figure 3.25 
and 3.26. With the regular chain elongation by adding alternate phenylalanine and 
aspartic acid, its conformational stability was weakened as was shown by the random coil 
features in HP 10 (see Figure 3.34). The extra aromatic interactions in HP 10 generated 
by the added phenylalanine residues were not sufficient to balance the repulsive 
electrostatic interactions between the newly introduced aspartic acid. The β-hairpin 
conformational stabilities of these peptides are therefore chain-length dependent. 
 
Comparison of the Conformation of H-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-OH 
(HP 11) and H-Phe-Glu-Phe-Glu-Phe-Glu-Phe-Glu-OH (HP 12) in HFIP  
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Figure 3.35 CD spectra of HP 11 and HP 12: HP 12 in HFIP (0.5mg/ml, red, solid line); HP 12 in HFIP 
(0.1mg/ml, blue, solid line); HP 12 in HFIP (0.05mg/ml, green, solid line); HP 11 in HFIP (1mg/ml, red, 
dash line); HP 11 in HFIP (0.5mg/ml, blue, dash line); HP 11 in HFIP (0.1mg/ml, green, dash line) 
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Polypeptides (FD)n and (FE)n were merged in HP 18 and HP 19, respectively, as 
imaginary β-strand part. However, HP 18 and HP 19 adopted very different 
conformations in HFIP, as was shown by Figure 3.17. A series of aforementioned 
peptides had revealed the conformational discrepancies between the Asp- and 
Glu-containing peptides. All the present experimental results exclusively favored the 
tendency that aspartic acid was not as prone as glutamic acid in terms of propelling the 
formation of β-strand conformation. HP 12 and HP 11 serve as the proper models to 
compare the differences between glutamic acid and aspartic acid as their potencies as 
individual amino acids to force the formations of β-strand, since the absence of 
-D-Pro-Gly- moiety makes the comparison more reasonable, reliable and straightforward.  
 
The CD spectra of HP 11 and HP 12 (see Figure 3.35) revealed a significant difference 
between their conformations adopted in HFIP. HP 12 adoped mainly β-strand 
conformation, with a negative band at ~216 nm and a positive band at ~193 nm, whereas 
HP 11 was present the unordered structure. Furthermore, HP 12 manifested a obvious 
tendency to undergo self aggregation as their CD spectra of a typical β-strand at different 
concentrations did not superimpose perfectly. This experiment revealed the inherent 
differences between the aspartic acid and glutamic acid in their tendencies to reinforce 
the β-strand conformation, serving as one of the most convinced proofs to explain the 
huge conformational discrepancies between their parent peptide HP 18 and HP 19. 
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Comparison of the Conformation of H-Glu-Phe-Glu-Phe-Glu-Phe-Glu-D-Pro-Gly- 
Glu-Phe-Glu-Phe-Glu-Phe-Glu-OH (HP 19) and H-Glu-Phe-Glu-Phe-Glu-Phe-Asp- 
D-Pro-Gly-Asp-Phe-Glu-Phe-Glu-Phe-Glu-OH (HP 16) in HFIP  
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Figure 3.36 CD spectra of HP 19 and HP 16: HP 19 in HFIP (0.3mg/ml, blue); HP 16 in HFIP (0.5mg/ml, 
red) 
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The unique difference between HP 19 and HP 16 lies solely in the residues resided at the 
"corner positions". These positions are occupied by glutamic acids in HP 19, while by 
aspartic acids in HP 16. The distinctions between the turn moieties have been displayed 
by the conformational discrepancies between HP 2 and HP 1 (see Figure 3.21). The 
influences of these short peptides were "transplanted" into HP 19 and HP 16 and 
therefore exerted on their conformations. As shown in Figure 3.36, the content of 
β-hairpin conformation from HP 19 was higher than that of HP 16. The unique 
difference between these two peptides at the corner positions engendered the huge 
distinctions as the inclination of the conformation was concerned. This experiment 
revealed again the significance of the corner residues in stabilizing/destabilizing the 
β-hairpin conformations.  
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Comparison of the Conformation of H-Asp-Phe-Asp-Phe-Asp-Phe-Asp-D-Pro-Gly- 
Asp-Phe-Asp-Phe-Asp-Phe-Asp-OH (HP 18) and H-Asp-Phe-Asp-Phe-Asp-Phe-Glu- 
D-Pro-Gly-Glu-Phe-Asp-Phe-Asp-Phe-Asp-OH (HP 15) in HFIP 
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Figure 3.37 CD spectra of HP 18 and HP 15: HP 18 in HFIP (1mg/ml, red, solid line); HP 18 in HFIP 
(0.3mg/ml, blue, solid line); HP 15 in HFIP (2mg/ml, red, dotted line); HP 15 in HFIP (0.5mg/ml, blue, 
dotted line); HP 15 in HFIP (0.1mg/ml, green, dotted line) 
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The substitution of the "corner residues" aspartic acids by glutamic acids did not 
transform the conformation of peptide HP 18 from random coil to ordered structure. The 
total repulsive ionic interactions between the aspartate side chains could not be 
compensated by the tiny positive contributions ascribed to the introduction of the 
methylene groups from glutamic acids at the "corner positions" in terms of structure 
stabilization, as shown in CD spectra of HP 15 which revealed the conformation of 
random coil (see Figure 3.37). 
 
However, the substitution of the corner resides did generate the conformational changes, 
which could be deduced from the “shoulder” at the wavelength around 220 nm. It’s 
regarded as the appearance of β turn motif in the concerned peptide. The substitute of the 
corner residues from aspartic acid to glutamic acid increased the proportions of the 
ordered structures in the inhomogeneous peptide solution, despite not being able to fold 
the peptide into a fully ordered structure. It could be imagined, that if the content of 
orderd structure from a predominant random coil peptide solution enhanced gradually, 
the ellipiticities at the wavelength around 200 nm would also be increased, from negative 
to positive. Form the comparison of the structures of peptide HP 15 and HP 18, it could 
be deduced that content of their ordered β-hairpin conformation is different. Furthermore, 
it can be assumend that β-hairpin conformation is structurally composed of β-turn and 
β-strand which are supposed to insert their influences separately on the stability of 
β-hairpin peptide. 
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Comparison of the Conformation of H-Glu-Phe-Ser-Phe-Glu-Phe-Ser-D-Pro-Gly- 
Glu-Phe-Ser-Phe-Glu-Phe-Ser-OH (HP 20) and H-Glu-Phe-Glu-Phe-Glu-Phe-Glu- 
D-Pro-Gly-Glu-Phe-Glu-Phe-Glu-Phe-Glu-OH (HP 19) in HFIP 
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Figure 3.38 CD spectra of HP 19 and HP 20: 0.3 mg/ml HP 19 in HFIP (blue); 0.5 mg/ml HP 20 in HFIP 
(red) 
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Glutamic acid residues were substituted in some certain positions (see also sequential 
difference between HP 19 and HP 20) in HP 19 by serine residues in order to reduce the 
interactions between the side-chains of glutamic acid residues resided in the opposite 
positions on the β-strands of β-hairpin peptide HP 19. This Glu-Glu interactions in 
HP 19 were replaced by Glu-Ser interactions in HP 20 provided that HP 20 would also 
adopt β-hairpin conformation under the same condition.  
 
As shown in Figure 3.38, HP 20 still adopted mainly β-hairpin conformation in HFIP, as 
its counterpart peptide HP 19, but to a less degree, revealed by the weakening of the 
intensities of the positive bands at ~193 nm and 201 nm. The repulsive electrostatic 
interactions between the side chains of glutamic acids in HP 19 was basically eliminated 
in HP 20, since the hydroxymethyl groups of the serine side-chains remained under most 
cases unionized. On the other hand, however, the hydrophobic interactions between the 
side chains of glutamic acids were weakened alonog with the substitution of glutamic 
acid by serine. This change partially accounted for the destabilization of the β hairpin 
conformation of HP 20 relative to HP 19. This experiment revealed the importance of the 
hydrophobic interactions between the methylene groups in the side-chains of glutamic 
acids in stabilizing the β-hairpin conformation. One can therefore hypothesize that the 
β-hairpin conformation of peptide HP 19 would possibly be further stabilized if the 
side-chains of glutamic acids elongated by one more methylene group. 
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Comparison of the conformation of H-Asp-Phe-Ser-Phe-Asp-Phe-Ser-D-Pro-Gly- 
Asp-Phe-Ser-Phe-Asp-Phe-Ser-OH (HP 17) and H-Asp-Phe-Asp-Phe-Asp-Phe-Asp- 
D-Pro-Gly-Asp-Phe-Asp-Phe-Asp-Phe-Asp-OH (HP 18) in HFIP 
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Figure 3.39 CD spectra of HP 18 and HP 17: 2mg/ml HP 17 in HFIP (red); 1 mg/ml HP 18 in HFIP (blue) 
 
3.5 Results and Discussion 
 258 
Aspartic acid residues were substituted in some certain positions in HP 18 by serine 
residues (see alsio sequential difference between HP 18 and HP 17) in order to reduce 
the interactions between the side chains of aspartic acid residues resided in the opposite 
positions on the β-strands of β-hairpin peptide HP 18. In spite of the elimination of such 
a negative factor that destabilizes the β-hairpin conformation of the peptide, HP 17 did 
still adopt the partial random coil conformation in HFIP. However, comparison of the CD 
spectra of peptide HP 18 and HP 17 revealed that, upon substitution of aspartic acid by 
serine residues, the proportion of ordered fractions in inhomogeneous peptide solution 
was increased, as was revealed by the weakening of the negative band and the appearance 
of the positive shoulder at the wavelength above 190 nm (see Figure 3.39). This 
experiment indicated again that the ionic interactions between the side chains of aspartic 
acid residues are one of the major factors that destabilize the potential β-hairpin 
conformations of peptides, and that the hydrophobic interactions brought forward by the 
aggregations of methylene groups from the side chains of Asp/Glu play a role in 
stabilizing the potential β-hairpin conformation. 
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Comparison of the Conformation of H-Phe-Asp-Phe-Asp-D-Pro-Gly-Asp-Phe-Asp- 
Phe-D-Pro-Gly-Phe-Asp-Phe-Asp-OH (HP 14) H-Asp-Phe-Asp-Phe-Asp-Phe-Asp- 
D-Pro-Gly-Asp-Phe-Asp-Phe-Asp-Phe-Asp-OH (HP 18) and H-Glu-Phe-Glu-Phe- 
Glu-Phe-Glu-D-Pro-Gly-Glu-Phe-Glu-Phe-Glu-Phe-Glu-OH (HP 19) in HFIP 
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Figure 3.40 CD spectra of HP 18, HP 19 and HP 14: HP 14 in HFIP (0.5mg/ml, red, solid line); HP 14 in 
HFIP (0.25mg/ml, blue, solid line); HP 18 in HFIP (1mg/ml, red, dotted line); HP 19 in HFIP (0.3mg/ml, 
blue, dotted line) 
 
HP 14 contains two -D-Pro-Gly- moieties which are supposed to change the directions of 
the peptide chain, the hereby-designed peptide will thus theoretically be composed of two 
turn moieties and three antiparallel β-strands which are brought together by intra-chain 
hydrogen bonds and aromatic interactions as well as hydrophobic interactions between 
the side-chains of the residues positioned on the strands. These moieties are connected in 
tandem in the primary sequence to adopt the shape of "S" in terms of secondary structure. 
The cluster of converged aromatic groups and other hydrophobic groups are supposed to 
generate the additive aromatic interactions as well as hydrophobic interactions that will 
understandably reinforce the theoretical "double β hairpin" conformation of HP 14. This 
hypothesis was validated by the CD spectra of HP 14 in HFIP, as shown in Figure3.40. 
Compared with the relevant "single β-hairpin" HP 19, which contains "advantageous" 
glutamic acid residues as the propensity to induce β-hairpin conformation is concerned, 
HP 14 exhibited a more abundant β-hairpin content, proven by a stronger ellipticity at the 
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wavelength ~193 nm, despite an increase in repulsive interactions between the side 
chains of the aspartic acid residues in HP 14. The additive aromatic interactions and 
hydrophobic interactions "spanning over strands" aggregated by the change of the chain 
directions offset the negative factors which destabilize the hairpin conformation and 
reinforce the conformation of the potential β-hairpin conformation.  
 
On the other hand, as far as the stability of β-hairpin conformation is concerned, HP 14 
possesses obvious advantages over HP 18, which is also composed of aspartic acid and 
phenylalanines, while having a single -D-Pro-Gly- moiety. The conformation of peptide 
HP 18 was mainly unordered even at the relatively high concentration of 2 mg/ml, while 
HP 14 adopted β-hairpin conformation even at the dilute concentration of 0.25 mg/ml 
(see Figure 3.40). 
 
This experiment showed clearly that the aggregation of aromatic interactions and 
hydrophobic interactions between the strands of peptides play crucially important role in 
stabilizing the β-sheet (which is well known by the fact of peptide aggregations) or 
β-hairpin conformation. Furthermore, these forces seem to be additive. As the hydrogen 
bonds between the strands can not be viewed as additive HP 14 since they could not be 
formed spanned over a strand, they did not offer extra contributions for the stabilization 
of the β-hairpin conformation. 
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Comparison of the Conformation of H-Asp(OtBu)-Phe-Ser(tBu)-Phe-N-Hmb- 
Asp(OtBu)-Phe-Ser(tBu)-D-Pro-Gly-N-Hmb-Asp(OtBu)-Phe-Ser(tBu)-Phe- 
Asp(OtBu)-Phe-Ser(tBu)-OH (Prot. HP17-Hmb) and H-Asp-Phe-Ser-Phe-Asp-Phe- 
Ser-D-Pro-Gly-Asp-Phe-Ser-Phe-Asp-Phe-Ser-OH (HP 17) in HFIP and ACN/H2O 
(1:1) 
. 
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Figure 3.41 CD spectra of Prot. HP 17-Hmb and HP 17: Prot. HP 17-Hmb in HFIP (2mg/ml, red, solid 
line); 0.5 mg/ml Prot. HP 17-Hmb in HFIP (0.5mg/ml, blue, solid line); Prot. HP 17-Hmb in ACN/H2O 
(1:1) (2mg/ml, green, solid line); HP 17 in HFIP (2mg/ml, red, dotted line) 
 
The differences of the CD spectra between HP 17 and its side chain fully protected, 
backbone Hmb protected counterparts Prot. HP 17-Hmb were obvious as shown in 
Figure 3.41. Peptide Prot. HP 17-Hmb adopted partially ordered conformation 
containing elements of β-strand in HFIP, as was revealed by the positive band at ~193 nm. 
On the other hand, some fractions of this peptide adopted unordered conformation in 
HFIP, validated by the negative band at ~ 205 nm, while peptide HP 17 did not reveal 
abundance of ordered structure. It exhibited no positive band above 190 nm, as shown in 
Figure 3.41. 
 
The tert-butyl protecting groups on the side-chains of aspartic acid residues prevent the 
repulsive ionic interactions between the neighboring strands of Prot. HP 17-Hmb; 
meanwhile the hydrophobic interactions between the tert-butyl groups stabilize the 
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β-hairpin conformation. The cooperative influences of the elimination of ionic 
interactions and introduction of hydrophobic interactions significantly increase the 
β-hairpin content in Prot. HP 17-Hmb. 
 
The backbone Hmb exerted obvious influences on the conformation of peptide 
Prot. HP 17-Hmb. The backbone protecting groups such as Hmb is a well-known 
functionality that prevents the formation of the secondary structures such as β-sheet 
through the block of the hydrogen bonds between the backbone NH and CO groups, its 
introduction is thus understandably able to jeopardize the β-hairpin conformation of 
Prot. HP 17-Hmb. While the side chain protecting groups in this peptide eliminated the 
adverse electrostatic interactions and introduced the extra hydrophobic intra-chain 
interactions as well. With the heterogeneous influences of tert-butyl side-chain protecting 
groups and Hmb of back-bone protecting groups on the formation of peptide 
Prot. HP 17-Hmb, and the original properties of peptide HP 17 toward the β-hairpin 
conformation, the actual structure of peptide Prot. HP 17-Hmb decided by these factors 
was consequently a balanced structure between β-hairpin and random coil, exhibited by 
its CD spectrograms (see Figure 3.41). 
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3.6 Synthetic Experimental Section 
 
3.6.1 General Methods (see also Chapter 2.6.1) 
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3.6.2 Peptide Synthesis (see also Chapter 2.6.2) 
 
Loading of o-chlorotritylchloride Resin and Quantification 
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N-Hmb-Asp(OtBu)-OH (29) 
 
HO
MeO
NH
COOH
O
O
tBu
a
b
c
 
 
H-Asp(OtBu)-OH · H2O (2.36 g, 11.4 mmol) was dissolved in 20 ml H2O and the pH was 
adjusted to pH 9.0 with 2 M NaOH. Finely powered 2-hydroxy-4-methoxy- 
benzaldehyde 27 (1.7 g, 11.4 mmlol) was added and the resulting suspension was left 
stirring for 2 hours at room temperature, while the pH was kept at 9-9.5 with 2 M NaOH. 
Then the reaction mixture was cooled to 5 ºC, and 15 ml 0.76 M aq. NaBH4 (11.4 mmol) 
and 2 M NaOH (3 drops) were added dropwise over 20 minutes. After 1 hour at 5-10 ºC, 
the mixture was neutralized to pH 6-7 with 2 M HCl under vigorous stirring while the 
temperature was kept below 20 ºC. The product was precipitated in the cold and was 
collected by filtration. 
 
Yield: 2.38 g (70%) 
 
Formula: C16H23NO6  
 
Molecular Mass: 325.36 g/mol 
 
[α]21D = -5.8 (c = 1.0, H2O) 
 
MS (MALDI-ToF): m·z-1 = 326.47 [M+H]+, 348.46 [M+Na]+, 364.42 [M+K]+ 
 
Analytical HPLC: Method I, tR = 17.88 min, 100% 
 
1H NMR (500.15 MHz, D6-DMSO): δ [ppm] = 1.39 (s, 9H, C(CH3)3), 2.49 (s, 1H, NH), 
2.59 (dd, 2J = 16.5 Hz, 3J = 6.9 Hz, 1H, CH2CO2tBu), 2.68 (dd, 2J = 16.5 Hz, 3J = 5.5 Hz, 
1H, CH2CO2tBu), 3.44 (t, 3J = 6.9 Hz, 1H, NHCH(CH2CO2tBu)COO), 3.68 (s, 3H, 
OCH3), 3.91, 3.92 (d, 2H, CH2NH), 6.35-6.41 (m, 2H, CaH, CbH), 7.10 (d, 3J = 8.0 Hz, 
1H, CcH) 
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N,O-bis-Fmoc-N-Hmb-Asp(OtBu)-OH (34) 
 
O
MeO N
COOH
O O
O
O
O
O
 
 
2.1 equiv Fmoc-Cl 37 (3.260 g, 12.6 mmol) in 1,4-Dioxane (14 ml) were added to an 
ice-cold solution of N-Hmb-Asp(OtBu)-OH 29 (1.952g, 6 mmol) in H2O 
(60 ml)/1,4-Dioxane(30 ml) containing 3.2 equiv Na2CO3 (2.04 g, 19.2 mmol) during 1h. 
The solution was stirred for 1-2 hours and a precipitate formed. The mixture was 
extracted with diethyl ether (3×100 ml) and the combined ethereal solutions were washed 
with 0.5 M HCl (3×100 ml) and dried (Na2SO4). After removal of the solvent, the oily 
residue was chromatographed (0.04-.063 mm silica gel, packed with CH2Cl2) with 
Hexane/EtOAc/CH2Cl2 (6:3:1) as eluent. The content of eluent was shifted to 
MeOH/EtOAc (2:8) as the first side-product (mono-Fmoc derivative) had been eluted. 
Alternatively, the target product can be purified by the RP-HPLC. 
 
Yield: 1.90 g (41%) 
 
Formula: C46H43NO10 
 
Molecular Mass: 769.83 g/mol 
 
MS (MALDI-ToF): m·z-1 = 792.14 [M+Na]+, 808.05 [M+K]+, 814.13 [M+2Na-H]+ 
 
TLC: Rf = 0.21 (CH2Cl2/MeOH 96:4)  
 
Preparative RP-HPLC: Apparatus B, Method 10, tR = 20.1 min 
 
Analytical RP-HPLC: Method II, tR = 40.78 min, 100% (220 nm) 
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1H NMR (500.15 MHz, CDCl3): δ [ppm] = 1.36 (s, 9H, C(CH3)3), 2.44 (dd, 2J = 16.5 Hz, 
3J = 6.0 Hz, 1H, CH2CO2tBu), 2.57 (dd, 2J = 16.5 Hz, 3J = 6.5 Hz, 1H, CH2CO2tBu), 
3.76 (s, 3H, CH3O), 4.17 (t, 3J = 6.0 Hz, 1H, CO2CH2CH), 4.23 (t, 3J = 7.0 Hz, 1H, 
OCOCH2CH), 4.31,4.34 (s,s 2H, CHHN), 4.42-4.52 (m, 4H, OCOCH2, NCO2CH2), 4.50 
(dd, 3J = 6.0 Hz, 3J = 6.5 Hz, 1H, NHCH(CH2CO2tBu)COO), 6.45-7.84 (m, 19H, HAryl)  
 
H-Glu-D-Pro-Gly-Glu-OH (HP 1) 
 
The synthesis of the fully protected peptide Prot. HP 1 was 
carried out according to the general procedure of manual SPPS 
(Fmoc/tBu), with Fmoc-Glu(OtBu)-OH being loaded on the 
o-chlorotrityl resin (0.8 mmol/g, 0.2 mmol), and TBTU as 
coupling reagent. Deprotection of peptide Prot. HP 1 was 
achieved with the deprotection cocktail TFA/H2O/TIS 
(95:2.5:2.5). 
 
(Except otherwise mentioned, all the yields listed in this project represent those after 
RP-HPLC. vide infra) 
 
Yield: H-Glu(OtBu)-D-Pro-Gly-Glu(OtBu)-OH (Prot. HP 1) 0.0922 g/0.17 mmol 
H-Glu-D-Pro-Gly-Glu-OH (HP 1) 0.0710 g/0.16 mmol (80.0%) 
 
Formula: C17H26N4O9 
 
Molecular Mass: 430.41 g/mol 
 
MS (MALDI-ToF): m·z-1 = 431.49 [M+H]+, 453.48 [M+Na]+, 469.48 [M+K]+, 475.48 
[M+2Na-H]+  
Calculated Mass: [C17H27N4O9]+ = 431.43, [C17H26N4O9Na]+ = 453.41, [C17H26N4O9K]+ 
= 469.52, [C17H25N4O9Na2]+ = 475.39 
 
Preparative RP-HPLC: Apparatus A, Method 3, tR = 9.67 min 
 
Analytical RP-HPLC: Method I, tR = 6.15 min, 100% (220 nm) 
H2N
O
N
OHN
H
NHOOC
O
COOH
COOH
HP 1
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H-Asp-D-Pro-Gly-Asp-OH (HP 2)  
 
The synthesis of the fully protected peptide Prot. HP 2 was 
carried out according to the general procedure of manual SPPS 
(Fmoc/tBu), with Fmoc-Asp(OtBu)-OH being loaded on the 
o-chlorotrityl resin (0.8 mmol/g, 0.2 mmol), and TBTU as 
coupling reagent. Deprotection of peptide Prot. HP 2 was 
achieved with the deprotection cocktail TFA/H2O/TIS 
(95:2.5:2.5). 
 
Yield: H-Asp(OtBu)-D-Pro-Gly-Asp(OtBu)-OH (Prot. HP 2) 0.0771 g/0.15 mmol 
       H-Asp-D-Pro-Gly-Asp-OH (HP 2) 0.0420 g/0.10 mmol (50.0%) 
 
Formula: C15H22N4O9 
 
Molecular Weight: 402.37 
 
MS (MALDI-ToF): m·z-1 = 403.61 [M+H]+, 425.61 [M+Na]+, 441.60 [M+K]+, 447.61 
[M+2Na-H]+ 
Calculated Mass: [C15H23N4O9]+ = 403.37, [C15H22N4O9Na]+ = 425.36, [C15H22N4O 9K]+ 
= 441.10, [C15H21N4O9Na2]+ = 447.11 
 
Preparative RP-HPLC: Apparatus A, Method 3, tR = 8.42 min 
 
Analytical RP-HPLC: Method I, tR = 5.42 min, 100% (220 nm) 
 
H-Asp-D-Pro-Gly-Lys-OH (HP 3) 
 
The synthesis of the fully protected peptide Prot. HP 3 was 
carried out according to the general procedure of manual SPPS 
(Fmoc/tBu), with Fmoc-Lys(Boc)-OH being loaded on the 
o-chlorotrityl resin (0.8 mmol/g, 0.2 mmol), and TBTU as 
coupling reagent. Deprotection of peptide Prot. HP 3 was 
achieved with the deprotection cocktail TFA/H2O/TIS 
(95:2.5:2.5). 
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Yield: H-Asp(OtBu)-D-Pro-Gly-Lys(Boc)-OH (Prot. HP 3) 0.0865 g/0.15 mmol 
H-Asp-D-Pro-Gly-Lys-OH (HP 3) 0.0498 g/0.12 mmol (60.0%) 
 
Formula: C17H29N5O7 
 
Molecular Mass: 415.20 g/mol 
 
MS (MALDI-ToF): m·z-1 = 416.79 [M+H]+, 438.79 [M+Na]+, 454.76 [M+K]+, 460.78 
[M+2Na-H]+  
Calculated Mass: [C17H30N5O7]+ = 416.21, [C17H29N5O7Na]+ = 438.20, [C17H29N5O7K]+ 
= 454.17, [C17H28N5O7Na2]+ = 460.18 
 
Preparative RP-HPLC: Apparatus A, Method 3, tR = 7.02 min 
 
Analytical RP-HPLC: Method I, tR = 7.02 min, 100% (220 nm) 
 
H-Phe-D-Pro-Gly-Phe-OH (HP 4) 
 
The synthesis of peptide HP 4 was carried out according to the 
general procedure of manual SPPS (Fmoc/tBu), with Fmoc-Phe-OH 
being loaded on the o-chlorotrityl resin (0.8 mmol/g, 0.2 mmol), and 
TBTU as coupling reagent.  
 
Yield: H-Phe-D-Pro-Gly-Phe-OH (HP 4) 0.0839 g/0.18 mmol 
(90.0%) 
 
Formula: C25H30N4O5 
 
Molecular Mass: 466.22 g/mol 
 
MS (MALDI-ToF): m·z-1 = 467.53 [M+H]+, 489.50 [M+Na]+, 505.49 [M+K]+, 511.52 
[M+2Na-H]+ 
Calculated Mass: [C25H31N4O5]+ = 467.23, [C25H30N4O5Na]+ = 489.21, [C25H30N4O5K]+ 
= 505.19, [C25H29N4O5Na2]+ = 511.19 
 
Preparative RP-HPLC: Apparatus A, Method 9, tR = 29.44 min 
 
Analytical RP-HPLC: Method I, tR = 21.44 min, 100% (220 nm) 
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H-Phe-Asp-D-Pro-Gly-Lys-Phe-OH (HP 5) 
 
The synthesis of the fully protected peptide Prot. HP 5 
was carried out according to the general procedure of 
manual SPPS (Fmoc/tBu), with Fmoc-Phe-OH being 
loaded on the o-chlorotrityl resin (0.8 mmol/g, 0.2 mmol), 
and TBTU as coupling reagent. Deprotection of 
peptide Prot. HP 5 was achieved with the deprotection 
cocktail TFA/H2O/TIS (95:2.5:2.5). 
 
Yield: H-Phe-Asp(OtBu)-D-Pro-Gly-Lys(Boc)-Phe-OH  
(Prot. HP 5) 0.1298 g/0.15 mmol 
H-Phe-Asp-D-Pro-Gly-Lys-Phe-OH (HP 5) 0.0927 g/0.13 mmol (65.0%) 
 
Formula: C35H47N7O9 
 
Molecular Mass: 709.34 g/mol 
 
MS (MALDI-ToF): m·z-1 = 710.22 [M+H]+, 732.16 [M+Na]+, 748.13 [M+K]+, 754.14 
[M+2Na-H]+ 
Calculated Mass: [C35H48N7O9]+ = 710.35, [C35H47N7O9Na]+ = 732.33, [C35H47N7O9K]+ 
= 748.31, [C35H46N7O9Na2]+ = 754.32 
 
Preparative RP-HPLC: Apparatus A, Method 23, tR = 21.50 min 
 
Analytical RP-HPLC: Method I, tR = 18.17 min, 100% (220 nm) 
 
H-Phe-Asp-D-Pro-Gly-Asp-Phe-OH (HP 6) 
 
The synthesis of the fully protected peptide Prot. HP 6 
was carried out according to the general procedure of 
manual SPPS (Fmoc/tBu), with Fmoc-Phe-OH being 
loaded on the o-chlorotrityl resin (0.8 mmol/g, 0.3 mmol), 
TBTU as coupling reagent. Deprotection of 
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peptide Prot. HP 6 was achieved with the deprotection cocktail TFA/H2O/TIS 
(95:2.5:2.5). 
 
Yield: H-Phe-Asp(OtBu)-D-Pro-Gly-Asp(OtBu)-Phe-OH  
(Prot. HP 6) 0.2183 g/0.27 mmol 
H-Phe-Asp-D-Pro-Gly-Asp-Phe-OH (HP 6) 0.1688 g/0.24 mmol (80.0%) 
 
Formula: C33H40N6O11 
 
Molecular Mass: 696.28 g/mol 
 
MS (MALDI-ToF): m·z-1 = 697.21 [M+H]+, 719.31 [M+Na]+, 735.31 [M+K]+, 741.33 
[M+2Na-H]+ 
Calculated MS: [C33H41N6O11]+ = 697.28, [C33H40N6O11Na]+ = 719.27, [C33H40N6O11K]+ 
= 735.82, [C33H39N6O11Na2]+ = 741.69 
 
Preparative RP-HPLC: Apparatus A, Method 11, tR = 10.18 min 
 
Analytical RP-HPLC: Method I, tR = 19.24 min, 100% (220 nm) 
 
H-Asp-Phe-D-Pro-Gly-Phe-Asp-OH (HP 7) 
 
The synthesis of the fully protected peptide Prot. HP 7 
was carried out according to the general procedure of 
SPPS (Fmoc/tBu), operating automatically on the CEM 
Microwave Peptide Synthesizer, with 
Fmoc-Asp(OtBu)-OH being loaded on the o-chlorotrityl 
resin (0.8 mmol/g, 0.25 mmol), and TBTU as coupling 
reagent. The Nα-Fmoc-deprotecting cocktail 20% piperidine/DMF did not contain HOBt 
as additive. Deprotection of peptide Prot. HP 7 was achieved with the deprotection 
cocktail TFA/H2O/TIS (95:2.5:2.5). 
 
Yield: H-Asp(OtBu)-Phe-D-Pro-Gly-Phe-Asp(OtBu)-OH  
(Prot. HP 7) 0.1911 g/0.24 mmol 
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H-Asp-Phe-D-Pro-Gly-Phe-Asp-OH (HP 7) 0.1326 g/0.19 mmol (76.0%) 
 
Formula: C33H40N6O11 
 
Molecular Mass: 696.28 g/mol 
 
MS (MALDI-ToF): m·z-1 = 697.19 [M+H]+, 719.18 [M+Na]+, 735.15 [M+K]+ 
Calculated Mass: [C33H41N6O11]+=697.28, [C33H40N6O11Na]+=719.27, 
[C33H40N6O11K]+=735.24 
 
Preparative RP-HPLC: Apparatus A, Method 12, tR=23.82 min 
 
Analytical RP-HPLC: Method I, tR = 21.12 min, 100% (220 nm) 
 
H-Phe-Glu-D-Pro-Gly-Glu-Phe-OH (HP 8) 
 
The synthesis of the fully protected peptide Prot. HP 8 
was carried out according to the general procedure of 
SPPS (Fmoc/tBu), operating automatically on the CEM 
Microwave Peptide Synthesizer, with Fmoc-Phe-OH 
being loaded on the o-chlorotrityl resin (0.8 mmol/g, 
0.25 mmol), TBTU as coupling reagent. The 
Nα-Fmoc-deprotecting cocktail 20% piperidine/DMF did 
not contain HOBt as additive. Deprotection of the peptide Prot. HP 8 was achieved with 
the deprotection cocktail TFA/H2O/TIS (95:2.5:2.5). 
 
Yield: H-Phe-Glu(OtBu)-D-Pro-Gly-Glu(OtBu)-Phe-OH  
(Prot. HP 8) 0.2157 g/0.25 mmol 
H-Phe-Glu-D-Pro-Gly-Glu-Phe-OH (HP 8) 0.1355 g/0.19 mmol (76.0%) 
 
Formula: C35H44N6O11 
 
Molecular Mass: 724.31 g/mol 
 
MS (MALDI-ToF): m·z-1 = 725.31 [M+H]+, 747.34 [M+Na]+, 763.37 [M+K]+, 769.41 
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[M+2Na-H]+ 
Calculated Mass: [C35H45N6O11]+ = 725.31, [C35H44N6O11Na]+ = 747.30, 
[C35H44N6O11K]+ = 763.27, [C35H43N6O11Na2]+ = 769.28 
 
Preparative RP-HPLC: Apparatus A, Method 12, tR = 26.55 min 
 
Analytical RP-HPLC: Method I, tR = 18.90 min, 100% (220 nm) 
 
H-Phe-Glu-Phe-Glu-D-Pro-Gly-Glu-Phe-Glu-Phe-OH (HP 9) 
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The synthesis of the fully protected peptide Prot. HP 9 was carried out according to the 
general procedure of SPPS (Fmoc/tBu), operating automatically on the CEM Microwave 
Peptide Synthesizer, with Fmoc-Phe-OH being loaded on the o-chlorotrityl resin 
(0.8 mmol/g, 0.25 mmol), and TBTU as coupling reagent. The Nα-Fmoc-deprotecting 
cocktail 20% piperidine/DMF did not contain HOBt as additive. Deprotection of the 
peptide Prot. HP 9 was achieved with the deprotection cocktail TFA/H2O/TIS 
(95:2.5:2.5). 
 
Yield: H-Phe-Glu(tBu)-Phe-Glu(tBu)-D-Pro-Gly-Glu(tBu)-Phe-Glu(tBu)-Phe-OH  
(Prot. HP 9) 0.3598 g/0.24 mmol 
H-Phe-Glu-Phe-Glu-D-Pro-Gly-Glu-Phe-Glu-Phe-OH (HP 9)  
0.2297 g/0.18 mmol (72.0%) 
 
Formula: C63H76N10O19 
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Molecular Mass: 1276.53 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1278.10 [M+H]+, 1299.26 [M+Na]+, 1315.33 [M+K]+, 
1321.68 [M+2Na-H]+ 
Calculated Mass: [C63H77N10O19]+ = 1277.54, [C63H76N10O19Na]+ = 1299.52, 
[C63H76N10O19K]+ = 1315.49, [C63H75N10O19Na2]+ = 1321.50 
 
Preparative RP-HPLC: Apparatus A, Method 13, tR = 29.01 min 
 
Analytical RP-HPLC: Method I, tR = 19.03 min, 100% (220nm) 
 
H-Phe-Asp-Phe-Asp-D-Pro-Gly-Asp-Phe-Asp-Phe-OH (HP 10) 
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The synthesis of the fully protected peptide Prot. HP 10 was carried out according to the 
general procedure of manual SPPS (Fmoc/tBu), with Fmoc-Phe-OH being loaded on the 
o-chlorotrityl resin (0.8 mmol/g, 0.3 mmol), and TBTU as coupling reagent.  
Deprotection of the peptide Prot. HP 10 was achieved with the deprotection cocktail 
Reagent K (TFA/Phenol/H2O/thiolanisole/ethane-1,2-dithiol 82.5:5:5:5:2.5). Aspartimide 
formation took place if the applied deprotection cocktail is composed of TFA/H2O/TIS 
(95:2.5:2.5). 
 
Yield: 
H-Phe-Asp(OtBu)-Phe-Asp(OtBu)-D-Pro-Gly-Asp(OtBu)-Phe-Asp(OtBu)-Phe-OH  
(Prot. HP 10) 0.2889 g/0.20 mmol 
H-Phe-Asp-Phe-Asp-D-Pro-Gly-Asp-Phe-Asp-Phe-OH  
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(HP 10) 0.1831 g/0.15 mmol (50.0%) 
 
Formula: C59H68N10O19 
 
Molecular Mass: 1220.47 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1221.26 [M+H]+, 1243.77 [M+Na]+, 1259.76 [M+K]+, 
1265.75 [M+2Na-H]+ 
Calculated Mass: [C59H69N10O19]+ = 1221.47, [C59H68N10O19Na]+ = 1243.46, 
[C59H68N10O19K]+ = 1259.43, [C59H67N10O19Na2]+ = 1265.44 
 
Preparative RP-HPLC: Apparatus B, Method 14, tR = 21.9 min 
 
Analytical RP-HPLC: Method I, tR = 19.75 min, 100% (220nm) 
 
H-Phe-Asp-Phe-Asp-Phe-Asp-Phe-Asp-OH (HP 11) 
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The synthesis of the fully protected peptide Prot. HP 11 was carried out according to the 
general procedure of SPPS (Fmoc/tBu), operating automatically on the CEM Microwave 
Peptide Synthesizer, with Fmoc-Asp(OtBu)-OH being loaded on the o-chlorotrityl resin 
(0.8 mmol/g, 0.25 mmol), and TBTU as coupling reagent. The Nα-Fmoc-deprotecting 
cocktail 20% piperidine/DMF did not contain HOBt as additive. Aspartimide formation 
in the peptide Prot. HP 11 was found. Deprotection of the peptide was achieved with the 
deprotection cocktail Reagent K (TFA/Phenol/H2O/thiolanisole/ethane-1,2-dithiol, 
82.5:5:5:5:2.5). Aspartimide derivatives were separated from the target peptide HP 60 
through RP-HPLC operations. 
 
H-Phe-Asp(OtBu)-Phe-Asp(OtBu)-Phe-Asp(OtBu)-Phe-Asp(OtBu)-OH (Prot. HP 11) 
Yield (HP 11) (crude peptide): 0.3236g/0.251mmol (100%) 
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Formula (Prot. HP 11): C68H90N8O17 
Formula (Prot. HP 11 Aspartimide Formation): C64H80N8O16 
Formula (HP 11): C52H58N8O17 
Formula (HP 11 Aspartimide Formation): C52H56N8O16 
 
Molecular Mass (Prot. HP 11): 1290.64 g/mol 
Molecular Mass (Prot. HP 11 Aspartimide Formation): 1216.57 g/mol 
Molecular Mass (HP 11): 1066.39 g/mol 
Molecular Mass (HP 11 Aspartimide Formation): 1048.38 g/mol 
 
MS (MALDI-ToF)( Prot. HP 11): m·z-1 = 1291.69 [M+H]+, 1313.59 [M+Na]+, 1329.04 
[M+K]+, 1335.44 [M+2Na-H]+ 
Calculated Mass (Prot. HP 11): [C68H91N8O17]+ = 1291.65, [C68H90N8O17Na]+ = 1313.63, 
[C68H90N8O17K]+ = 1329.61, [C68H89N8O17Na2]+ = 1335.61 
 
MS (MALDI-ToF)(Prot. HP 11 Aspartimide Formation): m·z-1 = 1217.45 [M+H]+, 
1239.14 [M+Na]+ 
Calculated Mass (Prot. HP 11 Aspartimide Formation): [C64H81N8O16]+ = 1217.58, 
[C64H80N8O16Na]+ = 1239.56 
 
MS (MALDI-ToF)(HP 11): m·z-1 = 1067.75 [M+H]+, 1089.73 [M+Na]+, 1105.35 
[M4-12+K]+ 
Calculated Mass (HP 11): [C52H59N8O17]+ = 1067.40, [C52H58N8O17Na]+ = 1089.38, 
[C52H58N8O17K]+ = 1105.36 
 
MS (MALDI-ToF)(HP 11 Aspartimide Formation): m·z-1 = 1049.08 [M+H]+, 1071.26 
[M+Na]+ 
Calculated Mass (HP 11 Aspartimide Formation): [C52H57N8O16]+ = 1049.39, 
[C52H56N8O16Na]+ = 1071.37 
 
Preparative RP-HPLC: Apparatus B, Method 15, tR = 23.6 min 
 
Analytical RP-HPLC: Method I, tR = 23.07 min, 100% (220 nm)   
 
3.6 Synthetic Experimental Section 
 278 
H-Phe-Glu-Phe-Glu-Phe-Glu-Phe-Glu-OH (HP 12) 
 
N
H O
H
N
O
N
H O
H
N
O
N
H O
H
N
O
N
H
COOH
O
H2N
Ph Ph Ph Ph
HP 12
COOH COOH COOHCOOH
 
The synthesis of the fully protected peptide Prot. HP 12 was carried out according to the 
general procedure of SPPS (Fmoc/tBu), operating automatically on the CEM Microwave 
Peptide Synthesizer, with Fmoc-Glu(OtBu)-OH being loaded on the o-chlorotrityl resin 
(0.8 mmol/g, 0.25 mmol), and TBTU as coupling reagent. The Nα-Fmoc-deprotecting 
cocktail 20% piperidine/DMF did not contain HOBt as additive. Deprotection of peptide 
Prot. HP 12 was achieved with the deprotection cocktail Reagent K 
(TFA/Phenol/H2O/thiolanisole/ethane-1,2-dithiol, 82.5:5:5:5:2.5). 
 
Yield:  
H-Phe-Glu(OtBu)-Phe-Glu(OtBu)-Phe-Glu(OtBu)-Phe-Glu(OtBu)-OH (Prot. HP 12) 
(no yield data) 
H-Phe-Glu-Phe-Glu-Phe-Glu-Phe-Glu-OH (HP 12) 0.1235 mg/0.11 mmol (44.0%) 
 
Formula: C56H66N8O17 
 
Molecular Mass: 1122.45 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1123.51 [M+H]+, 1145.47 [M+Na]+, 1161.42 [M+K]+, 
1167.35 [M+2Na-H]+ 
Calculated Mass: [C56H67N8O17]+ = 1123.46, [C56H66N8O17Na]+ = 1145.44, 
[C56H66N8O17K]+ = 1161.42, [C56H65N8O17Na2]+ = 1167.43 
 
Preparative RP-HPLC: Apparatus B, Method 15, tR = 24.8 min 
 
Analytical RP-HPLC: Method II, tR = 19.63 min, 100% (220 nm) 
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H-Glu-Phe-Glu-D-Pro-Gly-Glu-Phe-Glu-OH (HP 13) 
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The synthesis of the fully protected peptide Prot. HP 13 was carried out according to the 
general procedure of SPPS (Fmoc/tBu), operating automatically on the CEM Microwave 
Peptide Synthesizer, with Fmoc-Glu(OtBu)-OH being loaded on the o-chlorotrityl resin 
(0.8 mmol/g, 0.25 mmol), TBTU as coupling reagent. The Nα-Fmoc-deprotecting cocktail 
20% piperidine/DMF did not contain HOBt as additive. Deprotection of peptide 
Prot. HP 13 was achieved with the deprotection cocktail TFA/H2O/TIS (95:2.5:2.5). 
 
Yield: 
H-Glu(OtBu)-Phe-Glu(OtBu)-D-Pro-Gly-Glu(OtBu)-Phe-Glu(OtBu)-OH (Prot. HP 13) 
0.2481 g/0.23 mmol (crude product, after lyophilization) 
0.1290 g/0.11 mmol (after HPLC) 
H-Glu-Phe-Glu-D-Pro-Gly-Glu-Phe-Glu-OH (HP 13) 0.0884 g/0.09 mmol (36.0%) 
 
Formula: C45H58N8O17 
 
Molecular Mass: 982.39 g/mol 
 
MS (MALDI-ToF): m·z-1 = 983.71 [M+H]+, 1005.11 [M+Na]+, 1021.14 [M+K]+, 
1043.08 [M+Na+K-H]+ 
Calculated Mass: [C45H59N8O17]+ = 983.40, [C45H58N8O17Na]+ = 1005.38, 
[C45H58N8O17K]+ = 1021.36, [C45H57N8O17KNa]+ = 1043.34 
 
Preparative RP-HPLC: Apparatus A, Method 13, tR = 25.11 min 
 
Analytical RP-HPLC: Method I, tR = 15.05 min, 100% (220nm) 
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H-Phe-Asp-Phe-Asp-D-Pro-Gly-Asp-Phe-Asp-Phe-D-Pro-Gly-Phe-Asp-Phe-Asp-OH 
(HP 14) 
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The synthesis of the fully protected peptide Prot. HP 14 was carried out according to the 
general procedure of SPPS (Fmoc/tBu), operating automatically on the CEM Microwave 
Peptide Synthesizer, with Fmoc-Asp(OtBu)-OH being loaded on the o-chlorotrityl resin 
(0.8 mmol/g, 0.25 mmol), and TBTU as coupling reagent. The Nα-Fmoc-deprotecting 
cocktail 20% piperidine/DMF did not contain no HOBt as additive. Aspartimide 
formation in the sequence Prot. HP 14 was found. Deprotection of peptide Prot. HP 14 
was achieved with the deprotection cocktail Reagent K (TFA/Phenol/H2O/thiolanisole/ 
ethane-1,2-dithiol, 82.5:5:5:5:2.5). The deprotection reaction at ambient temperature last 
1.5 hours before the quantitative cleavage of the side-chain protecting groups was 
achieved. Aspartimide derivatives were separated from the target peptide by RP-HPLC 
operations. 
 
Yield: 
H-Phe-Asp(OtBu)-Phe-Asp(OtBu)-D-Pro-Gly-Asp(OtBu)-Phe-Asp(OtBu)-Phe-D-Pro- 
Gly-Phe-Asp(OtBu)-Phe-Asp(OtBu)-OH (Prot. HP 14) (no yield data) 
 
H-Phe-Asp-Phe-Asp-D-Pro-Gly-Asp-Phe-Asp-Phe-D-Pro-Gly-Phe-Asp-Phe-Asp-OH 
(HP 14) 0.0190 g/0.01 mmol (4.0%) 
 
Formula (Prot. HP 14): C116H154N16O29 
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Formula (HP 14): C92H106N16O29 
Formula (Prot. HP 14 Aspartimide Formation): C112H144N16O28 
Formula (HP 14 Aspartimide Formaiton): C92H104N16O28 
 
Molecular Mass (Prot. HP 14): 2235.11 g/mol 
Molecular Mass (HP 14): 1898.73 g/mol 
Molecular Mass (Prot. HP 14 Aspartimide Formation): 2161.04 g/mol 
Molecular Mass (HP 14 Aspartimide Formation): 1880.72 g/mol 
 
MS (MALDI-ToF)( Prot. HP 14): m·z-1 = 2257.33 [M+Na]+, 2273.77 [M+K]+ 
Calculated Mass: [C116H154N16O29Na]+ = 2258.10, [C116H154N16O29K]+ = 2274.07 
 
MS (MALDI-ToF)( Prot. HP 14 Aspartimide Formation): m·z-1 = 2183.07 [M+Na]+, 
2200.34 [M+K]+ 
Calculated Mass: [C112H144N16O28Na]+ = 2184.02, [C112H144N16O28K]+ = 2200.00 
 
MS (MALDI-ToF)(HP 14): m·z-1 = 1899.03 [M+H]+, 1921.27 [M+Na]+, 1939.52 
[M+K]+ 
Calculated Mass: [C92H107N16O29]+ = 1899.74, [C92H106N16O29Na]+ = 1921.72, 
[C92H106N16O29K]+ = 1937.69 
MS (MALDI-ToF)(HP 14 Aspartimide Formation): m·z-1 =  1903.17 [M+Na]+, 
1919.59 [M+K]+ 
Calculated Mass: [C112H144N16O28Na]+ = 1903.71, [C112H144N16O28K]+ = 1919.68 
 
Preparative RP-HPLC: Apparatus A, Method 16, tR = 15.58 min 
 
Analytical RP-HPLC: Method II, tR = 31.47 min, 100% (220 nm) 
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H-Asp-Phe-Asp-Phe-Asp-Phe-Glu-D-Pro-Gly-Glu-Phe-Asp-Phe-Asp-Phe-Asp-OH 
(HP 15 A) 
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The synthesis of the fully protected peptide Prot. HP 15 A was carried out according to 
the general procedure of SPPS (Fmoc/tBu), operating automatically on the CEM 
Microwave Peptide Synthesizer, with Fmoc-Asp(OtBu)-OH being loaded on the 
o-chlorotrityl resin (0.8 mmol/g, 0.25 mmol), and TBTU as coupling reagent. The 
Nα-Fmoc-deprotecting cocktail 20% piperidine/DMF did not contain HOBt as additive. 
Aspartimide formation in Prot. HP 15 A was found. Deprotection of peptide 
Prot. HP 15 A was achieved with the deprotection cocktail Reagent K 
(TFA/Phenol/H2O/thiolanisole/ethane-1,2-dithiol 82.5:5:5:5:2.5). The deprotection 
reaction at ambient temperature took 3 hours before the quantitative cleavage of the 
side-chain protecting groups was achieved. Aspartimide derivatives were separated from 
the target peptide by RP-HPLC operations. 
 
Yield: 
H-Asp(OtBu)-Phe-Asp(OtBu)-Phe-Asp(OtBu)-Phe-Glu(OtBu)-D-Pro-Gly-Glu(OtBu)- 
Phe-Asp(OtBu)-Phe-Asp(OtBu)-Phe-Asp(OtBu)-OH (Prot. HP 15 A) (no yield data) 
H-Asp-Phe-Asp-Phe-Asp-Phe-Glu-D-Pro-Gly-Glu-Phe-Asp-Phe-Asp-Phe-Asp-OH 
(HP 15 A) 0.0205 g/0.01 mmol (4.0%) 
 
Formula (Prot. HP 15 A): C127H174N16O33 
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Formula (HP 15 A): C95H110N16O33 
Formula (Prot. HP 15 A Aspartimide): C123H164N16O32 
Formula (HP 15 A Aspartimide): C95H108N16O32 
 
Molecular Mass (Prot. HP 15 A): 2451.24 g/mol 
Molecular Mass (HP 15 A): 2002.74 g/mol 
Molecular Mass (Prot. HP 15 A Aspartimide): 2377.17 g/mol 
Molecular Mass (HP 15 A Aspartimide): 1984.73 g/mol 
 
MS (MALDI-ToF)(Prot. HP 15 A): m·z-1 = 2452.64 [M+H]+, 2474.78 [M+Na]+, 
2490.90 [M+K]+, 2496.56.44 [M+2Na-H]+ 
Calculated Mass (Prot. HP 15 A): [C127H175N16O33]+ = 2452.25, [C127H174N16O33Na]+ = 
2474.23, [C127H174N16O33K]+ = 2490.20, [C127H173N16O33Na2]+ = 2496.21 
 
MS (MALDI-ToF)(HP 15 A): m·z-1 = 2003.71 [M+H]+, 2024.68 [M+Na]+, 2045.98 
[M+K]+ 
Calculated Mass (HP 15 A): [C95H111N16O33]+ = 2003.75, [C95H110N16O33Na]+ = 2025.73, 
[C95H110N16O33K]+ = 2043.13 
 
MS (MALDI-ToF)(Prot. HP 15 A Aspartimide Formation): m·z-1 = 2378.37 [M+H]+, 
2399.21 [M+Na]+, 2419.10 [M+K]+, 2437.08 [M+Na+K-H]+ 
Calculated Mass (Prot. HP 15 A Aspartimide Formation): [C123H165N16O32]+ = 2378.18, 
[C123H164N16O32Na]+ = 2400.16, [C123H164N16O32K]+ = 2416.13, [C122H164N16O32KNa]+ = 
2438.11 
 
MS (MALDI-ToF)(HP 15 A Aspartimide Formation): m·z-1 = 1985.26 [M+H]+, 2007.41 
[M+Na]+, 2029.27 [M+2Na-H]+ 
Calculated Mass (HP 15 A Aspartimide Formation): [C95H109N16O32]+ = 1985.26, 
[C95H108N16O32Na]+ = 2007.72.16, [C95H107N16O32Na2]+ = 2029.71 
 
HP 15 A: 
Preparative RP-HPLC: Apparatus A, Method 17, tR = 27.45min 
 
Analytical RP-HPLC: Method II, tR = 21.39 min, 100% (220 nm) 
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Analysis of the Proportion of Aspartimide Formation in the Synthesis of 
Prot. HP 15 A 
The crude peptide Prot. HP 15 A was cleaved from the resin; the solvent was removed 
under reduced pressure. The remaining residue was lyophilized before analysis by 
analytical RP-HPLC (Method II). 1-2 mg of crude peptide Prot. HP 15 A was dissolved 
in acetonitrile/H2O with the addition of minimal amount of DMF in order to increase the 
solubility. Two fractions were obtained from the chromatography, both of which were 
collected and analyzed by MALDI-ToF-MS.  
 
First fraction: (tR = 36.63-36.92 min, 35.38 %) 
MS (MALDI-ToF) : m·z-1 = 2399.69 [M+Na]+, 2419.54 [M+K]+, 2438.62 [M+Na+K-H]+ 
 
Second fraction: (tR = 37.94 min, 64.62 %) 
MS (MALDI-ToF) : m·z-1 = 2474.98 [M+Na]+,  2491.93 [M+K]+, 2496.53 [M+2Na-H]+ 
 
The first fraction sampled from analytical RP-HPLC was found to be Prot. HP 15 A with 
a single aspartimide, while the second fraction was the target peptide Prot. HP 15 A, 
which means that ca. 35.38 % of aspartimide formation of Prot. HP 15 A was caused 
with this method of peptide synthesis (microwave as the input energy, no HOBt additive 
in the Fmoc deprotection cocktail 20% piperidine/DMF). 
 
H-Asp-Phe-Asp-Phe-Asp-Phe-Glu-D-Pro-Gly-Glu-Phe-Asp-Phe-Asp-Phe-Asp-OH 
(HP 15 B) 
 
N
H O
H
H
N
HOOC
O
N
H
HOOC
O
H
N
O
N
H
HOOC
O
H
N
O
N
H O
N
OHN
H
N
O
N
HO
H
N
COOH
O
N
HO
H
N
COOH
O
N
HO
H
N
HO
O
COOH
O
COOH
COOH
Ph
Ph
Ph Ph Ph Ph
HP 15 B  
3.6 Synthetic Experimental Section 
 285
 
The synthesis of the fully protected peptide Prot. HP 15 B was carried out according to 
the general procedure of SPPS (Fmoc/tBu), operating automatically on the CEM 
Microwave Peptide Synthesizer, with Fmoc-Asp(OtBu)-OH being loaded on the 
o-chlorotrityl resin (0.8 mmol/g, 0.25 mmol), TBTU as coupling reagent. The unique 
difference of synthetic methodology of peptide HP 15 B to that of HP 15 A was that the 
Nα-Fmoc-deprotecting cocktail 20% piperidine/DMF contained 0.1 M HOBt as additive 
for the synthesis of Prot. HP 15 B. Aspartimide formation in the sequence 
Prot. HP 15 B was also found, but to a lower extent (15.36%:35.38%) than that from the 
Prot. HP 15 A.  
 
Deprotection of the peptide was achieved with the deprotection cocktail Reagent K 
(TFA/Phenol/H2O/thiolanisole/ethane-1,2-dithiol 82.5:5:5:5:2.5). The deprotection 
reaction at ambient temperature took 3 hours before the quantitative cleavage of the 
side-chain protecting groups was achieved. Aspartimide derivatives were separated from 
the target peptide by RP-HPLC. 
 
H-Asp(OtBu)-Phe-Asp(OtBu)-Phe-Asp(OtBu)-Phe-Glu(OtBu)-D-Pro-Gly-Glu(OtBu) 
-Phe -Asp(OtBu)-Phe-Asp(OtBu)-Phe-Asp(OtBu)-OH (Prot. HP 15 B) 
H-Asp-Phe-Asp-Phe-Asp-Phe-Glu-D-Pro-Gly-Glu-Phe-Asp-Phe-Asp-Phe-Asp-OH 
(HP 15 B) 0.0420 g/0.02 mmol (8.0%) 
 
Formula (Prot. HP 15 B): C127H174N16O33 
Formula (HP 15 B): C95H110N16O33 
Formula (Prot. HP 15 B Aspartimide): C123H164N16O32 
Formula (HP 15 B Aspartimide): C95H108N16O32 
 
Molecular Mass (Prot. HP 15 B): 2451.24 g/mol 
Molecular Mass (HP 15 B): 2002.74 g/mol 
Molecular Mass (Prot. HP 15 B Aspartimide): 2377.17 g/mol 
Molecular Mass (HP 15 B Aspartimide): 1984.73 g/mol 
 
MS (MALDI-ToF)(Prot. HP 15 B): m·z-1 = 2452.47 [M+H]+, 2473.67 [M+Na]+, 2489.82 
[M+K]+, 2495.20 [M+2Na-H]+, 2511.73 [M+Na+K-H]+ 
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Calculated Mass (Prot. HP 15 B): [C127H175N16O33]+ = 2452.25, [C127H174N16O33Na]+ = 
2474.23, [C127H174N16O33K]+ = 2490.20, [C127H173N16O33Na2]+ = 2496.21, 
[C127H173N16O33KNa]+ = 2512.19 
 
MS (MALDI-ToF)(Prot. HP 15 B Aspartimide Formation): m·z-1 = 2399.21 [M+Na]+, 
2419.70 [M+K]+ 
Calculated Mass (Prot. HP 15 B Aspartimide Formation): [C123H164N16O32Na]+ = 
2400.16, [C123H164N16O32K]+ = 2416.13 
 
Analysis of the Proportion of Aspartimide Formation in the Synthesis of 
Prot. HP 15 B 
 
The crude peptide Prot. HP 15 B was cleaved from the resin; the solvent was removed 
under the reduced pressure. The remaining residue was lyophilized analyzed by analytical 
RP-HPLC (Method II). 1-2 mg of crude peptide Prot. HP 15 B was dissolved in 
acetonitrile/H2O with the addition of a minimal amount of DMF in order to increase the 
solubility. Two fractions were obtained from the chromatography, both of which were 
collected and analyzed by MALDI-ToF-MS.  
 
First fraction: (tR = 36.57-36.99 min, 15.36 %) 
MS (MALDI-ToF) : m·z-1 = 2399.69 [M+Na]+, 2419.54 [M+K]+, 2438.62 [M+Na+K-H]+ 
 
Second fraction: (tR = 38.39 min, 84.64 %)  
MS (MALDI-ToF) : m·z-1 = 2474.56 [M+Na]+,  2491.89 [M+K]+ 
 
The first fraction sampled from analytical RP-HPLC was approved to be the 
mono-aspartimide formation of Prot. HP 15 B, while the second fraction was the target 
peptide Prot. HP 15 B, which means that only ca. 15% of aspartimide formation of 
Prot. HP 15 B was observed with this method of peptide synthesis (microwave as the 
input energy, 0.1 M HOBt additive in the Fmoc deprotection cocktail 20% 
piperidine/DMF).  
 
The addition of 0.1 M HOBt to 20 % piperidine/DMF significantly decreased the 
occurrence of aspartimide formation in the template peptide Prot. HP 15  in this project, 
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with the microwave as the input energy in the peptide synthesis process. The explanation 
for this phenomenon is still to be explored. 
 
H-Glu-Phe-Glu-Phe-Glu-Phe-Asp-D-Pro-Gly-Asp-Phe-Glu-Phe-Glu-Phe-Glu-OH 
(HP 16) 
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The synthesis of the fully protected peptide Prot. HP 16 was carried out according to the 
general procedure of SPPS (Fmoc/tBu), operating automatically on the CEM Microwave 
Peptide Synthesizer, with Fmoc-Glu(OtBu)-OH being loaded on the o-chlorotrityl resin 
(0.8 mmol/g, 0.25 mmol), and TBTU as coupling reagent. The Nα-Fmoc-deprotecting 
cocktail 20% piperidine/DMF did not contain HOBt as additive. No aspartimide 
formation was found. Deprotection of peptide Prot. HP 16 was achieved with the 
deprotection cocktail Reagent K (TFA/Phenol/H2O/thiolanisole/ethane-1,2-dithiol 
82.5:5:5:5:2.5). The deprotection reaction at ambient temperature took 3 hours before the 
quantitative cleavage of the side-chain protecting groups was achieved.  
 
Yield: 
H-Glu(OtBu)-Phe-Glu(OtBu)-Phe-Glu(OtBu)-Phe-Asp(OtBu)-D-Pro-Gly-Asp(OtBu)- 
Phe-Glu(OtBu)-Phe-Glu(OtBu)-Phe-Glu(OtBu)-OH (Prot. HP 16) (no yield data) 
H-Glu-Phe-Glu-Phe-Glu-Phe-Asp-D-Pro-Gly-Asp-Phe-Glu-Phe-Glu-Phe-Glu-OH 
(HP 16) 0.0895 g/0.043 mmol (17.2%) 
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Formula (HP 16): C99H118N16O33 
 
Molecular Mass (HP 16): 2058.80 g/mol 
 
MS (MALDI-ToF)(HP 16): m·z-1 = 2059.98 [M+H]+, 2081.96 [M+Na]+, 2097.99 
[M+K]+  
Calculated Mass (HP 16): [C99H118N16O33]+ = 2059.81, [C99H118N16NaO33]+ = 2081.79, 
[C99H118KN16O33]+ = 2097.77 
 
Preparative RP-HPLC: Apparatus A, Method 17, tR = 29.56 min 
 
Analytical RP-HPLC: Method II, tR = 22.51 min, 100% (220 nm) 
 
H-Asp-Phe-Ser-Phe-Asp-Phe-Ser-D-Pro-Gly-Asp-Phe-Ser-Phe-Asp-Phe-Ser-OH 
(HP 17) 
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The synthesis of the fully protected derivative of peptide Prot. HP 17 was carried out 
according to the general procedure of manual SPPS (Fmoc/tBu), with Fmoc-Ser(tBu)-OH 
being loaded on the o-chlorotrityl resin (0.76 mmol/g, 0.25 mmol), and TBTU as 
coupling reagent. 4 equiv amino acid and 4 equiv TBTU were applied in each coupling 
step. Deprotection of peptide Prot. HP 17 was achieved with the deprotection cocktail 
TFA/H2O/TIS (95:2.5:2.5). However, quantitative cleavage of the side-chain protecting 
groups was not obtained after 8 hours deprotection reaction at ambient temperature. 
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Yield: 
H-Asp(OtBu)-Phe-Ser(tBu)-Phe-Asp(OtBu)-Phe-Ser(tBu)-D-Pro-Gly-Asp(OtBu)-Phe- 
Ser(tBu)-Phe-Asp(OtBu)-Phe-Ser(tBu)-OH (Prot. HP 17) 
(0.8541 g, crude product, after lyophilization) 
 
H-Asp-Phe-Ser-Phe-Asp-Phe-Ser-D-Pro-Gly-Asp-Phe-Ser-Phe-Asp-Phe-Ser-OH 
(HP 17) 0.0155 g/0.0083 mmol (3.3%) 
 
Formula: C89H106N16O29 
 
Molecular Mass: 1863.94 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1886.83  [M+Na]+, 1904.83 [M+K]+, 1910.61 [M+2Na-H]+ 
Calculated Mass: [C89H106N16O29Na]+ = 1885.73, [C89H106N16O29K]+ = 1903.03, 
[C89H105N16O29Na2]+ = 1908.91 
 
Preparative RP-HPLC: Apparatus A, Method 18, tR = 29.30 min 
 
Analytical RP-HPLC: Method II, tR = 21.97 min, 100% (220nm) 
 
H-Asp-Phe-Asp-Phe-Asp-Phe-Asp-D-Pro-Gly-Asp-Phe-Asp-Phe-Asp-Phe-Asp-OH 
(HP 18) 
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The synthesis of the fully protected peptide Prot. HP 18 was carried out according to the 
general procedure of manual SPPS (Fmoc/tBu), with Fmoc-Asp(OtBu)-OH being loaded 
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on the o-chlorotrityl resin (0.8 mmol/g, 0.3 mmol), and TBTU as coupling reagent. 
Deprotection of peptide Prot. HP 18 was achieved with the deprotection cocktail 
TFA/H2O/TIS (95:2.5:2.5). No aspartimide formation was found in the crude product. 
 
Yield:  
H-Asp-Phe-Asp-Phe-Asp-Phe-Asp-D-Pro-Gly-Asp-Phe-Asp-Phe-Asp-Phe-Asp-OH 
(HP 18) 0.0205 g/0.0010 mmol (0.33%) 
 
Formula: C93H106N16O33 
 
Molecular Mass: 1975.98 g/mol 
 
MS (MALDI-ToF): m·z-1 = 1978.37 [M+H]+, 1999.42 [M+Na]+, 2015.59 [M+K]+, 
2021.27 [M+2Na-H]+, 2043.09 [M+3Na-2H]+, 2064.99 [M+4Na-3H]+ 
Calculated Mass: [C93H107N16O33]+ = 1976.99, [C93H106N16O33Na]+ = 1998.97, 
[C93H106N16O33K]+ = 2015.08, [C93H105N16O33Na2]+ = 2020.95, [C93H104N16O33Na3]+ = 
2042.94, [C93H103N16O33Na4]+ = 2064.93 
 
Preparative RP-HPLC: Apparatus A, Method 18, tR = 31.00 min 
 
Analytical RP-HPLC: Method II, tR = 21.18 min, 100% (220 nm) 
 
H-Glu-Phe-Glu-Phe-Glu-Phe-Glu-D-Pro-Gly-Glu-Phe-Glu-Phe-Glu-Phe-Glu-OH 
(HP 19) 
 
N
H O
H
H
N
O
N
H O
H
N
O
N
H O
H
N
O
N
H O
N
OHN
H
N
O
N
HO
H
N
O
N
HO
H
N
O
N
HO
H
N
HO
O
O
COOH
COOH
Ph
Ph
Ph Ph Ph Ph
HP 19
COOH COOHCOOH
COOH COOH COOH
 
3.6 Synthetic Experimental Section 
 291
The synthesis of the fully protected peptide Prot. HP 19 was carried out according to the 
general procedure of manual SPPS (Fmoc/tBu), with Fmoc-Glu(OtBu)-OH being loaded 
on the o-chlorotrityl resin (0.8 mmol/g, 0.3 mmol), and TBTU as coupling reagent. 
Deprotection of peptide Prot. HP 19 was achieved with the deprotection cocktail 
TFA/H2O/TIS (95:2.5:2.5). The deprotection reaction at ambient temperature took 2 
hours before the quantitative cleavage of the side-chain protecting groups was achieved. 
 
Yield:  
H-Glu-Phe-Glu-Phe-Glu-Phe-Glu-D-Pro-Gly-Glu-Phe-Glu-Phe-Glu-Phe-Glu-OH 
(HP 19) 0.0085 g/0.0041 mmol 
 
Formula: C101H122N16O33 
 
Molecular Mass: 2086.84 g/mol 
 
MS (MALDI-ToF): m·z-1 = 2086.92 [M+H] +, 2108.32 [M+Na]+, 2124.35 [M+K]+, 
2130.26 [M+2Na-H]+, 2152.09 [M+3Na-2H]+, 2174.76 [M+4Na-3H]+ 
Calculated Mass: [C101H123N16O33]+ = 2087.84, [C101H122N16O33Na]+ = 2109.83, 
[C101H122N16O33K]+ = 2125.80, [C101H121N16O33Na2]+ = 2131.81, [C101H120N16O33Na3]+ 
= 2153.80, [C101H119N16O33Na4]+ = 2175.79 
 
Preparative RP-HPLC: Apparatus A, Method 19, tR = 21.38 min 
 
Analytical RP-HPLC: Method II, tR = 21.84 min, 100% (220 nm) 
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H-Glu-Phe-Ser-Phe-Glu-Phe-Ser-D-Pro-Gly-Glu-Phe-Ser-Phe-Glu-Phe-Ser-OH 
(HP 20-1) (Manual Synthesis) 
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The synthesis of the fully protected peptide Prot. HP 20-1 was carried out according to 
the general procedure of manual SPPS (Fmoc/tBu), with Fmoc-Ser(OtBu)-OH being 
loaded on the o-chlorotrityl resin (0.76 mmol/g, 0.25 mmol), and TBTU as coupling 
reagent. 4 equiv amino acid and 4 equiv TBTU were applied in each coupling step. 
Deprotection of the peptide was achieved with the deprotection cocktail TFA/H2O/TIS 
(95:2.5:2.5). The deprotection reaction at ambient temperature took 3 hours before the 
quantitative cleavage of the side-chain protecting groups was observed. 
 
Yield: 
H-Glu(OtBu)-Phe-Ser(tBu)-Phe-Glu(OtBu)-Phe-Ser(tBu)-D-Pro-Gly-Glu(OtBu)-Phe- 
Ser(tBu)-Phe-Glu(OtBu)-Phe-Ser(tBu)-OH (Prot. HP 20-1)  
(0.4357 g/0.184 mmol, crude product, after lyophilization) 
H-Glu-Phe-Ser-Phe-Glu-Phe-Ser-D-Pro-Gly-Glu-Phe-Ser-Phe-Glu-Phe-Ser-OH 
(HP 20-1) 0.0112 g/0.0058 mmol (2.32%) 
 
Formula of Prot. HP 20-1: C125H178N16O29 
 
Molecular Mass (Prot. HP 20-1): 2367.29 g/mol 
 
MS (MALDI-ToF) (Prot. HP 20-1): m·z-1 = 2390.68 [M+Na]+, 2406.70 [M+K]+, 
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2412.69 [M+2Na-H]+ 
Calculated Mass (Prot. HP 20-1): [C125H178N16O29Na]+ = 2390.28, 
[C125H178N16O29K]+ = 2406.26, [C125H177N16O29Na2]+ = 2412.27 
 
Formula: C93H114N16O29 
 
Molecular Mass: 1918.79 g/mol 
 
MS (MALDI-ToF) (HP 20-1): m·z-1 = 1941.36 [M+Na]+, 1957.61 [M+K]+, 1963.54 
[M+2Na-H]+, 1979.66 [M+2Na-H+H2O]+, 1985.58 [M+3Na-2H]+ 
Calculated Mass (HP 20-1): [C93H114N16O29Na]+ = 1941.78, [C93H114N16O29NK]+ = 
1957.77, [C93H113N16O29Na2]+ = 1963.77, [C93H115N16O30Na2]+ = 1981.78, 
[C93H112N16NO29Na3]+ = 1985.76 
 
Preparative RP-HPLC: Apparatus A, Method 20, tR = 19.66 min 
 
Analytical RP-HPLC: Method II, tR = 21.29 min, 100% (220 nm) 
 
H-Glu-Phe-Ser-Phe-Glu-Phe-Ser-D-Pro-Gly-Glu-Phe-Ser-Phe-Glu-Phe-Ser-OH  
(HP 20-2) (Microwave Peptide Synthesizer) 
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The comparison of peptide synthesis between manual and microwave methodology was 
carried out, using peptide HP 20-1 and HP 20-2 as the reference peptides for comparison.   
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The synthesis of the fully protected peptide Prot. HP 20-2 was carried out according to 
the general procedure of SPPS (Fmoc/tBu), operating automatically on the CEM 
Microwave Peptide Synthesizer, with Fmoc-Ser(tBu)-OH being loaded on the 
o-chlorotrityl resin (0.8 mmol/g, 0.25 mmol), and TBTU as coupling reagent. The 
Nα-Fmoc-deprotecting cocktail 20% piperidine/DMF did not contain HOBt as additive. 
Deprotection of peptide Prot. HP 20-2 was achieved with the deprotection cocktail 
TFA/H2O/TIS (95:2.5:2.5). The deprotection reaction at ambient temperature took 3 
hours before the quantitative cleavage of the side-chain protecting groups was achieved. 
 
Yield:  
H-Glu(OtBu)-Phe-Ser(tBu)-Phe-Glu(OtBu)-Phe-Ser(tBu)-D-Pro-Gly-Glu(OtBu)-Phe- 
Ser(tBu)-Phe-Glu(OtBu)-Phe-Ser(tBu)-OH (Prot. HP 20-2)  
0.5796 g/0.245 mmol (raw product, after lyophilization) 
H-Glu-Phe-Ser-Phe-Glu-Phe-Ser-D-Pro-Gly-Glu-Phe-Ser-Phe-Glu-Phe-Ser-OH 
(HP 20-2) 0.0165 g/0.0086 mmol (3.4%) 
 
Formula of Prot. HP 20-2: C125H178N16O29 
 
Molecular Mass (Prot. HP 20-2): 2367.29 g/mol 
 
MS (MALDI-ToF) (Prot. HP 20-2): m·z-1 = 2389.25 [M+Na]+, 2406.22 [M+K]+, 
2410.93 [M+2Na-H]+ 
Calculated Mass (P_HP 3c-2): [C125H178N16O29Na]+ = 2390.28, [C125H178N16O29K]+ = 
2406.26, [C125H177N16O29Na2]+ = 2412.27 
 
Formula (HP 20-2): C93H114N16O29 
 
Molecular Mass (HP 20-2): 1918.79 g/mol 
 
MS (MALDI-ToF) (HP 20-2): m·z-1 = 1941.56 [M+Na]+, 1957.81 [M+K]+, 1963.45 
[M+2Na-H]+ 
 
Calculated Mass (HP 20-2): [C93H114N16O29Na]+ = 1941.78, [C93H114N16O29NK]+ = 
1957.77, [C93H113N16O29Na2]+ = 1963.77 
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H-1Asp-2Phe-3Ser-4Phe-5Asp-6Phe-7Ser-8D-Pro-9Gly-10Asp-11Phe-12Ser-13Phe-14Asp- 
15Phe-16Ser-OH (HP 17-Hmb) 
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The synthesis of the fully protected derivative of peptide HP 17-Hmb, namely, 
H-1Asp(OtBu)-2Phe-3Ser(tBu)-4Phe-N-Hmb-5Asp(OtBu)-6Phe-7Ser(tBu)-8D-Pro-9Gly-N-
Hmb-10Asp(OtBu)-11Phe-12Ser(tBu)-13Phe-14Asp(OtBu)-15Phe-16Ser(tBu)-OH 
(Prot. HP17-Hmb), was carried out according to the general procedure of manual SPPS 
(Fmoc/tBu), with Fmoc-Ser(OtBu)-OH being loaded on the o-chlorotrityl resin 
(0.6 mmol/g, 0.1 mmol). The residues 5Asp and 10Asp were incorporated into the peptide 
chain in the form of N,O-bisFmoc-N-Hmb-Asp(OtBu)-OH 22 (3 equiv), using 3 equiv 
HATU as the coupling reagent and 6 equiv DIPEA as the base. The duration of coupling 
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5Asp and 10Asp derivatives to the peptide chain on the solid support took 3 hours at room 
temperature. The coupling of 9Gly and 4Phe residue derivative to the peptide chain was 
also achieved through the coupling reagent HATU. For the coupling of other residues to 
the peptide chain, TBTU was applied as the coupling reagent. From the coupling of 7Ser 
on, the amounts of the amino acid derivatives were increased to 4 equiv. In a similar way, 
the amount of TBTU and DIPEA were increased to 4 equiv and 8 equiv, respectively 
(with the exception of 5Asp derivative with 3 equiv amino acid derivative, 3 equiv HATU, 
6 equiv DIPEA). Cleavage of the peptide Prot. HP17-Hmb from the resin was achieved 
by the treatment of the peptidyl resin with 1% TFA in DCM. The solvents were removed 
under reduced pressure and the peptide solids were dissolved in acetonitrile and 
lyophilized. The hereby obtained fully protected peptide Prot. HP17-Hmb was dissolved 
in acetonitrile with the addition of minimal DMF to enhance the solubility and 
subsequently purified with RP-HPLC. The puried solid peptide of Prot. HP17-Hmb was 
then given to the reagent K for the cleavage of the side-chain tBu-type protecting groups 
as well as backbone Hmb protecting groups. The deprotection reaction took 
approximately 5 hours at room temperature. The solvent was then removed under 
reduced pressure. The obtained solid residue was dissolved in minimal TFA and slowly 
added to an ice-cold diethyl ether resided in ice-water bath. The target peptides 
precipitated upon the addition of the solution into the cold ether. This suspension was 
stirred for approximately 30 minutes at 0 ºC before centrifugation. The solid peptide was 
again added to another portion of fresh ice-cold diethyl ether and stirred for 30 minutes in 
the ice-water bath. Likewise, the ether solution was removed by centrifugation. The 
obtained peptide solid was triturated in acetonitrile/H2O and dried by lyophilization. 
 
Yield: Prot. HP17-Hmb 0.1293 g/0.05 mmol (crude products after lyophilization) 
 
 HP 17-Hmb 0.0372 g/0.02 mmol (20.0%) 
 
Formula (Prot. HP17-Hmb): C137H186N16O33 
 
Molecular Mass (Prot. HP17-Hmb): 2583.33 g/mol 
 
MS (MALDI-ToF) (Prot. HP17-Hmb): m·z-1 = 2606.08 [M+Na]+, 2622.47 [M+K]+, 
2627.13 [M+2Na-H]+, 2644.54 [M+Na+K-H]+ 
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Calculated Mass (Prot. HP17-Hmb): [C137H186N16O33Na]+ = 2606.32, 
[C137H186N16O33K]+ = 2622.29, [C137H185N16O33Na2]+ = 2628.31,  
[C137H185N16O33NaK]+ = 2644.28 
 
Preparative RP-HPLC (Prot. HP17-Hmb): Apparatus A, Method 17, tR = 24.49 min 
 
Analytical RP-HPLC: Method II, tR = 39.45 min, 100% (220 nm) 
 
Formula (HP 17-Hmb): C89H106N16O29 
 
Molecular Mass (HP 17-Hmb): 1863.94 g/mol 
 
MS (MALDI-ToF) (HP 17-Hmb): m·z-1 = 1885.72 [M+Na]+, 1903.11 [M+K]+ 
Calculated Mass: [C89H106N16O29Na]+ = 1885.73, [C89H106N16O29K]+ = 1903.03,  
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3.7 Summary 
 
 
In summary, a series of peptides designed as models for the research of β-hairpin 
conformation and templates for biomineralization have been synthesized by microwave 
SPPS or traditional manual SPPS. Moreover, DFSFDFSpGDFSFDFS HP 17 was 
successfully synthesized through the Hmb backbone protection strategy. The introduction 
of the backbone protection groups Hmb eliminated the intra-chain hydrogen bonds 
between the neighbouring β-strands in the reference peptide and hence drastically 
increased the solubility of the fully protected peptides Prot. HP 17-Hmb, which could be 
easily dissolved in DMF/ACN mixture solvent and consequently purified by RP-HPLC. 
The function of Hmb to break the inter/intra-chain hydrogen bond had also been 
validated by the CD spectra of Prot. HP 17-Hmb. In conclusion, the backbone protection 
methodology successfully avoided the inherent problems residing in the SPPS of β-sheet 
related peptides. The intra/inter-chain hydrogen bonds between the neighbouring 
β-strands greatly impeded the flexibility and accessibility of the growing peptide chains, 
leading to insufficiently coupling and truncated sequences, and not being appropriate for 
HPLC purification. The Hmb backbone protection methodology could successfully 
suppress such problems. 
 
Through the conformation studies of the synthesized peptide, it could be deduced that 
aspartic acids are less appropriate as components of amphiphilic β-hairpin peptides than 
glutamic acids. This has been proven by the fact that aspartic acids appear less frequently 
than glutamic acids in the database of naturally occurred β-sheet proteins and peptides. 
By comparison of the conformation of homologous peptides DFDFDFDpGDFDFDFD 
HP 18 and EFEFEFEpGEFEFEFE HP 19, it was found that Asp-containing peptide 
HP 18 adopted bascially random coil in HFIP, while under the same conditions, 
Glu-containing peptide HP 19 adopted mainly ordered β-hairpin conformation. The 
distinction between the conformations of HP 18 and HP 19 might be based on the fact 
that there is one more methylene group in glutamic acid than in aspartic acid, which 
3.7 Summary 
 299
makes the side chain of glutamic acid more flexible and thus being able to adopt the 
favourable conformation when interacting with the counterpart glutamic acids on the 
neighbouring β-strands. This extra flexibility enables the glutamic acids to dodge the 
disadvantage repulsive ionic interaction between the β-strands in the β-hairpin peptide, 
obviating the factors which could probably jeopardize the β-hairpin conformation. 
Another important factor which makes peptide HP 19 adopt β-hairpin conformation 
while HP 18 random coil might originate from the extra methylene group in glutamic 
acid. It introduces the additional beneficial hydrophobic interactions between the side 
chains of glutamic acids residing on the neighbouring β-strands in the β-hairpin peptide 
HP 19, which could perhaps hugely reinforce its stability. This result exhibited the 
importance of hydrophobic interactions in stabilizing the β-hairpin conformation. It could 
thus be imagined that if one more methylene group is inserted in the side chain of 
glutamic acid, that is to say, to substitute glutamic acid rediues by 2-amino adipic acids, 
the stability of β-hairpin conformation of such a peptide could possibly be further 
reinforced relative to HP 19. The distinction between aspartic acid and glutamic acid 
with respect to β-sheet stabilization has been validated by the comparison of the 
conformations of peptide FDFDFDFDFD HP 11 and FEFEFEFE HP 12, in which turn 
motif -D-Pro-Gly- has been excluded and only β-strand sequences has been maintained. 
The conformational distinctions between peptide HP 11 and HP 12 clearly indicate the 
inherent differences between aspartic acid and glutamic acid in their inclination to 
stabilize the β-strand conformation. 
 
The β-turn structure is formed by the -D-Pro-Gly- motif, a β-turn inducer. From the CD 
spectra of EpGE HP 1 and DpGD HP 2, it could be deduced that they adopt basically 
β-turn conformations in H2O. The -D-Por-Gly- motif alternated the direction of peptide 
and led to the folding of the chain as they are supposed to. The incorporation of β-turn 
motif is a crucial factor to nucleate the β-hairpin conformation in designed peptide. 
 
As is shown by Figure 3.21-23, HP 1 and HP 2 adopted β-turn conformations in H2O, 
but the ordered structures were converted to random coil in HFIP. While FpGF HP 4, in 
which phenylalanines occupy the corner positions, adopt mainly β-turn conformation 
both in H2O and HFIP. This distinction could be based on the inherent differences in the 
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properties of H2O and HFIP and the pattern of hydrogen bond network in the peptide. In 
contrast to water, halogenated alcohols such as HFIP or TFE are better proton donors and 
poorer proton acceptors. It was therefore proposed that HIFP/TFE is likely to bind 
preferentially to the mainchain carbonyl oxygen group. Such a preference leads to 
enhanced intra-hydrogen bond of amide groups as solvent exposure of amide is 
minimized. (Carbonyl oxygen is often able to accept two hydrogen bonds.) Indirect 
effects on H-bond result from altered dielectric constants. As the solvent dielectric 
constant is lowered from 79 of water to 27 (pure TFE at 25ºC), electrostatic interactions 
become stronger. TFE could be regarded as mainly weakening hydrophobic-hydrophobic 
interactions and only slightly enhancing local helical interactions. The ability of 
HFIP/TFE to disfavor hydrophobic interactions between residues distant in the amino 
acid sequence, which is found in the interior of native state protein or across strands in 
some β-sheets, accounts for their abilities to disrupt these structures. Structures that rely 
on sequence local interactions, such as helices, are preferentially stabilized. In conclusion, 
the increase of the strength of intra-chain hydrogen bond in peptide HP 1 and HP 2 
caused by HFIP is not strong enough to compensate the enhancement of repulsive 
electrostatic interactions, which is also generated by the introduction of HFIP, between 
the side chains of Glu or Asp. The conformational dependence of solvent is thus a 
balance between the advantageous factors such as hydrophobic interactions/hydrogen 
bonds and disadvantageous factors such as repulsive electrostatic interactions. In addition, 
the pattern of hydrogen bond network could also exert influence on the stability 
of β-turn/hairpin conformation and their dependence of solvent, which is confirmed by 
the fact that HP 4, in which phenylalanines occupy the corner positions of the turn motif 
and thus possibly alternate the pattern of hydrogen bond network, adopt β-turn 
conformation both in H2O and HFIP. The role of hydrogen bond network pattern, in 
another word the occupation of corner positions in β turn motif, in stabilizing β-hairpin 
conformation is further testified by the conformational differences between FDpGDF 
HP 6 and DFpGFD HP 7, in which the positions of aspartic acids and phenylalanines are 
exchanged, the stability of β-hairpin conformation is superior in HP 7 (phenylalanines 
occupy the corner position) to that in HP 6 (aspartic acids occupy the corner position).  
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In summary, the stability of β-hairpin conformation is cooperatively determined by the 
primary sequence of correlative peptides, the choice of β-turn motif, the occupation of the 
corner residues in β-turn, the pattern of hydrogen bond network, type of the solvent, 
environmental pH value, and the length of the peptide. Intra-chain hydrogen bonds, 
electrostatic interactions and hydrophobic interactions could be regarded as the basic 
strength in deciding the stability of β hairpin conformation, their influence on the stability 
of β-hairpin conformation could be sophisticated and should be analyzed by individual 
case. 
 
The comparison of manual SPPS and microwave SPPS has also been carried out in this 
project. It could be deduced that microwave methodology is superior to traditional 
manual SPPS when certain difficult sequences are involved. Microwave is assumably 
capable of destroying the intra/inter-hydrogen bonds during the chain elongation on the 
solid support, therefore the introduction of microwave irradiation during the synthesis of 
β-sheet or β-hairpin peptides could be beneficial, validated by the increase of the yield of 
target peptides and decrease of the truncated sequences. However, the effects of 
microwave in SPPS should be regarded as ambiguous. This kind of energy input seemed 
to be prone to promote the extent of some side-reactions in SPPS such as aspartimide 
formation. The introduction of weak acid like HOBt into Fmoc deprotecting reagent 20 % 
piperidine in DMF could reduce the aspartimide side products to some extent, but not 
able to suppress it completely. While under the same synthetic conditions, no detectable 
aspartimide derivatives are found in the traditional manual methodology.  
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